Header Logo

HAGOP M KANTARJIAN

TitleProfessor
InstitutionMD Anderson
DepartmentLeukemia
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Short NJ, Jabbour E, Nasr LF, Jain N, Haddad FG, Issa GC, Sasaki K, Senapati J, Kebriaei P, Garris R, Konopleva M, Ravandi F, Kantarjian H. Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. Am J Hematol. 2024 Apr 12. PMID: 38607091.
      Citations:    
    2. Jabbour E, Haddad FG, Sasaki K, Carter BZ, Alvarado Y, Nasnas C, Nasr L, Masarova L, Daver N, Pemmaraju N, Short NJ, Skinner J, Kadia T, Borthakur G, Garcia-Manero G, Ravandi F, Issa GC, Andreeff M, Kantarjian H. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer. 2024 Apr 09. PMID: 38591430.
      Citations:    
    3. Barosi G, Tefferi A, Gangat N, Szuber N, Rambaldi A, Odenike O, Kr?ger N, Gagelmann N, Talpaz M, Kantarjian H, Gale RP. Methodological challenges in the development of endpoints for myelofibrosis clinical trials. Lancet Haematol. 2024 Apr 08. PMID: 38604205.
      Citations:    
    4. Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Jain N, Cortes JE, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica. 2024 Apr 04. PMID: 38572554.
      Citations:    Fields:    
    5. Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, Alvarado Y, Bose P, Jabbour E, Yilmaz M, DiNardo C, Issa G, Montalban-Bravo G, Short N, Sasaki K, Bull-Linderman D, Daver N, Garcia-Manero G, Ravandi F, Kadia T. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2024 Apr; 11(4):e287-e298. PMID: 38548404.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    6. Bazinet A, Desikan SP, Li Z, Rodriguez-Sevilla JJ, Venugopal S, Urrutia S, Montalban-Bravo G, Sasaki K, Chien KS, Hammond D, Kanagal-Shamanna R, Ganan-Gomez I, Kadia TM, Borthakur G, DiNardo CD, Daver NG, Jabbour EJ, Ravandi F, Kantarjian H, Garcia-Manero G, Bazinet A, Desikan SP, Li Z, Rodriguez-Sevilla JJ, Venugopal S, Urrutia S, Montalban-Bravo G, Sasaki K, Chien KS, Hammond D, Kanagal-Shamanna R, Ganan-Gomez I, Kadia TM, Borthakur G, DiNardo CD, Daver NG, Jabbour EJ, Ravandi F, Kantarjian H, Garcia-Manero G. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax. Clin Cancer Res. 2024 Apr 01; 30(7):1319-1326. PMID: 38300723.
      Citations:    Fields:    Translation:HumansCells
    7. Zhao Y, Short NJ, Kantarjian HM, Chang TC, Ghate PS, Qu C, Macaron W, Jain N, Thakral B, Phillips A, Khoury JD, Garcia-Manero G, Zhang W, Fan Y, Yang H, Garris R, Nasr LF, Kriwacki R, Roberts KG, Konopleva MY, Jabbour EJ, Mullighan CG. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood. 2024 Mar 29. PMID: 38551807.
      Citations:    Fields:    
    8. Haddad FG, Sasaki K, Issa GC, Jabbour E, Kantarjian H. The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in chronic myeloid leukemia. Am J Hematol. 2024 Mar 28. PMID: 38546372.
      Citations:    Fields:    
    9. Zhao Y, Laird AD, Roberts KG, Yafawi RL, Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, G?kbuget N, O'Brien SM, Jabbour EJ, Cassaday RD, Loyd MR, Olsen SR, Neale GA, Liu X, Vandendries E, Advani AS, Mullighan CG. Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL. Blood Adv. 2024 Mar 26. PMID: 38607410.
      Citations:    
    10. Kantarjian H, Branford S, Breccia M, Cortes J, Haddad FG, Hochhaus A, Hughes T, Issa GC, Jabbour E, Nicolini FE, Sasaki K, Xavier-Mahon F. Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? Leukemia. 2024 Mar 26. PMID: 38531949.
      Citations:    Fields:    
    11. Bataller A, Gener-Ricos G, Almanza E, Chien KS, Urrutia S, Bazinet A, Rodriguez-Sevilla JJ, Hammond D, Sasaki K, Takahashi K, DiNardo CD, Ravandi F, Borthakur G, Kadia TM, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Adv. 2024 Mar 21. PMID: 38513082.
      Citations:    Fields:    
    12. Jen WY, Jabbour E, Kantarjian HM, Short NJ. SOHO State of the Art Updates and Next Questions | Novel Agents and the Diminishing Role of Allogeneic Stem Cell Transplant in B-Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Mar 06. PMID: 38538495.
      Citations:    Fields:    
    13. Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Rausch CR, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Ravandi F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol. 2024 Apr; 11(4):e276-e286. PMID: 38452788.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    14. Chien KS, Ong F, Kim K, Li Z, Kanagal-Shamanna R, DiNardo CD, Takahashi K, Montalban-Bravo G, Hammond D, Sasaki K, Pierce SA, Kantarjian HM, Garcia-Manero G. Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms. Cancer Med. 2024 Mar; 13(5):e7093. PMID: 38497538; PMCID: PMC10945882.
      Citations:    Fields:    Translation:Humans
    15. Daver NG, Montesinos P, DeAngelo DJ, Wang ES, Papadantonakis N, Todisco E, Sweet KL, Pemmaraju N, Lane AA, Torres-Mi?ana L, Thompson JE, Konopleva MY, Sloss CM, Watkins K, Bedse G, Du Y, Malcolm KE, Zweidler-McKay PA, Kantarjian HM. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study. Lancet Oncol. 2024 Mar; 25(3):388-399. PMID: 38423051.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    16. Haddad FG, Nasnas C, Sasaki K, Paul S, Issa GC, Rausch C, Jabbour E, Kantarjian H. Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib. Clin Lymphoma Myeloma Leuk. 2024 Feb 29. PMID: 38503634.
      Citations:    Fields:    
    17. Montalban-Bravo G, Rodriguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, Hammond D, Chien K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia. 2024 Feb 28. PMID: 38418609.
      Citations:    Fields:    
    18. Short NJ, Jabbour EJ, Jain N, Senapati J, Nasr LF, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian HM, Short NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian H. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Adv. 2024 Feb 27; 8(4):909-915. PMID: 38207208; PMCID: PMC10875259.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    19. Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM, Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv. 2024 Feb 27; 8(4):927-935. PMID: 38113472; PMCID: PMC10877112.
      Citations: 1     Fields:    Translation:Humans
    20. Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJ. Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial. Am J Hematol. 2024 May; 99(5):836-843. PMID: 38400519; PMCID: PMC11001510.
      Citations:    Fields:    
    21. Short NJ, Jabbour E, Kantarjian H. SOHO State of the Art Updates and Next Questions, Measurable Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Feb 21. PMID: 38485650.
      Citations:    Fields:    
    22. Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, Short N, Sasaki K, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol. 2024 Apr; 99(4):792-796. PMID: 38361282.
      Citations:    Fields:    Translation:Humans
    23. Dinh A, Savoy JM, Kontoyiannis DP, Takahashi K, Issa GC, Kantarjian HM, DiNardo CD, Rausch CR. Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 2024 Feb 10. PMID: 38340331.
      Citations:    Fields:    
    24. Jabbour E, Zugmaier G, Agrawal V, Mart?nez-S?nchez P, Rif?n Roca JJ, Cassaday RD, B?ll B, Rijneveld A, Abdul-Hay M, Huguet F, Cluzeau T, D?az MT, Vucinic V, Gonz?lez-Campos J, Rambaldi A, Schwartz S, Berthon C, Hern?ndez-Rivas JM, Gordon PR, Br?ggemann M, Hamidi A, Chen Y, Wong HL, Panwar B, Katlinskaya Y, Markovic A, Kantarjian H. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol. 2024 Apr; 99(4):586-595. PMID: 38317420.
      Citations:    Fields:    Translation:Humans
    25. Sasaki K, Ravandi F, Kadia T, DiNardo CD, Yilmaz M, Short N, Jabbour E, Patel KP, Loghavi S, Pierce S, Borthakur G, Kantarjian H. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Feb 03. PMID: 38431521.
      Citations:    Fields:    
    26. Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol. 2024 Mar; 11(3):e186-e195. PMID: 38316133.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    27. Haddad FG, Kantarjian H, Haddad FG, Kantarjian H. Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors. J Natl Compr Canc Netw. 2024 02; 22(1). PMID: 38394773.
      Citations:    Fields:    Translation:Humans
    28. Jabbour EJ, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, Jorgensen JL, Wang SA, Alvarado Y, Wang X, DiNardo CD, Masarova L, Kadia TM, Garris R, Ravandi F, Kantarjian HM, Jabbour E, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, Jorgensen J, Wang SA, Alvarado Y, Wang X, DiNardo C, Masarova L, Kadia T, Garris RS, Ravandi F, Kantarjian H. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024 Feb 01; 143(5):417-421. PMID: 37879077.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    29. Jabbour E, Apperley J, Cortes J, Rea D, Deininger M, Abruzzese E, Chuah C, DeAngelo DJ, Hochhaus A, Lipton JH, Mauro M, Nicolini F, Pinilla-Ibarz J, Rosti G, Rousselot P, Shah NP, Talpaz M, Vorog A, Ren X, Kantarjian H. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024 Mar; 38(3):475-481. PMID: 38287132; PMCID: PMC10912029.
      Citations: 1     Fields:    Translation:Humans
    30. Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol. 2024 Jan 26; JCO2301911. PMID: 38277619.
      Citations:    Fields:    
    31. Roboz GJ, Sanz GF, Griffiths EA, Yee KWL, Kantarjian HM, R?cher C, Byrne MT, Patkowska E, Kim HJ, Thomas X, Moors I, Stock W, Illes A, Fenaux P, Miyazaki Y, Yamauchi T, O'Connell C, Hao Y, Keer HN, Azab M, D?hner H. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial. Blood Adv. 2024 Jan 17. PMID: 38231126.
      Citations:    Fields:    
    32. Kantarjian HM, Jabbour EJ, Lipton JH, Castagnetti F, Br?mmendorf TH. A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Jan 12. PMID: 38278737.
      Citations:    Fields:    
    33. Senapati J, Kantarjian H, Haddad FG, Short NJ, Welch MA, Jain N, Jabbour E. SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Jan 08. PMID: 38195323.
      Citations:    Fields:    
    34. Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Patel PA, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern AE, O'Connell CL, Roboz GJ, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Shastri A, Dao KH, Oganesian A, Hao Y, Keer HN, Azab M, Savona MR. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024 Jan; 11(1):e15-e26. PMID: 38135371.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    35. Bataller A, Abuasab T, McCall D, Wang W, Cuglievan B, Issa GC, Jabbour E, Short N, DiNardo CD, Tang G, Garcia-Manero G, Kantarjian HM, Sasaki K. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies. Haematologica. 2024 Jan 01; 109(1):293-297. PMID: 37646654; PMCID: PMC10772528.
      Citations:    Fields:    Translation:Humans
    36. Short NJ, Jabbour E, Jamison T, Paul S, Cuglievan B, McCall D, Gibson A, Jain N, Haddad FG, Nasr LF, Marx KR, Rausch C, Savoy JM, Garris R, Ravandi F, Kantarjian H. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 04; 24(4):e168-e173. PMID: 38212207.
      Citations:    Fields:    Translation:HumansCells
    37. Kantarjian H, Zeidan AM, Fathi AT, Stein E, Rajkumar V, Tefferi A. Traditional Medicare or Medicare Advantage? The Leukemia and Cancer Perspective. Mayo Clin Proc. 2024 Jan; 99(1):15-21. PMID: 38108685.
      Citations:    Fields:    Translation:Humans
    38. Haddad FG, Jabbour E, Short NJ, Jain N, Kantarjian H. SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2023 Dec 14. PMID: 38185587.
      Citations:    Fields:    
    39. Birdwell CE, Fiskus W, Kadia TM, Mill CP, Sasaki K, Daver N, DiNardo CD, Pemmaraju N, Borthakur G, Davis JA, Das K, Sharma S, Horrigan S, Ruan X, Su X, Khoury JD, Kantarjian H, Bhalla KN. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia. 2024 Mar; 38(3):545-556. PMID: 38086946.
      Citations:    Fields:    Translation:HumansAnimals
    40. Zhao Y, Short NJ, Kantarjian HM, Chang TC, Ghate PS, Qu C, Macaron W, Jain N, Thakral B, Phillips AH, Khoury J, Garcia-Manero G, Zhang W, Fan Y, Yang H, Garris RS, Nasr LF, Kriwacki RW, Roberts KG, Konopleva M, Jabbour EJ, Mullighan CG. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. medRxiv. 2023 Dec 09. PMID: 38106221; PMCID: PMC10723521.
      Citations:    
    41. Jen WY, Sasaki K, Rausch CR, DiNardo CD, Kadia TM, Yilmaz M, Borthakur G, Alvarado Y, McCue D, Mccue D, Kantarjian HM, Ravandi F, McCue D. Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients. Leuk Lymphoma. 2024 Mar; 65(3):378-382. PMID: 38054837.
      Citations:    Fields:    Translation:Humans
    42. Kantarjian H, Welch MA, Sasaki K. Early mortality after chemotherapy as a quality indicator-the leukemia perspective. Blood Cancer J. 2023 12 01; 13(1):176. PMID: 38040680; PMCID: PMC10692074.
      Citations:    Fields:    Translation:Humans
    43. Ravandi F, Bashey A, Foran J, Stock W, Mawad R, Short N, Yilmaz M, Kantarjian H, Odenike O, Patel A, Garcha R, Ainsworth WB, Clynes R, Kanodia J, Ding Y, Li H, Kye S, Mims A. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. Blood Adv. 2023 11 14; 7(21):6492-6505. PMID: 37647601; PMCID: PMC10632668.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    44. Montalban-Bravo G, Jabbour E, Borthakur G, Kadia T, Ravandi F, Chien K, Pemmaraju N, Hammond D, Dong XQ, Huang X, Schneider H, John R, Kanagal-Shamana R, Loghavi S, Kantarjian H, Garcia-Manero G. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. Br J Haematol. 2024 Mar; 204(3):898-909. PMID: 37946611.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    45. Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce S, Chien KS, Sasaki K, Kadia TM, Hammond DE, Borthakur G, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood. 2023 11 09; 142(19):1647-1657. PMID: 37441846.
      Citations: 3     Fields:    Translation:Humans
    46. Briski R, Garcia-Manero G, Kantarjian H, Ravandi F. The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia. Ther Adv Hematol. 2023; 14:20406207231205429. PMID: 37854355; PMCID: PMC10580721.
      Citations:    
    47. Kantarjian HM, Logan AC, Zaman F, G?kbuget N, Bargou RC, Zeng Y, Zugmaier G, Locatelli F. Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab. Ther Adv Hematol. 2023; 14:20406207231201454. PMID: 37822571; PMCID: PMC10563488.
      Citations:    
    48. Kantarjian HM. What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia. Leukemia. 2023 11; 37(11):2324-2325. PMID: 37798329.
      Citations:    Fields:    Translation:Humans
    49. Aminu M, Daver N, Godoy MCB, Shroff G, Wu C, Torre-Sada LF, Goizueta A, Shannon VR, Faiz SA, Altan M, Garcia-Manero G, Kantarjian H, Ravandi-Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Naing A, Kim ST, Kontoyiannis DP, Khawaja F, Chung C, Wu J, Sheshadri A. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. Front Immunol. 2023; 14:1249511. PMID: 37841255; PMCID: PMC10570510.
      Citations:    Fields:    Translation:Humans
    50. Sasaki K, Haddad FG, Short NJ, Jain N, Issa G, Jabbour E, Kantarjian H. Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019. Cancer. 2023 12 01; 129(23):3805-3814. PMID: 37769040.
      Citations: 1     Fields:    Translation:HumansCells
    51. Hammond D, Loghavi S, Wang SA, Konopleva MY, Kadia TM, Daver NG, Ohanian M, Issa GC, Alvarado Y, Short NJ, Sasaki K, Pemmaraju N, Montalban-Bravo G, Lachowiez CA, Maiti A, Garcia-Manero G, Jabbour EJ, Borthakur G, Ravandi F, Takahashi K, Pierce SR, Kantarjian HM, DiNardo CD. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood Cancer J. 2023 09 21; 13(1):148. PMID: 37735426; PMCID: PMC10514257.
      Citations: 1     Fields:    Translation:Humans
    52. Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, Mannis G, Chai-Ho W, Tanaka TN, Bradley TJ, Jeyakumar D, Wang ES, Sweet K, Kantarjian HM, Garcia-Manero G, Komrokji R, Xing G, Ramsingh G, Renard C, Zeidner JF, Sallman DA. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. J Clin Oncol. 2023 11 01; 41(31):4893-4904. PMID: 37703506; PMCID: PMC10617926.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    53. Masarova L, Bose P, Pemmaraju N, Zhou L, Pierce S, Estrov Z, Kantarjian H, Verstovsek S, Masarova L, Bose P, Pemmaraju N, Zhou L, Pierce S, Estrov Z, Kantarjian H, Verstovsek S. Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years. Acta Haematol. 2023; 146(6):522-529. PMID: 37699357.
      Citations:    Fields:    Translation:Humans
    54. Fenaux P, Gobbi M, Kropf PL, Issa JJ, Roboz GJ, Mayer J, Krauter J, Robak T, Kantarjian H, Novak J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, Brandwein J, Gercheva-Kyuchukova L, Demeter J, Griffiths E, Yee K, D?hner K, Hao Y, Keer H, Azab M, D?hner H. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study. Blood Adv. 2023 09 12; 7(17):5027-5037. PMID: 37276510; PMCID: PMC10471926.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    55. Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol. 2023 Nov; 98(11):1780-1790. PMID: 37665752.
      Citations: 4     Fields:    
    56. Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica. 2023 09 01; 108(9):2331-2342. PMID: 36951163; PMCID: PMC10483357.
      Citations: 2     Fields:    Translation:Humans
    57. Kantarjian HM, Welch MA, Jabbour E. Revisiting six established practices in the treatment of chronic myeloid leukaemia. Lancet Haematol. 2023 Oct; 10(10):e860-e864. PMID: 37652074.
      Citations: 2     Fields:    
    58. Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N, Jabbour E, DiNardo CD, Pemmaraju N, Jain N, Ferrajoli A, Ylimaz M, Bose P, Tidwell RS, Marx KR, Rausch CR, Kanagal-Shamanna R, Wang S, Islam R, Champlin R, Shpall E, Konopleva M, Garcia-Manero G, Kantarjian H. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol. 2023 11; 98(11):1711-1720. PMID: 37635400.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    59. Sasaki K, Ravandi F, DiNardo C, Welch MA, Kadia T, Kantarjian H. Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2023 12; 23(12):905-910. PMID: 37730483.
      Citations: 1     Fields:    Translation:Humans
    60. Montalban-Bravo G, Kanagal-Shamanna R, Li Z, Hammond D, Chien K, Rodriguez-Sevilla JJ, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2023 11; 203(4):581-592. PMID: 37608562.
      Citations:    Fields:    Translation:Humans
    61. Sasaki K, Morita K, Kantarjian H, Garcia-Manero G, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Wierda W, Daver N, Takahashi K, DiNardo C, Bravo GM, Issa GC, Pierce SA, Soltysiak KA, Tingen MS, Cortes JE. Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results. Clin Lymphoma Myeloma Leuk. 2023 11; 23(11):e369-e378. PMID: 37690903.
      Citations:    Fields:    Translation:Humans
    62. Locatelli F, Shah B, Thomas T, Velasco K, Adedokun B, Aldoss I, Gore L, Hoelzer D, Bassan R, Park JH, Boissel N, Kantarjian H. Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review. Leuk Lymphoma. 2023 10; 64(10):1615-1633. PMID: 37526512.
      Citations: 1     Fields:    Translation:Humans
    63. Urrutia S, Chien KS, Li Z, Bataller A, Almanza E, Sasaki K, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Alvarado Y, Daver N, Kanagal-Shamanna R, Bueso-Ramos C, Pierce SA, Kantarjian H, Garcia-Manero G. Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. Am J Hematol. 2023 10; 98(10):E281-E284. PMID: 37515433.
      Citations:    Fields:    Translation:Humans
    64. Short NJ, Ong F, Ravandi F, Nogueras-Gonzalez G, Kadia TM, Daver N, DiNardo CD, Konopleva M, Borthakur G, Oran B, Al-Atrash G, Mehta R, Jabbour EJ, Yilmaz M, Issa GC, Maiti A, Champlin RE, Kantarjian H, Shpall EJ, Popat U. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Adv. 2023 07 25; 7(14):3573-3581. PMID: 37104058; PMCID: PMC10368841.
      Citations:    Fields:    Translation:Humans
    65. Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, Alvarado Y, Short NJ, Pemmaraju N, Loghavi S, Patel KP, Kanagal-Shamanna R, Yilmaz M, Masarova L, Jabbour E, Kantarjian H. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol. 2023 10; 98(10):1619-1626. PMID: 37485584.
      Citations:    Fields:    Translation:Humans
    66. Mi YC, Zhu HH, Qin YZ, Zhang ZL, Liu YJ, Wen LJ, You MJ, Zhang C, Such E, Luo H, Yuan HJ, Zhou HS, Liu HX, Xu R, Li J, Li JH, Hao JP, Jin J, Yu L, Zhang JY, Liu LP, Zhang LP, Huang RB, Shen SH, Gao SJ, Wang W, Yan XJ, Zhang XY, Du X, Chu XX, Yu YF, Wang Y, Lu Y, Cai Z, Su Z, Taussig DC, MacMahon S, Ball ED, Wang HY, Welch JS, Yin CC, Borthakur G, Sanz MA, Kantarjian HM, Huang JY, Hu J, Chen SN. A global study for acute myeloid leukemia with RARG rearrangement. Blood Adv. 2023 07 11; 7(13):2972-2982. PMID: 36799929; PMCID: PMC10320208.
      Citations: 1     Fields:    Translation:Humans
    67. Bazinet A, Kadia T, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen J, Patel K, DiNardo C, Daver N, Alvarado Y, Haddad FG, Pierce S, Nogueras Gonzalez G, Maiti A, Sasaki K, Yilmaz M, Thompson P, Wierda W, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, Huang X, Kantarjian H, Ravandi F. Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Adv. 2023 07 11; 7(13):3284-3296. PMID: 36884300; PMCID: PMC10336257.
      Citations:    Fields:    Translation:Humans
    68. Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol. 2023 07 08; 16(1):73. PMID: 37422688; PMCID: PMC10329789.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    69. Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, Turkalj S, Jakobsen NA, Luskin MR, Duose DY, Tidwell RSS, Short NJ, Borthakur G, Kadia TM, Masarova L, Tippett GD, Bose P, Jabbour EJ, Ravandi F, Daver NG, Garcia-Manero G, Kantarjian H, Garcia JS, Vyas P, Takahashi K, Konopleva M, DiNardo CD. A Phase Ib/II Study of Ivosidenib with Venetoclax ? Azacitidine in IDH1-Mutated Myeloid Malignancies. Blood Cancer Discov. 2023 07 05; 4(4):276-293. PMID: 37102976; PMCID: PMC10320628.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    70. Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J. 2023 06 29; 13(1):101. PMID: 37386016; PMCID: PMC10310786.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    71. Kantarjian HM, Tefferi A. Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress. Am J Hematol. 2023 09; 98(9):1350-1353. PMID: 37357837.
      Citations:    Fields:    Translation:Humans
    72. Horst HA, Zugmaier G, Martinelli G, Mergen N, Velasco K, Zaman F, Kantarjian H. CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis. Am J Hematol. 2023 08; 98(8):E222-E225. PMID: 37345570.
      Citations:    Fields:    Translation:Humans
    73. Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, DiNardo CD, Daver N, Yilmaz M, Abbas HA, Short NJ, Issa G, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi A, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia T. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol. 2023 09; 98(9):1383-1393. PMID: 37334870.
      Citations:    Fields:    Translation:Humans
    74. DiNardo CD, Venugopal S, Lachowiez C, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway H, Sekeres M, Sukkur A, Hammond D, Chien K, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia T, Short NJ, Daver N, Borthakur G, Ravandi F, Kantarjian HM, Patel B, Dezern A, Roboz G, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv. 2023 06 13; 7(11):2378-2387. PMID: 35973199; PMCID: PMC10220255.
      Citations:    
    75. Radich JP, Wall M, Branford S, Campbell CD, Chaturvedi S, DeAngelo DJ, Deininger M, Guinney J, Hochhaus A, Hughes TP, Kantarjian HM, Larson RA, Li S, Maegawa R, Mishra K, Obourn V, Pinilla-Ibarz J, Purkayastha D, Sadek I, Saglio G, Shrestha A, White BS, Druker BJ. Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis. Haematologica. 2023 06 01; 108(6):1567-1578. PMID: 36727397; PMCID: PMC10230428.
      Citations: 1     Fields:    Translation:Humans
    76. Bhattacharya S, Piya S, Ma H, Sharma P, Zhang Q, Baran N, Ruvolo VR, McQueen T, Davis RE, Pourebrahim R, Konopleva M, Kantarjian H, Cosford NDP, Andreeff M, Borthakur G. Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia. Mol Cancer Res. 2023 06 01; 21(6):548-563. PMID: 36787422.
      Citations:    Fields:    Translation:Animals
    77. Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. The role of therapy in the outcome of patients with myelofibrosis. Cancer. 2023 09 15; 129(18):2828-2835. PMID: 37243913.
      Citations: 1     Fields:    Translation:Humans
    78. Gener-Ricos G, Haddad FG, Sasaki K, Issa GC, Skinner J, Masarova L, Borthakur G, Alvarado Y, Garcia-Manero G, Jabbour E, Kantarjian H. Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. Clin Lymphoma Myeloma Leuk. 2023 10; 23(10):742-748. PMID: 37308342.
      Citations:    Fields:    Translation:Humans
    79. Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv. 2023 05 23; 7(10):1958-1966. PMID: 36287248; PMCID: PMC10189379.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    80. Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, Patel KP, Loghavi S, Haddad FG, Yilmaz M, Issa GC, Kebriaei P, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Kantarjian H. Ultrasensitive NGS MRD assessment in Ph+?ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol. 2023 08; 98(8):1196-1203. PMID: 37183966.
      Citations:    Fields:    Translation:Humans
    81. Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023 Jun; 10(6):e433-e444. PMID: 37187201.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    82. Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, Kanagal-Shamanna R, Jorgensen J, Khouri I, Kebriaei P, Alvarado Y, Kadia T, Paul S, Garcia-Manero G, Dabaja B, Yilmaz M, Jacob J, Garris R, O'Brien S, Ravandi F, Jabbour E. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol. 2023 05 02; 16(1):44. PMID: 37131217; PMCID: PMC10155451.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    83. Pemmaraju N, Kantarjian H. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023. Clin Adv Hematol Oncol. 2023 May; 21(5):257-264. PMID: 37145496.
      Citations: 1     Fields:    Translation:HumansCells
    84. Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver N, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, DiNardo C, Sasaki K, Borthakur G, Thakral B, Kanagal-Shamanna R, Patel K, Ravandi F, Roberts K, Mullighan C, Kantarjian H, Jain N. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol. 2023 05; 7:e2200707. PMID: 37196217; PMCID: PMC10309573.
      Citations:    Fields:    Translation:HumansCells
    85. Urrutia S, Li Z, Almanza E, Bataller A, Kanagal-Shamanna R, Senapati J, Sasaki K, Chien K, Montalban-Bravo G, DiNardo C, Borthakur G, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations. Leukemia. 2023 06; 37(6):1397-1400. PMID: 37185307.
      Citations:    Fields:    Translation:HumansCells
    86. Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, Kantarjian HM. Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J. 2023 04 24; 13(1):58. PMID: 37088793; PMCID: PMC10123066.
      Citations: 6     Fields:    Translation:Humans
    87. Montalban-Bravo G, Ma F, Thongon N, Yang H, Gomez IG, Rodriguez-Sevilla JJ, Adema V, Wildeman B, Lockyer P, Kim YJ, Tanaka T, Darbaniyan F, Pancholy S, Zhang G, Al-Atrash G, Dwyer K, Takahashi K, Garcia-Manero G, Kantarjian H, Colla S. Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS -mutated chronic myelomonocytic leukemia. bioRxiv. 2023 Apr 08. PMID: 37066354; PMCID: PMC10104149.
      Citations:    
    88. Garcia-Manero G, Goldberg AD, Winer ES, Altman JK, Fathi AT, Odenike O, Roboz GJ, Sweet K, Miller C, Wennborg A, Hickman DK, Kanagal-Shamanna R, Kantarjian H, Lancet J, Komrokji R, Attar EC, Sallman DA. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Lancet Haematol. 2023 Apr; 10(4):e272-e283. PMID: 36990622.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    89. Short NJ, Kantarjian H. Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past. Lancet Haematol. 2023 May; 10(5):e382-e388. PMID: 37003279.
      Citations: 1     Fields:    Translation:Humans
    90. Mill CP, Fiskus W, Das K, Davis JA, Birdwell CE, Kadia TM, DiNardo CD, Daver N, Takahashi K, Sasaki K, McGeehan GM, Ruan X, Su X, Loghavi S, Kantarjian H, Bhalla KN. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. Leukemia. 2023 06; 37(6):1336-1348. PMID: 36977823; PMCID: PMC10244173.
      Citations:    Fields:    Translation:Humans
    91. Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv. 2023 03 28; 7(6):933-942. PMID: 36322818; PMCID: PMC10027507.
      Citations: 6     Fields:    Translation:Humans
    92. Almanza-Huante E, Bataller A, Urrutia S, Gener-Ricos G, Briski RE, Kanagal-Shamanna R, Lu KH, Westin SN, Yap TA, Takahashi K, Ravandi F, Alvarado Y, Kadia T, Sasaki K, Kantarjian HM, Garcia-Manero G. Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours. Br J Haematol. 2023 05; 201(3):e25-e29. PMID: 36951293.
      Citations:    Fields:    Translation:Humans
    93. Jabbour E, Short NJ, Jain N, Haddad FG, Welch MA, Ravandi F, Kantarjian H. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol. 2023 03 16; 16(1):22. PMID: 36927623; PMCID: PMC10018889.
      Citations: 4     Fields:    Translation:HumansCells
    94. Desikan SP, Senapati J, Jabbour E, Abuasab T, Short N, Tang G, Wang S, Kebriaei P, Kadia T, Borthakur G, Ravandi F, Roberts K, Mullighan C, Konopleva M, Kantarjian H, Jain N. Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. Am J Hematol. 2023 06; 98(6):E142-E144. PMID: 36877196.
      Citations:    Fields:    Translation:Humans
    95. Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023 03; 615(7954):920-924. PMID: 36922593; PMCID: PMC10060155.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    96. Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, Daver NG, DiNardo CD, Jabbour EJ, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva MY, Andreeff M, Ravandi-Kashani F, Sasaki K, Issa GC. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer. 2023 06 15; 129(12):1856-1865. PMID: 36892949.
      Citations:    Fields:    Translation:Humans
    97. Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, Flinn IW, Pollyea DA, Kambhampati S, Tanaka TN, Zeidner JF, Garcia-Manero G, Jeyakumar D, Komrokji R, Lancet J, Kantarjian HM, Gu L, Zhang Y, Tan A, Chao M, O'Hear C, Ramsingh G, Lal I, Vyas P, Daver NG. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. J Clin Oncol. 2023 05 20; 41(15):2815-2826. PMID: 36888930; PMCID: PMC10414740.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    98. Haddad FG, Kantarjian HM, Bidikian A, Jabbour EJ, Short NJ, Ning J, Xiao L, Pemmaraju N, DiNardo CD, Kadia TM, Marx KR, Garcia-Manero G, Ravandi F, Sasaki K, Issa GC. Association between bariatric surgery and outcomes in chronic myeloid leukemia. Cancer. 2023 06 15; 129(12):1866-1872. PMID: 36882573.
      Citations:    Fields:    Translation:Humans
    99. Queudeville M, Stein AS, Locatelli F, Ebinger M, Handgretinger R, G?kbuget N, Gore L, Zeng Y, Gokani P, Zugmaier G, Kantarjian HM. Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2023 05 01; 129(9):1384-1393. PMID: 36829303.
      Citations: 1     Fields:    Translation:Humans
    100. Pemmaraju N, Kantarjian H, Sweet K, Wang E, Senapati J, Wilson NR, Konopleva M, Frankel AE, Gupta V, Mesa R, Ulrickson M, Gorak E, Bhatia S, Budak-Alpdogan T, Mason J, Garcia-Romero MT, Lopez-Santiago N, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran J, Fathi AT, Hall AC, Jacoby MA, Lancet J, Mannis G, Stein AS, Mims A, Rizzieri D, Olin R, Perl A, Schiller G, Shami P, Stone RM, Strickland S, Wieduwilt MJ, Daver N, Ravandi F, Vasu S, Guzman M, Roboz GJ, Khoury J, Qazilbash M, Aung PP, Cuglievan B, Madanat Y, Kharfan-Dabaja MA, Pawlowska A, Taylor J, Tallman M, Dhakal P, Lane AA. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2023 02 09; 141(6):567-578. PMID: 36399715.
      Citations: 3     Fields:    Translation:HumansCells
    101. Siddiqui M, Konoplev S, Issa G, Kantarjian H, Daver N, Ravandi F, Kadia T, Tang G, Wang SA, Thakral B, Medeiros LJ, Pozdnyakova O, Pierce S, Montalban-Bravo G, Chien K, Hammond D, Sasaki K, Garcia-Manero G, Hasserjian RP. Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements. Am J Hematol. 2023 04; 98(4):E91-E94. PMID: 36661399.
      Citations:    Fields:    Translation:Humans
    102. Sawyers JD, Jammal NJ, Short NJ, Kantarjian H, Jabbour EJ. The emerging use of chemotherapy-free regimens in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2023 Feb; 21(2):68-75. PMID: 36780472.
      Citations:    Fields:    Translation:HumansCells
    103. Rausch CR, Kantarjian HM, Jabbour EJ. SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches. Clin Lymphoma Myeloma Leuk. 2023 04; 23(4):238-243. PMID: 36872149.
      Citations:    Fields:    Translation:Humans
    104. Jabbour EJ, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM, Jain N, Yilmaz M, DiNardo CD, Patel KP, Kanagal-Shamanna R, Champlin R, Khouri IF, Dellasala S, Pierce SA, Kantarjian H. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol. 2023 04; 98(4):658-665. PMID: 36683287.
      Citations: 1     Fields:    Translation:Humans
    105. Sasaki K, Ravandi F, Kadia TM, Borthakur G, Short NJ, Jain N, Daver NG, Jabbour EJ, Garcia-Manero G, Loghavi S, Patel KP, Montalban-Bravo G, Masarova L, DiNardo CD, Kantarjian HM. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer. 2023 04 01; 129(7):1017-1029. PMID: 36715486.
      Citations: 1     Fields:    Translation:Humans
    106. Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023 01; 29(1):115-126. PMID: 36658425.
      Citations: 28     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    107. Bidikian A, Jabbour E, Issa GC, Short NJ, Sasaki K, Kantarjian H. Chronic myeloid leukemia without major molecular response after 2?years of treatment with tyrosine kinase inhibitor. Am J Hematol. 2023 04; 98(4):639-644. PMID: 36606715.
      Citations: 4     Fields:    Translation:Humans
    108. Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. 2023 03; 98(3):493-501. PMID: 36600670.
      Citations: 1     Fields:    Translation:HumansCells
    109. Senapati J, Abuasab T, Haddad FG, Ravandi F, Kadia T, DiNardo C, Daver N, Pemmaraju N, Alvarado Y, Brandt MA, Kantarjian H, Borthakur G. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol. 2023 03; 98(3):E53-E56. PMID: 36565294.
      Citations: 1     Fields:    Translation:Humans
    110. Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer. 2023 02 15; 129(4):560-568. PMID: 36458426.
      Citations: 1     Fields:    Translation:Humans
    111. Boddu PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, Jain N, Ayres M, Chen Y, Keating MJ, Kantarjian HM, Gandhi V, Kadia TM. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer. 2023 02 15; 129(4):580-589. PMID: 36448227.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    112. Bazinet A, Kantarjian HM. Moving toward individualized target-based therapies in acute myeloid leukemia. Ann Oncol. 2023 02; 34(2):141-151. PMID: 36423744.
      Citations: 3     Fields:    Translation:Humans
    113. Shallis RM, Daver NG, Altman JK, Hasserjian RP, Kantarjian HM, Platzbecker U, Santini V, Wei AH, Sallman DA, Zeidan AM. TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity. Cancer. 2023 01 15; 129(2):175-180. PMID: 36397669.
      Citations: 3     Fields:    Translation:HumansCells
    114. Ghobadi A, Slade M, Kantarjian H, Alvarenga J, Aldoss I, Mohammed KA, Jabbour E, Faramand R, Shah B, Locke F, Fingrut W, Park JH, Short NJ, Gao F, Uy GL, Westervelt P, DiPersio JF, Champlin RE, Al Malki MM, Ravandi F, Kebriaei P. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood. 2022 11 17; 140(20):2101-2112. PMID: 35877996; PMCID: PMC9837437.
      Citations:    Fields:    
    115. Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2022 Nov 16. PMID: 36402146.
      Citations: 13     Fields:    
    116. Daver NG, Maiti A, Kadia TM, Vyas P, Majeti R, Wei AH, Garcia-Manero G, Craddock C, Sallman DA, Kantarjian HM. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. Cancer Discov. 2022 11 02; 12(11):2516-2529. PMID: 36218325; PMCID: PMC9627130.
      Citations: 16     Fields:    Translation:Humans
    117. Senapati J, Jabbour E, Kantarjian H, Short NJ. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia. 2023 01; 37(1):5-17. PMID: 36309558.
      Citations: 4     Fields:    Translation:Humans
    118. Bidikian A, Kantarjian H, Jabbour E, Short NJ, Patel K, Ravandi F, Sasaki K, Issa GC. Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood Cancer J. 2022 10 28; 12(10):144. PMID: 36307398; PMCID: PMC9616867.
      Citations: 5     Fields:    Translation:Humans
    119. Jabbour E, Short NJ, Jain N, Thompson PA, Kadia TM, Ferrajoli A, Huang X, Yilmaz M, Alvarado Y, Patel KP, Garcia-Manero G, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2022 Dec; 9(12):e878-e885. PMID: 36279879.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    120. Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, Nguyen AT, Miller PG, McConkey ME, Quevedo Barrios VA, Furudate K, Zhang L, Kanagal-Shamanna R, Zhang J, Little L, Gumbs C, Daver N, DiNardo CD, Kadia T, Ravandi F, Kantarjian H, Garcia-Manero G, Futreal PA, Ebert BL, Takahashi K. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022 10 20; 140(16):1753-1763. PMID: 35512188; PMCID: PMC9837415.
      Citations:    Fields:    
    121. Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N, Dinardo C, Short NJ, Yilmaz M, Pemmaraju N, Takahashi K, Jabbour EJ, Pierce S, Konopleva M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol. 2022 Dec; 97(12):1599-1606. PMID: 36117258.
      Citations:    
    122. Short NJ, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, Huang X, Gonzalez GN, Hwang H, Qi X, Kantarjian H, Zhou S, Ravandi F. Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis. Leukemia. 2022 12; 36(12):2817-2826. PMID: 36261575.
      Citations: 8     Fields:    Translation:Humans
    123. Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo C, Garcia-Manero G, Pemmaraju N, Jabbour EJ, Takahashi K, Ohanian M, Daver N, Alvarado Y, Brandt M, Pierce S, Kantarjian H. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol. 2022 Nov; 97(11):1427-1434. PMID: 36053747.
      Citations:    
    124. Kantarjian H, Paul S, Thakkar J, Jabbour E. The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA. Lancet Haematol. 2022 Nov; 9(11):e854-e861. PMID: 36174582.
      Citations: 2     Fields:    Translation:Humans
    125. Venugopal S, DiNardo CD, Loghavi S, Qiao W, Ravandi F, Konopleva M, Kadia T, Bhalla K, Jabbour E, Issa GC, Macaron W, Daver N, Borthakur G, Montalban-Bravo G, Yilmaz M, Patel KP, Kanagal-Shamanna R, Chien K, Maiti A, Kantarjian H, Short NJ. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. Am J Hematol. 2022 Dec; 97(12):1560-1567. PMID: 36087091.
      Citations:    
    126. Pratz KW, DiNardo CD, Selleslag D, Li J, Yamamoto K, Konopleva M, Stevens D, Kantarjian H, Traina F, Venditti A, Mayer J, Montez M, Jin H, Duan Y, Brackman D, Zha J, Potluri J, Werner M, Jonas BA. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A. Am J Hematol. 2022 Nov; 97(11):E416-E419. PMID: 36054316.
      Citations:    
    127. Jonas BA, DiNardo C, Fracchiolla N, Pristupa A, Ishizawa K, Jin J, Konopleva M, Ofran Y, Montesinos P, Kovacsovics T, Jang JH, Kantarjian H, Duan Y, Potluri J, Werner M, Pratz KW. Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study. Am J Hematol. 2022 11; 97(11):E422-E425. PMID: 36053878; PMCID: PMC10286746.
      Citations:    
    128. Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol. 2022 Nov; 97(11):1443-1452. PMID: 36054614.
      Citations:    
    129. Short NJ, Macaron W, Kadia T, Dinardo C, Issa GC, Daver N, Wang S, Jorgensen J, Nguyen D, Bidikian A, Patel KP, Loghavi S, Konopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall E, Popat U, Al-Atrash G, Pierce S, Kantarjian HM, Ravandi F. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease?(MRD) recurrence following MRD-negative remission. Am J Hematol. 2022 Nov; 97(11):E408-E411. PMID: 36054774.
      Citations:    
    130. Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol. 2022 Oct; 9(10):e756-e765. PMID: 36063832.
      Citations:    
    131. Jabbour E, Haddad FG, Short NJ, Kantarjian H. Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review. JAMA Oncol. 2022 09 01; 8(9):1340-1348. PMID: 35834222.
      Citations:    Fields:    
    132. Kantarjian HM, Jabbour E, Deininger M, Abruzzese E, Apperley J, Cortes J, Chuah C, DeAngelo DJ, DiPersio J, Hochhaus A, Lipton J, Nicolini FE, Pinilla-Ibarz J, Rea D, Rosti G, Rousselot P, Shah NP, Talpaz M, Srivastava S, Ren X, Mauro M. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. Am J Hematol. 2022 11; 97(11):1419-1426. PMID: 36054756; PMCID: PMC9804741.
      Citations:    
    133. Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol. 2022 Nov; 97(11):1413-1418. PMID: 36054032.
      Citations:    
    134. Short NJ, Kantarjian H. Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions. Am J Hematol. 2022 Dec; 97(12):1616-1626. PMID: 35871436.
      Citations:    Fields:    
    135. Sasaki K, Jabbour E, Montalban-Bravo G, Darbaniyan F, Do KA, Class C, Short NJ, Kanagal-Shamana R, Kadia T, Borthakur G, Pemmaraju N, Cortes J, Ravandi F, Alvarado Y, Chien K, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Soltysiak K, Yang H, Kantarjian HM, Garcia-Manero G. Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS. NEJM Evid. 2022 Oct; 1(10):EVIDoa2200034. PMID: 38319837.
      Citations: 1     Translation:Humans
    136. Yang H, Garcia-Manero G, Sasaki K, Montalban-Bravo G, Tang Z, Wei Y, Kadia T, Chien K, Rush D, Nguyen H, Kalia A, Nimmakayalu M, Bueso-Ramos C, Kantarjian H, Medeiros LJ, Luthra R, Kanagal-Shamanna R. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance. Leukemia. 2022 09; 36(9):2306-2316. PMID: 35915143; PMCID: PMC9417987.
      Citations:    
    137. Zeidan AM, Gobbi M, Roboz GJ, Robak T, Kantarjian HM, Jedrzejczak WW, Miyazaki Y, Min YH, Yeh SP, Brandwein JM, Gercheva L, Demeter J, Griffiths EA, Yee KWL, Issa JJ, Bewersdorf JP, Keer H, Hao Y, Azab M, Fenaux P, Mayer J, Krauter J, Nov?k J, Thomas X, Ojeda-Uribe M, D?hner H. Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood. 2022 07 21; 140(3):285-289. PMID: 35507690; PMCID: PMC9305088.
      Citations:    Fields:    Translation:Humans
    138. Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, Rosenblat TL, Brooks CL, Habboubi N, Mughal TI, Kantarjian H, Konopleva M, Lane AA. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 09 10; 40(26):3032-3036. PMID: 35820082; PMCID: PMC9462530.
      Citations:    Fields:    
    139. Nichols ED, Jabbour E, Jammal N, Chew S, Bryan J, Issa G, Garcia-Manero G, Sasaki K, DiPippo A, Kantarjian H. Real-life incidence of thrombotic events in leukemia patients treated with ponatinib. Am J Hematol. 2022 Sep; 97(9):E350-E352. PMID: 35759571.
      Citations:    Fields:    
    140. Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver N, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour E. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022 07 12; 6(13):4006-4014. PMID: 35533262; PMCID: PMC9278301.
      Citations:    Fields:    Translation:Humans
    141. Tashakori M, Kadia T, Loghavi S, Daver N, Kanagal-Shamanna R, Pierce S, Sui D, Wei P, Khodakarami F, Tang Z, Routbort M, Bivins CA, Jabbour EJ, Medeiros LJ, Bhalla K, Kantarjian HM, Ravandi F, Khoury JD. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood. 2022 07 07; 140(1):58-72. PMID: 35390143; PMCID: PMC9346958.
      Citations: 1     Fields:    Translation:Humans
    142. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol. 2022 Sep; 97(9):1236-1256. PMID: 35751859.
      Citations:    Fields:    
    143. Senapati J, Verstovsek S, Masarova L, Pemmaraju N, Patel KP, Montalban-Bravo G, Pierce SA, Zhou L, Garcia-Manero G, Kantarjian HM, Bose P. Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma. 2022 11; 63(11):2701-2705. PMID: 35787095.
      Citations:    Fields:    
    144. Short NJ, Kantarjian H. Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia. Lancet Haematol. 2022 Jul; 9(7):e535-e545. PMID: 35772432.
      Citations:    Fields:    Translation:HumansCells
    145. Pollyea DA, DiNardo CD, Arellano ML, Pigneux A, Fiedler W, Konopleva M, Rizzieri DA, Smith BD, Shinagawa A, Lemoli RM, Dail M, Duan Y, Chyla B, Potluri J, Miller CL, Kantarjian HM. Impact of Venetoclax and Azacitidine in Treatment-Na?ve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. Clin Cancer Res. 2022 07 01; 28(13):2753-2761. PMID: 35046058.
      Citations: 2     Fields:    Translation:Humans
    146. Konopleva M, Thirman MJ, Pratz KW, Garcia JS, Recher C, Pullarkat V, Kantarjian HM, DiNardo CD, Dail M, Duan Y, Chyla B, Potluri J, Miller CL, Wei AH. Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Na?ve Acute Myeloid Leukemia. Clin Cancer Res. 2022 07 01; 28(13):2744-2752. PMID: 35063965.
      Citations: 1     Fields:    Translation:Humans
    147. Jabbour EJ, Short NJ, Jain N, Jammal N, Jorgensen J, Wang S, Wang X, Ohanian M, Alvarado Y, Kadia T, Sasaki K, Garris R, Garcia-Manero G, Ravandi F, Kantarjian HM. Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher. Am J Hematol. 2022 Sep; 97(9):1135-1141. PMID: 35713551.
      Citations:    Fields:    
    148. Khoury JD, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Solary E, Berti E, Busque L, Colmenero I, Fontenay M, Germing U, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic?Neoplasms. Leukemia. 2022 07; 36(7):1703-1719. PMID: 35732831; PMCID: PMC9252913.
      Citations: 2     Fields:    Translation:Humans
    149. Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2022 11 20; 40(33):3848-3857. PMID: 35704787; PMCID: PMC9671758.
      Citations:    Fields:    
    150. Paul S, Kantarjian H, Sasaki K, Marx K, Jain N, Savoy JM, DiPippo A, Jammal N, Bravo GM, Kadia T, Garcia-Manero G, Short NJ, Ravandi F, Jabbour E. Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Am J Hematol. 2023 01; 98(1):E11-E14. PMID: 35633516.
      Citations:    Fields:    
    151. Verma V, Yegya-Raman N, Sprave T, Han G, Kantarjian HM, Welsh JW, Chang JY, Lin SH. A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases. Int J Radiat Oncol Biol Phys. 2022 12 01; 114(5):977-988. PMID: 35675852.
      Citations:    Fields:    
    152. Cherng HJ, Khwaja R, Kanagal-Shamanna R, Tang G, Burger J, Thompson P, Ferrajoli A, Estrov Z, Sasaki K, Sampath D, Wang X, Kantarjian H, Keating M, Wierda WG, Jain N. TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. Am J Hematol. 2022 08; 97(8):1005-1012. PMID: 35567779; PMCID: PMC9354943.
      Citations:    Fields:    Translation:Humans
    153. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022 08; 97(8):1035-1043. PMID: 35583199.
      Citations: 1     Fields:    Translation:Humans
    154. Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver N, Kadia T, DiNardo C, Jabbour E, Pierce S, Qazilbash M, Konopleva M, Kantarjian H. Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Adv. 2022 05 24; 6(10):3027-3035. PMID: 35061885; PMCID: PMC9131912.
      Citations: 1     Fields:    Translation:HumansCells
    155. Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J. 2022 05 02; 12(5):77. PMID: 35501304; PMCID: PMC9061716.
      Citations:    Fields:    Translation:Humans
    156. Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Takahashi K, Jabbour E. Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022 May; 36(5):1448. PMID: 35411096.
      Citations:    Fields:    
    157. Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 2022 May; 9(5):e350-e360. PMID: 35483396; PMCID: PMC9946440.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    158. Kim K, Konopleva M, DiNardo CD, Borthakur G, Loghavi S, Tang G, Daver N, Pemmaraju N, Jabbour E, Rausch CR, Yilmaz M, Sasaki K, Short NJ, Jain N, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol. 2022 07; 97(7):885-894. PMID: 35413152.
      Citations:    Fields:    Translation:Humans
    159. Cai T, Black KL, Skwarska A, Naqvi AS, Taylor D, Zhao M, Yuan Q, Sugita M, Zhang Q, Galetto R, Cavazos A, Han L, Kuruvilla V, Ma H, Weng C, Liu CG, Liu X, Konoplev S, Gu J, Tang G, Su X, Al-Atrash G, Ciurea S, Neelapu SS, Lane AA, Kantarjian H, Guzman ML, Pemmaraju N, Smith J, Thomas-Tikhonenko A, Konopleva M, Gouble A, Filipe S. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nat Commun. 2022 04 28; 13(1):2228. PMID: 35484100; PMCID: PMC9051102.
      Citations:    Fields:    Translation:HumansAnimalsCells
    160. Advani AS, DeAngelo DJ, Wang T, Neuhof A, Vandendries E, Kantarjian H, Jabbour E, Stelljes M. Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial. Clin Lymphoma Myeloma Leuk. 2022 09; 22(9):e836-e843. PMID: 35643855.
      Citations:    Fields:    
    161. Sheshadri A, Goizueta AA, Shannon VR, London D, Garcia-Manero G, Kantarjian HM, Ravandi-Kashani F, Kadia TM, Konopleva MY, DiNardo CD, Pierce S, Zarifa A, Albittar AA, Zhong LL, Akhmedzhanov FO, Arain MH, Alfayez M, Alotaibi A, Altan M, Naing A, Mendoza TR, Godoy MCB, Shroff G, Kim ST, Faiz SA, Kontoyiannis DP, Khawaja F, Jennings K, Daver NG. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer. 2022 07 15; 128(14):2736-2745. PMID: 35452134; PMCID: PMC9232977.
      Citations:    Fields:    Translation:Humans
    162. Sasaki K, Ravandi F, Kadia T, DiNardo C, Borthakur G, Short N, Jain N, Daver N, Jabbour E, Garcia-Manero G, Khoury J, Konoplev S, Loghavi S, Patel K, Montalban-Bravo G, Masarova L, Konopleva M, Kantarjian H. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol. 2022 07; 97(7):865-876. PMID: 35384048.
      Citations:    Fields:    Translation:Humans
    163. Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short NJ, Jabbour E, Kantarjian H. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol. 2022 07; 97(7):856-864. PMID: 35357036.
      Citations: 1     Fields:    Translation:Humans
    164. Haddad F, Kantarjian H, Issa GC, Jabbour E, Sasaki K. Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia. Leuk Lymphoma. 2022 07; 63(7):1714-1717. PMID: 35361036.
      Citations:    Fields:    Translation:Humans
    165. Gaballa MR, Banerjee P, Jiang X, Ganesh C, Khazal S, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta R, Alatrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi F, Kantarjian H, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei P, Milton DR. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood. 2022 03 24; 139(12):1908-1919. PMID: 34914826; PMCID: PMC8952188.
      Citations: 3     Fields:    Translation:Humans
    166. Januzzi JL, Garasic JM, Kasner SE, McDonald V, Petrie MC, Seltzer J, Mauro M, Croce K, Berman E, Deininger M, Pinilla-Ibarz J, Kim DW, DeAngelo DJ, Kantarjian H, Xu J, Hall T, Srivastava S, Naranjo D, Cortes J, Hochhaus A, Nicolini F. Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. J Hematol Oncol. 2022 Mar 23; 15(1):33. PMID: 35317837; PMCID: PMC8941744.
      Citations:    Fields:    
    167. Short NJ, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol. 2022 06 01; 97(6):E201-E204. PMID: 35266566.
      Citations:    Fields:    Translation:HumansCells
    168. Jammal N, Kantarjian HM, Haddad F, Jabbour EJ. Management of acute lymphoblastic leukemia in older adults. Clin Adv Hematol Oncol. 2022 Mar; 20(3):161-168. PMID: 36607346.
      Citations:    Fields:    
    169. Mukherjee A, Jabbour EJ, Gulbis AM, Kadia T, Jain N, Ledesma C, Burger J, Ferrajoli A, Wierda W, Medeiros LJ, Kantarjian H, Champlin R, Khouri IF, Milton DR. Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma. 2022 04; 63(4):885-893. PMID: 35225133; PMCID: PMC9730341.
      Citations:    Fields:    Translation:Humans
    170. Piya S, Yang Y, Bhattacharya S, Sharma P, Ma H, Mu H, He H, Ruvolo V, Baran N, Davis RE, Jain AK, Konopleava M, Kantarjian H, Andreeff M, You MJ, Borthakur G. Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL. Leukemia. 2022 05; 36(5):1261-1273. PMID: 35173274; PMCID: PMC9061299.
      Citations:    Fields:    Translation:HumansAnimalsCells
    171. DiNardo CD, Garcia-Manero G, Kantarjian HM. Time to blur the blast boundaries. Cancer. 2022 04 15; 128(8):1568-1570. PMID: 35133004.
      Citations: 2     Fields:    Translation:Humans
    172. Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Takahashi K, Jabbour E. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022 05; 36(5):1253-1260. PMID: 35132195.
      Citations:    Fields:    Translation:HumansCells
    173. Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, Daver N, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol. 2022 01 29; 15(1):12. PMID: 35093134; PMCID: PMC8800349.
      Citations: 1     Fields:    Translation:Humans
    174. Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer. 2022 04 15; 128(8):1658-1665. PMID: 35077575.
      Citations:    Fields:    Translation:Humans
    175. Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, Wang X, Carlos BR, Yilmaz M, Kadia T, Andreeff M, Ravandi F, Konopleva M, Kantarjian HM, DiNardo CD. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 2022 01 25; 12(1):10. PMID: 35078972; PMCID: PMC8789767.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    176. Reville PK, Sasaki K, Kantarjian HM, Daver NG, Yilmaz M, Dinardo CD, Short NJ, Borthakur G, Pemmaraju N, Mehta RS, Pierce S, Konoplev SN, Khoury JD, Garcia-Manero G, Konopleva MY, Jabbour E, Ravandi F, Kadia TM. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. Am J Hematol. 2022 03 01; 97(3):329-337. PMID: 34981570; PMCID: PMC8884919.
      Citations: 1     Fields:    Translation:Humans
    177. Januzzi JL, Garasic JM, Kasner SE, McDonald V, Petrie MC, Seltzer J, Mauro M, Croce K, Berman E, Deininger M, Pinilla-Ibarz J, Kim DW, DeAngelo DJ, Kantarjian H, Xu J, Hall T, Srivastava S, Naranjo D, Cortes J, Hochhaus A, Nicolini F. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. J Hematol Oncol. 2022 01 06; 15(1):1. PMID: 34991679; PMCID: PMC8734305.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    178. Short NJ, Kantarjian H, Dombret H, Ad?s L. The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs. Cancer J. 2022 Jan-Feb 01; 28(1):29-36. PMID: 35072371.
      Citations:    Fields:    Translation:Humans
    179. Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K, Oran B. Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022 Jan; 36(1):298. PMID: 34876697.
      Citations:    Fields:    
    180. Gibson A, Trabal A, McCall D, Khazal S, Toepfer L, Bell DH, Roth M, Mahadeo KM, Nunez C, Short NJ, DiNardo C, Konopleva M, Issa GC, Ravandi F, Jain N, Borthakur G, Kantarjian HM, Jabbour E, Cuglievan B. Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers (Basel). 2021 Dec 29; 14(1). PMID: 35008312; PMCID: PMC8750927.
      Citations: 2     
    181. Ohanian M, Cancelas JA, Davenport R, Pullarkat V, Hervig T, Broome C, Marek K, Kelly M, Gul Z, Rugg N, Nestheide S, Kinne B, Szczepiorkowski Z, Kantarjian H, Pehta J, Biehl R, Yu A, Aung F, Antebi B, Fitzpatrick GM. Freeze-dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies. Am J Hematol. 2022 03 01; 97(3):256-266. PMID: 34748664.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    182. Sasaki K, Kantarjian H, Jabbour E. Prediction for sustained deep molecular response for treatment-free remission. Leuk Lymphoma. 2022 01; 63(1):5-6. PMID: 34930078.
      Citations:    Fields:    Translation:Humans
    183. Sivina M, Kim E, Wierda WG, Ferrajoli A, Jain N, Thompson P, Kantarjian H, Keating M, Burger JA. Ibrutinib induces durable remissions in treatment-na?ve patients with CLL and 17p deletion and/or TP53 mutations. Blood. 2021 12 16; 138(24):2589-2592. PMID: 34521099; PMCID: PMC8832441.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    184. Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, Haddad F, Jain N, Ravandi F, Short NJ, DiNardo CD, Takahashi K, Konopleva MY, Daver NG, Kadia T, Garcia-Manero G, Garris R, O'Brien S, Jabbour E. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv. 2021 12 14; 5(23):5415-5419. PMID: 34525185; PMCID: PMC9153023.
      Citations:    Fields:    Translation:Humans
    185. El Hussein S, Daver N, Liu JL, Kornblau S, Fang H, Konoplev S, Kantarjian H, Khoury JD. Microsatellite Instability Assessment by Immunohistochemistry in Acute Myeloid Leukemia: A Reappraisal and Review of the Literature. Clin Lymphoma Myeloma Leuk. 2022 06; 22(6):e386-e391. PMID: 34980577.
      Citations:    Fields:    Translation:HumansCells
    186. Awada H, Durmaz A, Gurnari C, Kishtagari A, Meggendorfer M, Kerr CM, Kuzmanovic T, Durrani J, Shreve J, Nagata Y, Radivoyevitch T, Advani AS, Ravandi F, Carraway HE, Nazha A, Haferlach C, Saunthararajah Y, Scott J, Visconte V, Kantarjian H, Kadia T, Sekeres MA, Haferlach T, Maciejewski JP. Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. Blood. 2021 11 11; 138(19):1885-1895. PMID: 34075412; PMCID: PMC8767789.
      Citations: 2     Fields:    Translation:Humans
    187. Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, Daver N, Jabbour E, Garcia-Manero G, Bravo GM, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022 01 01; 97(1):68-78. PMID: 34716921.
      Citations:    Fields:    Translation:Humans
    188. Kantarjian HM, Wood BL, Horst HA, Zeng Y, Martinelli G, Zugmaier G, Br?ggemann M. Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Cancers (Basel). 2021 Nov 09; 13(22). PMID: 34830762; PMCID: PMC8616108.
      Citations: 1     
    189. Tanaka T, Morita K, Loghavi S, Wang F, Furudate K, Sasaki Y, Little L, Gumbs C, Matthews J, Daver N, Pemmaraju N, DiNardo CD, Sasaki K, Yilmaz M, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Al-Atrash G, Garcia-Manero G, Wang SA, Futreal PA, Takahashi K. Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. Blood. 2021 11 04; 138(18):1733-1739. PMID: 34115096; PMCID: PMC8569418.
      Citations: 1     Fields:    Translation:Humans
    190. Samra B, Khoury JD, Morita K, Ravandi F, Richard-Carpentier G, Short NJ, El Hussein S, Thompson P, Jain N, Kantarjian H, Jabbour E. Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. Blood Adv. 2021 10 26; 5(20):3913-3918. PMID: 34464974; PMCID: PMC8945626.
      Citations:    Fields:    Translation:Humans
    191. Kantarjian H, Short NJ, DiNardo C, Stein EM, Daver N, Perl AE, Wang ES, Wei A, Tallman M. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. Lancet Haematol. 2021 Dec; 8(12):e922-e933. PMID: 34687602; PMCID: PMC8996707.
      Citations: 2     Fields:    Translation:Humans
    192. Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma. 2022 03; 63(3):672-675. PMID: 34668451.
      Citations:    Fields:    Translation:Humans
    193. DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, Zeidan AM, Fathi AT, Kantarjian HM, Bennett JM, Frattini MG, Martin-Regueira P, Lersch F, Gong J, Hasan M, Vyas P, de Botton S, D?hner H. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021 11; 22(11):1597-1608. PMID: 34672961.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    194. Pemmaraju N, Wilson NR, Khoury JD, Jain N, Daver N, Pierce S, Jabbour E, Kadia T, DiNardo C, Garcia-Manero G, Qazilbash M, Konopleva M, Kantarjian H. Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood. 2021 10 14; 138(15):1373-1377. PMID: 34098573.
      Citations: 2     Fields:    Translation:HumansCells
    195. Kantarjian HM, Jain N, Garcia-Manero G, Welch MA, Ravandi F, Wierda WG, Jabbour EJ. The cure of leukemia through the optimist's prism. Cancer. 2022 01 15; 128(2):240-259. PMID: 34614211; PMCID: PMC8738114.
      Citations:    Fields:    Translation:Humans
    196. George B, Kantarjian H, Baran N, Krocker JD, Rios A. TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation. Int J Mol Sci. 2021 Oct 05; 22(19). PMID: 34639121; PMCID: PMC8509740.
      Citations: 3     Fields:    Translation:Humans
    197. Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad F, Tang Z, Patel KP, Cuglievan B, Daver N, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi F. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021 09 29; 11(9):162. PMID: 34588432; PMCID: PMC8481264.
      Citations: 2     Fields:    Translation:Humans
    198. Venugopal S, Maiti A, DiNardo CD, Qiao W, Ning J, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leuk Lymphoma. 2021 12; 62(14):3501-3505. PMID: 34474640; PMCID: PMC10423012.
      Citations:    Fields:    Translation:Humans
    199. Kantarjian HM, Begna KH, Altman JK, Goldberg SL, Sekeres MA, Strickland SA, Arellano ML, Claxton DF, Baer MR, Gautier M, Berman E, Seiter K, Solomon SR, Schiller GJ, Luger SM, Butrym A, Gaidano G, Thomas XG, Montesinos P, Rizzieri DA, Quick DP, Venugopal P, Gaur R, Maness LJ, Kadia TM, Ravandi F, Buyse ME, Chiao JH. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). Cancer. 2021 12 01; 127(23):4421-4431. PMID: 34424530; PMCID: PMC9523989.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    200. Short NJ, Kantarjian H, Jabbour E. SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2022 02; 22(2):61-66. PMID: 34561201.
      Citations:    Fields:    Translation:HumansCells
    201. Alwash Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, Daver N, Ravandi F, Kadia TM, Konopleva M, Dinardo CD, Issa GC, Loghavi S, Takahashi K, Jabbour E, Guerra V, Kornblau S, Kantarjian H, Short NJ. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol. 2021 11 01; 96(11):1420-1428. PMID: 34351647; PMCID: PMC9167467.
      Citations: 2     Fields:    Translation:Humans
    202. Short NJ, Kantarjian H. When Less Is More: Reevaluating the Role of Intensive Chemotherapy for Older Adults With Acute Myeloid Leukemia in the Modern Era. J Clin Oncol. 2021 10 01; 39(28):3104-3108. PMID: 34406793; PMCID: PMC8478366.
      Citations: 3     Fields:    Translation:Humans
    203. Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver N, DiNardo C, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma. 2021 12; 62(14):3402-3410. PMID: 34380367; PMCID: PMC8939853.
      Citations: 1     Fields:    Translation:Humans
    204. Abou Dalle I, Kantarjian H, Daver N, Masarova L, Pemmaraju N, Bose P, Garcia-Manero G, Verstovsek S. Phase II study of single-agent nivolumab in patients with myelofibrosis. Ann Hematol. 2021 Dec; 100(12):2957-2960. PMID: 34350483.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    205. Maiti A, DiNardo CD, Qiao W, Kadia TM, Jabbour EJ, Rausch CR, Daver NG, Short NJ, Borthakur G, Pemmaraju N, Yilmaz M, Alvarado Y, Montalbano KS, Wade A, Maduike RE, Guerrero JA, Vaughan K, Bivins CA, Pierce S, Ning J, Ravandi F, Kantarjian HM, Konopleva MY. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Cancer. 2021 11 15; 127(22):4213-4220. PMID: 34343352; PMCID: PMC8556232.
      Citations: 4     Fields:    Translation:Humans
    206. Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. 2021 11; 195(3):378-387. PMID: 34340254.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    207. Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021 Aug; 8(8):e552-e561. PMID: 34329576; PMCID: PMC8884174.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    208. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219. PMID: 34110383; PMCID: PMC8193546.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    209. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 08 01; 106(8):2121-2130. PMID: 33853292; PMCID: PMC8327731.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    210. Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021 10 15; 127(20):3772-3781. PMID: 34255353; PMCID: PMC10462434.
      Citations: 12     Fields:    Translation:Humans
    211. Jabbour E, Patel K, Jain N, Duose D, Luthra R, Short NJ, Zugmaier G, San Lucas A, Velasco K, Tran Q, Zaman F, Konopleva M, Kantarjian H. Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study. Am J Hematol. 2021 10 01; 96(10):E379-E383. PMID: 34161631.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    212. Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, Boquimpani C, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Cacciatore S, Titorenko K, Aimone P, Saglio G, le Coutre P, Etienne G, Pasquini R, Zanichelli M, Bendit I, Hochhaus A. Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021 Jul; 35(7):2142-2143. PMID: 34108614; PMCID: PMC8414785.
      Citations: 2     Fields:    
    213. Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J. 2021 06 30; 11(6):123. PMID: 34193815; PMCID: PMC8245494.
      Citations: 5     Fields:    Translation:Humans
    214. Venugopal S, Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, Daver N, Pemmaraju N, Sasaki K, Montalban-Bravo G, Marx KR, Pierce S, Popat UR, Shpall EJ, Kanagal-Shamanna R, Garcia-Manero G, Kantarjian HM, Kadia TM. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer. 2021 10 01; 127(19):3541-3551. PMID: 34182597.
      Citations: 4     Fields:    Translation:Humans
    215. Short NJ, Kantarjian H, Jabbour E. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. Leukemia. 2021 11; 35(11):3044-3058. PMID: 34172894.
      Citations: 4     Fields:    Translation:Humans
    216. Kanagal-Shamanna R, Montalban-Bravo G, Sasaki K, Darbaniyan F, Jabbour E, Bueso-Ramos C, Wei Y, Chien K, Kadia T, Ravandi F, Borthakur G, Soltysiak KA, Routbort M, Patel K, Pierce S, Medeiros LJ, Kantarjian HM, Garcia-Manero G. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer. 2021 10 01; 127(19):3552-3565. PMID: 34161603; PMCID: PMC10015977.
      Citations: 3     Fields:    Translation:Humans
    217. Desai PM, Brown J, Gill S, Solh MM, Akard LP, Hsu JW, Ustun C, Andreadis C, Frankfurt O, Foran JM, Lister J, Schiller GJ, Wieduwilt MJ, Pagel JM, Stiff PJ, Liu D, Khan I, Stock W, Kambhampati S, Tallman MS, Morris L, Edwards J, Pusic I, Kantarjian HM, Mamelok R, Wong A, Van Syoc R, Kellerman L, Panuganti S, Mandalam R, Abboud CN, Ravandi F. Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. J Clin Oncol. 2021 10 10; 39(29):3261-3272. PMID: 34156898; PMCID: PMC8500663.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    218. Sasaki K, Kantarjian HM, Morita K, Short NJ, Konopleva M, Jain N, Ravandi F, Garcia-Manero G, Wang S, Khoury JD, Jorgensen JL, Champlin RE, Khouri IF, Kebriaei P, Schroeder HM, Khouri M, Garris R, Takahashi K, O'Brien SM, Jabbour EJ. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2021 09 15; 127(18):3381-3389. PMID: 34138471.
      Citations: 1     Fields:    Translation:HumansCells
    219. Borthakur G, Kantarjian H. Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J. 2021 06 16; 11(6):114. PMID: 34135311; PMCID: PMC8209225.
      Citations: 7     Fields:    Translation:HumansCells
    220. Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K, Oran B. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022 01; 36(1):257-262. PMID: 34135465.
      Citations: 3     Fields:    Translation:Humans
    221. Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, Daver N, Kadia T, DiNardo CD, Konopleva M, Cortes JE, Yilmaz M, Chien K, Pierce S, Kantarjian H, Short NJ. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol. 2021 06 15; 14(1):94. PMID: 34130720; PMCID: PMC8204504.
      Citations: 3     Fields:    Translation:Humans
    222. Issa GC, Ravandi F, DiNardo CD, Jabbour E, Kantarjian HM, Andreeff M. Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021 09; 35(9):2482-2495. PMID: 34131281.
      Citations: 13     Fields:    Translation:Humans
    223. Kim K, Jabbour E, Short NJ, Kebriaei P, Kantarjian H, Ravandi F. Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant. Curr Oncol Rep. 2021 06 14; 23(8):95. PMID: 34125415.
      Citations:    Fields:    Translation:HumansCells
    224. Wei AH, Roboz GJ, Kantarjian HM. Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid Leukemia. J Clin Oncol. 2021 09 01; 39(25):2742-2748. PMID: 34086506.
      Citations:    Fields:    Translation:Humans
    225. Kantarjian HM, Short NJ, Fathi AT, Marcucci G, Ravandi F, Tallman M, Wang ES, Wei AH. Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. Clin Lymphoma Myeloma Leuk. 2021 09; 21(9):580-597. PMID: 34176779.
      Citations: 6     Fields:    Translation:Humans
    226. Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T, Pemmaraju N, Short N, Kebriaei P, Ning J, Cortes J, Jabbour E, Kantarjian H. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):1000-1007. PMID: 33991360; PMCID: PMC9096877.
      Citations: 2     Fields:    Translation:HumansCells
    227. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021 09 01; 39(25):2768-2778. PMID: 34043428; PMCID: PMC8407653.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    228. Short NJ, Tallman MS, Pollyea DA, Ravandi F, Kantarjian H. Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape. J Clin Oncol. 2021 08 10; 39(23):2535-2538. PMID: 34043455.
      Citations: 5     Fields:    Translation:Humans
    229. Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):914-924. PMID: 33901324.
      Citations: 4     Fields:    Translation:Humans
    230. Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429. PMID: 34007049.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    231. Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Estrov Z, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clin Infect Dis. 2021 05 18; 72(10):1755-1763. PMID: 32236406; PMCID: PMC8130026.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    232. Kantarjian H. Emil J. Freireich: Legend in cancer research (March 16, 1927-February 1, 2021). Bone Marrow Transplant. 2021 07; 56(7):1764-1767. PMID: 33981012.
      Citations:    Fields:    
    233. Isidori A, Cerchione C, Daver N, DiNardo C, Garcia-Manero G, Konopleva M, Jabbour E, Ravandi F, Kadia T, Burguera AF, Loscocco F, Visani G, Martinelli G, Kantarjian H, Romano A, Curti A. Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Front Oncol. 2021; 11:656218. PMID: 34041025; PMCID: PMC8143531.
      Citations: 18     
    234. Wang F, Morita K, DiNardo CD, Furudate K, Tanaka T, Yan Y, Patel KP, MacBeth KJ, Wu B, Liu G, Frattini M, Matthews JA, Little LD, Gumbs C, Song X, Zhang J, Thompson EJ, Kadia TM, Garcia-Manero G, Jabbour E, Ravandi F, Bhalla KN, Konopleva M, Kantarjian HM, Andrew Futreal P, Takahashi K. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun. 2021 05 10; 12(1):2607. PMID: 33972549; PMCID: PMC8110775.
      Citations: 12     Fields:    Translation:HumansCells
    235. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2021 May 10; 12(1):2823. PMID: 33972555; PMCID: PMC8110810.
      Citations: 1     Fields:    
    236. Yilmaz M, Daver N, Borthakur G, Kadia T, DiNardo C, Kanagal-Shamanna R, Loghavi S, Oran B, Popat UR, Pierce S, Jabbour E, Short NJ, Issa G, Ohanian M, Konopleva M, Patel K, Kantarjian H, Ravandi F. FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. Am J Hematol. 2021 08 01; 96(8):E275-E279. PMID: 33891709; PMCID: PMC9154045.
      Citations:    Fields:    Translation:Humans
    237. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124. PMID: 33914911.
      Citations:    Fields:    Translation:Humans
    238. Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv. 2021 04 27; 5(8):2173-2183. PMID: 33885753; PMCID: PMC8095152.
      Citations: 4     Fields:    Translation:Humans
    239. Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver N, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. 2021 07 01; 96(7):E246-E249. PMID: 33811786.
      Citations: 1     Fields:    Translation:HumansCells
    240. Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021 04 13; 5(7):1876-1883. PMID: 33792630; PMCID: PMC8045494.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    241. Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia. 2021 05; 35(5):1494-1499. PMID: 33846541.
      Citations: 2     Fields:    Translation:Humans
    242. Short NJ, Konopleva M, Kadia T, Kebriaei P, Daver N, Huang X, Masarova L, Cook R, Jain N, Jabbour E, Kantarjian H, Ravandi F. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2021 07 01; 96(7):E229-E232. PMID: 33780038; PMCID: PMC9278812.
      Citations: 4     Fields:    Translation:HumansCells
    243. Kantarjian HM. Remembering Emil J Freireich: Trailblazing pioneer and giant in cancer research. Am J Hematol. 2021 06 01; 96(6):647-649. PMID: 33735488.
      Citations:    Fields:    
    244. Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, DiNardo CD, Kadia TM, Garcia-Manero G, Daver N, Montalban Bravo G, Cortes JE, Ravandi F, Jabbour E. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer. 2021 08 01; 127(15):2641-2647. PMID: 33823073.
      Citations: 4     Fields:    Translation:HumansCells
    245. Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, Jabbour E, Kantarjian HM. De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021 06 15; 127(12):2049-2061. PMID: 33818756.
      Citations: 8     Fields:    Translation:Humans
    246. Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021 08 01; 127(15):2648-2656. PMID: 33793964.
      Citations: 3     Fields:    Translation:HumansCells
    247. Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer. 2021 07 15; 127(14):2489-2499. PMID: 33793970; PMCID: PMC8249340.
      Citations: 4     Fields:    Translation:Humans
    248. Sasaki K, Jabbour E, Short NJ, Jain N, Ravandi F, Pui CH, Kantarjian H. Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017. Am J Hematol. 2021 06 01; 96(6):650-658. PMID: 33709456; PMCID: PMC9517941.
      Citations: 5     Fields:    Translation:HumansCellsPHPublic Health
    249. Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, Pollyea DA, McCloskey JK, Odenike O, Ossenkoppele GJ, Patel PA, Roshal M, Frattini MG, Lersch F, Franovic A, Nabhan S, Fan B, Choe S, Wang H, Wu B, Hua L, Almon C, Cooper M, Kantarjian HM, Tallman MS, D?hner H, L?wenberg B. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021 04 01; 137(13):1792-1803. PMID: 33024987; PMCID: PMC8020270.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    250. Zeng Z, Ly C, Daver N, Cortes J, Kantarjian HM, Andreeff M, Konopleva M. High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells. Ann Hematol. 2021 Jun; 100(6):1485-1496. PMID: 33787984.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    251. Kantarjian HM. Honoring Emil J. Freireich: A Visionary Medical Cancer Researcher-March 21, 1927-February 1, 2021. Blood Cancer Discov. 2021 May; 2(3):190-191. PMID: 35015670; PMCID: PMC8514001.
      Citations:    Fields:    
    252. Cerchione C, Daver N, DiNardo C, Jabbour EJ, Konopleva M, Ravandi-Kashani F, Kadia T, Martelli MP, Isidori A, Martinelli G, Kantarjian H, Romano A. IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. Front Oncol. 2021; 11:639387. PMID: 33898313; PMCID: PMC8063727.
      Citations: 7     
    253. Jabbour E, Kantarjian H. A new era in the treatment of acute lymphoblastic leukemia. Blood. 2021 03 25; 137(12):1563-1564. PMID: 33764428; PMCID: PMC9999037.
      Citations: 1     Fields:    Translation:Humans
    254. Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi A, Mehta R, Oran B, Olson A, Hosing C, Qazilbash M, Khouri I, Ciurea S, Shpall E, Jorgensen J, Wang S, Jain N, Jabbour E, Kantarjian H, Champlin R, Konopleva M, Kebriaei P. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 07; 56(7):1746-1749. PMID: 33767403.
      Citations:    Fields:    Translation:Humans
    255. Jabbour E, Paul S, Kantarjian H. The clinical development of antibody-drug conjugates - lessons from leukaemia. Nat Rev Clin Oncol. 2021 07; 18(7):418-433. PMID: 33758376.
      Citations: 6     Fields:    Translation:HumansAnimals
    256. Cortes JE, Kantarjian HM, Mauro MJ, An F, Nick S, Leip E, Gambacorti-Passerini C, Br?mmendorf TH. Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy. Eur J Haematol. 2021 Jun; 106(6):808-820. PMID: 33638218.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    257. Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2021 06 15; 127(12):2025-2038. PMID: 33740268.
      Citations: 1     Fields:    Translation:HumansCells
    258. Kantarjian HM, Kadia TM, DiNardo CD, Welch MA, Ravandi F. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. Cancer. 2021 04 15; 127(8):1186-1207. PMID: 33734442.
      Citations: 18     Fields:    Translation:Humans
    259. Morita K, Jain N, Kantarjian H, Takahashi K, Fang H, Konopleva M, El Hussein S, Wang F, Short NJ, Maiti A, Sasaki K, Garcia-Manero G, Konoplev S, Ravandi F, Khoury JD, Jabbour E. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol. 2021 05 01; 96(5):589-598. PMID: 33639000.
      Citations: 7     Fields:    Translation:Humans
    260. Stein AS, Martinelli G, Kantarjian H, Chen Y, Zugmaier G, Topp MS, G?kbuget N, Horst HA, Boissel N, Br?ggemann M. Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis. Cancer Med. 2021 04; 10(8):2601-2610. PMID: 33734596; PMCID: PMC8026950.
      Citations: 1     Fields:    Translation:Humans
    261. Reville PK, Kantarjian HM, Ravandi F, Jabbour E, DiNardo CD, Daver N, Pemmaraju N, Ohanian M, Alvarado Y, Xiao L, Alatrash G, Loghavi S, Rausch CR, Borthakur G, Konopleva M, Cortes J, Kadia TM. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J. 2021 03 17; 11(3):60. PMID: 33731681; PMCID: PMC7969746.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    262. Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J. 2021 03 06; 11(3):52. PMID: 33677472; PMCID: PMC7936977.
      Citations: 2     Fields:    Translation:Humans
    263. Kantarjian HM. Emil J. Freireich 1927-2021. Nat Cancer. 2021 03; 2(3):251-252. PMID: 35121959.
      Citations:    
    264. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021 03 01; 106(3):894-898. PMID: 32499238; PMCID: PMC7927994.
      Citations: 13     Fields:    Translation:Humans
    265. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2021 Feb 23; 14(1):34. PMID: 33618754; PMCID: PMC7901199.
      Citations:    Fields:    
    266. Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021 02 22; 11(2):41. PMID: 33619261; PMCID: PMC7900255.
      Citations: 45     Fields:    Translation:HumansAnimals
    267. Loghavi S, DiNardo CD, Furudate K, Takahashi K, Tanaka T, Short NJ, Kadia T, Konopleva M, Kanagal-Shamanna R, Farnoud NR, Pierce S, Khoury JD, Jorgensen JL, Patel KP, Daver N, Yilmaz M, Medeiros LJ, Kantarjian H, Ravandi F, Wang SA. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol. 2021 03; 192(6):1054-1063. PMID: 33618432; PMCID: PMC8944196.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    268. Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. Am J Hematol. 2021 05 01; 96(5):E154-E157. PMID: 33580980; PMCID: PMC8237705.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    269. Kantarjian HM, Stock W, Cassaday RD, DeAngelo DJ, Jabbour E, O'Brien SM, Wang T, Paccagnella ML, Nguyen K, Sleight B, Vandendries E, Neuhof A, Laird AD, Advani AS, Stelljes M. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res. 2021 05 15; 27(10):2742-2754. PMID: 33602684.
      Citations: 3     Fields:    Translation:Humans
    270. Wei AH, Ribera JM, Larson RA, Ritchie D, Ghobadi A, Chen Y, Anderson A, Dos Santos CE, Franklin J, Kantarjian H. Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia. 2021 08; 35(8):2220-2231. PMID: 33542479; PMCID: PMC8324476.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    271. Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021 02 01; 11(2):25. PMID: 33563904; PMCID: PMC7873265.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    272. Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol. 2020; 10:582213. PMID: 33585199; PMCID: PMC7878971.
      Citations: 5     
    273. Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Ruiz Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver N. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. Front Immunol. 2020; 11:590494. PMID: 33552049; PMCID: PMC7859512.
      Citations: 4     Fields:    Translation:HumansCells
    274. Montalban-Bravo G, Darbaniyan F, Kanagal-Shamanna R, Ganan-Gomez I, Class CA, Sasaki K, Naqvi K, Wei Y, Yang H, Soltysiak KA, Chien KS, Bueso-Ramos C, Do KA, Kantarjian H, Garcia-Manero G. Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. Leuk Res. 2021 02; 101:106511. PMID: 33517186.
      Citations: 3     Fields:    Translation:HumansCells
    275. Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021 06 01; 127(11):1894-1900. PMID: 33449377.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    276. Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbel G, Attar EC, Kantarjian HM, Lancet JE, List AF, Komrokji RS, Fenaux P. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021 05 10; 39(14):1584-1594. PMID: 33449813; PMCID: PMC8099410.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    277. Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, Boquimpani C, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Cacciatore S, Titorenko K, Aimone P, Saglio G, le Coutre P, Etienne G, Pasquini R, Zanichelli M, Bendit I, Hochhaus A. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021 02; 35(2):440-453. PMID: 33414482; PMCID: PMC7862065.
      Citations: 24     Fields:    Translation:Humans
    278. Masarova L, Bose P, Pemmaraju N, Daver N, Zhou L, Pierce S, Kantarjian H, Estrov Z, Verstovsek S. Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk. 2021 05; 21(5):318-327.e6. PMID: 33551345; PMCID: PMC8849582.
      Citations: 3     Fields:    Translation:Humans
    279. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021 03 01; 96(3):282-291. PMID: 33264443; PMCID: PMC8128145.
      Citations: 15     Fields:    Translation:Humans
    280. Koller PB, Zhang H, Kantarjian H, Jabbour E, Pierce S, Gocho Y, Roberts KG, Yang W, Mullighan CG, Yang J, Konopleva M, Jain N. GATA3 rs3824662A allele in B-cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with CRLF2 rearrangement and poor prognosis. Am J Hematol. 2021 03 01; 96(3):E71-E74. PMID: 33275800.
      Citations: 2     Fields:    Translation:Humans
    281. Short NJ, Rafei H, Daver N, Hwang H, Ning J, Jorgensen JL, Kadia TM, DiNardo CD, Wang SA, Jabbour E, Popat U, Oran B, Cortes J, Konopleva M, Yilmaz M, Issa GC, Kantarjian H, Ravandi F. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv. 2020 12 22; 4(24):6117-6126. PMID: 33351107; PMCID: PMC7757010.
      Citations: 12     Fields:    Translation:Humans
    282. Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Maus MV, Frigault MJ, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W, UCART19 Group, Boissel N, Baruchel A. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020 12 12; 396(10266):1885-1894. PMID: 33308471.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    283. Assi R, Kantarjian H, Keating M, Pemmaraju N, Verstovsek S, Garcia-Manero G, Ravandi F, Borthakur G, Dahl J, Jabbour E, Cortes JE. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. Leuk Lymphoma. 2021 04; 62(4):909-917. PMID: 33283580.
      Citations: 1     Fields:    Translation:Humans
    284. Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021 03; 2(2):125-134. PMID: 33681815; PMCID: PMC7935111.
      Citations: 9     Fields:    Translation:Humans
    285. Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, Huang X, Nogueras Gonzalez G, Hwang H, Qi X, Kantarjian H, Ravandi F. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. JAMA Oncol. 2020 Dec 01; 6(12):1890-1899. PMID: 33030517; PMCID: PMC7545346.
      Citations: 30     Fields:    Translation:Humans
    286. Samra B, Kantarjian HM, Sasaki K, Alotaibi AS, Konopleva M, O'Brien S, Ferrajoli A, Garris R, Nunez CA, Kadia TM, Short NJ, Jabbour E. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant. Acta Haematol. 2021; 144(3):285-292. PMID: 33238261.
      Citations:    Fields:    Translation:HumansCells
    287. Stock W, Martinelli G, DeAngelo DJ, Advani AS, O'Brien S, Liedtke M, Merchant AA, Cassaday RD, Wang T, Zhang H, Vandendries E, Jabbour E, Marks DI, Kantarjian HM, Stelljes M, G?kbuget N. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021 03 15; 127(6):905-913. PMID: 33231879; PMCID: PMC7983935.
      Citations: 8     Fields:    Translation:HumansCells
    288. Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Issa GC, Andreeff M, Kantarjian H, Kadia TM. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020 11 24; 4(22):5681-5689. PMID: 33211826; PMCID: PMC7686900.
      Citations: 11     Fields:    Translation:Humans
    289. Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol. 2021 02 01; 96(2):E50-E53. PMID: 33156969.
      Citations: 3     Fields:    Translation:Humans
    290. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 Nov 19; 11(1):5996. PMID: 33214561; PMCID: PMC7677309.
      Citations: 3     Fields:    
    291. Chew S, Jammal N, Kantarjian H, Jabbour E. Monoclonal antibodies in frontline acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2020 12; 33(4):101226. PMID: 33279178.
      Citations: 1     Fields:    Translation:Humans
    292. Jammal N, Chew S, Jabbour E, Kantarjian H. Antibody based therapy in relapsed acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2020 12; 33(4):101225. PMID: 33279181.
      Citations: 1     Fields:    Translation:Humans
    293. Chifotides HT, Masarova L, Alfayez M, Daver N, Alvarado Y, Jabbour E, Konopleva M, Kantarjian HM, Patel KP, DiNardo CD, Verstovsek S. Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv. 2020 11 10; 4(21):5336-5342. PMID: 33112940; PMCID: PMC7656917.
      Citations: 9     Fields:    Translation:Humans
    294. Zugmaier G, Stein AS, Chen Y, Ribera JM, Horst HA, Kantarjian HM, Topp MS, G?kbuget N, Dombret H, Bargou RC. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. Cancer. 2021 02 15; 127(4):554-559. PMID: 33141929; PMCID: PMC7894150.
      Citations: 3     Fields:    Translation:HumansCells
    295. Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer. 2021 02 01; 127(3):381-390. PMID: 33119202.
      Citations: 1     Fields:    Translation:HumansCells
    296. DiNardo CD, Stein AS, Stein EM, Fathi AT, Frankfurt O, Schuh AC, Martinelli G, Patel PA, Tan P, Zeidan AM, Kantarjian HM, Stone RM, Frattini MG, Lersch F, Gong J, Gianolio DA, Zhang V, Franovic A, Fan B, Goldwasser M, Daigle S, Choe S, Wu B, Winkler T, Vyas P, D?hner H, Raffoux E, de Botton S. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2021 01 01; 39(1):57-65. PMID: 33119479; PMCID: PMC7771719.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    297. Jabbour E, Kantarjian H. The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2021 01; 21(1):63-65. PMID: 33191168.
      Citations:    Fields:    Translation:Humans
    298. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 10 21; 11(1):5327. PMID: 33087716; PMCID: PMC7577981.
      Citations: 66     Fields:    Translation:HumansAnimals
    299. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2020 10 08; 13(1):132. PMID: 33032648; PMCID: PMC7542942.
      Citations: 7     Fields:    Translation:Humans
    300. Saini N, Marin D, Ledesma C, Delgado R, Rondon G, Popat UR, Bashir Q, Hosing CM, Nieto Y, Alousi AM, Qazilbash MH, Ciurea S, Shpall E, Khouri I, Kantarjian H, Jabbour E, Ravandi F, Champlin RE, Kebriaei P. Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood. 2020 10 08; 136(15):1786-1789. PMID: 32492706; PMCID: PMC8209550.
      Citations: 3     Fields:    Translation:Humans
    301. Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia T, Daver N, Pemmaraju N, Konopleva M, Borthakur G, Takahashi K, Patel K, Soltysiak KA, Chien KS, Sakurai K, Pierce S, Kantarjian HM, Garcia-Manero G. Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). Am J Hematol. 2020 12; 95(12):E326-E329. PMID: 32886803.
      Citations:    Fields:    Translation:HumansCells
    302. Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour EJ. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma. 2021 01; 62(1):224-228. PMID: 32955970.
      Citations:    Fields:    Translation:HumansCells
    303. Cortes J, Podoltsev N, Kantarjian H, Borthakur G, Zeidan AM, Stahl M, Taube T, Fagan N, Rajeswari S, Uy GL. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. Int J Hematol. 2021 Jan; 113(1):92-99. PMID: 32951163.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    304. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736. PMID: 32896301; PMCID: PMC7549397.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    305. Lachowiez C, Bannon S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, Daver N, Borthakur G, Pemmaraju N, Ravandi F, Patel KP, Garcia-Manero G, Takahashi K, Kantarjian H, Bhalla K, DiNardo CD. Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. Am J Hematol. 2020 11; 95(11):E313-E315. PMID: 32804409.
      Citations:    Fields:    Translation:Humans
    306. Jabbour E, Kantarjian H. Management of Older Patients with Acute Lymphocytic Leukemia - Novel Treatment Strategies. Clin Lymphoma Myeloma Leuk. 2020 09; 20 Suppl 1:S30-S31. PMID: 32862859.
      Citations: 1     Fields:    Translation:Humans
    307. Lonial S, Kantarjian H, Freireich EJ. Message from the Chairmen. Clin Lymphoma Myeloma Leuk. 2020 09; 20 Suppl 1:S1. PMID: 32862847.
      Citations:    Fields:    Translation:Humans
    308. DiNardo CD, Beird HC, Estecio M, Hardikar S, Takahashi K, Bannon SA, Borthakur G, Jabbour E, Gumbs C, Khoury JD, Routbort M, Gong T, Kondo K, Kantarjian H, Garcia-Manero G, Chen T, Futreal PA. Germline DNMT3A mutation in familial acute myeloid leukaemia. Epigenetics. 2021 05; 16(5):567-576. PMID: 32856987; PMCID: PMC8078744.
      Citations: 3     Fields:    Translation:HumansCells
    309. Borthakur G, Zeng Z, Cortes JE, Chen HC, Huang X, Konopleva M, Ravandi F, Kadia T, Patel KP, Daver N, Kelly MA, McQueen T, Wang RY, Kantarjian H, Andreeff M. Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol. 2020 11; 95(11):1296-1303. PMID: 32697348.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    310. Chen J, Haughey M, Vandendries E, DeAngelo DJ, Kantarjian HM, Ruiz-Garcia A. Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clin Transl Sci. 2021 01; 14(1):184-193. PMID: 32812370; PMCID: PMC7877846.
      Citations: 1     Fields:    Translation:Humans
    311. Cassaday RD, Marks DI, DeAngelo DJ, Jabbour EJ, Advani AS, O'Brien S, Wang T, Neuhof A, Vandendries E, Kantarjian HM, Stock W, Stelljes M. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. Br J Haematol. 2020 11; 191(3):e77-e81. PMID: 32805058.
      Citations:    Fields:    Translation:Humans
    312. Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes J. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 2020 11; 95(11):1288-1295. PMID: 32681739.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    313. DeAngelo DJ, Advani AS, Marks DI, Liedtke M, Stock W, Jabbour E, Merchant A, Wang T, Vandendries E, Neuhof A, Kantarjian H, O'Brien S, Stelljes M, G?kbuget N. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020 08 07; 10(8):81. PMID: 32769965; PMCID: PMC7414105.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    314. Garcia-Manero G, Griffiths EA, Steensma DP, Roboz GJ, Wells R, McCloskey J, Odenike O, DeZern AE, Yee K, O'Connell C, Michaelis LC, Brandwein J, Kantarjian H, Oganesian A, Azab M, Savona MR, Busque L. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 2020 08 06; 136(6):674-683. PMID: 32285126; PMCID: PMC7414597.
      Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
    315. Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma. 2020 12; 61(13):3120-3127. PMID: 32755333.
      Citations: 2     Fields:    Translation:Humans
    316. Samra B, Alotaibi AS, Short NJ, Khoury JD, Ravandi F, Garris R, Jain N, Konopleva M, Kantarjian H, Jabbour E. Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Am J Hematol. 2020 09; 95(9):E245-E247. PMID: 32501545.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    317. Ohanian M, Kantarjian HM, Shoukier M, Dellasala S, Musaelyan A, Nogueras Gonzalez GM, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Tamamyan G, Champlin R, Pierce S, Ferrajoli A, Kadia T, Cortes JE. The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol. 2020 Oct; 95(10):1127-1134. PMID: 32557828.
      Citations: 1     Fields:    
    318. Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, Sasaki K, Kantarjian HM, Estrov Z, Verstovsek S. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer. 2020 10 01; 126(19):4322-4331. PMID: 32697338; PMCID: PMC7875207.
      Citations: 4     Fields:    Translation:Humans
    319. Hu B, Lin X, Lee HC, Huang X, Tidwell RSS, Ahn KW, Hu ZH, Jabbour E, Verstovsek S, Ravandi F, Garcia-Manero G, Kharfan-Dabaja MA, Hossain NM, Marks DI, Kamble RT, Inamoto Y, Kindwall-Keller T, Saad A, Litzow MR, Savani BN, Hale GA, Bacher U, Gerds AT, Liesveld JL, Ustun C, Olsson RF, Daly A, Grunwald MR, Solh M, DeFilipp Z, Aljurf M, Wirk B, Akpek G, Nishihori T, Cerny J, Seo S, Hsu JW, Champlin R, de Lima M, Alyea E, Popat U, Sobecks R, Scott BL, Kantarjian H, Cortes J, Saber W. Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leuk Lymphoma. 2020 12; 61(12):2811-2820. PMID: 32662346; PMCID: PMC8424781.
      Citations: 1     Fields:    Translation:Humans
    320. Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Jul; 7(7):e523-e533. PMID: 32589978.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    321. Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, DiNardo CD, Daver N, Pemmaraju N, Kantarjian H, Borthakur G. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia. 2021 03; 35(3):691-700. PMID: 32561839.
      Citations: 6     Fields:    Translation:Humans
    322. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924. PMID: 32546726.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    323. Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, DiNardo CD, Daver N, Short NJ, Alvarado Y, Cortes J, Kim C, Kelsh M, Katz A, Williams R, Yang Z, Mehta B, Kantarjian H. Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2020 11; 20(11):e871-e882. PMID: 32792304.
      Citations: 4     Fields:    Translation:Humans
    324. Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020 06 05; 13(1):70. PMID: 32503572; PMCID: PMC7275444.
      Citations: 27     Fields:    Translation:HumansCells
    325. Short NJ, Kantarjian H, Kanagal-Shamanna R, Sasaki K, Ravandi F, Cortes J, Konopleva M, Issa GC, Kornblau SM, Garcia-Manero G, Garris R, Higgins J, Pratt G, Williams LN, Valentine CC, Rivera VM, Pritchard J, Salk JJ, Radich J, Jabbour E. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer J. 2020 05 26; 10(5):61. PMID: 32457305; PMCID: PMC7250857.
      Citations: 3     Fields:    Translation:HumansCells
    326. Short NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel KP, Konopleva M, Papageorgiou I, Pemmaraju N, Borthakur G, Ravandi F, DiNardo CD, Kadia TM, Kantarjian H, Lamba JK, Daver N. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol. 2020 09; 95(9):E225-E228. PMID: 32356320.
      Citations: 3     Fields:    Translation:Humans
    327. Borghaei H, Orlowski RZ, Subklewe M, Roboz GJ, Zugmaier G, Kufer P, Iskander K, Kantarjian HM, Einsele H. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020 07 15; 126(14):3192-3201. PMID: 32401342.
      Citations: 40     Fields:    Translation:HumansCells
    328. Choe S, Wang H, DiNardo CD, Stein EM, Roboz GJ, Altman JK, Mims AS, Watts JM, Pollyea DA, Fathi AT, Tallman MS, Kantarjian HM, Stone RM, Quek L, Konteatis Z, Dang L, Nicolay B, Nejad P, Liu G, Zhang V, Liu H, Goldwasser M, Liu W, Marks K, Bowden C, Biller SA, Attar EC, Wu B, de Botton S. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Adv. 2020 05 12; 4(9):1894-1905. PMID: 32380538; PMCID: PMC7218420.
      Citations: 53     Fields:    Translation:Humans
    329. Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Treating Leukemia in the Time of COVID-19. Acta Haematol. 2021; 144(2):132-145. PMID: 32392559; PMCID: PMC7270066.
      Citations: 18     Fields:    Translation:HumansCellsPHPublic Health
    330. Jabbour E, Advani AS, DeAngelo DJ, Marks DI, Stock W, O'Brien S, Cassaday RD, Wang T, Neuhof A, Vandendries E, Kantarjian H, Stelljes M, G?kbuget N. Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. Leuk Lymphoma. 2020 08; 61(8):2012-2015. PMID: 32378440.
      Citations: 1     Fields:    Translation:Humans
    331. Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver N, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J. 2020 05 04; 10(5):47. PMID: 32366832; PMCID: PMC7198507.
      Citations: 2     Fields:    Translation:Humans
    332. Abou Dalle I, Ghorab A, Patel K, Wang X, Hwang H, Cortes J, Issa GC, Yalniz F, Sasaki K, Chihara D, Price A, Kadia T, Pemmaraju N, Daver N, DiNardo C, Ravandi F, Kantarjian HM, Borthakur G. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J. 2020 05 04; 10(5):48. PMID: 32366841; PMCID: PMC7198530.
      Citations: 2     Fields:    Translation:Humans
    333. Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi F. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1670-1677. PMID: 32324887; PMCID: PMC7189293.
      Citations: 9     Fields:    Translation:Humans
    334. Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1690-1699. PMID: 32330243; PMCID: PMC7189295.
      Citations: 1     Fields:    Translation:Humans
    335. Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2020 07; 95(7):734-739. PMID: 32170867.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    336. Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K, Marx K, Daver NG, Kadia TM, Konopleva MY, Masarova L, Borthakur G, DiNardo CD, Naqvi K, Pierce S, Kantarjian HM, Short NJ. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol. 2020; 143(6):567-573. PMID: 32289808; PMCID: PMC7839068.
      Citations: 18     Fields:    Translation:Humans
    337. Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv. 2020 04 14; 4(7):1311-1320. PMID: 32251497; PMCID: PMC7160266.
      Citations: 38     Fields:    Translation:Humans
    338. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020 06; 95(6):691-709. PMID: 32239758.
      Citations: 54     Fields:    Translation:HumansCells
    339. Garcia-Manero G, Pemmaraju N, Alvarado Y, Naqvi K, Ravandi F, Jabbour E, De Lumpa R, Kantarjian H, Advani A, Mukherjee S, Gerds A, Carraway HE, Nazha A, Iwamura H, Murase M, Bavisotto L, Kurman M, Maier G, Johansen M, Sekeres MA. Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. Leuk Lymphoma. 2020 08; 61(8):1943-1953. PMID: 32264726.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    340. Bazarbachi A, Bug G, Ciceri F, Dalle IA, Floisand Y, Giebel S, Gilleece M, Gorin NC, Jabbour E, Aljurf M, Kantarjian H, Kharfan-Dabaja M, Labopin M, Lanza F, Peric Z, Prebet T, Ravandi F, Schmid C, Shouval R, Spyridonidis A, Versluis J, Vey N, Savani BN, Nagler A, Baron F, Brissot E, D?hner H, Esteve J, Malard F, Ruggeri A, Sanz J, Mohty M. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2020 06; 105(6):1507-1516. PMID: 32241850; PMCID: PMC7271578.
      Citations: 27     Fields:    Translation:Humans
    341. Montalban-Bravo G, Luthra R, Patel KP, Sasaki K, Bueso-Ramos CE, Khoury JD, Routbort MJ, Bassett R, Hidalgo-Lopez JE, Zhao C, Lin P, Loghavi S, Ok CY, Kadia T, DiNardo CD, Kantarjian H, Garcia-Manero G, Kanagal-Shamanna R, Quesada AE. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol. 2020 09; 33(9):1678-1689. PMID: 32238878.
      Citations: 2     Fields:    Translation:HumansCells
    342. Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622. PMID: 32112433.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    343. Sallman DA, Barnard J, Al Ali NH, Garcia-Manero G, Sekeres MA, DeZern A, Steensma DP, Roboz G, Jabbour E, Maciejewski JP, Pierce S, Padron E, Lancet JE, Kantarjian H, List AF, Komrokji RS. Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. Clin Lymphoma Myeloma Leuk. 2020 09; 20(9):e597-e605. PMID: 32303488.
      Citations: 1     Fields:    Translation:HumansCells
    344. DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R, Pomilio G, Ivey A, Salmon JM, Glytsou C, Fleming SA, Zhang Q, Ma H, Patel KP, Kornblau SM, Xu Z, Chua CC, Chen X, Blombery P, Flensburg C, Cummings N, Aifantis I, Kantarjian H, Huang DCS, Roberts AW, Majewski IJ, Konopleva M, Wei AH. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020 03 12; 135(11):791-803. PMID: 31932844; PMCID: PMC7068032.
      Citations: 113     Fields:    Translation:Humans
    345. Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood. 2020 03 12; 135(11):862-865. PMID: 31961918; PMCID: PMC8212349.
      Citations: 8     Fields:    Translation:HumansCells
    346. Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Roboz GJ, Collins R, Sekeres MA, Stone RM, Attar EC, Frattini MG, Tosolini A, Xu Q, See WL, MacBeth KJ, Tallman MS, Kantarjian HM, de Botton S. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020 Apr; 7(4):e309-e319. PMID: 32145771.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    347. Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N, Oran B. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer. 2020 05 15; 126(10):2193-2205. PMID: 32125707.
      Citations: 12     Fields:    Translation:Humans
    348. Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Larson RA, Lipton JH, Mayer J, Pane F, Radich JP, Richter J, Rosti G, Rousselot P, Saglio G, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hochhaus A, Kim DW, Mahon FX, Nicolini F, Niederwieser D, Rea D, Sau?ele S, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 04; 34(4):966-984. PMID: 32127639; PMCID: PMC7214240.
      Citations: 204     Fields:    Translation:Humans
    349. Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492. PMID: 32099037.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    350. Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. Blood. 2020 02 13; 135(7):510-513. PMID: 31895947; PMCID: PMC7019190.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    351. Roboz GJ, DiNardo CD, Stein EM, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM, de Botton S. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020 02 13; 135(7):463-471. PMID: 31841594; PMCID: PMC7019193.
      Citations: 94     Fields:    Translation:HumansCTClinical Trials
    352. Jain N, Stock W, Zeidan A, Atallah E, McCloskey J, Heffner L, Tomlinson B, Bhatnagar B, Feingold J, Ungar D, Chao G, Zhang X, Qin Y, Havenith K, Kantarjian H, Wieduwilt MJ. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. Blood Adv. 2020 02 11; 4(3):449-457. PMID: 32012214; PMCID: PMC7013258.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    353. Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020 02 11; 4(3):482-495. PMID: 32027746; PMCID: PMC7013259.
      Citations: 20     Fields:    Translation:Humans
    354. Chien KS, Class CA, Montalban-Bravo G, Wei Y, Sasaki K, Naqvi K, Ganan-Gomez I, Yang H, Soltysiak KA, Kanagal-Shamanna R, Do KA, Kantarjian HM, Garcia-Manero G. LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. Leuk Lymphoma. 2020 06; 61(6):1493-1499. PMID: 32036728; PMCID: PMC7836710.
      Citations: 3     Fields:    Translation:HumansCells
    355. Kurzrock R, Kantarjian HM, Kesselheim AS, Sigal EV. New drug approvals in oncology. Nat Rev Clin Oncol. 2020 03; 17(3):140-146. PMID: 32020042.
      Citations: 7     Fields:    Translation:Humans
    356. Xie W, Tang G, Wang E, Kim Y, Cloe A, Shen Q, Zhou Y, Garcia-Manero G, Loghavi S, Hu AY, Wang S, Bueso-Ramos CE, Kantarjian HM, Medeiros LJ, Hu S. t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm? Ann Hematol. 2020 Mar; 99(3):487-500. PMID: 32006151.
      Citations:    Fields:    Translation:HumansCells
    357. Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HM, Nogueras-Gonz?lez GM. Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1502-1511. PMID: 31999839.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    358. Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HM. Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1448-1459. PMID: 31999850.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    359. Rausch CR, Jabbour EJ, Kantarjian HM, Kadia TM. Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. Cancer. 2020 03 15; 126(6):1152-1160. PMID: 31794095.
      Citations: 6     Fields:    Translation:Humans
    360. Molica M, Naqvi K, Cortes JE, Paul S, Kadia TM, Breccia M, Kantarjian H, Jabbour EJ. Treatment-free remission in chronic myeloid leukemia. Clin Adv Hematol Oncol. 2019 Dec; 17(12):686-696. PMID: 31851157.
      Citations: 2     Fields:    Translation:Humans
    361. Jabbour E, Advani A, Stock W, Liedtke M, Martinelli G, O'Brien S, Wang T, Laird AD, Vandendries E, Neuhof A, Nguyen K, Dakappagari N, DeAngelo DJ, Kantarjian H, G?kbuget N, Stelljes M. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leuk Res. 2020 01; 88:106283. PMID: 31790983.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    362. Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Patel K, Soltysiak KA, Cortes J, Kantarjian HM, Garcia-Manero G. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer. 2020 02 15; 126(4):765-774. PMID: 31742675.
      Citations: 16     Fields:    Translation:Humans
    363. Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150. PMID: 31682008.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    364. Montalban-Bravo G, Class CA, Ganan-Gomez I, Kanagal-Shamanna R, Sasaki K, Richard-Carpentier G, Naqvi K, Wei Y, Yang H, Soltysiak KA, Chien K, Bueso-Ramos C, Do KA, Kantarjian H, Garcia-Manero G. Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. Leukemia. 2020 03; 34(3):872-881. PMID: 31719677; PMCID: PMC7056563.
      Citations: 5     Fields:    Translation:HumansCells
    365. Kantarjian HM, Stein AS, Fielding AK, Heffner L, Litzow M, O'Brien S, Zugmaier G, Gao S, Nagorsen D, Forman SJ, G?kbuget N, Br?ggemann M, Bargou RC, Dombret H, Rigal-Huguet F, Topp MS. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood Adv. 2019 10 22; 3(20):3033-3037. PMID: 31648325; PMCID: PMC6849936.
      Citations: 4     Fields:    Translation:Humans
    366. Abou Dalle I, Kantarjian HM, Short NJ, Konopleva M, Jain N, Garcia-Manero G, Garris R, Qiao W, Cortes JE, O'Brien S, Kebriaei P, Kadia T, Jabbour E, Ravandi F. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. Am J Hematol. 2019 12; 94(12):1388-1395. PMID: 31595534.
      Citations: 7     Fields:    Translation:HumansCells
    367. Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol. 2019 12; 94(12):1382-1387. PMID: 31595538.
      Citations: 5     Fields:    Translation:Humans
    368. Getta B, Masarova L, Famulare C, Schulman J, Arcila ME, Kantarjian HM, Levine RL, Rampal RK, Verstovsek S, Santos FPS, Datoguia TS, Puga RD, Alves Paiva RM, Hamerschlak N, Campregher PV. Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. Leukemia. 2020 03; 34(3):799-810. PMID: 31628430; PMCID: PMC7158221.
      Citations: 16     Fields:    Translation:Humans
    369. Rambaldi A, Ribera JM, Kantarjian HM, Ottmann OG, Stein AS, Tuglus CA, Zhao X, Kim C, Martinelli G, Dombret H. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia. Cancer. 2020 01 15; 126(2):304-310. PMID: 31626339; PMCID: PMC7003760.
      Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
    370. Rafei H, Kantarjian HM, Jabbour EJ. Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia. Br J Haematol. 2020 01; 188(2):207-223. PMID: 31566728.
      Citations: 6     Fields:    Translation:HumansCells
    371. Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2020 04; 20(4):212-218. PMID: 32035785.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    372. Fares J, Khalil M, Chaftari AM, Hachem R, Jiang Y, Kantarjian HM, Raad II. Impact of Catheter Management on Clinical Outcome in Adult Cancer Patients With Gram-Negative Bacteremia. Open Forum Infect Dis. 2019 Oct; 6(10):ofz357. PMID: 31660336; PMCID: PMC6765346.
      Citations: 4     
    373. Ravandi F, Koumenis I, Johri A, Tallman M, Roboz GJ, Strickland S, Garcia-Manero G, Borthakur G, Naqvi K, Meyer M, Pudipeddi M, Nidarmarthy S, Vaddi K, Kantarjian H. Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. Haematologica. 2020 06; 105(6):1567-1574. PMID: 31558670; PMCID: PMC7271599.
      Citations: 10     Fields:    Translation:Humans
    374. Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020 01 01; 126(1):67-75. PMID: 31553487; PMCID: PMC8529949.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    375. Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver N. CPX-351 (vyxeos) in AML. Leuk Lymphoma. 2020 02; 61(2):288-297. PMID: 31547736.
      Citations: 18     Fields:    Translation:Humans
    376. Abou Dalle I, Kantarjian H, Burger J, Estrov Z, Ohanian M, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Jabbour E, Cortes J. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Med. 2019 11; 8(15):6559-6565. PMID: 31502383; PMCID: PMC6825993.
      Citations: 5     Fields:    Translation:Humans
    377. Abou Dalle I, Kantarjian H, Bannon SA, Kanagal-Shamanna R, Routbort M, Patel KP, Hu S, Bhalla K, Garcia-Manero G, DiNardo CD. Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. Am J Hematol. 2020 02; 95(2):227-229. PMID: 31400013.
      Citations: 8     Fields:    Translation:Humans
    378. Jones G, Kantarjian H. The many roads to universal health care in the USA. Lancet Oncol. 2019 10; 20(10):e601-e605. PMID: 31473128.
      Citations: 4     Fields:    Translation:Humans
    379. Marks DI, van Oostrum I, Mueller S, Welch V, Vandendries E, Loberiza FR, Su Y, Kantarjian HM, B?hme S, Stelljes M. Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment. Cancer Med. 2019 10; 8(13):5959-5968. PMID: 31436395; PMCID: PMC6792500.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    380. Jabbour EJ, Kantarjian HM, Thomas X, Larson RA, Yoon SS, Ghobadi A, Topp MS, Tran Q, Franklin JL, Forman SJ, Stein AS, G?kbuget N. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer. 2019 Dec 01; 125(23):4181-4192. PMID: 31433496.
      Citations: 12     Fields:    Translation:Humans
    381. Botella C, Ravandi F, Kadia T, Kantarjian HM, Cortes J, Juliusson G, Lazarevic V, Recher C, Bertoli S, Micol JB, Wei AH, Tiong IS, Wall M, Estey E, Shaw C, Thiede C, Serve H, Ehninger G, Kramer M, Krug U, Angenendt L, R?llig C, Montesinos P, Mart?nez-Cuadr?n D, Barragan E, Garc?a R, Mart?nez P, H?glund M, Lehmann S, Pigneux A, Dumas PY, Dombret H, Preudhomme C, Terr? C, R?cil Z, Nov?k J, ??k P, Exeler R, Wagenf?hr L, St?lzel F, Stelljes M, Lenz G, Mikesch JH, Berdel WE, Schliemann C. Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. J Clin Oncol. 2019 10 10; 37(29):2632-2642. PMID: 31430225; PMCID: PMC8462529.
      Citations: 15     Fields:    Translation:Humans
    382. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488. PMID: 31400961; PMCID: PMC6778960.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    383. Gong Z, Xu ML, Chen M, Cui W, Kantarjian HM, Cortes JE, Zhou T, Tang G, Wang W, Medeiros LJ, Hu S. Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia. Am J Hematol. 2019 10; 94(10):E256-E259. PMID: 31273842.
      Citations:    Fields:    Translation:HumansCells
    384. Chung W, Kelly AD, Kropf P, Fung H, Jelinek J, Su XY, Roboz GJ, Kantarjian HM, Azab M, Issa JJ. Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. Clin Epigenetics. 2019 07 22; 11(1):106. PMID: 31331399; PMCID: PMC6647096.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    385. Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer. 2019 Nov 01; 125(21):3755-3766. PMID: 31310323.
      Citations: 10     Fields:    Translation:HumansCells
    386. Sasaki K, Kantarjian HM, Jabbour EJ. Reply to Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope? Cancer. 2019 11 01; 125(21):3891-3892. PMID: 31291004.
      Citations:    Fields:    Translation:Humans
    387. Paul S, Rausch CR, Welch MA, Kantarjian HM, Jabbour EJ. SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 08; 19(8):471-479. PMID: 31307896.
      Citations:    Fields:    Translation:Humans
    388. Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, Kadia TM, Naqvi K, Cortes J, Konopleva M. Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. Leuk Lymphoma. 2019 12; 60(13):3292-3295. PMID: 31246142.
      Citations: 2     Fields:    Translation:Humans
    389. Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Konopleva M, Andreeff M, Cortes J, Ravandi F, Nogueras Gonz?lez GM. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol. 2019 09; 94(9):984-991. PMID: 31237017.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    390. Shih YT, Cortes JE, Kantarjian HM. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. Lancet Haematol. 2019 Aug; 6(8):e398-e408. PMID: 31208943; PMCID: PMC6658341.
      Citations: 14     Fields:    Translation:Humans
    391. Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer. 2019 09 15; 125(18):3219-3224. PMID: 31150121.
      Citations: 5     Fields:    Translation:Humans
    392. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103. PMID: 31141631.
      Citations: 139     Fields:    Translation:HumansCTClinical Trials
    393. Boddu P, Jain P, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jabbour E, Cortes J, Kantarjian H. Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leuk Lymphoma. 2019 12; 60(13):3172-3180. PMID: 31125272.
      Citations:    Fields:    Translation:Humans
    394. Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Koller PB, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. 2020 03; 105(3):697-707. PMID: 31123034; PMCID: PMC7049339.
      Citations: 30     Fields:    Translation:HumansCells
    395. Khogeer H, Rahman H, Jain N, Angelova EA, Yang H, Quesada A, Ok CY, Sui D, Wei P, Al Fattani A, Pierce S, Loghavi S, Lamb A, Hu P, Thakral B, Kanagal-Shamanna R, Jorgensen JL, Jabbour EJ, Kantarjian HM, Medeiros LJ, Khoury JD. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol. 2019 08; 186(4):538-548. PMID: 31115909.
      Citations: 9     Fields:    Translation:HumansCells
    396. Guerra VA, Jabbour EJ, Ravandi F, Kantarjian H, Short NJ. Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia. Ther Adv Hematol. 2019; 10:2040620719849496. PMID: 31205644; PMCID: PMC6535741.
      Citations: 7     
    397. Rafei H, Kantarjian HM, Jabbour EJ. Recent advances in the treatment of acute lymphoblastic leukemia. Leuk Lymphoma. 2019 11; 60(11):2606-2621. PMID: 31092071.
      Citations: 20     Fields:    Translation:HumansAnimals
    398. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv. 2019 05 14; 3(9):1533-1539. PMID: 31076409; PMCID: PMC6517659.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    399. Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, Bannon SA, Benton CB, Garcia-Manero G, Kantarjian H, Luthra R, Medeiros LJ, Patel KP, Quesada AE. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019 07; 94(7):757-766. PMID: 30963592.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    400. Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019 Jun; 6(6):e317-e327. PMID: 31060979; PMCID: PMC9012213.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    401. Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. Cancer Cell. 2019 05 13; 35(5):721-737.e9. PMID: 31056398; PMCID: PMC6620028.
      Citations: 79     Fields:    Translation:HumansAnimalsCells
    402. Kantarjian HM. Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2019 May; 17(5):268-270. PMID: 31188803.
      Citations:    Fields:    Translation:Humans
    403. Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F. Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. Am J Hematol. 2019 07; 94(7):E188-E190. PMID: 30977182; PMCID: PMC6566858.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    404. Marks DI, Kebriaei P, Kantarjian H, Advani AS, Merchant A, Stock W, Cassaday RD, Wang T, Zhang H, Loberiza F, Vandendries E, DeAngelo DJ, Stelljes M, G?kbuget N. Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2019 09; 25(9):1720-1729. PMID: 31039409.
      Citations: 11     Fields:    Translation:Humans
    405. Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019 04 25; 380(17):1628-1637. PMID: 31018069.
      Citations: 83     Fields:    Translation:HumansCellsCTClinical Trials
    406. Stein AS, Kantarjian H, Litzow MR, Rambaldi A, Ribera JM, Zhang A, Zimmerman Z, Zugmaier G, G?kbuget N, Bargou R, Topp MS. Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 08; 25(8):1498-1504. PMID: 31002989.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    407. Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2019 08 01; 125(15):2579-2586. PMID: 30985931; PMCID: PMC6625850.
      Citations: 20     Fields:    Translation:Humans
    408. Pollyea DA, Tallman MS, Kantarjian HM, Collins R, Stein AS, Frattini MG, Xu Q, Tosolini A, See WL, MacBeth KJ, Agresta SV, Attar EC, DiNardo CD, Stein EM, de Botton S. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019 11; 33(11):2575-2584. PMID: 30967620; PMCID: PMC9724489.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    409. Schuh AC, Wei AH, Durrant S, Bacon CL, Tran Q, Zimmerman Z, Kantarjian H, Dombret H, Topp MS. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2019 09; 60(9):2214-2222. PMID: 30947585.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    410. Richard-Carpentier G, Kantarjian H, Jabbour E. Recent Advances in Adult Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep. 2019 04; 14(2):106-118. PMID: 30879177.
      Citations: 12     Fields:    Translation:Humans
    411. Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J, Oganesian A, Azab M, Garcia-Manero G. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 2019 Apr; 6(4):e194-e203. PMID: 30926081.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    412. Kantarjian HM, DeAngelo DJ, Liedtke M, Stock W, O'Brien SM, Jabbour E, Wang T, Liang White J, Sleight B, Vandendries E, Advani AS, Stelljes M, G?kbuget N. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019 07 15; 125(14):2474-2487. PMID: 30920645; PMCID: PMC6618133.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    413. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019 03 26; 3(6):922-933. PMID: 30902805; PMCID: PMC6436014.
      Citations: 21     Fields:    Translation:Humans
    414. Jain P, Kantarjian H, Boddu PC, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE, Nogueras-Gonz?lez GM. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 03 26; 3(6):851-861. PMID: 30885996; PMCID: PMC6436011.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    415. Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJ. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. Am J Hematol. 2019 06; 94(6):E158-E160. PMID: 30838674; PMCID: PMC6602057.
      Citations: 6     Fields:    Translation:Humans
    416. Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso Pierola A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Kanagal-Shamanna R, Patel K, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer. 2019 07 01; 125(13):2233-2241. PMID: 30861111; PMCID: PMC6742577.
      Citations: 5     Fields:    Translation:Humans
    417. Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol. 2019 May; 109(5):545-552. PMID: 30830579.
      Citations: 13     Fields:    Translation:Humans
    418. Paul S, Rausch CR, Nasnas PE, Kantarjian H, Jabbour EJ. Treatment of relapsed/refractory acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2019 Mar; 17(3):166-175. PMID: 30969955.
      Citations: 14     Fields:    Translation:Humans
    419. Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer. 2019 06 01; 125(11):1855-1866. PMID: 30811597.
      Citations: 5     Fields:    Translation:Humans
    420. Tallman MS, Estey EH, Naoe T, Lengfelder E, Burnett AK, Chen SJ, Mathews V, Iland H, Rego E, Kantarjian H, Avvisati G, Platzbecker U, Ravandi F, Russell NH, Lo-Coco F, Sanz MA, Fenaux P, L?wenberg B, D?hner H, Ad?s L, Montesinos P. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019 04 11; 133(15):1630-1643. PMID: 30803991; PMCID: PMC6509567.
      Citations: 140     Fields:    Translation:Humans
    421. Pemmaraju N, Kantarjian H, Nastoupil L, Dupuis M, Zhou L, Pierce S, Patel KP, Masarova L, Cortes J, Verstovsek S. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood. 2019 05 23; 133(21):2348-2351. PMID: 30796023; PMCID: PMC6634962.
      Citations: 13     Fields:    Translation:Humans
    422. Piya S, Mu H, Bhattacharya S, Lorenzi PL, Davis RE, McQueen T, Ruvolo V, Baran N, Wang Z, Qian Y, Crews CM, Konopleva M, Ishizawa J, You MJ, Kantarjian H, Andreeff M, Borthakur G. BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. J Clin Invest. 2019 05 01; 129(5):1878-1894. PMID: 30829648; PMCID: PMC6486356.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    423. Short NJ, Kantarjian H, Ravandi F, Daver N. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther Adv Hematol. 2019; 10:2040620719827310. PMID: 30800259; PMCID: PMC6378516.
      Citations: 32     
    424. Kadia TM, Kantarjian HM, Konopleva M. Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy. Oncotarget. 2019 Feb 08; 10(12):1250-1265. PMID: 30815228; PMCID: PMC6383813.
      Citations: 6     Fields:    
    425. Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CD. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud. 2019 02; 5(1). PMID: 30709875; PMCID: PMC6371746.
      Citations: 11     Fields:    Translation:Humans
    426. Kantarjian H, O'Brien S. Poor Penetration of Existing Effective Chemoimmunotherapy for the Treatment of Older Patients With Newly Diagnosed Acute Lymphocytic Leukemia (ALL) or Refractory/Relapsed ALL. J Oncol Pract. 2019 02; 15(2):77-79. PMID: 30763202.
      Citations:    Fields:    Translation:Humans
    427. Fredell MN, Kantarjian HM, Shih YT, Ho V, Mukherjee B. How much of US health care spending provides direct care or benefit to patients? Cancer. 2019 05 01; 125(9):1404-1409. PMID: 30695098.
      Citations: 1     Fields:    Translation:Humans
    428. Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau JB, Kwari MI, Ravandi F, Anderson BD, Iizuka K, Jin C, Zhang C, Plunkett WK. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer. 2019 05 15; 125(10):1665-1673. PMID: 30668890.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    429. Hibma JE, Kantarjian HM, DeAngelo DJ, Boni JP. Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling. Br J Clin Pharmacol. 2019 03; 85(3):590-600. PMID: 30536405; PMCID: PMC6379221.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    430. Jabbour E, Advani AS, Stelljes M, Stock W, Liedtke M, O'Brien S, White JL, Wang T, Luisa Paccagnella M, Sleight B, Vandendries E, DeAngelo DJ, Kantarjian HM, G?kbuget N, Martinelli G. Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. Am J Hematol. 2019 04; 94(4):408-416. PMID: 30623490.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    431. Yilmaz M, Wang F, Loghavi S, Bueso-Ramos C, Gumbs C, Little L, Song X, Zhang J, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Short N, Garcia-Manero G, Estrov Z, Kantarjian H, Futreal A, Takahashi K, Ravandi F. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Blood Cancer J. 2019 01 16; 9(2):7. PMID: 30651532; PMCID: PMC6335405.
      Citations: 25     Fields:    Translation:Humans
    432. Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, Lam YL, Sweat R, Follit C, Jain V, Lind E, Borthakur G, Garcia-Manero G, Ravandi F, Kantarjian HM, Cortes J, Collins R, Buelow DR, Baker SD, Druker BJ, Tyner JW. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat Commun. 2019 01 16; 10(1):244. PMID: 30651561; PMCID: PMC6335421.
      Citations: 51     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    433. Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, Hagiwara K, Pelletier S, Gingras S, Berns H, Payne-Turner D, Hill A, Iacobucci I, Shi L, Pounds S, Cheng C, Pei D, Qu C, Newman S, Devidas M, Dai Y, Reshmi SC, Gastier-Foster J, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Rambaldi A, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Racevskis J, Zhang Y, Bhatia R, Kohlschmidt J, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Evans WE, Jeha S, Pui CH, Yang J, Paietta E, Downing JR, Relling MV, Zhang J, Loh ML, Hunger SP, Mullighan CG, Mr?zek K. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019 02; 51(2):296-307. PMID: 30643249; PMCID: PMC6525306.
      Citations: 141     Fields:    Translation:HumansAnimalsCells
    434. Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma. 2019 07; 60(7):1767-1774. PMID: 30632841; PMCID: PMC6594864.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    435. Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, Kadia T, Pemmaraju N, Jabbour E, Cortes J. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. J Hematol Oncol. 2019 01 03; 12(1):1. PMID: 30606227; PMCID: PMC6318861.
      Citations: 9     Fields:    Translation:Humans
    436. Badar T, Luthra R, Kantarjian H, Jabbour E, Borthakur G, Garcia-Manero G, Huang X, Singh R, Alvarez B, Austermiller B, Morrison TB, Patel KP, Cortes J. New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia. Appl Immunohistochem Mol Morphol. 2019 01; 27(1):33-39. PMID: 28682832.
      Citations:    Fields:    Translation:Humans
    437. Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 03; 19(3):142-148.e1. PMID: 30635233.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    438. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019 Jan; 6(1):e29-e37. PMID: 30545576; PMCID: PMC6563344.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    439. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019 03 07; 133(10):1011-1019. PMID: 30530801; PMCID: PMC6405333.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    440. Boddu PC, Kadia TM, Garcia-Manero G, Cortes J, Alfayez M, Borthakur G, Konopleva M, Jabbour EJ, Daver NG, DiNardo CD, Naqvi K, Yilmaz M, Short NJ, Pierce S, Kantarjian HM, Ravandi F. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Cancer. 2019 04 01; 125(7):1091-1100. PMID: 30521114; PMCID: PMC6561101.
      Citations: 20     Fields:    Translation:Humans
    441. Benton CB, Chien KS, Tefferi A, Rodriguez J, Ravandi F, Daver N, Jabbour E, Jain N, Alvarado Y, Kwari M, Pierce S, Maiti A, Hornbaker M, Santos MA, Martinez S, Siguero M, Zblewski D, Al-Kali A, Hogan WJ, Kantarjian H, Pardanani A, Garcia-Manero G. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. Hematol Oncol. 2019 Feb; 37(1):96-102. PMID: 30153704; PMCID: PMC6386594.
      Citations: 5     Fields:    Translation:HumansCells
    442. Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, Sekeres MA, Stein AS, Kantarjian HM, Levine RL, Vyas P, MacBeth KJ, Tosolini A, VanOostendorp J, Xu Q, Gupta I, Lila T, Risueno A, Yen KE, Wu B, Attar EC, Tallman MS, de Botton S. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019 02 14; 133(7):676-687. PMID: 30510081; PMCID: PMC6384189.
      Citations: 109     Fields:    Translation:HumansCTClinical Trials
    443. Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer. 2019 02 15; 125(4):559-574. PMID: 30508305.
      Citations: 26     Fields:    Translation:Humans
    444. Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018 Dec; 5(12):e618-e627. PMID: 30501869; PMCID: PMC10020885.
      Citations: 50     Fields:    Translation:HumansCellsCTClinical Trials
    445. Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019 05 01; 125(9):1470-1481. PMID: 30500073; PMCID: PMC6467779.
      Citations: 84     Fields:    Translation:HumansCells
    446. Short NJ, Jabbour E, Albitar M, de Lima M, Gore L, Jorgensen J, Logan AC, Park J, Ravandi F, Shah B, Radich J, Kantarjian H. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. Am J Hematol. 2019 02; 94(2):257-265. PMID: 30394566; PMCID: PMC6572728.
      Citations: 22     Fields:    Translation:Humans
    447. Savoy JM, Welch MA, Nasnas PE, Kantarjian H, Jabbour E. Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia. Ther Adv Hematol. 2018; 9(12):347-356. PMID: 33815734; PMCID: PMC7992772.
      Citations:    
    448. Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol. 2019 01; 94(1):74-79. PMID: 30328139; PMCID: PMC6570401.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    449. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383. PMID: 30409776; PMCID: PMC6397669.
      Citations: 151     Fields:    Translation:HumansCTClinical Trials
    450. Hsu JI, Dayaram T, Tovy A, De Braekeleer E, Jeong M, Wang F, Zhang J, Heffernan TP, Gera S, Kovacs JJ, Marszalek JR, Bristow C, Yan Y, Garcia-Manero G, Kantarjian H, Vassiliou G, Futreal PA, Donehower LA, Takahashi K, Goodell MA. PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. Cell Stem Cell. 2018 11 01; 23(5):700-713.e6. PMID: 30388424; PMCID: PMC6224657.
      Citations: 90     Fields:    Translation:HumansAnimalsCells
    451. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019 01 03; 133(1):7-17. PMID: 30361262; PMCID: PMC6318429.
      Citations: 444     Fields:    Translation:Humans
    452. Angelova E, Audette C, Kovtun Y, Daver N, Wang SA, Pierce S, Konoplev SN, Khogeer H, Jorgensen JL, Konopleva M, Zweidler-McKay PA, Medeiros LJ, Kantarjian HM, Jabbour EJ, Khoury JD. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. Haematologica. 2019 04; 104(4):749-755. PMID: 30361418; PMCID: PMC6442980.
      Citations: 22     Fields:    Translation:HumansCellsCTClinical Trials
    453. Rassidakis GZ, Herold N, Myrberg IH, Tsesmetzis N, Rudd SG, Henter JI, Schaller T, Ng SB, Chng WJ, Yan B, Ng CH, Ravandi F, Andreeff M, Kantarjian HM, Medeiros LJ, Xagoraris I, Khoury JD. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens. Blood Cancer J. 2018 10 19; 8(11):98. PMID: 30341277; PMCID: PMC6195559.
      Citations: 8     Fields:    Translation:Humans
    454. Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G, Jabbour E, O'Brien S, Ravandi F, Wierda W, Estrov Z, Borthakur G, Kadia T, Cleeland C, Cortes JE, Kantarjian H. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018 11; 7(11):5457-5469. PMID: 30318751; PMCID: PMC6246941.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    455. Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, Kebriaei P, Burger J, Khoury J, Jorgensen J, Jain N, Konopleva M, Garcia-Manero G, Kadia T, Cortes J, Jacob J, Montalbano K, Garris R, O'Brien S, Kantarjian HM. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018 10 15; 124(20):4044-4055. PMID: 30307611; PMCID: PMC6515924.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    456. Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, Dinardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TM. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018 11 01; 124(21):4192-4201. PMID: 30307606; PMCID: PMC6800043.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    457. Kantarjian H, Light DW, Ho V. The "American (cancer) patients first" plan to reduce drug prices-A critical assessment. Am J Hematol. 2018 12; 93(12):1444-1450. PMID: 30218454.
      Citations:    Fields:    Translation:Humans
    458. Jones GH, Bruera E, Abdi S, Kantarjian HM. The opioid epidemic in the United States-Overview, origins, and potential solutions. Cancer. 2018 11 15; 124(22):4279-4286. PMID: 30299538.
      Citations: 5     Fields:    Translation:HumansPHPublic Health
    459. Kantarjian HM, Keating MJ, Freireich EJ. Toward the potential cure of leukemias in the next decade. Cancer. 2018 11 15; 124(22):4301-4313. PMID: 30291792.
      Citations: 13     Fields:    Translation:Humans
    460. Jabbour E, Pui CH, Kantarjian H. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia. JAMA Oncol. 2018 10 01; 4(10):1413-1420. PMID: 29931220.
      Citations: 28     Fields:    Translation:Humans
    461. Hidalgo-L?pez JE, Kanagal-Shamanna R, Gong Z, Wang W, Hu S, Medeiros LJ, Bassett RL, d'Orcy E, Yin CC, Cortes J, Jabbour EJ, Kantarjian HM, Bueso-Ramos CE, Quesada AE. Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value. Cancer. 2018 10 01; 124(19):3849-3855. PMID: 30321462.
      Citations: 3     Fields:    Translation:Humans
    462. Naqvi K, Kantarjian HM. Reply to Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it? Cancer. 2018 11 01; 124(21):4261. PMID: 30276797.
      Citations:    Fields:    Translation:Humans
    463. Benton CB, Khan M, Sallman D, Nazha A, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G, Nogueras Gonz?lez GM. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am J Hematol. 2018 10; 93(10):1245-1253. PMID: 30051599; PMCID: PMC6750209.
      Citations: 14     Fields:    Translation:HumansCells
    464. Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018; 8:369. PMID: 30319961; PMCID: PMC6167965.
      Citations: 10     
    465. Assi R, Gur HD, Loghavi S, Konoplev SN, Konopleva M, Daver N, Tashakori M, Kadia T, Routbort M, Salem A, Kanagal-Shamanna R, Quesada A, Jabbour EJ, Kornblau SM, Medeiros LJ, Kantarjian H, Khoury JD. P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival. Am J Hematol. 2018 11; 93(11):1376-1383. PMID: 30117185.
      Citations: 8     Fields:    Translation:HumansCells
    466. Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood. 2018 11 08; 132(19):2100-2103. PMID: 30242087; PMCID: PMC6236463.
      Citations: 17     Fields:    Translation:Humans
    467. Abaza Y, Hidalgo-Lopez JE, Verstovsek S, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Alvarado Y, Burger J, Schneider H, Soltysiak KA, Wei Y, Kantarjian HM, Bueso-Ramos CE, Garcia-Manero G. Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res. 2018 10; 73:78-85. PMID: 30245189; PMCID: PMC6750211.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    468. Abaza Y, Cortes J, Ravandi F, Kadia T, Garcia-Manero G, Pemmaraju N, Shetty A, Pierce S, Qiao W, Kantarjian HM, Borthakur G. Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. Am J Hematol. 2018 11; 93(11):E357-E360. PMID: 30074261.
      Citations:    Fields:    Translation:Humans
    469. Miyazaki Y, Tuechler H, Sanz G, Garcia-Manero G, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Maciejewski J, Machherndl-Spandl S, Magalhaes SMM, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Greenberg PL, Schanz J, Sol? F, Santini V, L?bbert M, Pfeilst?cker M, Haase D. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. Leuk Res. 2018 10; 73:51-57. PMID: 30219650.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    470. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674. PMID: 30185431; PMCID: PMC6265645.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    471. Ottmann O, Saglio G, Apperley JF, Arthur C, Bullorsky E, Charbonnier A, Dipersio JF, Kantarjian H, Khoury HJ, Kim DW, Healey D, Strauss L, Cortes JE. Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. Blood Cancer J. 2018 09 03; 8(9):88. PMID: 30190469; PMCID: PMC6127283.
      Citations: 7     Fields:    Translation:Humans
    472. Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hobbs G, Jagasia M, Kantarjian HM, Maness L, Metheny L, Moore JO, Pallera A, Pancari P, Patnaik M, Purev E, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 09; 16(9):1108-1135. PMID: 30181422.
      Citations: 71     Fields:    Translation:HumansCells
    473. Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol. 2018 09; 93(9):1136-1141. PMID: 30028037.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    474. Ok CY, Loghavi S, Sui D, Wei P, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Tang G, Tang Z, Jorgensen JL, Luthra R, Ravandi F, Kantarjian HM, DiNardo CD, Medeiros LJ, Wang SA, Patel KP. Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica. 2019 02; 104(2):305-311. PMID: 30171025; PMCID: PMC6355476.
      Citations: 18     Fields:    Translation:Humans
    475. Numan Y, Alfayez M, Maiti A, Alvarado Y, Jabbour EJ, Ferrajoli A, Konoplev SN, Kantarjian HM, Bose P. First report of clinical response to Venetoclax in Early T-cell Precursor Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2018; 2. PMID: 31080940; PMCID: PMC6508880.
      Citations: 12     Fields:    
    476. Loghavi S, Sui D, Wei P, Garcia-Manero G, Pierce S, Routbort MJ, Jabbour EJ, Pemmaraju N, Kanagal-Shamanna R, Gur HD, Hu S, Zuo Z, Medeiros LJ, Kantarjian HM, Khoury JD. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Adv. 2018 08 14; 2(15):1807-1816. PMID: 30054307; PMCID: PMC6093727.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    477. Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Sep; 5(9):e411-e421. PMID: 30115541; PMCID: PMC6775639.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    478. Pellegrino M, Sciambi A, Treusch S, Durruthy-Durruthy R, Gokhale K, Jacob J, Chen TX, Geis JA, Oldham W, Matthews J, Kantarjian H, Futreal PA, Patel K, Jones KW, Takahashi K, Eastburn DJ. High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics. Genome Res. 2018 09; 28(9):1345-1352. PMID: 30087104; PMCID: PMC6120635.
      Citations: 58     Fields:    Translation:HumansCells
    479. Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol. 2018; 140(1):30-39. PMID: 30071517.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    480. Cicconi L, Fenaux P, Kantarjian H, Tallman M, Sanz MA, Lo-Coco F. Molecular remission as a therapeutic objective in acute promyelocytic leukemia. Leukemia. 2018 08; 32(8):1671-1678. PMID: 30026570.
      Citations: 17     Fields:    Translation:Humans
    481. Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun. 2018 07 10; 9(1):2670. PMID: 29991687; PMCID: PMC6039465.
      Citations: 26     Fields:    Translation:HumansCells
    482. Yalniz FF, Daver N, Rezvani K, Kornblau S, Ohanian M, Borthakur G, DiNardo CD, Konopleva M, Burger J, Gasior Y, Pierce S, Kantarjian H, Garcia-Manero G. A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):658-663.e2. PMID: 30001986; PMCID: PMC6750214.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    483. Boddu P, Gurguis C, Sanford D, Cortes J, Akosile M, Ravandi F, Garcia-Manero G, Patel KP, Kadia T, Brandt M, Maduike R, Kantarjian H, Borthakur G. Response kinetics and factors predicting survival in core-binding factor leukemia. Leukemia. 2018 12; 32(12):2698-2701. PMID: 29884905.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    484. Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, Perl AE, Marie JP, Martinelli G, Kantarjian HM, Levis MJ. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood. 2018 08 09; 132(6):598-607. PMID: 29875101; PMCID: PMC6085992.
      Citations: 55     Fields:    Translation:HumansCellsCTClinical Trials
    485. DiNardo CD, Stein EM, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM, de Botton S. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018 Jun 21; 378(25):2386-2398. PMID: 29860938.
      Citations: 414     Fields:    Translation:HumansCTClinical Trials
    486. Gur HD, Loghavi S, Garcia-Manero G, Routbort M, Kanagal-Shamanna R, Quesada A, Khogeer H, Pierce S, Medeiros LJ, Kantarjian H, Khoury JD. Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. Am J Surg Pathol. 2018 06; 42(6):799-806. PMID: 29596070.
      Citations: 9     Fields:    Translation:Humans
    487. Cortes J, Perl AE, Kantarjian H, Martinelli G, Kovacsovics T, Estey E, Strickland S, Altman JK, Burnett A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M, D?hner H, Rousselot P, Steffen B, Dombret H, Baldus CD, Kr?mer A. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018 07; 19(7):889-903. PMID: 29859851; PMCID: PMC8152787.
      Citations: 101     Fields:    Translation:HumansCTClinical Trials
    488. Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Horst HA, Klimek VM, Cortes JE, Carella AM, Egyed M, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK, Pigneux A, R?cher C, Krug U. Phase 3 results for vosaroxin/cytarabine in the subset of patients =60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. 2018 11; 103(11):e514-e518. PMID: 29794146; PMCID: PMC6278965.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    489. Kantarjian H, Jabbour E. Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:574-578. PMID: 30231308.
      Citations: 10     Fields:    Translation:HumansCells
    490. Short NJ, Kantarjian H, Pui CH, Goldstone A, Jabbour E. SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2018 07; 18(7):439-446. PMID: 29853276.
      Citations: 7     Fields:    Translation:HumansAnimals
    491. Gambacorti-Passerini C, Cortes JE, Lipton JH, Kantarjian HM, Kim DW, Schafhausen P, Crescenzo R, Bardy-Bouxin N, Shapiro M, Noonan K, Leip E, DeAnnuntis L, Khoury HJ, Br?mmendorf TH. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica. 2018 08; 103(8):1298-1307. PMID: 29773593; PMCID: PMC6068045.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    492. Cortes J, Tamura K, DeAngelo DJ, de Bono J, Lorente D, Minden M, Uy GL, Kantarjian H, Chen LS, Gandhi V, Godin R, Keating K, McEachern K, Vishwanathan K, Pease JE, Dean E. Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer. 2018 05; 118(11):1425-1433. PMID: 29765150; PMCID: PMC5988656.
      Citations: 23     Fields:    Translation:HumansCellsCTClinical Trials
    493. Kantarjian HM, Prat F, Steensma DP, Kurzrock R, Stewart DJ, Sekeres MA, Leveque J. Cancer research in the United States: A critical review of current status and proposal for alternative models. Cancer. 2018 07 15; 124(14):2881-2889. PMID: 29757456.
      Citations: 5     Fields:    Translation:Humans
    494. Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE, Nogueras-Gonz?lez GM. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48. PMID: 29741984; PMCID: PMC6226369.
      Citations: 27     Fields:    Translation:Humans
    495. Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018 06 15; 124(12):2561-2569. PMID: 29723393.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    496. Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018 07 01; 124(13):2740-2747. PMID: 29723397; PMCID: PMC6388399.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    497. Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018 06 20; 36(18):1788-1797. PMID: 29702001; PMCID: PMC6008108.
      Citations: 66     Fields:    Translation:Humans
    498. Patnaik MM, Pierola AA, Vallapureddy R, Yalniz FF, Kadia TM, Jabbour EJ, Lasho T, Hanson CA, Ketterling RP, Kantarjian HM, Tefferi A, Garcia-Manero G. Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. Leukemia. 2018 11; 32(11):2512-2518. PMID: 29749401; PMCID: PMC6202273.
      Citations: 7     Fields:    Translation:Humans
    499. Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, Daver N, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur G. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018 07 01; 124(13):2758-2765. PMID: 29660836; PMCID: PMC6800041.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    500. Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 06 15; 124(12):2534-2540. PMID: 29645075.
      Citations: 8     Fields:    Translation:HumansCells
    501. Short NJ, Kantarjian H, Jabbour E, Ravandi F. Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep. 2018 04; 13(2):91-99. PMID: 29423571.
      Citations: 6     Fields:    Translation:Humans
    502. Stewart DJ, Stewart AA, Wheatley-Price P, Batist G, Kantarjian HM, Schiller J, Clemons M, Bradford JP, Gillespie L, Kurzrock R. The importance of greater speed in drug development for advanced malignancies. Cancer Med. 2018 05; 7(5):1824-1836. PMID: 29601671; PMCID: PMC5943431.
      Citations: 6     Fields:    Translation:Humans
    503. Cortes JE, Kim DW, Pinilla-Ibarz J, Paquette R, Chuah C, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Baccarani M, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM, le Coutre PD, Nicolini FE, Rea D, M?ller MC, Guilhot F. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 07 26; 132(4):393-404. PMID: 29567798; PMCID: PMC6071555.
      Citations: 119     Fields:    Translation:HumansCellsCTClinical Trials
    504. Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov Z. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol. 2018 Jul; 97(7):1183-1191. PMID: 29557496; PMCID: PMC6506234.
      Citations: 4     Fields:    Translation:HumansCells
    505. Kvasnicka HM, Bueso-Ramos CE, Sun W, Cortes J, Kantarjian HM, Verstovsek S, Thiele J. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. J Hematol Oncol. 2018 03 15; 11(1):42. PMID: 29544547; PMCID: PMC5856218.
      Citations: 36     Fields:    Translation:Humans
    506. Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol. 2018 Apr; 5(4):e136-e146. PMID: 29550383.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    507. Kantarjian HM, Su Y, Jabbour EJ, Bhattacharyya H, Yan E, Cappelleri JC, Marks DI. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer. 2018 05 15; 124(10):2151-2160. PMID: 29508899.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    508. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018 03; 93(3):442-459. PMID: 29411417.
      Citations: 98     Fields:    Translation:HumansCells
    509. Assi R, Kantarjian H, Ravandi F, Daver N. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol. 2018 03; 25(2):136-145. PMID: 29206680.
      Citations: 26     Fields:    Translation:Humans
    510. Yilmaz M, Kantarjian H, Ravandi-Kashani F, Short NJ, Jabbour E. Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives. Clin Adv Hematol Oncol. 2018 Mar; 16(3):216-223. PMID: 29742077.
      Citations: 8     Fields:    Translation:HumansCells
    511. Kantarjian HM, Paul S. Hepatitis C: When high drug prices preclude patient benefit. Cancer. 2018 04 15; 124(8):1644-1646. PMID: 29486061.
      Citations:    Fields:    Translation:HumansCells
    512. Rausch CR, Paul S, Marx KR, Jabbour E, Pemmaraju N, Ferrajoli A, Kantarjian H. L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-induced Hyperbilirubinemia. Clin Lymphoma Myeloma Leuk. 2018 05; 18(5):e191-e195. PMID: 29550108.
      Citations: 8     Fields:    Translation:Humans
    513. Wierzbowska A, Wawrzyniak E, Pluta A, Robak T, Mazur GJ, Dmoszynska A, Cermak J, Lysak D, Arthur C, Doyle M, Xiu L, Ravandi F, Kantarjian HM, Oriol A. Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial. Am J Hematol. 2018 05; 93(5):E125-E127. PMID: 29417613.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    514. Daver N, Boddu P, Garcia-Manero G, Yadav SS, Sharma P, Allison J, Kantarjian H. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 2018 05; 32(5):1094-1105. PMID: 29487386; PMCID: PMC6916728.
      Citations: 66     Fields:    Translation:HumansCells
    515. Savona MR, Pollyea DA, Stock W, Oehler VG, Schroeder MA, Lancet J, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE. Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clin Cancer Res. 2018 05 15; 24(10):2294-2303. PMID: 29463550.
      Citations: 49     Fields:    Translation:HumansCellsCTClinical Trials
    516. Naqvi K, Cortes JE, Luthra R, O'Brien S, Wierda W, Borthakur G, Kadia T, Garcia-Manero G, Ravandi F, Rios MB, Dellasala S, Pierce S, Jabbour E, Patel K, Kantarjian H. Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Int J Hematol. 2018 Jun; 107(6):689-695. PMID: 29464484.
      Citations: 3     Fields:    Translation:Humans
    517. Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia. 2018 10; 32(10):2278-2281. PMID: 29479067.
      Citations: 2     Fields:    Translation:Humans
    518. Jabbour E, DerSarkissian M, Duh MS, McCormick N, Cheng WY, McGarry LJ, Souroutzidis A, Huang H, O'Brien S, Ravandi F, Kantarjian HM. Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2018 04; 18(4):257-265. PMID: 29519619.
      Citations: 16     Fields:    Translation:HumansCells
    519. Kurt H, Zheng L, Kantarjian HM, Tang G, Ravandi-Kashani F, Garcia-Manero G, Gong Z, Amin HM, Konoplev SN, Routbort MJ, Han X, Wang W, Medeiros LJ, Hu S. Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. Mod Pathol. 2018 07; 31(7):1141-1154. PMID: 29449681.
      Citations: 5     Fields:    Translation:HumansCells
    520. Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):230-234. PMID: 28859185; PMCID: PMC5838597.
      Citations: 43     Fields:    Translation:HumansCellsCTClinical Trials
    521. Jabbour EJ, DeAngelo DJ, Stock W, Liedtke M, O'Brien S, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS, Kantarjian HM, Stelljes M, G?kbuget N. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer. 2018 04 15; 124(8):1722-1732. PMID: 29381191.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    522. Kantarjian HM, Sekeres MA, Szer J, Platzbecker U, Gaidano G, Wiktor-Jedrzejczak W, Carpenter N, Mehta B, Franklin J, Fenaux P, Kuendgen A, Giagounidis A. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet Haematol. 2018 Mar; 5(3):e117-e126. PMID: 29396092.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    523. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood. 2018 04 19; 131(16):1820-1832. PMID: 29358183; PMCID: PMC5909764.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    524. Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, DiNardo CD, Konopleva M, Daver N, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, Kadia T. Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Leuk Lymphoma. 2018 09; 59(9):2238-2241. PMID: 29338567.
      Citations: 5     Fields:    Translation:Humans
    525. Masarova L, Alhuraiji A, Bose P, Daver N, Pemmaraju N, Cortes J, Pierce S, Kantarjian H, Verstovsek S. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol. 2018 Mar; 100(3):257-263. PMID: 29226426; PMCID: PMC5814342.
      Citations: 8     Fields:    Translation:HumansCells
    526. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248. PMID: 29352703.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    527. Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018 03; 68(2):153-165. PMID: 29338071; PMCID: PMC6652174.
      Citations: 177     Fields:    Translation:Humans
    528. DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018 02; 19(2):216-228. PMID: 29339097.
      Citations: 235     Fields:    Translation:HumansCTClinical Trials
    529. Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G, Ga?an-Gomez I. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018 Feb 09; 9(11):9714-9727. PMID: 29515765; PMCID: PMC5839396.
      Citations: 23     Fields:    
    530. Masarova L, Kantarjian H, Ravandi F, Sharma P, Garcia-Manero G, Daver N. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice. Adv Exp Med Biol. 2018; 995:97-116. PMID: 30539507.
      Citations: 8     Fields:    Translation:Humans
    531. Jabbour E, Yilmaz M, Khoury JD, Ravandi F, Jain N, Garcia-Manero G, Konopleva M, Short NJ, Thompson PA, Wierda W, Daver N, Cortes J, O'brien S, Kantarjian H, D?ll J, Einsele H, Topp MS. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol. 2018 03; 93(3):371-374. PMID: 29178361.
      Citations: 37     Fields:    Translation:HumansCells
    532. DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018 03; 93(3):401-407. PMID: 29218851.
      Citations: 126     Fields:    Translation:HumansCells
    533. Sasaki K, Kantarjian H, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour E, Cortes JE. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer. 2018 03 15; 124(6):1160-1168. PMID: 29266206; PMCID: PMC5851790.
      Citations: 11     Fields:    Translation:Humans
    534. Nazha A, Sekeres MA, Komrokji R, Steensma DP, Kantarjian H, Roboz G, Fenaux P, Prebet T, Azarnia N, Zbyszewski PS, Fruchtman SM, Santini V, Silverman LR, Garcia-Manero G, Platzbecker U. Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. Blood Cancer J. 2017 12 14; 7(12):644. PMID: 29238044; PMCID: PMC5802598.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    535. Gong Z, Medeiros LJ, Cortes JE, Chen Z, Zheng L, Li Y, Bai S, Lin P, Miranda RN, Jorgensen JL, McDonnell TJ, Wang W, Kantarjian HM, Hu S. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. Blood Adv. 2017 Dec 12; 1(26):2541-2552. PMID: 29296906; PMCID: PMC5728641.
      Citations: 13     Fields:    
    536. Roboz GJ, Kantarjian HM, Yee KWL, Kropf PL, O'Connell CL, Griffiths EA, Stock W, Daver NG, Jabbour E, Ritchie EK, Walsh KJ, Rizzieri D, Lunin SD, Curio T, Chung W, Hao Y, Lowder JN, Azab M, Issa JJ. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. 2018 01 15; 124(2):325-334. PMID: 29211308; PMCID: PMC5814873.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    537. Staquicini DI, D'Angelo S, Ferrara F, Karjalainen K, Sharma G, Smith TL, Tarleton CA, Jaalouk DE, Kuniyasu A, Baze WB, Chaffee BK, Hanley PW, Barnhart KF, Koivunen E, Sidman RL, Cortes JE, Kantarjian HM, Arap W, Pasqualini R, Marchi? S. Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in vitro and formal toxicity study of BMTP-78 in rodents and primates. Pharmacogenomics J. 2018 05 22; 18(3):436-443. PMID: 29205207; PMCID: PMC6824482.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    538. Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285. PMID: 29134664.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    539. Jain P, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z, Nogueras Gonz?lez GM. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol. 2018 01; 180(1):33-40. PMID: 29164608; PMCID: PMC5745295.
      Citations: 11     Fields:    Translation:HumansCells
    540. Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, Estrov Z, Pierce S, Pemmaraju N. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol. 2018 Jan; 97(1):109-121. PMID: 29143068.
      Citations: 8     Fields:    Translation:HumansCells
    541. Masarova L, Yin CC, Cortes JE, Konopleva M, Borthakur G, Newberry KJ, Kantarjian HM, Bueso-Ramos CE, Verstovsek S. Histomorphological responses after therapy with pegylated interferon a-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol. 2017; 6:30. PMID: 29152412; PMCID: PMC5679503.
      Citations: 11     
    542. Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver N. Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma. 2018 07; 59(7):1672-1676. PMID: 29119847.
      Citations: 12     Fields:    Translation:Humans
    543. Alhuraiji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, Daver N, Kadia T, Pemmaraju N, Pierce S, Garcia-Manero G, Wierda W, Verstovsek S, Jabbour E, Cortes J. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol. 2018 01; 93(1):84-90. PMID: 29027261.
      Citations: 14     Fields:    Translation:Humans
    544. Huang X, Cao M, Wu S, Wang L, Hu J, Mehran RJ, Roth JA, Swisher SG, Wang RY, Kantarjian HM, Andreeff M, Sun X, Fang B. Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities. Oncotarget. 2017 Nov 24; 8(60):102150-102160. PMID: 29254232; PMCID: PMC5731942.
      Citations: 3     Fields:    
    545. El Fakih R, Jabbour E, Ravandi F, Hassanein M, Anjum F, Ahmed S, Kantarjian H. Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. Am J Hematol. 2018 Feb; 93(2):286-295. PMID: 28971501.
      Citations: 18     Fields:    Translation:HumansCells
    546. Kantarjian HM, Mamolo CM, Gambacorti-Passerini C, Cortes JE, Su Y, Reisman AL, Shapiro M, Lipton JH, Br?mmendorf TH. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. Cancer. 2018 02 01; 124(3):587-595. PMID: 29072772; PMCID: PMC5813200.
      Citations: 7     Fields:    Translation:HumansCells
    547. Short NJ, Kantarjian H, Jabbour E. Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia. Cancer. 2017 12 15; 123(24):4935-4936. PMID: 29053172.
      Citations: 1     Fields:    Translation:Humans
    548. Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma. 2018 06; 59(6):1312-1322. PMID: 28972430; PMCID: PMC6120342.
      Citations: 4     Fields:    Translation:Humans
    549. Boddu P, Oviedo SP, Rausch CR, Yam C, Daver N, Kantarjian H, Kadia TM. PET-CT in AML-related hemophagocytic lymphohistiocytosis. Leuk Lymphoma. 2018 06; 59(6):1486-1489. PMID: 28958191.
      Citations: 3     Fields:    Translation:Humans
    550. Xu C, Goggin TK, Su XY, Taverna P, Oganesian A, Lowder JN, Azab M, Kantarjian H. Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI-110) in Myeloid Malignancies. CPT Pharmacometrics Syst Pharmacol. 2017 10; 6(10):712-718. PMID: 28960845; PMCID: PMC5658282.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    551. Loghavi S, Curry JL, Garcia-Manero G, Patel KP, Xu J, Khoury JD, Torres-Cabala CA, Nagarajan P, Aung PP, Gibson BR, Goodwin BP, Kelly BC, Korivi BR, Medeiros LJ, Prieto VG, Kantarjian HM, Bueso-Ramos CE, Tetzlaff MT. Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. J Cutan Pathol. 2017 Dec; 44(12):1075-1079. PMID: 28885734.
      Citations: 8     Fields:    Translation:HumansCells
    552. Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver N, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia T. Clinical outcomes in adult patients with aplastic anemia: A single institution experience. Am J Hematol. 2017 Dec; 92(12):1295-1302. PMID: 28850699; PMCID: PMC5987765.
      Citations: 4     Fields:    Translation:Humans
    553. Khan M, Cortes J, Qiao W, Alzubaidi MA, Pierce SA, Ravandi F, Kantarjian HM, Borthakur G. Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):e19-e25. PMID: 29107583; PMCID: PMC5861376.
      Citations: 6     Fields:    Translation:Humans
    554. Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour EJ, Konopleva M, Garcia-Manero G, Cortes J, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia. 2018 01; 32(1):241-244. PMID: 28919634.
      Citations: 16     Fields:    Translation:HumansCells
    555. Brown PA, Shah B, Fathi A, Wieduwilt M, Advani A, Aoun P, Barta SK, Boyer MW, Bryan T, Burke PW, Cassaday R, Coccia PF, Coutre SE, Damon LE, DeAngelo DJ, Frankfurt O, Greer JP, Kantarjian HM, Klisovic RB, Kupfer G, Litzow M, Liu A, Mattison R, Park J, Rubnitz J, Saad A, Uy GL, Wang ES, Gregory KM, Ogba N. NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. J Natl Compr Canc Netw. 2017 09; 15(9):1091-1102. PMID: 28874594.
      Citations: 23     Fields:    Translation:Humans
    556. Jain N, Lu X, Daver N, Thakral B, Wang SA, Konoplev S, Patel K, Kanagal-Shamanna R, Valentine M, Tang G, Pemmaraju N, Jorgensen J, Kebriaei P, Nunez CA, Wierda W, Jabbour E, Roberts KG, Mullighan CG, Kantarjian H, Konopleva M. Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica. 2017 12; 102(12):e514-e517. PMID: 28860345; PMCID: PMC5709127.
      Citations: 5     Fields:    Translation:HumansCells
    557. Boddu P, Kantarjian H, Garcia-Manero G, Ravandi F, Jabbour E, Borthakur G, Daver N, Pemmaraju N, Pierce S, Cortes J, Kadia TM. Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):1012-1015. PMID: 28838278.
      Citations:    Fields:    Translation:HumansCells
    558. Abaza YM, Kadia TM, Jabbour EJ, Konopleva MY, Borthakur G, Ferrajoli A, Estrov Z, Wierda WG, Alfonso A, Chong TH, Chuah C, Koh LP, Goh BC, Chang JE, Durkes DE, Foudray MC, Kantarjian HM, Dong XQ, Garcia-Manero G. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. 2017 Dec 15; 123(24):4851-4859. PMID: 28841236; PMCID: PMC5901648.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    559. Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ, Tibes R. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017 10; 18(10):1317-1326. PMID: 28844816; PMCID: PMC5925750.
      Citations: 60     Fields:    Translation:HumansCTClinical Trials
    560. Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood. 2017 11 09; 130(19):2084-2091. PMID: 28835440; PMCID: PMC5680612.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    561. Masarova L, Verstovsek S, Kantarjian H, Daver N. Immunotherapy based approaches in myelofibrosis. Expert Rev Hematol. 2017 10; 10(10):903-914. PMID: 28799436.
      Citations: 2     Fields:    Translation:HumansCells
    562. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rumi E, Gattoni E, Pieri L, Zhen H, Granier M, Assad A, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood. 2017 10 12; 130(15):1768-1771. PMID: 28827411; PMCID: PMC5639482.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    563. Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, DiNardo C, Burger J, Cortes J, Jain N, Wierda W, Chamoun S, Konopleva M, Jabbour E. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17(12):897-901. PMID: 28927784.
      Citations: 45     Fields:    Translation:Humans
    564. Boddu P, Kantarjian H, Borthakur G, Kadia T, Daver N, Pierce S, Andreeff M, Ravandi F, Cortes J, Kornblau SM. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Adv. 2017 Aug 22; 1(19):1546-1550. PMID: 29296796; PMCID: PMC5728474.
      Citations: 24     Fields:    
    565. Paul S, Rausch CR, Kantarjian H, Jabbour EJ. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin. Future Oncol. 2017 Oct; 13(25):2233-2242. PMID: 28776425.
      Citations: 4     Fields:    Translation:Humans
    566. Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 09 28; 130(13):1514-1522. PMID: 28774880; PMCID: PMC5620419.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    567. Kantarjian H, Talpaz M. New Series: SOHO 'State of the Art Updates and Next Questions'. Clin Lymphoma Myeloma Leuk. 2017 08; 17(8):463. PMID: 28842135.
      Citations:    Fields:    
    568. Jain P, Kantarjian H, Jain N, Short NJ, Yin CC, Kanagal-Shamanna R, Khoury J, Konopleva M, Sasaki K, Kadia TM, Garris R, Pierce S, Estrov Z, Wierda W, Cortes J, O'Brien S, Ravandi F, Jabbour E. Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens. Am J Hematol. 2017 10; 92(10):E595-E597. PMID: 28646517; PMCID: PMC5689471.
      Citations: 2     Fields:    Translation:Humans
    569. Boddu P, Takahashi K, Pemmaraju N, Daver N, Benton CB, Pierce S, Konopleva M, Ravandi F, Cortes J, Kantarjian H, DiNardo CD. Influence of IDH on FLT3-ITD status in newly diagnosed AML. Leukemia. 2017 11; 31(11):2526-2529. PMID: 28751773.
      Citations: 12     Fields:    Translation:HumansCells
    570. Daver N, Kantarjian H. FLT3 inhibition in acute myeloid leukaemia. Lancet Oncol. 2017 08; 18(8):988-989. PMID: 28759368.
      Citations: 2     Fields:    Translation:Humans
    571. Khan M, Cortes J, Kadia T, Naqvi K, Brandt M, Pierce S, Patel KP, Borthakur G, Ravandi F, Konopleva M, Kornblau S, Kantarjian H, Bhalla K, DiNardo CD. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. Int J Mol Sci. 2017 Jul 26; 18(8). PMID: 28933735; PMCID: PMC5578010.
      Citations: 11     Fields:    Translation:HumansCells
    572. Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017 Nov 15; 123(22):4391-4402. PMID: 28743165; PMCID: PMC5673547.
      Citations: 47     Fields:    Translation:Humans
    573. Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F, Nogueras Gonz?lez GM. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Haematologica. 2017 10; 102(10):1709-1717. PMID: 28729302; PMCID: PMC5622855.
      Citations: 7     Fields:    Translation:Humans
    574. Jabbour E, Guastad Daver N, Short NJ, Huang X, Chen HC, Maiti A, Ravandi F, Cortes J, Abi Aad S, Garcia-Manero G, Estrov Z, Kadia T, O'Brien S, Dabaja B, Bueso-Ramos C, Strati P, Bivins C, Pierce S, Kantarjian H. Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol. 2017 Sep; 92(9):924-928. PMID: 28556489; PMCID: PMC5901967.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    575. Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 25; 1(17):1312-1323. PMID: 29296774; PMCID: PMC5727976.
      Citations: 26     Fields:    
    576. Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820. PMID: 28718728; PMCID: PMC5773400.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    577. Gong Z, Medeiros LJ, Cortes JE, Zheng L, Khoury JD, Wang W, Tang G, Loghavi S, Luthra R, Yang W, Kantarjian HM, Hu S. Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. Blood Cancer J. 2017 07 14; 7(7):e583. PMID: 28708130; PMCID: PMC5549254.
      Citations: 16     Fields:    Translation:Humans
    578. Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439. PMID: 28708931; PMCID: PMC5739034.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    579. Yao Z, Deng L, Xu-Monette ZY, Manyam GC, Jain P, Tzankov A, Visco C, Bhagat G, Wang J, Dybkaer K, Tam W, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Winter JN, Fayad L, Liu Y, Song Y, Orlowski RZ, Kantarjian H, Medeiros LJ, Li Y, Cortes J, Young KH, M?ller MB, Piris MA. Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia. 2018 02; 32(2):353-363. PMID: 28745330; PMCID: PMC5985660.
      Citations: 19     Fields:    Translation:Humans
    580. Boddu P, Kantarjian H, Garcia-Manero G, Allison J, Sharma P, Daver N. The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma. 2018 04; 59(4):790-802. PMID: 28679300; PMCID: PMC5872841.
      Citations: 42     Fields:    Translation:HumansCells
    581. Kantarjian HM, DeAngelo DJ, Advani AS, Kebriaei P, Cassaday RD, Merchant AA, Fujishima N, Uchida T, Ejduk AA, O'Brien SM, Jabbour EJ, Zhang H, Sleight BJ, Vandendries ER, Marks DI, Stelljes M, Calbacho M. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017 Aug; 4(8):e387-e398. PMID: 28687420.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    582. Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017 08 31; 130(9):1125-1131. PMID: 28674026; PMCID: PMC5580275.
      Citations: 75     Fields:    Translation:Humans
    583. Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol. 2017 Jul 01; 28(7):1554-1559. PMID: 28379307; PMCID: PMC5834082.
      Citations: 11     Fields:    Translation:Humans
    584. Otrock ZK, Daver N, Kantarjian HM, Eby CS. Diagnostic Challenges of Hemophagocytic Lymphohistiocytosis. Clin Lymphoma Myeloma Leuk. 2017 07; 17S:S105-S110. PMID: 28760295.
      Citations: 16     Fields:    Translation:Humans
    585. Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D'Anca M, Storti P, Samur MK, Ganan-Gomez I, Fulciniti MT, Mistry N, Jiang S, Bao N, Marchica V, Neri A, Bueso-Ramos C, Wu CJ, Zhang L, Liang H, Peng X, Giuliani N, Draetta G, Clise-Dwyer K, Kantarjian H, Munshi N, Orlowski R, Garcia-Manero G, DePinho RA, Colla S. ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Cancer Cell. 2017 07 10; 32(1):88-100.e6. PMID: 28669490; PMCID: PMC5593798.
      Citations: 51     Fields:    Translation:HumansCells
    586. Zeng Z, Liu W, Tsao T, Qiu Y, Zhao Y, Samudio I, Sarbassov DD, Kornblau SM, Baggerly KA, Kantarjian HM, Konopleva M, Andreeff M. High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. Haematologica. 2017 09; 102(9):1537-1548. PMID: 28659338; PMCID: PMC5685227.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    587. DeAngelo DJ, Stock W, Stein AS, Shustov A, Liedtke M, Schiffer CA, Vandendries E, Liau K, Ananthakrishnan R, Boni J, Laird AD, Fostvedt L, Kantarjian HM, Advani AS. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017 Jun 27; 1(15):1167-1180. PMID: 29296758; PMCID: PMC5728308.
      Citations: 38     Fields:    
    588. Takahashi K, Wang F, Kantarjian H, Song X, Patel K, Neelapu S, Gumbs C, Little L, Tippen S, Thornton R, DiNardo CD, Ravandi F, Bueso-Ramos C, Zhang J, Wu X, Garcia-Manero G, Futreal PA. Copy number alterations detected as clonal hematopoiesis of indeterminate potential. Blood Adv. 2017 Jun 27; 1(15):1031-1036. PMID: 29296745; PMCID: PMC5728325.
      Citations: 15     Fields:    
    589. Cortes JE, Gambacorti-Passerini C, Kim DW, Kantarjian HM, Lipton JH, Lahoti A, Talpaz M, Matczak E, Barry E, Leip E, Khoury HJ, Br?mmendorf TH. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. Clin Lymphoma Myeloma Leuk. 2017 10; 17(10):684-695.e6. PMID: 28807791.
      Citations: 13     Fields:    Translation:HumansCells
    590. Daver N, McClain K, Allen CE, Parikh SA, Otrock Z, Rojas-Hernandez C, Blechacz B, Wang S, Minkov M, Jordan MB, Kantarjian HM, La Ros?e P. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer. 2017 Sep 01; 123(17):3229-3240. PMID: 28621800; PMCID: PMC5568927.
      Citations: 58     Fields:    Translation:Humans
    591. Short NJ, Kantarjian H, Jabbour E, Ravandi F. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia? Best Pract Res Clin Haematol. 2017 09; 30(3):193-200. PMID: 29050692.
      Citations: 12     Fields:    Translation:HumansCells
    592. Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, Daver N, Alvarado Y, Konopleva M, Kebriaei P, Wierda WG, DiNardo CD, Bivins C, McCue D, Richie MA, Ravandi F. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol. 2018 08; 182(3):442-444. PMID: 28616864; PMCID: PMC6511975.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    593. Muus P, Kantarjian H, Lyons RM, Larson RA, Sekeres MA, Becker PS, Orejudos A, Franklin J, Fenaux P. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. Br J Haematol. 2017 09; 178(6):906-913. PMID: 28616874; PMCID: PMC5600084.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    594. Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour E. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer. 2017 Oct 01; 123(19):3717-3724. PMID: 28608976; PMCID: PMC5689475.
      Citations: 7     Fields:    Translation:Humans
    595. Daher M, Hidalgo Lopez JE, Randhawa JK, Jabbar KJ, Wei Y, Pemmaraju N, Borthakur G, Kadia T, Konopleva M, Kantarjian HM, Hearn K, Estrov Z, Reyes S, Bueso-Ramos CE, Garcia-Manero G. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. Am J Hematol. 2017 Jul; 92(7):674-682. PMID: 28370157; PMCID: PMC5580683.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    596. Ragon BK, Daver N, Garcia-Manero G, Ravandi F, Cortes J, Kadia T, Oran B, Ohanian M, Ferrajoli A, Pemmaraju N, Kantarjian HM, Borthakur G. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. Am J Hematol. 2017 Sep; 92(9):845-850. PMID: 28494506; PMCID: PMC5779853.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    597. Kantarjian H, Jabbour E, Topp MS. Blinatumomab for Acute Lymphoblastic Leukemia. N Engl J Med. 2017 06 08; 376(23):e49. PMID: 28591537.
      Citations: 13     Fields:    Translation:Humans
    598. Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, Tallman MS, Willekens C, de Botton S. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 08 10; 130(6):722-731. PMID: 28588020; PMCID: PMC5572791.
      Citations: 464     Fields:    Translation:HumansCTClinical Trials
    599. Kantarjian HM, Schuster MW, Jain N, Advani A, Jabbour E, Gamelin E, Rasmussen E, Juan G, Anderson A, Chow VF, Friberg G, Vogl FD, Sekeres MA. A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia. Am J Hematol. 2017 Jul; 92(7):660-667. PMID: 28370201; PMCID: PMC5925751.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    600. Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res. 2017 08; 59:110-116. PMID: 28601551; PMCID: PMC5573611.
      Citations: 16     Fields:    Translation:Humans
    601. Jain P, Wang S, Patel KP, Sarwari N, Cortes J, Kantarjian H, Verstovsek S. Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome. Leuk Res. 2017 08; 59:105-109. PMID: 28599188; PMCID: PMC5573652.
      Citations: 4     Fields:    Translation:Humans
    602. Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes J, Estrov Z, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. 2017 Jul; 92(7):599-606. PMID: 28370097; PMCID: PMC5553721.
      Citations: 17     Fields:    Translation:HumansCells
    603. Masarova L, Todisco G, Manshouri T, Newberry KJ, Cortes JE, Kantarjian HM, Estrov Z, Verstovsek S. Therapy-related myelofibrosis does not appear to exist. Blood Adv. 2017 Jun 13; 1(14):863-866. PMID: 29296729; PMCID: PMC5737601.
      Citations: 1     Fields:    
    604. Falchi L, Kantarjian HM, Verstovsek S. Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era. Leukemia. 2017 09; 31(9):1845-1854. PMID: 28529308; PMCID: PMC5989314.
      Citations: 7     Fields:    Translation:Humans
    605. Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour E. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017 06; 92(6):E114-E117. PMID: 28295472; PMCID: PMC5828013.
      Citations: 7     Fields:    Translation:Humans
    606. Kongtim P, Adekola K, Milton DR, Ramlal R, Jimenez A, Chen J, Rondon G, Ahmed S, Kebriaei P, Betul O, Hosing CM, Popat U, Khouri I, Jabbour E, Cortes JE, Kantarjian HM, Champlin RE, Ciurea SO. Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Leukemia. 2017 07; 31(7):1654-1657. PMID: 28400618; PMCID: PMC6192023.
      Citations: 1     Fields:    Translation:Humans
    607. Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017 Aug 15; 123(16):3050-3060. PMID: 28387922; PMCID: PMC5544569.
      Citations: 15     Fields:    Translation:Humans
    608. Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE, Nicolini FE. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017 Aug 01; 123(15):2875-2880. PMID: 28387926; PMCID: PMC5573914.
      Citations: 30     Fields:    Translation:HumansCells
    609. Salem A, Loghavi S, Tang G, Huh YO, Jabbour EJ, Kantarjian H, Wang W, Hu S, Luthra R, Medeiros LJ, Khoury JD. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm. Am J Hematol. 2017 Jun; 92(6):520-528. PMID: 28253536; PMCID: PMC5860811.
      Citations: 8     Fields:    Translation:HumansCells
    610. Yilmaz M, Kantarjian H, Jabbour E. Treatment of acute lymphoblastic leukemia in older adults: now and the future. Clin Adv Hematol Oncol. 2017 Apr; 15(4):266-274. PMID: 28591103.
      Citations: 6     Fields:    Translation:Humans
    611. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 07; 31(7):1659. PMID: 28338082.
      Citations: 3     Fields:    
    612. Rytting ME, Jabbour EJ, O'Brien SM, Kantarjian HM. Acute lymphoblastic leukemia in adolescents and young adults. Cancer. 2017 Jul 01; 123(13):2398-2403. PMID: 28328172.
      Citations: 16     Fields:    Translation:Humans
    613. Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, Estrov Z, Kantarjian H, Verstovsek S. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017 Apr; 4(4):e165-e175. PMID: 28291640; PMCID: PMC5421384.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    614. IRIS Investigators, Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017 03 09; 376(10):917-927. PMID: 28273028; PMCID: PMC5901965.
      Citations: 335     Fields:    Translation:Humans
    615. Kantarjian H, Stein A, G?kbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Fo? R, Bassan R, Arslan ?, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Br?ggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017 03 02; 376(9):836-847. PMID: 28249141; PMCID: PMC5881572.
      Citations: 495     Fields:    Translation:HumansCTClinical Trials
    616. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood. 2017 05 04; 129(18):2584-2587. PMID: 28246192; PMCID: PMC5418636.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    617. Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H, COMFORT-I investigators. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017 02 22; 10(1):55. PMID: 28228106; PMCID: PMC5322633.
      Citations: 124     Fields:    Translation:HumansCTClinical Trials
    618. Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol. 2017 Apr; 92(4):351-358. PMID: 28076892; PMCID: PMC5439522.
      Citations: 3     Fields:    Translation:HumansCells
    619. Maiti A, Cortes J, Ferrajoli A, Estrov Z, Borthakur G, Garcia-Manero G, Jabbour E, Ravandi F, O'Brien S, Kantarjian H. Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-6. PMID: 28278723; PMCID: PMC5478443.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    620. Kantarjian H, Patel Y. High cancer drug prices 4 years later-Progress and prospects. Cancer. 2017 04 15; 123(8):1292-1297. PMID: 28182263.
      Citations: 7     Fields:    Translation:Humans
    621. Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O'Brien S, Wierda WG. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017 Jun 15; 123(12):2268-2273. PMID: 28171709; PMCID: PMC5980235.
      Citations: 42     Fields:    Translation:Humans
    622. Savage P, Mahmoud S, Patel Y, Kantarjian H. Cancer Drugs: An International Comparison of Postlicensing Price Inflation. J Oncol Pract. 2017 06; 13(6):e538-e542. PMID: 28605615.
      Citations: 11     Fields:    Translation:Humans
    623. Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017 Mar; 92(3):238-243. PMID: 28006851; PMCID: PMC5495018.
      Citations: 12     Fields:    Translation:HumansCells
    624. Daver N, Kantarjian H. Malignancy-associated haemophagocytic lymphohistiocytosis in adults. Lancet Oncol. 2017 02; 18(2):169-171. PMID: 28214404.
      Citations: 8     Fields:    Translation:Humans
    625. Pemmaraju N, Kantarjian H, Jorgensen JL, Jabbour E, Jain N, Thomas D, O'Brien S, Wang X, Huang X, Wang SA, Konopleva M, Konoplev S, Kadia T, Garris R, Pierce S, Garcia-Manero G, Cortes J, Ravandi F. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol. 2017 Mar; 92(3):279-285. PMID: 28052371; PMCID: PMC5851443.
      Citations: 11     Fields:    Translation:Humans
    626. Pinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, Daver N, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya-Matsuoka C, Woodman K, Dinardo C, Jain N, Kadia TM, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS. Dorsal column myelopathy after intrathecal chemotherapy for leukemia. Am J Hematol. 2017 Feb; 92(2):155-160. PMID: 27874212; PMCID: PMC5338569.
      Citations: 1     Fields:    Translation:Humans
    627. Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA, Wong SL, Menon RM, Konopleva MY, Salem AH. Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments. Clin Ther. 2017 Feb; 39(2):359-367. PMID: 28161120.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    628. Dinardo CD, Luskin MR, Carroll M, Smith C, Harrison J, Pierce S, Kornblau S, Konopleva M, Kadia T, Kantarjian H, Wertheim GB, Master SR. Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML. Am J Hematol. 2017 Feb; 92(2):E14-E15. PMID: 27804182; PMCID: PMC5915352.
      Citations: 5     Fields:    Translation:HumansCells
    629. Burger JA, Li KW, Keating MJ, Sivina M, Amer AM, Garg N, Ferrajoli A, Huang X, Kantarjian H, Wierda WG, O'Brien S, Hellerstein MK, Turner SM, Emson CL, Chen SS, Yan XJ, Wodarz D, Chiorazzi N. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight. 2017 01 26; 2(2):e89904. PMID: 28138560; PMCID: PMC5256142.
      Citations: 38     Fields:    Translation:Humans
    630. Garcia-Manero G, Montalban-Bravo G, Berdeja JG, Abaza Y, Jabbour E, Essell J, Lyons RM, Ravandi F, Maris M, Heller B, DeZern AE, Babu S, Wright D, Anz B, Boccia R, Komrokji RS, Kuriakose P, Reeves J, Sekeres MA, Kantarjian HM, Ghalie R, Roboz GJ. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Cancer. 2017 May 15; 123(6):994-1002. PMID: 28094841; PMCID: PMC5432122.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    631. Han L, Jorgensen JL, Brooks C, Shi C, Zhang Q, Cavazos A, Pan R, Mu H, Wang SA, Zhou J, Ai-Atrash G, Ciurea SO, Rettig M, DiPersio JF, Cortes J, Huang X, Kantarjian HM, Andreeff M, Ravandi F, Konopleva M, Nogueras Gonz?lez GM. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia. Clin Cancer Res. 2017 07 01; 23(13):3385-3395. PMID: 28096272; PMCID: PMC5496806.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    632. Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb; 4(2):e67-e74. PMID: 28089238; PMCID: PMC5356368.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    633. Kelly AD, Kroeger H, Yamazaki J, Taby R, Neumann F, Yu S, Lee JT, Patel B, Li Y, He R, Liang S, Lu Y, Cesaroni M, Pierce SA, Kornblau SM, Bueso-Ramos CE, Ravandi F, Kantarjian HM, Jelinek J, Issa JP. A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome. Leukemia. 2017 10; 31(10):2011-2019. PMID: 28074068; PMCID: PMC5537054.
      Citations: 19     Fields:    Translation:HumansCells
    634. Masarova L, Kantarjian H, Garcia-Mannero G, Ravandi F, Sharma P, Daver N. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. Adv Exp Med Biol. 2017; 995:73-95. PMID: 28321813.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    635. Bennett CL, Sartor OA, Armitage JO, Kantarjian H. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA. Lancet Oncol. 2017 01; 18(1):22-23. PMID: 28049571.
      Citations: 3     Fields:    Translation:Humans
    636. Ravandi F, Othus M, O'Brien SM, Forman SJ, Ha CS, Wong JYC, Tallman MS, Paietta E, Racevskis J, Uy GL, Horowitz M, Takebe N, Little R, Borate U, Kebriaei P, Kingsbury L, Kantarjian HM, Radich JP, Erba HP, Appelbaum FR. US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. Blood Adv. 2016 Dec 27; 1(3):250-259. PMID: 29046900; PMCID: PMC5642915.
      Citations: 34     Fields:    
    637. Jabbour E, Kantarjian H. Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies. Blood Adv. 2016 Dec 27; 1(3):260-264. PMID: 29296940; PMCID: PMC5737178.
      Citations: 4     Fields:    
    638. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 03 09; 129(10):1275-1283. PMID: 28003274; PMCID: PMC5413297.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    639. Shah AR, Muzzafar T, Assi R, Schellingerhout D, Estrov Z, Tamamyan G, Kantarjian H, Daver N. Hemophagocytic lymphohistiocytosis in adults: An under recognized entity. BBA Clin. 2017 Jun; 7:36-40. PMID: 28070498; PMCID: PMC5219626.
      Citations: 7     
    640. Tamamyan G, Kadia T, Ravandi F, Borthakur G, Cortes J, Jabbour E, Daver N, Ohanian M, Kantarjian H, Konopleva M. Frontline treatment of acute myeloid leukemia in adults. Crit Rev Oncol Hematol. 2017 Feb; 110:20-34. PMID: 28109402; PMCID: PMC5410376.
      Citations: 42     Fields:    Translation:HumansAnimals
    641. Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver N. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol. 2017 Jan; 92(1):7-11. PMID: 27673440; PMCID: PMC5361214.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    642. Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, Van Etten RA. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. 2017 03; 102(3):519-528. PMID: 27927766; PMCID: PMC5394958.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    643. Jain N, Roberts KG, Jabbour E, Patel K, Eterovic AK, Chen K, Zweidler-McKay P, Lu X, Fawcett G, Wang SA, Konoplev S, Harvey RC, Chen IM, Payne-Turner D, Valentine M, Thomas D, Garcia-Manero G, Ravandi F, Cortes J, Kornblau S, O'Brien S, Pierce S, Jorgensen J, Shaw KR, Willman CL, Mullighan CG, Kantarjian H, Konopleva M. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017 02 02; 129(5):572-581. PMID: 27919910; PMCID: PMC5290985.
      Citations: 95     Fields:    Translation:HumansCells
    644. Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, Zhao L, Patel K, Neelapu S, Gumbs C, Bueso-Ramos C, DiNardo CD, Colla S, Ravandi F, Zhang J, Huang X, Wu X, Samaniego F, Garcia-Manero G, Futreal PA. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 2017 01; 18(1):100-111. PMID: 27923552; PMCID: PMC5405697.
      Citations: 100     Fields:    Translation:HumansCells
    645. Cortes J, Kantarjian H. Chronic myeloid leukemia: sequencing of TKI therapies. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):164-169. PMID: 27913476; PMCID: PMC6142480.
      Citations: 5     Fields:    Translation:Humans
    646. Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom RT, Hobbs G, Jagasia M, Kantarjian HM, Kropf P, Metheny L, Moore JO, Ontiveros E, Purev E, Quiery A, Reddy VV, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Tibes R, Yang DT, Gregory K, Sundar H, Deininger M, Radich JP. NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. J Natl Compr Canc Netw. 2016 12; 14(12):1505-1512. PMID: 27956535.
      Citations: 23     Fields:    Translation:Humans
    647. Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA. Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clin Cancer Res. 2017 06 01; 23(11):2891-2904. PMID: 27903673; PMCID: PMC5449263.
      Citations: 59     Fields:    Translation:HumansAnimalsCells
    648. Kantarjian HM, Vandendries E, Advani AS. Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia. N Engl J Med. 2016 11 24; 375(21):2100-2101. PMID: 27959720.
      Citations: 7     Fields:    Translation:Humans
    649. Chen Q, Jain N, Ayer T, Wierda WG, Flowers CR, O'Brien SM, Keating MJ, Kantarjian HM, Chhatwal J. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. J Clin Oncol. 2017 Jan 10; 35(2):166-174. PMID: 27870563; PMCID: PMC5559889.
      Citations: 49     Fields:    Translation:Humans
    650. Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen IM, Pei D, Iacobucci I, Valentine M, Pounds SB, Shi L, Li Y, Zhang J, Cheng C, Rambaldi A, Tosi M, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Wiernik PH, Bhatia R, Aldoss I, Kohlschmidt J, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Mullighan CG, Mr?zek K. High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol. 2017 Feb; 35(4):394-401. PMID: 27870571; PMCID: PMC5455698.
      Citations: 114     Fields:    Translation:Humans
    651. Ding LW, Sun QY, Tan KT, Chien W, Mayakonda A, Yeoh AEJ, Kawamata N, Nagata Y, Xiao JF, Loh XY, Lin DC, Garg M, Jiang YY, Xu L, Lim SL, Liu LZ, Madan V, Sanada M, Hema Preethi SS, Lill M, Kantarjian HM, Kornblau SM, Miyano S, Liang DC, Ogawa S, Shih LY, Yang H, Koeffler HP, Fern?ndez LT. Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia. Cancer Res. 2017 01 15; 77(2):390-400. PMID: 27872090; PMCID: PMC5243866.
      Citations: 42     Fields:    Translation:HumansAnimals
    652. Jain P, Kantarjian H, Jabbour E, Kanagal-Shamanna R, Patel K, Pierce S, Garcia-Manero G, Borthakur G, Ravandi F, O'Brien S, Cortes J. Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML). Am J Hematol. 2017 Jan; 92(1):E3-E4. PMID: 27727470; PMCID: PMC5551407.
      Citations: 5     Fields:    Translation:HumansCells
    653. Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I, Shao Y, Chen IM, Valentine M, Pei D, Mungall KL, Mungall AJ, Ma Y, Moore R, Marra M, Stonerock E, Gastier-Foster JM, Devidas M, Dai Y, Wood B, Borowitz M, Larsen EE, Maloney K, Mattano LA, Angiolillo A, Salzer WL, Burke MJ, Gianni F, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger SM, Bhatia R, Aldoss I, Forman SJ, Kohlschmidt J, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Loh ML, Hunger SP, Mullighan CG, Mr?zek K. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun. 2016 11 08; 7:13331. PMID: 27824051; PMCID: PMC5105166.
      Citations: 95     Fields:    Translation:HumansAnimalsCells
    654. Paul S, Kantarjian H, Jabbour EJ. Adult Acute Lymphoblastic Leukemia. Mayo Clin Proc. 2016 Nov; 91(11):1645-1666. PMID: 27814839.
      Citations: 61     Fields:    Translation:HumansCells
    655. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 02; 31(2):318-324. PMID: 27795561.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    656. Koller PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, Verstovsek S, Borthakur G, Estrov Z, Wierda WG, Garcia-Manero G, Ferrajoli A, Ravandi F, O'Brien SM, Cortes JE. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer. 2017 02 15; 123(4):609-616. PMID: 27763690; PMCID: PMC5293656.
      Citations:    Fields:    Translation:Humans
    657. Stringaris K, Marin D, Barrett AJ, Hills R, Sobieski C, Cao K, Saltarrelli JG, Daher M, Shaim H, Smith N, Linch D, Gale R, Allen C, Sekine T, Mehta R, Champlin R, Shpall EJ, Kantarjian H, Garcia-Manero G, Rezvani K. KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. Blood. 2016 12 15; 128(24):2819-2823. PMID: 27760759; PMCID: PMC5159704.
      Citations: 10     Fields:    Translation:Humans
    658. Jain P, Keating MJ, Wierda WG, Sivina M, Thompson PA, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien S, Burger JA. Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 01; 23(9):2154-2158. PMID: 27797975; PMCID: PMC5397369.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    659. Jabbour E, Faderl S, Sasaki K, Kadia T, Daver N, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. 2017 Feb 15; 123(4):629-637. PMID: 27741352.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    660. Economides MP, Mahale P, Kyvernitakis A, Turturro F, Kantarjian H, Naing A, Hosry J, Shigle TL, Kaseb A, Torres HA. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. Aliment Pharmacol Ther. 2016 12; 44(11-12):1235-1241. PMID: 27730654; PMCID: PMC5123740.
      Citations: 12     Fields:    Translation:HumansCells
    661. Kantarjian HM. The Affordable Care Act, or Obamacare, 3 years later: A reality check. Cancer. 2017 01 01; 123(1):25-28. PMID: 27727444.
      Citations:    Fields:    
    662. Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D, Yoshida K, Ganesan S, Hattori N, Fulton N, Tan KT, Alpermann T, Kuo MC, Rostami S, Matthews J, Sanada M, Liu LZ, Shiraishi Y, Miyano S, Chendamarai E, Hou HA, Malnassy G, Ma T, Garg M, Ding LW, Sun QY, Chien W, Ikezoe T, Lill M, Biondi A, Larson RA, Powell BL, Chng WJ, Tien HF, Heuser M, Ganser A, Koren-Michowitz M, Kornblau SM, Kantarjian HM, Nowak D, Hofmann WK, Yang H, Stock W, Ghavamzadeh A, Alimoghaddam K, Haferlach T, Ogawa S, Shih LY, Mathews V, Koeffler HP, L?bbert M. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia. 2016 12; 30(12):2430. PMID: 27713533; PMCID: PMC7609306.
      Citations: 14     Fields:    
    663. Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017 02 01; 123(3):459-467. PMID: 27696391; PMCID: PMC5321542.
      Citations: 18     Fields:    Translation:Humans
    664. Rozovski U, Verstovsek S, Manshouri T, Dembitz V, Bozinovic K, Newberry K, Zhang Y, Bove JE, Pierce S, Kantarjian H, Estrov Z. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis. Haematologica. 2017 01; 102(1):79-84. PMID: 27686378; PMCID: PMC5210235.
      Citations: 11     Fields:    Translation:Humans
    665. Maiti A, Cortes JE, Brown YD, Kantarjian HM. Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors. Leuk Lymphoma. 2017 03; 58(3):722-725. PMID: 27658536; PMCID: PMC5250544.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    666. Kelsh M, Chia V, Advani A, Doubek M, Fielding AK, Giebel S, Haddad V, Hoelzer D, Holland C, Ifrah N, Katz A, Maniar T, Martinelli G, Morgades M, O'Brien S, Ribera JM, Rowe JM, Stein A, Wadleigh M, Kantarjian H, G?kbuget N, Bassan R, Dombret H, Topp M. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J. 2016 Sep 23; 6(9):e473. PMID: 27662202; PMCID: PMC5056974.
      Citations: 39     Fields:    
    667. Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. 2017 02 01; 123(3):426-435. PMID: 27657543; PMCID: PMC5258784.
      Citations: 28     Fields:    Translation:Humans
    668. Cortes JE, Khoury HJ, Kantarjian HM, Lipton JH, Kim DW, Schafhausen P, Matczak E, Leip E, Noonan K, Gambacorti-Passerini C, Br?mmendorf TH. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol. 2016 12; 91(12):1206-1214. PMID: 27531525; PMCID: PMC5303616.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    669. Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017 01 01; 123(2):294-302. PMID: 27602508; PMCID: PMC5321541.
      Citations: 29     Fields:    Translation:HumansCells
    670. Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Huang X, Cortes J, Kantarjian H, Konopleva M, Andreeff M. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med. 2016 09 07; 8(355):355ra117. PMID: 27605552; PMCID: PMC5111086.
      Citations: 56     Fields:    Translation:HumansAnimalsCells
    671. Gupta V, Harrison C, Hexner EO, Al-Ali HK, Foltz L, Montgomery M, Sun W, Gopalakrishna P, Kantarjian H, Verstovsek S. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica. 2016 12; 101(12):e482-e484. PMID: 27587385; PMCID: PMC5479619.
      Citations: 23     Fields:    Translation:Humans
    672. Ribera JM, Fielding AK, Advani A, Bassan R, Chia V, Doubek M, Giebel S, Hoelzer D, Ifrah N, Katz A, Kelsh M, Martinelli G, Morgades M, O'Brien S, Rowe JM, Stieglmaier J, Wadleigh M, Kantarjian H, G?kbuget N, Dombret H. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016 12; 101(12):1524-1533. PMID: 27587380; PMCID: PMC5479605.
      Citations: 57     Fields:    Translation:HumansCells
    673. Short NJ, Benton CB, Chen HC, Qiu P, Gu L, Pierce S, Brandt M, Maiti A, Min TL, Naqvi K, Quintas-Cardama A, Konopleva M, Kadia T, Cortes J, Garcia-Manero G, Ravandi F, Jabbour E, Kantarjian H, Andreeff M. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. Am J Hematol. 2016 12; 91(12):1221-1226. PMID: 27474808; PMCID: PMC5118152.
      Citations: 2     Fields:    Translation:Humans
    674. Zeng Z, Wang RY, Qiu YH, Mak DH, Coombes K, Yoo SY, Zhang Q, Jessen K, Liu Y, Rommel C, Fruman DA, Kantarjian HM, Kornblau SM, Andreeff M, Konopleva M. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. Oncotarget. 2016 Aug 23; 7(34):55083-55097. PMID: 27391151; PMCID: PMC5342403.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    675. Zimmerman Z, Kantarjian HM, Topp MS. Correction regarding data on blinatumomab-associated seizures. Nat Rev Clin Oncol. 2016 10; 13(10):650. PMID: 27550855.
      Citations: 1     Fields:    Translation:Humans
    676. Jain P, Kanagal-Shamanna R, Wierda W, Keating M, Sarwari N, Rozovski U, Thompson P, Burger J, Kantarjian H, Patel KP, Medeiros LJ, Luthra R, Estrov Z. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol. 2016 11; 91(11):E478-E479. PMID: 27468087; PMCID: PMC5073031.
      Citations: 9     Fields:    Translation:Humans
    677. Greenberg PL, Tuechler H, Sanz G, Garcia-Manero G, Bennett JM, Bowen D, Kantarjian H, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Schanz J, Sol? F, Fenaux P, Dreyfus F, Kuendgen A, Pfeilst?cker M, Germing U, Haase D. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood. 2016 10 20; 128(16):2096-2097. PMID: 27535995; PMCID: PMC5341483.
      Citations: 9     Fields:    Translation:Humans
    678. Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 2016 10; 6(10):1106-1117. PMID: 27520294; PMCID: PMC5436271.
      Citations: 344     Fields:    Translation:HumansCTClinical Trials
    679. Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour E. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016 Dec 15; 122(24):3812-3820. PMID: 27508525; PMCID: PMC5321530.
      Citations: 7     Fields:    Translation:HumansCells
    680. Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver N, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 2016 Nov 15; 122(21):3336-3343. PMID: 27509035; PMCID: PMC5073019.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    681. Sasaki K, Jabbour E, Cortes J, Kadia T, Garcia-Manero G, Borthakur G, Jain P, Pierce S, Daver N, Takahashi K, O'Brien S, Kantarjian H, Ravandi F. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clin Lymphoma Myeloma Leuk. 2016 11; 16(11):616-624. PMID: 27601000; PMCID: PMC5408349.
      Citations: 5     Fields:    Translation:Humans
    682. Naqvi K, Daver N, Pemmaraju N, Bose P, Garcia-Manero G, Cortes J, Kantarjian HM, Verstovsek S. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leuk Lymphoma. 2017 04; 58(4):866-871. PMID: 27494751; PMCID: PMC5521009.
      Citations: 2     Fields:    Translation:Humans
    683. Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ, Forget MA. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016 09 01; 126(9):3363-76. PMID: 27482888; PMCID: PMC5004935.
      Citations: 172     Fields:    Translation:HumansCellsCTClinical Trials
    684. Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016 Dec 01; 122(23):3650-3656. PMID: 27479888; PMCID: PMC5321539.
      Citations: 51     Fields:    Translation:HumansCellsCTClinical Trials
    685. Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos CE, Newberry KJ, Prijic S, Knez L, Bozinovic K, Harris DM, Spaeth EL, Post SM, Multani AS, Rampal RK, Ahn J, Levine RL, Creighton CJ, Kantarjian HM, Estrov Z. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med. 2016 08 22; 213(9):1723-40. PMID: 27481130; PMCID: PMC4995084.
      Citations: 69     Fields:    Translation:HumansAnimalsCells
    686. List AF, Kantarjian H, Freireich EJ. Proceedings of the Third Annual Meeting of the Society of Hematologic Oncology. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S1. PMID: 27521304.
      Citations:    Fields:    Translation:Humans
    687. Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016 Nov 15; 122(22):3484-3491. PMID: 27463065; PMCID: PMC5269552.
      Citations: 71     Fields:    
    688. Ravandi F, Gojo I, Patnaik MM, Minden MD, Kantarjian H, Johnson-Levonas AO, Fancourt C, Lam R, Jones MB, Knox CD, Rose S, Patel PS, Tibes R. A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). Leuk Res. 2016 09; 48:92-100. PMID: 27544076; PMCID: PMC5408350.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    689. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M?nster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016 08; 91(8):819-23. PMID: 27178680; PMCID: PMC5558853.
      Citations: 36     Fields:    Translation:HumansCells
    690. Badar T, Handisides DR, Benito JM, Richie MA, Borthakur G, Jabbour E, Harutyunyan K, Konoplev S, Faderl S, Kroll S, Andreeff M, Pearce T, Kantarjian HM, Cortes JE, Thomas DA, Konopleva M. Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia. Am J Hematol. 2016 08; 91(8):800-5. PMID: 27169385; PMCID: PMC4946992.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    691. Chihara D, Masarova L, Newberry KJ, Maeng H, Ravandi F, Garcia-Manero G, Ferrajoli A, Cortes J, Kantarjian H, Verstovsek S. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leuk Res. 2016 09; 48:1-5. PMID: 27416326; PMCID: PMC5407688.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    692. Tuechler H, Sanz G, Garcia-Manero G, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Levis A, Luebbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SM, Miyazaki Y, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Greenberg PL, Pfeilst?cker M, Schanz J, Sol? F, Kuendgen A, Germing U, Haase D. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016 08 18; 128(7):902-10. PMID: 27335276; PMCID: PMC5161006.
      Citations: 45     Fields:    Translation:Humans
    693. Masarova L, Wang W, Newberry KJ, Kantarjian H, Verstovsek S. Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis. Blood. 2016 08 11; 128(6):877-80. PMID: 27325105; PMCID: PMC4982456.
      Citations: 3     Fields:    Translation:Humans
    694. Shah NP, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Saglio G, Rousselot P, Hochhaus A. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016 09; 91(9):869-74. PMID: 27192969; PMCID: PMC5094534.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    695. Chihara D, Kantarjian H, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Poku R, Jain P, Thompson P, Brandt M, Luthra R, Burger J, Keating M, Ravandi F. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016 Sep; 174(5):760-6. PMID: 27301277; PMCID: PMC5396841.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    696. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, G?kbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016 Aug 25; 375(8):740-53. PMID: 27292104; PMCID: PMC5594743.
      Citations: 358     Fields:    Translation:HumansCTClinical Trials
    697. Sun QY, Ding LW, Tan KT, Chien W, Mayakonda A, Lin DC, Loh XY, Xiao JF, Meggendorfer M, Alpermann T, Garg M, Lim SL, Madan V, Hattori N, Nagata Y, Miyano S, Yeoh AE, Hou HA, Jiang YY, Takao S, Liu LZ, Tan SZ, Lill M, Hayashi M, Kinoshita A, Kantarjian HM, Kornblau SM, Ogawa S, Haferlach T, Yang H, Koeffler HP. Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD). Leukemia. 2017 01; 31(1):1-10. PMID: 27389053; PMCID: PMC5214979.
      Citations: 31     Fields:    Translation:HumansCells
    698. Piya S, Kornblau SM, Ruvolo VR, Mu H, Ruvolo PP, McQueen T, Davis RE, Hail N, Kantarjian H, Andreeff M, Borthakur G. Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. Blood. 2016 09 01; 128(9):1260-9. PMID: 27268264; PMCID: PMC5009514.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    699. Tamamyan GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, Konopleva MY, Garcia-Manero G, Benton CB, Chihara D, Rytting ME, Wang S, Abdelall W, Konoplev SN, Daver NG. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer. 2016 09 15; 122(18):2857-66. PMID: 27244347; PMCID: PMC5014667.
      Citations: 30     Fields:    Translation:Humans
    700. Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE, Garris R, Issa GC, Garcia-Manero G, Luthra R, Thomas D, Kantarjian H, Ravandi F. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016 07 28; 128(4):504-7. PMID: 27235138; PMCID: PMC4965905.
      Citations: 63     Fields:    Translation:HumansCells
    701. Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu? C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na?ve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016 07 10; 34(20):2333-40. PMID: 27217448; PMCID: PMC5118045.
      Citations: 243     Fields:    Translation:HumansCTClinical Trials
    702. Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Dal Cin P, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O'Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016 05 20; 7:11589. PMID: 27199251; PMCID: PMC4876453.
      Citations: 131     Fields:    Translation:Humans
    703. Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Jain P, Satta T, Pierce S, Rios MB, Cortes JE. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica. 2016 08; 101(8):e324-7. PMID: 27175025; PMCID: PMC4967581.
      Citations: 2     Fields:    Translation:Humans
    704. Chen Z, Wang W, Cortes JE, Liu E, Miranda RN, Zhao C, Yuan J, Lu X, Yang W, Ameri MD, Kantarjian HM, Medeiros LJ, Hu S. Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood Cancer J. 2016 05 06; 6:e418. PMID: 27152845; PMCID: PMC4916296.
      Citations: 5     Fields:    Translation:Humans
    705. Kantarjian HM, Stein AS, Grande Garcia C, Larson RA, Stelljes M, Zugmaier G, Benjamin JE, Zhang A, Jia C, Bargou RC, G?kbuget N, Topp MS. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Cancer. 2016 07 15; 122(14):2178-85. PMID: 27143254.
      Citations: 26     Fields:    Translation:Humans
    706. Gorkin L, Kantarjian H. Targeted therapy: Generic imatinib - impact on frontline and salvage therapy for CML. Nat Rev Clin Oncol. 2016 May; 13(5):270-2. PMID: 27098218; PMCID: PMC5450934.
      Citations: 4     Fields:    Translation:Humans
    707. Cortes JE, Jean Khoury H, Kantarjian H, Mauro MJ, Matczak E, Pavlov D, Aguiar JM, Fly KD, Dimitrov S, Leip E, Shapiro M, Lipton JH, Durand JB, Gambacorti-Passerini C, Br?mmendorf TH. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol. 2016 06; 91(6):606-16. PMID: 26971533; PMCID: PMC5548463.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    708. Lipton JH, Chuah C, Rosti G, Simpson D, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW, EPIC investigators, Guerci-Bresler A, Assouline S, Etienne G, Nicolini FE, le Coutre P, Guilhot F, Hochhaus A. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016 05; 17(5):612-21. PMID: 27083332.
      Citations: 79     Fields:    Translation:HumansCellsCTClinical Trials
    709. Jabbour E, Kantarjian H. Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphoma. Lancet. 2016 Jun 11; 387(10036):2360-1. PMID: 27080497.
      Citations: 1     Fields:    Translation:Humans
    710. Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D, Yoshida K, Ganesan S, Hattori N, Fulton N, Tan KT, Alpermann T, Kuo MC, Rostami S, Matthews J, Sanada M, Liu LZ, Shiraishi Y, Miyano S, Chendamarai E, Hou HA, Malnassy G, Ma T, Garg M, Ding LW, Sun QY, Chien W, Ikezoe T, Lill M, Biondi A, Larson RA, Powell BL, Chng WJ, Tien HF, Heuser M, Ganser A, Koren-Michowitz M, Kornblau SM, Kantarjian HM, Nowak D, Hofmann WK, Yang H, Stock W, Ghavamzadeh A, Alimoghaddam K, Haferlach T, Ogawa S, Shih LY, Mathews V, Koeffler HP, L?bbert M. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia. 2016 08; 30(8):1672-81. PMID: 27063598; PMCID: PMC4972641.
      Citations: 36     Fields:    Translation:Humans
    711. Hong M, Hao S, Patel KP, Kantarjian HM, Garcia-Manero G, Yin CC, Medeiros LJ, Lin P, Lu X. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup. Cancer Genet. 2016 05; 209(5):205-14. PMID: 27134073.
      Citations: 4     Fields:    Translation:HumansCells
    712. Cortes J, Beitinjaneh A, Chen HC, de Lima M, Patel K, Ravandi F, Wang X, Brandt M, Andersson BS, Ciurea S, Santos FP, de Padua Silva L, Shpall EJ, Champlin RE, Kantarjian H, Borthakur G, Oran B. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biol Blood Marrow Transplant. 2016 07; 22(7):1218-1226. PMID: 27058617; PMCID: PMC6201699.
      Citations: 26     Fields:    Translation:HumansCells
    713. Roberts DA, Kantarjian HM, Steensma DP. Contract research organizations in oncology clinical research: Challenges and opportunities. Cancer. 2016 May 15; 122(10):1476-82. PMID: 27018651.
      Citations: 3     Fields:    Translation:Humans
    714. Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, Kadia T, Andreff M, Konopleva M, DiNardo C, Daver N, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016 Mar 22; 7(12):14172-87. PMID: 26871476; PMCID: PMC4924706.
      Citations: 35     Fields:    Translation:HumansCells
    715. Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE, DiGiuseppe JA, Chen Z, Kantarjian HM, Medeiros LJ, Hu S. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016 06 02; 127(22):2742-50. PMID: 27006386; PMCID: PMC4915795.
      Citations: 45     Fields:    Translation:HumansCellsCTClinical Trials
    716. Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016 06 15; 122(12):1871-9. PMID: 26990290; PMCID: PMC5779863.
      Citations: 51     Fields:    Translation:HumansCellsCTClinical Trials
    717. Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, DeZern AE, Zell K, Zimmerman C, Ali NA, Jabbour E, Greenberg MD, Kantarjian HM, Maciejewski JP, List AF, Sekeres MA, MDS Clinical Research Consortium. The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica. 2016 06; 101(6):e224-7. PMID: 26992944; PMCID: PMC5013943.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    718. Daver N, Cortes J, Kantarjian H, Ravandi F. Acute myeloid leukemia: advancing clinical trials and promising therapeutics. Expert Rev Hematol. 2016 May; 9(5):433-45. PMID: 26910051; PMCID: PMC5006674.
      Citations: 5     Fields:    Translation:Humans
    719. Garcia-Manero G, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Steensma DP, Kambhampati S, Godley LA, Atallah E, Collins R, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N, Silverman LR, ONTIME study investigators, Fenaux P, Platzbecker U, Kreuzer KA. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016 Apr; 17(4):496-508. PMID: 26968357.
      Citations: 58     Fields:    Translation:HumansCellsCTClinical Trials
    720. Kantarjian H, Tefferi A. In Reply--Lowering the High Cost of Cancer Drugs. Mayo Clin Proc. 2016 Mar; 91(3):401-3. PMID: 26944248.
      Citations:    Fields:    Translation:Humans
    721. Kantarjian H, Chapman R. 340B Drug Pricing Program Reform-Reply. JAMA Oncol. 2016 Mar; 2(3):403-4. PMID: 26967191.
      Citations:    Fields:    Translation:Humans
    722. Jain N, Steensma D, Stewart DJ, Kantarjian H. Insurance Denial of Coverage for Patients Enrolled in Cancer Clinical Trials Is Still a Problem in the Affordable Care Act Era. J Oncol Pract. 2016 Apr; 12(4):283-5. PMID: 26907450.
      Citations: 1     Fields:    Translation:Humans
    723. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, Sarbassov dos D, Lorenzi PL, Huang X, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE, Andreeff M. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal. 2016 Feb 16; 9(415):ra17. PMID: 26884599; PMCID: PMC4815038.
      Citations: 86     Fields:    Translation:AnimalsCells
    724. Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol. 2016 Jun; 91(4):385-9. PMID: 26800008; PMCID: PMC5834229.
      Citations:    Fields:    Translation:Humans
    725. Jain P, Kantarjian H, Sasaki K, Jabbour E, Dasarathula J, Nogueras Gonzalez G, Verstovsek S, Borthakur G, Wierda W, Kadia T, Dellasala S, Pierce S, Ravandi F, O'Brien S, Cortes J. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. Br J Haematol. 2016 Apr; 173(1):114-26. PMID: 26846160; PMCID: PMC4809772.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    726. Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin KM, Meyer LH, Davis RE, Burger JA, K?hrer S, J?ger U, M?schen M. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia. 2016 06; 30(6):1246-54. PMID: 26847027; PMCID: PMC5459356.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    727. Chen Z, Cortes JE, Jorgensen JL, Wang W, Yin CC, You MJ, Jabbour E, Kantarjian HM, Medeiros LJ, Hu S. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia. 2016 07; 30(7):1606-9. PMID: 26837843; PMCID: PMC5115880.
      Citations: 14     Fields:    Translation:Humans
    728. Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM, Hochhaus A, le Coutre PD, Etienne G, Dorlhiac-Llacer PE. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016 05; 30(5):1044-54. PMID: 26837842; PMCID: PMC4858585.
      Citations: 257     Fields:    Translation:Humans
    729. DiNardo CD, Garcia-Manero G, Pierce S, Nazha A, Bueso-Ramos C, Jabbour E, Ravandi F, Cortes J, Kantarjian H. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Am J Hematol. 2016 Feb; 91(2):227-32. PMID: 26799610; PMCID: PMC5486407.
      Citations: 16     Fields:    Translation:Humans
    730. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016 Feb; 91(2):252-65. PMID: 26799612.
      Citations: 58     Fields:    Translation:Humans
    731. Jones GH, Carrier MA, Silver RT, Kantarjian H. Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. Blood. 2016 Mar 17; 127(11):1398-402. PMID: 26817958; PMCID: PMC4915805.
      Citations: 11     Fields:    
    732. Kadia TM, Ravandi F, Cortes J, Kantarjian H. New drugs in acute myeloid leukemia. Ann Oncol. 2016 05; 27(5):770-8. PMID: 26802152; PMCID: PMC4843183.
      Citations: 36     Fields:    Translation:Humans
    733. Roboz GJ, Montesinos P, Selleslag D, Wei A, Jang JH, Falantes J, Voso MT, Sayar H, Porkka K, Marlton P, Almeida A, Mohan S, Ravandi F, Garcia-Manero G, Skikne B, Kantarjian H. Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future Oncol. 2016 Feb; 12(3):293-302. PMID: 26785287; PMCID: PMC5684733.
      Citations: 13     Fields:    Translation:Humans
    734. George B, Kantarjian H, Jabbour E, Jain N. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. Immunotherapy. 2016 Feb; 8(2):135-43. PMID: 26780449; PMCID: PMC5618942.
      Citations: 6     Fields:    Translation:Humans
    735. Jain N, Lamb AV, O'Brien S, Ravandi F, Konopleva M, Jabbour E, Zuo Z, Jorgensen J, Lin P, Pierce S, Thomas D, Rytting M, Borthakur G, Kadia T, Cortes J, Kantarjian HM, Khoury JD. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016 Apr 14; 127(15):1863-9. PMID: 26747249; PMCID: PMC4915808.
      Citations: 90     Fields:    Translation:HumansCells
    736. Pemmaraju N, Kantarjian H, Ravandi F, Nogueras-Gonzalez GM, Huang X, O'Brien S, Wierda W, Garcia-Manero G, Thomas D, Pierce S, Verstovsek S, Borthakur G, Cortes J. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clin Lymphoma Myeloma Leuk. 2016 Apr; 16(4):213-222.e2. PMID: 26838606; PMCID: PMC4811701.
      Citations: 8     Fields:    Translation:Humans
    737. Sanford D, Garcia-Manero G, Jorgensen J, Konoplev S, Pierce S, Cortes J, Kantarjian H, Ravandi F. CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count. Leuk Lymphoma. 2016 08; 57(8):1965-8. PMID: 26726757; PMCID: PMC5594739.
      Citations: 1     Fields:    Translation:HumansCells
    738. Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016 Mar 10; 127(10):1269-75. PMID: 26729897; PMCID: PMC4786836.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    739. Chamseddine AN, Jabbour E, Kantarjian HM, Bohannan ZS, Garcia-Manero G. Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions. Curr Oncol Rep. 2016 Jan; 18(1):4. PMID: 26700507.
      Citations: 9     Fields:    Translation:Humans
    740. Kantarjian H. Acute myeloid leukemia--major progress over four decades and glimpses into the future. Am J Hematol. 2016 Jan; 91(1):131-45. PMID: 26598393.
      Citations: 41     Fields:    Translation:Humans
    741. Falchi L, Verstovsek S, Ravandi-Kashani F, Kantarjian HM. The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy. Cancer. 2016 Apr 15; 122(8):1160-8. PMID: 26716387; PMCID: PMC5042140.
      Citations: 8     Fields:    Translation:Humans
    742. Nazha A, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, Steensma DP, DeZern AE, Zimmerman C, Jabbour EJ, Zell K, List AF, Kantarjian HM, Maciejewski JP, Komrokji RS, MDS Clinical Research Consortium. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leuk Res. 2016 Feb; 41:43-7. PMID: 26777537; PMCID: PMC4986515.
      Citations: 7     Fields:    Translation:Humans
    743. Kantarjian HM, Lioure B, Kim SK, Atallah E, Leguay T, Kelly K, Marolleau JP, Escoffre-Barbe M, Thomas XG, Cortes J, Jabbour E, O'Brien S, Bories P, Oprea C, Hatteville L, Dombret H. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):139-45. PMID: 26775883; PMCID: PMC5557033.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    744. Sasaki K, Lahoti A, Jabbour E, Jain P, Pierce S, Borthakur G, Daver N, Kadia T, Pemmaraju N, Ferrajoli A, O'Brien S, Kantarjian H, Cortes J. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):152-62. PMID: 26796981; PMCID: PMC4769134.
      Citations: 11     Fields:    Translation:Humans
    745. Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M, Chonghaile TN, M?schen M. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Rep. 2015 Dec 29; 13(12):2715-27. PMID: 26711339; PMCID: PMC4700051.
      Citations: 55     Fields:    Translation:HumansAnimalsCells
    746. Ravandi F, DeAngelo DJ, Kadia T, Kantarjian H, Scheuenpflug J, Zhao C, Guo W, Smith BD, Pigneux A, Raffoux E, Delaunay J, Thomas X. Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies. Blood Cancer J. 2015 Dec 11; 5:e375. PMID: 26657199; PMCID: PMC4735070.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    747. Wetzler M, Kantarjian HM, Lipton JH, Akard L, Baccarani M, Khoury HJ, Li E, Munteanu M, Cortes J, Nicolini FE. Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses. Blood Cancer J. 2015 Dec 11; 5:e376. PMID: 26657200; PMCID: PMC4735071.
      Citations:    Fields:    Translation:Humans
    748. Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol. 2016 Jan; 172(1):80-8. PMID: 26648336; PMCID: PMC5471614.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    749. Takahashi K, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, DiNardo C, Jabbour E, Pierce S, Estrov Z, Konopleva M, Andreeff M, Ravandi F, Cortes J. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):163-8.e1-2. PMID: 26752456; PMCID: PMC4804759.
      Citations: 8     Fields:    Translation:Humans
    750. Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE, Talpaz M, Baccarani M, Li J, Parker WT, Lustgarten S, Clackson T, Haluska FG, Guilhot F, Kantarjian HM, Soverini S, Hughes TP, Rivera VM, Branford S, M?ller MC, Hochhaus A. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. 2016 Feb 11; 127(6):703-12. PMID: 26603839; PMCID: PMC4760131.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    751. Yamazaki J, Taby R, Jelinek J, Raynal NJ, Cesaroni M, Pierce SA, Kornblau SM, Bueso-Ramos CE, Ravandi F, Kantarjian HM, Issa JP. Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia. J Natl Cancer Inst. 2015 Nov 13; 108(2). PMID: 26568194; PMCID: PMC4862435.
      Citations: 8     Fields:    Translation:HumansCells
    752. Cortes JE, Khoury HJ, Kantarjian HM, Kim DW, Schafhausen P, Conlan MG, Shapiro M, Turnbull K, Leip E, Gambacorti-Passerini C, Lipton JH, Br?mmendorf TH. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. Br J Haematol. 2016 Jan; 172(1):97-110. PMID: 26537529; PMCID: PMC4737299.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    753. Kantarjian H, Chapman R. Value of the 340B Drug Discount Program. JAMA Oncol. 2015 Nov; 1(8):1029-30. PMID: 26313652.
      Citations: 3     Fields:    Translation:Humans
    754. Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016 Jan 21; 127(3):303-9. PMID: 26492934; PMCID: PMC4760129.
      Citations: 164     Fields:    Translation:Humans
    755. Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400. PMID: 26492205; PMCID: PMC4826052.
      Citations: 38     Fields:    Translation:Humans
    756. Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour EJ, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res. 2015 Dec; 39(12):1367-74. PMID: 26547258; PMCID: PMC4822515.
      Citations: 20     Fields:    Translation:HumansCells
    757. Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Takahashi K, Pemmaraju N, Daver N, Pierce SA, O'Brien SM, Cortes JE. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 2016 Jan 15; 122(2):238-48. PMID: 26479889; PMCID: PMC4707980.
      Citations: 16     Fields:    Translation:Humans
    758. Stewart DJ, Batist G, Kantarjian HM, Bradford JP, Schiller JH, Kurzrock R. The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases. Clin Cancer Res. 2015 Oct 15; 21(20):4561-8. PMID: 26473192.
      Citations: 11     Fields:    Translation:Humans
    759. Zeidan AM, Sekeres MA, Garcia-Manero G, Steensma DP, Zell K, Barnard J, Ali NA, Zimmerman C, Roboz G, DeZern A, Nazha A, Jabbour E, Kantarjian H, Gore SD, Maciejewski JP, List A, Komrokji R, MDS Clinical Research Consortium. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 2016 Mar; 30(3):649-57. PMID: 26464171; PMCID: PMC4775363.
      Citations: 21     Fields:    Translation:Humans
    760. Carter BZ, Mak PY, Mak DH, Ruvolo VR, Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE, Konopleva M, Andreeff M. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget. 2015 Oct 13; 6(31):30487-99. PMID: 26431162; PMCID: PMC4741546.
      Citations: 25     Fields:    Translation:HumansCells
    761. Garg M, Nagata Y, Kanojia D, Mayakonda A, Yoshida K, Haridas Keloth S, Zang ZJ, Okuno Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ding LW, Alpermann T, Sun QY, Lin DC, Chien W, Madan V, Liu LZ, Tan KT, Sampath A, Venkatesan S, Inokuchi K, Wakita S, Yamaguchi H, Chng WJ, Kham SK, Yeoh AE, Sanada M, Schiller J, Kreuzer KA, Kornblau SM, Kantarjian HM, Haferlach T, Lill M, Kuo MC, Shih LY, Blau IW, Blau O, Yang H, Ogawa S, Koeffler HP. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood. 2015 Nov 26; 126(22):2491-501. PMID: 26438511; PMCID: PMC4661172.
      Citations: 89     Fields:    Translation:HumansCells
    762. Akard L, Kantarjian HM, Wetzler M, Lipton JH, Baccarani M, Jean Khoury H, Kurtin S, Li E, Munteanu M, Cortes J, Nicolini FE. Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate. Leuk Lymphoma. 2016; 57(3):654-65. PMID: 26436949; PMCID: PMC5552050.
      Citations: 4     Fields:    Translation:Humans
    763. Thompson PA, Kantarjian HM, Cortes JE. Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015. Mayo Clin Proc. 2015 Oct; 90(10):1440-54. PMID: 26434969; PMCID: PMC5656269.
      Citations: 23     Fields:    Translation:HumansCells
    764. Alvarnas JC, Brown PA, Aoun P, Ballen KK, Barta SK, Borate U, Boyer MW, Burke PW, Cassaday R, Castro JE, Coccia PF, Coutre SE, Damon LE, DeAngelo DJ, Douer D, Frankfurt O, Greer JP, Johnson RA, Kantarjian HM, Klisovic RB, Kupfer G, Litzow M, Liu A, Rao AV, Shah B, Uy GL, Wang ES, Zelenetz AD, Gregory K, Smith C. Acute Lymphoblastic Leukemia, Version 2.2015. J Natl Compr Canc Netw. 2015 Oct; 13(10):1240-79. PMID: 26483064.
      Citations: 32     Fields:    Translation:Humans
    765. Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015 Nov; 16(15):1547-1555. PMID: 26432046; PMCID: PMC4816046.
      Citations: 83     Fields:    Translation:HumansCellsCTClinical Trials
    766. Chin L, Wargo JA, Spring DJ, Kantarjian H, Futreal PA. Cancer Genomics in Clinical Context. Trends Cancer. 2015 Sep; 1(1):36-43. PMID: 28741560.
      Citations: 5     Fields:    
    767. Masarova L, Cherry M, Newberry KJ, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience. Leuk Lymphoma. 2016; 57(1):237-9. PMID: 25904378; PMCID: PMC4712116.
      Citations: 14     Fields:    Translation:Humans
    768. Ravandi F, Kantarjian H. Time to abandon traditional chemotherapy for acute promyelocytic leukaemia? Lancet Oncol. 2015 Oct; 16(13):1274-5. PMID: 26384240.
      Citations: 1     Fields:    Translation:Humans
    769. Daver N, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Verstovsek S, Kadia T, Dinardo C, Pierce S, Huang X, Pemmaraju N, Diaz-Pines-Mateo M, Cortes J, Borthakur G. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 2016 Feb; 30(2):268-73. PMID: 26365212; PMCID: PMC4790089.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    770. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol. 2015 Dec; 171(5):726-35. PMID: 26358140; PMCID: PMC4715651.
      Citations: 28     Fields:    Translation:HumansCells
    771. Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JE. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol. 2015 Nov; 90(11):1065-70. PMID: 26299958; PMCID: PMC4618182.
      Citations: 10     Fields:    Translation:Humans
    772. Sanford D, Kantarjian H, Skinner J, Jabbour E, Cortes J. Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor. Haematologica. 2015 Dec; 100(12):e494-5. PMID: 26341741; PMCID: PMC4666339.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    773. Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for?Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. 2016 Jan; 22(1):47-53. PMID: 26343946; PMCID: PMC4892364.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    774. Kadia TM, Ravandi F, Cortes J, Kantarjian H. Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review. JAMA Oncol. 2015 Sep; 1(6):820-8. PMID: 26181162.
      Citations: 22     Fields:    Translation:Humans
    775. Kantarjian H, Mathisen MS, Lipton JH. Having "Skin in the Game" and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs. JAMA Oncol. 2015 Sep; 1(6):729-30. PMID: 26182331.
      Citations: 5     Fields:    Translation:Humans
    776. Jain P, Kantarjian H, Jabbour E, Gonzalez GN, Borthakur G, Pemmaraju N, Daver N, Gachimova E, Ferrajoli A, Kornblau S, Ravandi F, O'Brien S, Cortes J. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol. 2015 Sep; 2(9):e376-83. PMID: 26436130; PMCID: PMC4587395.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    777. Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64. PMID: 26308885; PMCID: PMC4666803.
      Citations: 61     Fields:    Translation:HumansCellsCTClinical Trials
    778. Tambaro FP, Garcia-Manero G, O'Brien SM, Faderl SH, Ferrajoli A, Burger JA, Pierce S, Wang X, Do KA, Kantarjian HM, Keating MJ, Wierda WG. Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome. Leukemia. 2016 Feb; 30(2):325-30. PMID: 26290497; PMCID: PMC4794262.
      Citations: 6     Fields:    Translation:Humans
    779. Gu J, Patel KP, Bai B, Liu CH, Tang G, Kantarjian HM, Tang Z, Abraham R, Luthra R, Medeiros LJ, Lin P, Lu X. Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression. Mol Cytogenet. 2015; 8:68. PMID: 26300976; PMCID: PMC4545786.
      Citations: 1     
    780. Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep; 16(9):1099-1110. PMID: 26296954; PMCID: PMC5557041.
      Citations: 114     Fields:    Translation:HumansCTClinical Trials
    781. Jones GH, Kantarjian H. Health care in the United States--basic human right or entitlement? Ann Oncol. 2015 Oct; 26(10):2193-5. PMID: 26276840.
      Citations: 2     Fields:    Translation:Humans
    782. Chhatwal J, Mathisen MS, Kantarjian HM. Reply to price and value in cancer care. Cancer. 2015 Nov 15; 121(22):4098-9. PMID: 26249735.
      Citations:    Fields:    Translation:Humans
    783. Wang W, Cortes JE, Lin P, Beaty MW, Ai D, Amin HM, McDonnell TJ, Ok CY, Kantarjian HM, Medeiros LJ, Hu S. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 2015 Oct 01; 126(14):1699-706. PMID: 26243778; PMCID: PMC4624442.
      Citations: 17     Fields:    Translation:HumansCells
    784. Kantarjian H, Yu PP. Artificial Intelligence, Big Data, and Cancer. JAMA Oncol. 2015 Aug; 1(5):573-4. PMID: 26181906.
      Citations: 25     Fields:    Translation:Humans
    785. DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, Routbort M, Patel KP, Pierce S, Garcia-Manero G, Cortes J, Kantarjian H. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015 Aug; 90(8):732-6. PMID: 26016821; PMCID: PMC4612499.
      Citations: 102     Fields:    Translation:Humans
    786. Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Colla S, Kantarjian HM, Killick S, Sekeres MA, List AF, Onida F, Komrokji RS, Tefferi A, Solary E, Fenaux P. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015 Jul 31; 5:e333. PMID: 26230957; PMCID: PMC4526779.
      Citations: 46     Fields:    Translation:Humans
    787. DiNardo CD, Jabbour E, Ravandi F, Takahashi K, Daver N, Routbort M, Patel KP, Brandt M, Pierce S, Kantarjian H, Garcia-Manero G. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia. 2016 Apr; 30(4):980-4. PMID: 26228814; PMCID: PMC4733599.
      Citations: 27     Fields:    Translation:Humans
    788. Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Horst HA, Klimek VM, Cortes J, Roboz GJ, Odenike O, Havelange V, Maertens J, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM, Pigneux A, Recher C, Thomas X, Derigs HG. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036. PMID: 26234174; PMCID: PMC4822512.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    789. Yilmaz M, Lahoti A, O'Brien S, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Kantarjian H, Cortes JE, Nogueras-Gonz?lez GM. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015 Nov 01; 121(21):3894-904. PMID: 26217876; PMCID: PMC4519988.
      Citations: 21     Fields:    Translation:Humans
    790. Badar T, Shetty A, Bueso-Ramos C, Cortes J, Konopleva M, Borthakur G, Pierce S, Huang X, Chen HC, Kadia T, Daver N, Dinardo C, O'Brien S, Garcia-Manero G, Kantarjian H, Ravandi F. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. Am J Hematol. 2015 Sep; 90(9):769-73. PMID: 26017166; PMCID: PMC4546505.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    791. Martinelli G, Oehler VG, Papayannidis C, Courtney R, Shaik MN, Zhang X, O'Connell A, McLachlan KR, Zheng X, Radich J, Baccarani M, Kantarjian HM, Levin WJ, Cortes JE, Jamieson C. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematol. 2015 Aug; 2(8):e339-46. PMID: 26688487.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    792. Sanford D, Lo-Coco F, Sanz MA, Di Bona E, Coutre S, Altman JK, Wetzler M, Allen SL, Ravandi F, Kantarjian H, Cortes JE. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Br J Haematol. 2015 Nov; 171(4):471-7. PMID: 26205361; PMCID: PMC4770883.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    793. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. PMID: 26211600; PMCID: PMC5365030.
      Citations: 44     Fields:    Translation:Humans
    794. Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJ. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015 Oct 15; 121(20):3612-21. PMID: 26193999; PMCID: PMC4866653.
      Citations: 88     Fields:    Translation:HumansCells
    795. Jones GH, Tefferi A, Steensma D, Kantarjian H. The Hippocratic Oath, the US Health Care System, and the Affordable Care Act in 2015. Am J Med. 2015 Nov; 128(11):1162-4. PMID: 26184683.
      Citations:    Fields:    Translation:Humans
    796. Takahashi K, Roh W, Zhang J, Propotopov A, Patel K, Strickland S, Kim A, Vnencak-Jones C, Pelletier S, Parmar S, Garcia-Manero G, Kornblau S, Chin L, Kantarjian H, Futreal PA, Ravandi F. Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission. Am J Hematol. 2015 Jul; 90(7):E134-5. PMID: 25801490; PMCID: PMC4948743.
      Citations: 1     Fields:    Translation:HumansCells
    797. Loghavi S, Al-Ibraheemi A, Zuo Z, Garcia-Manero G, Yabe M, Wang SA, Kantarjian HM, Yin CC, Miranda RN, Luthra R, Medeiros LJ, Bueso-Ramos CE, Khoury JD. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. Br J Haematol. 2015 Oct; 171(1):91-9. PMID: 26123119; PMCID: PMC5577911.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    798. Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, Singh R, Mehrotra M, Routbort MJ, Luthra M, Manshouri T, Santos FP, Kantarjian H, Verstovsek S. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015 Aug 06; 126(6):790-7. PMID: 26124496; PMCID: PMC4528066.
      Citations: 74     Fields:    Translation:HumansCTClinical Trials
    799. Cabrero M, Yu Y, Verma A, Yang H, Colla S, Jia Y, Zheng H, Bohannan Z, Ganan-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boultwood J, Garcia-Manero G, Wei Y. Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. Br J Haematol. 2016 Apr; 173(1):161-5. PMID: 26105212; PMCID: PMC5580681.
      Citations: 2     Fields:    Translation:HumansCells
    800. Chhatwal J, Mathisen M, Kantarjian H. Are high drug prices for hematologic malignancies justified? A critical analysis. Cancer. 2015 Oct 01; 121(19):3372-9. PMID: 26102457.
      Citations: 13     Fields:    Translation:Humans
    801. Daver N, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica. 2015 Aug; 100(8):1058-63. PMID: 26088933; PMCID: PMC5004422.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    802. Vannucchi AM, Kantarjian HM, Gotlib J, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S, COMFORT Investigators, Kiladjian JJ, Cervantes F. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015 Sep; 100(9):1139-45. PMID: 26069290; PMCID: PMC4800694.
      Citations: 83     Fields:    Translation:HumansCTClinical Trials
    803. Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Pierce SR, Newberry KJ, Daver N, Verstovsek S. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015 Sep; 39(9):950-6. PMID: 26183878; PMCID: PMC4546869.
      Citations: 21     Fields:    Translation:Humans
    804. Mattiuzzi G, Yilmaz M, Kantarjian H, Borthakur G, Konopleva M, Jabbour E, Brown Y, Pierce S, Cortes J. Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia. J Infect Chemother. 2015 Sep; 21(9):663-7. PMID: 26141814; PMCID: PMC5459324.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    805. Sanford D, DiNardo CD, Tang G, Cortes JE, Verstovsek S, Jabbour E, Ravandi F, Kantarjian H, Garcia-Manero G. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clin Lymphoma Myeloma Leuk. 2015 Sep; 15(9):556-62. PMID: 26141213; PMCID: PMC4837956.
      Citations: 4     Fields:    Translation:HumansCells
    806. Kantarjian HM, Chapman R. Role of the 340B Drug Discount Program in Recent Cancer Care Trends. J Oncol Pract. 2015 Jul; 11(4):303-7. PMID: 26036268.
      Citations: 1     Fields:    Translation:Humans
    807. Gambacorti-Passerini C, Kantarjian HM, Kim DW, Khoury HJ, Turkina AG, Matczak E, Bardy-Bouxin N, Shapiro M, Turnbull K, Leip E, Cortes JE, Br?mmendorf TH. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015 Sep; 90(9):755-68. PMID: 26040495; PMCID: PMC5132035.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    808. Yabe M, Tang G, Garcia-Manero G, Loghavi S, Lu X, Miranda RN, Medeiros LJ, Kantarjian HM, Bueso-Ramos CE, Khoury JD. Acute Myeloid Leukemia With t(v;5q33) Is Associated With Poor Overall Survival and Often Lacks Myelodysplastic Features. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 Suppl:S85-90. PMID: 26297286.
      Citations:    Fields:    Translation:Humans
    809. Kadia TM, Thomas XG, Dmoszynska A, Wierzbowska A, Minden M, Arthur C, Delaunay J, Ravandi F, Kantarjian H. Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts. Am J Hematol. 2015 Jul; 90(7):E139-41. PMID: 25858582; PMCID: PMC4478207.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    810. Baccarani M, Giles FJ, Santanastasio H, Leung M, Novick S, Kantarjian HM, Hochhaus A, le Coutre PD, M?ller MC, Reiter A. Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. J Cancer Res Clin Oncol. 2015 Nov; 141(11):2047-60. PMID: 26002753; PMCID: PMC4768228.
      Citations: 24     Fields:    Translation:HumansCellsCTClinical Trials
    811. Loghavi S, Pemmaraju N, Kanagal-Shamanna R, Mehrotra M, Medeiros LJ, Luthra R, Lin P, Huh Y, Kantarjian HM, Cortes JE, Verstovsek S, Patel KP. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood. 2015 May 21; 125(21):3360-3. PMID: 25999449.
      Citations: 7     Fields:    Translation:Humans
    812. Jabbour E, O'Brien S, Ravandi F, Kantarjian H. Monoclonal antibodies in acute lymphoblastic leukemia. Blood. 2015 Jun 25; 125(26):4010-6. PMID: 25999456; PMCID: PMC4548495.
      Citations: 59     Fields:    Translation:Humans
    813. Sevcikova K, Zhuang Z, Garcia-Manero G, Alvarez RH, Kantarjian HM, Mego M, Albarracin C, Tang G, Strom SS, Medeiros LJ, Hortobagyi GN, Reuben JM, Khoury JD. Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment. Leukemia. 2016 Jan; 30(1):242-7. PMID: 25975189.
      Citations: 3     Fields:    Translation:Humans
    814. Yamazaki J, Jelinek J, Lu Y, Cesaroni M, Madzo J, Neumann F, He R, Taby R, Vasanthakumar A, Macrae T, Ostler KR, Kantarjian HM, Liang S, Estecio MR, Godley LA, Issa JP. TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia. Cancer Res. 2015 Jul 15; 75(14):2833-43. PMID: 25972343; PMCID: PMC4506197.
      Citations: 42     Fields:    Translation:HumansCellsCTClinical Trials
    815. Masarova L, Newberry KJ, Pierce SA, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S. Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. Leuk Res. 2015 Aug; 39(8):822-7. PMID: 26012362; PMCID: PMC4547830.
      Citations: 8     Fields:    Translation:HumansCells
    816. Colla S, Ong DS, Ogoti Y, Marchesini M, Mistry NA, Clise-Dwyer K, Ang SA, Storti P, Viale A, Giuliani N, Ruisaard K, Ganan Gomez I, Bristow CA, Estecio M, Weksberg DC, Ho YW, Hu B, Genovese G, Pettazzoni P, Multani AS, Jiang S, Hua S, Ryan MC, Carugo A, Nezi L, Wei Y, Yang H, D'Anca M, Zhang L, Gaddis S, Gong T, Horner JW, Heffernan TP, Jones P, Cooper LJ, Liang H, Kantarjian H, Wang YA, Chin L, Bueso-Ramos C, Garcia-Manero G, DePinho RA. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell. 2015 May 11; 27(5):644-57. PMID: 25965571; PMCID: PMC4596059.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    817. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G, Goswami M, Young KH, Singh R, Medeiros LJ, Kantarjian HM, Luthra R, Wang SA. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol. 2015 May 08; 8:45. PMID: 25952993; PMCID: PMC4431603.
      Citations: 42     Fields:    Translation:Humans
    818. Garcia-Manero G, Tibes R, Kadia T, Kantarjian H, Arellano M, Knight EA, Xiong H, Qin Q, Munasinghe W, Roberts-Rapp L, Ansell P, Albert DH, Oliver B, McKee MD, Ricker JL, Khoury HJ. Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Invest New Drugs. 2015 Aug; 33(4):870-80. PMID: 25933833; PMCID: PMC5563391.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    819. Sasaki K, Strom SS, O'Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Jain P, Pierce S, Kantarjian H, Cortes JE. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015 May; 2(5):e186-93. PMID: 26688093; PMCID: PMC4884053.
      Citations: 86     Fields:    Translation:Humans
    820. Borthakur G, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Jabbour E, Mariani M, Capolongo L, Carpinelli P, Davite C, Kantarjian H, Cortes JE. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica. 2015 Jul; 100(7):898-904. PMID: 25887498; PMCID: PMC4486224.
      Citations: 22     Fields:    Translation:HumansCellsCTClinical Trials
    821. Jabbour E, O'Brien S, Konopleva M, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer. 2015 Aug 01; 121(15):2517-28. PMID: 25891003.
      Citations: 73     Fields:    Translation:HumansCells
    822. Wang E, Farmakiotis D, Yang D, McCue DA, Kantarjian HM, Kontoyiannis DP, Mathisen MS. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. J Antimicrob Chemother. 2015 Aug; 70(8):2362-8. PMID: 25855759; PMCID: PMC6366596.
      Citations: 21     Fields:    Translation:HumansAnimals
    823. Ohanian M, Kantarjian H, Guy D, Thomas D, Jabbour E, O'Brien S. Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas. Expert Opin Biol Ther. 2015 Apr; 15(4):601-11. PMID: 25775418.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    824. Dahl J, Mace M, Kantarjian H, Jabbour E. Blinatumomab for the treatment of adult acute lymphoblastic leukemia. Drugs Today (Barc). 2015 Apr; 51(4):231-41. PMID: 26020065.
      Citations: 1     Fields:    Translation:Humans
    825. Kurzrock R, Estrov Z, Talpaz M, Kantarjian HM. Meir Wetzler, MD. Cancer. 2015 Jul 01; 121(13):2106-7. PMID: 25832851.
      Citations:    Fields:    Translation:Humans
    826. Jain P, Keating M, Thompson PA, Trinh L, Wang X, Wierda W, Ferrajoli A, Burger J, Kantarjian H, Estrov Z, Abruzzo L, O'Brien S. High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome. Am J Hematol. 2015 Jun; 90(6):471-7. PMID: 25683856; PMCID: PMC4521389.
      Citations: 2     Fields:    Translation:HumansCells
    827. Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer. 2015 Jul 15; 121(14):2375-82. PMID: 25809968; PMCID: PMC5436272.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    828. Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):323-34. PMID: 25971713; PMCID: PMC5141582.
      Citations: 49     Fields:    Translation:Humans
    829. Cabrero M, Jabbour E, Ravandi F, Bohannan Z, Pierce S, Kantarjian HM, Garcia-Manero G. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. Leuk Res. 2015 May; 39(5):520-4. PMID: 25828745; PMCID: PMC4826042.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    830. Daver N, Cortes J, Ravandi F, Patel KP, Burger JA, Konopleva M, Kantarjian H. Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood. 2015 May 21; 125(21):3236-45. PMID: 25795921; PMCID: PMC4440880.
      Citations: 63     Fields:    Translation:Humans
    831. Jain P, Kantarjian H, Alattar ML, Jabbour E, Sasaki K, Nogueras Gonzalez G, Dellasala S, Pierce S, Verstovsek S, Wierda W, Borthakur G, Ravandi F, O'Brien S, Cortes J. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Lancet Haematol. 2015 Mar; 2(3):e118-28. PMID: 26687797; PMCID: PMC4854752.
      Citations: 29     Fields:    Translation:Humans
    832. Karjalainen K, Jaalouk DE, Bueso-Ramos C, Bover L, Sun Y, Kuniyasu A, Driessen WH, Rietz C, Zurita AJ, O'Brien S, Kantarjian HM, Cortes JE, Calin GA, Koivunen E, Arap W, Pasqualini R, Card?-Vila M. Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens. Clin Cancer Res. 2015 Jul 01; 21(13):3041-51. PMID: 25779950; PMCID: PMC4490100.
      Citations: 4     Fields:    Translation:HumansCells
    833. Kantarjian H, Rajkumar SV. Why are cancer drugs so expensive in the United States, and what are the solutions? Mayo Clin Proc. 2015 Apr; 90(4):500-4. PMID: 25792242.
      Citations: 28     Fields:    Translation:Humans
    834. Bachanova V, Frankel AE, Cao Q, Lewis D, Grzywacz B, Verneris MR, Ustun C, Lazaryan A, McClune B, Warlick ED, Kantarjian H, Weisdorf DJ, Miller JS, Vallera DA. Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clin Cancer Res. 2015 Mar 15; 21(6):1267-72. PMID: 25770294; PMCID: PMC4360883.
      Citations: 33     Fields:    Translation:HumansCellsCTClinical Trials
    835. Sanford DS, Kantarjian H, O'Brien S, Jabbour E, Cortes J, Ravandi F. The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2015 Apr; 15(4):365-73. PMID: 25764322.
      Citations: 6     Fields:    Translation:Humans
    836. Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015 Apr; 90(4):276-81. PMID: 25530214; PMCID: PMC4376596.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    837. Della Porta MG, Tuechler H, Malcovati L, Sanz G, Garcia-Manero G, Bennett JM, Bowen D, Kantarjian H, Levis A, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Greenberg PL, Cazzola M, Schanz J, Sol? F, Fenaux P, Dreyfus F, Kuendgen A, Pfeilst?cker M, Germing U, Haase D. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015 Jul; 29(7):1502-13. PMID: 25721895.
      Citations: 35     Fields:    Translation:Humans
    838. Daver N, Boumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, Kawedia JD, Basnett J, Culotta KS, Zeng Z, Lu H, Richie MA, Garris R, Xiao L, Liu W, Baggerly KA, Jabbour E, O'Brien S, Burger J, Bendall LJ, Thomas D, Konopleva M. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res. 2015 Jun 15; 21(12):2704-14. PMID: 25724525; PMCID: PMC4470787.
      Citations: 23     Fields:    Translation:HumansCellsCTClinical Trials
    839. Kadia T, Kantarjian H, Garcia-Manero G, Borthakur G, Wang X, Patel K, Jabbour E, Brandt M, Daver N, Pemmaraju N, Pierce S, Cortes J, Ravandi F. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol. 2015 Aug; 170(4):590-3. PMID: 25716073; PMCID: PMC4977576.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    840. Badar T, Cortes JE, Ravandi F, O'Brien S, Verstovsek S, Garcia-Manero G, Kantarjian H, Borthakur G. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2015 Jul; 15(7):433-438.e2. PMID: 25795639; PMCID: PMC4509631.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    841. Sasaki K, Gotlib JR, Mesa RA, Newberry KJ, Ravandi F, Cortes JE, Kelly P, Kutok JL, Kantarjian HM, Verstovsek S. Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leuk Lymphoma. 2015 Jul; 56(7):2092-7. PMID: 25641433; PMCID: PMC4919663.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    842. Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015 May; 100(5):653-61. PMID: 25682595; PMCID: PMC4420214.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    843. Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 2015 Jul; 100(7):927-34. PMID: 25682597; PMCID: PMC4486227.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    844. Cachia D, Kamiya-Matsuoka C, Pinnix CC, Chi L, Kantarjian HM, Cortes JE, Daver N, Woodman K. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol. 2015 Apr; 122(2):391-8. PMID: 25666482; PMCID: PMC4369460.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    845. Benton CB, Tanaka M, Wilson C, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S. Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities. Leuk Res. 2015 Apr; 39(4):419-23. PMID: 25687833; PMCID: PMC4847531.
      Citations: 7     Fields:    Translation:HumansCells
    846. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H, COMFORT-I investigators. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015 Apr; 100(4):479-88. PMID: 25616577; PMCID: PMC4380721.
      Citations: 88     Fields:    Translation:Humans
    847. Maddipoti S, Bueso-Ramos C, DiNardo CD, Yang H, Wei Y, Kondo K, Fang Z, Stevenson W, Chang KS, Pierce SA, Bohannan Z, Borthakur G, Kantarjian H, Garcia-Manero G, Est?cio MR. RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype. Br J Haematol. 2015 May; 169(3):344-51. PMID: 25612675; PMCID: PMC4762375.
      Citations: 13     Fields:    Translation:HumansCells
    848. Han L, Qiu P, Zeng Z, Jorgensen JL, Mak DH, Burks JK, Schober W, McQueen TJ, Cortes J, Tanner SD, Roboz GJ, Kantarjian HM, Kornblau SM, Guzman ML, Andreeff M, Konopleva M. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A. 2015 Apr; 87(4):346-56. PMID: 25598437; PMCID: PMC4388314.
      Citations: 51     Fields:    Translation:HumansCells
    849. Jabbour E, O'Brien S, Huang X, Thomas D, Rytting M, Sasaki K, Cortes J, Garcia-Manero G, Kadia T, Ravandi F, Pierce S, Kantarjian H. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol. 2015 Mar; 90(3):193-6. PMID: 25407953; PMCID: PMC5505232.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    850. Badar T, Cortes J, Borthakur G, O'Brien S, Wierda W, Garcia-Manero G, Ferrajoli A, Kadia T, Poku R, Kantarjian H, Mattiuzzi G. Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine. Biomed Res Int. 2015; 2015:497597. PMID: 25654108; PMCID: PMC4310492.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    851. Cortes JE, Kantarjian HM, Rea D, Wetzler M, Lipton JH, Akard L, Khoury HJ, Michallet M, Chuah C, Hellmann A, Digumarti R, Parikh PM, Legros L, Warzocha K, Baccarani M, Li E, Munteanu M, Nicolini FE, Guerci-Bresler A. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer. 2015 May 15; 121(10):1637-44. PMID: 25586015; PMCID: PMC5650096.
      Citations: 25     Fields:    Translation:Humans
    852. Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, George B, James D, Kantarjian H, Burger J, O'Brien S. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015 Mar 26; 125(13):2062-7. PMID: 25573991; PMCID: PMC4467871.
      Citations: 121     Fields:    Translation:Humans
    853. Arthur C, Cermak J, Delaunay J, Mazur G, Thomas X, Wierzbowska A, Jones MM, Berrak E, Kantarjian H, Mayer J. Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. J Blood Med. 2015; 6:25-9. PMID: 25678833; PMCID: PMC4295530.
      Citations: 1     
    854. Kazmi SM, Pemmaraju N, Patel KP, Cohen PR, Daver N, Tran KM, Ravandi F, Duvic M, Garcia-Manero G, Pierce S, Nazha A, Borthakur G, Kantarjian H, Cortes J. Characteristics of Sweet Syndrome in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):358-363. PMID: 25630528; PMCID: PMC4457594.
      Citations: 14     Fields:    Translation:HumansCells
    855. Kantarjian HM. In response to S.A. Glied. J Oncol Pract. 2015 Mar; 11(2):166. PMID: 25538083.
      Citations:    Fields:    
    856. DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol. 2015 Jan; 2(1):e12-20. PMID: 26687423; PMCID: PMC4936479.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    857. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Fu B, Tang G, Goswami M, Singh R, Kanagal-Shamanna R, Pierce SA, Young KH, Kantarjian HM, Medeiros LJ, Luthra R, Wang SA. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res. 2015 Mar; 39(3):348-54. PMID: 25573287; PMCID: PMC5548131.
      Citations: 43     Fields:    Translation:Humans
    858. Kantarjian HM, San-Miguel JF. Multiple myeloma and chronic leukaemias in 2014: improved understanding of disease biology and treatment. Nat Rev Clin Oncol. 2015 Feb; 12(2):71-2. PMID: 25511190.
      Citations: 4     Fields:    Translation:Humans
    859. Stein AS, Zugmaier G, O'Brien S, Fielding AK, Heffner L, Larson RA, Litzow M, Ribera JM, Rambaldi A, Schiller G, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM, Topp MS, G?kbuget N, Bargou RC, Dombret H, Neumann S, Fo? R, Br?ggemann M. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015 Jan; 16(1):57-66. PMID: 25524800.
      Citations: 442     Fields:    Translation:HumansCTClinical Trials
    860. Vu K, Luong NV, Hubbard J, Zalpour A, Faderl S, Thomas DA, Yang D, Kantarjian H, Kroll MH. A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center. Cancer Med. 2015 Jan; 4(1):27-35. PMID: 25487644; PMCID: PMC4312115.
      Citations: 14     Fields:    Translation:Humans
    861. Garcia-Manero G, Khoury HJ, Jabbour E, Lancet J, Winski SL, Cable L, Rush S, Maloney L, Hogeland G, Ptaszynski M, Calvo MC, Bohannan Z, List A, Kantarjian H, Komrokji R. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res. 2015 Mar 01; 21(5):985-94. PMID: 25480830; PMCID: PMC4348327.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    862. Walker GV, Shihadeh F, Kantarjian H, Allen P, Rondon G, Kebriaei P, O'Brien S, Kedir A, Said M, Grant JD, Thomas DA, Gidley PW, Arzu I, Pinnix C, Reed V, Dabaja BS. Comprehensive craniospinal radiation for controlling central nervous system leukemia. Int J Radiat Oncol Biol Phys. 2014 Dec 01; 90(5):1119-25. PMID: 25539370; PMCID: PMC4868499.
      Citations: 8     Fields:    Translation:Humans
    863. Verstovsek S, Hoffman R, Mascarenhas J, McCoon P, Tang W, Cortes J, Kantarjian H, Soria JC, Bahleda R, Ribrag V. A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. Leuk Res. 2015 Feb; 39(2):157-63. PMID: 25530567.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    864. Ohanian M, Rozovski U, Ravandi F, Garcia-Manero G, Jabbour E, Kantarjian HM, Estrov Z. Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. Br J Haematol. 2015 May; 169(4):595-7. PMID: 25413673; PMCID: PMC4414662.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    865. Kadia TM, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, Daver N, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur G. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2015 Feb; 90(2):120-4. PMID: 25368968; PMCID: PMC4447180.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    866. Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015 Mar 15; 121(6):876-82. PMID: 25410759; PMCID: PMC4378905.
      Citations: 26     Fields:    Translation:Humans
    867. Benjamini O, Jain P, Trinh L, Qiao W, Strom SS, Lerner S, Wang X, Burger J, Ferrajoli A, Kantarjian H, O'Brien S, Wierda W, Estrov Z, Keating M. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma. 2015 Jun; 56(6):1643-50. PMID: 25308294; PMCID: PMC4437921.
      Citations: 42     Fields:    Translation:Humans
    868. Eghtedar A, Rodriguez I, Kantarjian H, O'Brien S, Daver N, Garcia-Manero G, Ferrajoli A, Kadia T, Pierce S, Cortes J, Ravandi F. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. Leuk Lymphoma. 2015 May; 56(5):1342-5. PMID: 25120050; PMCID: PMC4417657.
      Citations: 8     Fields:    Translation:Humans
    869. Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015 Feb 15; 121(4):556-61. PMID: 25336333; PMCID: PMC4320000.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    870. Pemmaraju N, Kantarjian H, Garcia-Manero G, Pierce S, Cardenas-Turanzas M, Cortes J, Ravandi F. Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience. Am J Hematol. 2015 Jan; 90(1):27-30. PMID: 25251041; PMCID: PMC4276516.
      Citations: 17     Fields:    Translation:Humans
    871. Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi F. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015 Mar; 168(5):646-53. PMID: 25312977; PMCID: PMC4323735.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    872. Kantarjian H, O'Brien S, Jabbour E, Barnes G, Pathak A, Cortes J. Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies. Clin Lymphoma Myeloma Leuk. 2015 Jan; 15(1):13-21. PMID: 25458084.
      Citations: 12     Fields:    Translation:Humans
    873. Loghavi S, Zuo Z, Ravandi F, Kantarjian HM, Bueso-Ramos C, Zhang L, Singh RR, Patel KP, Medeiros LJ, Stingo F, Routbort M, Cortes J, Luthra R, Khoury JD. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014 Oct 04; 7:74. PMID: 25281355; PMCID: PMC4197326.
      Citations: 36     Fields:    Translation:Humans
    874. Tam CS, O'Brien S, Plunkett W, Wierda W, Ferrajoli A, Wang X, Do KA, Cortes J, Khouri I, Kantarjian H, Lerner S, Keating MJ. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 2014 Nov 13; 124(20):3059-64. PMID: 25281606; PMCID: PMC4231417.
      Citations: 37     Fields:    Translation:Humans
    875. Passamonti F, Vannucchi AM, Harrison C, Kantarjian H, Verstovsek S, Cervantes F, Morra E. Ruxolitinib and survival improvement in patients with myelofibrosis. Leukemia. 2015 Mar; 29(3):739-40. PMID: 25249013.
      Citations: 6     Fields:    Translation:Humans
    876. Kantarjian H, Cortes JE. Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia. J Clin Oncol. 2014 Sep 20; 32(27):3077. PMID: 25002733.
      Citations: 5     Fields:    Translation:Humans
    877. Kadia TM, Ravandi F, O'Brien S, Cortes J, Kantarjian HM. Progress in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):139-51. PMID: 25441110; PMCID: PMC4344862.
      Citations: 21     Fields:    Translation:Humans
    878. Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, Garcia-Manero G, Ravandi F, Jabbour E, Dellasala S, Pierce S, Verstovsek S. A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):171-6. PMID: 25441108; PMCID: PMC4344906.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    879. Cortes JE, Goldberg SL, Feldman EJ, Rizzeri DA, Hogge DE, Larson M, Pigneux A, Recher C, Schiller G, Warzocha K, Kantarjian H, Louie AC, Kolitz JE. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 2015 Jan 15; 121(2):234-42. PMID: 25223583; PMCID: PMC5542857.
      Citations: 52     Fields:    Translation:HumansCTClinical Trials
    880. Bejar R, Lord A, Stevenson K, Bar-Natan M, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone RM, Neuberg D, Steensma DP, Ebert BL, P?rez-Ladaga A. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014 Oct 23; 124(17):2705-12. PMID: 25224413; PMCID: PMC4208285.
      Citations: 229     Fields:    Translation:HumansAnimalsCells
    881. Zuo Z, Maiti S, Hu S, Loghavi S, Calin GA, Garcia-Manero G, Kantarjian HM, Medeiros LJ, Cooper LJ, Bueso-Ramos CE. Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Mod Pathol. 2015 Mar; 28(3):373-82. PMID: 25216221.
      Citations: 13     Fields:    Translation:Humans
    882. Platzbecker U, Sekeres MA, Kantarjian H, Mufti GJ, Jia C, Yang AS, Giagounidis A, Fenaux P. Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial. Leukemia. 2014 Dec; 28(12):2418-21. PMID: 25179731; PMCID: PMC4274610.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    883. Kantarjian H. Chemotherapy drug shortages in the United States revisited. J Oncol Pract. 2014 Sep; 10(5):329-31. PMID: 25232189.
      Citations: 2     Fields:    
    884. Freireich EJ, Kantarjian H, Keating MJ. The proceedings of the initial meeting of the Society of Hematologic Oncology 2013. Clin Lymphoma Myeloma Leuk. 2014 Sep; 14 Suppl:S1. PMID: 25486946.
      Citations:    Fields:    
    885. Strati P, Pemmaraju N, Estrov Z, Cardenas-Turanzas M, Pierce S, Newberry KJ, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clinical significance of microcytosis in patients with primary myelofibrosis. Leuk Res. 2014 Oct; 38(10):1212-6. PMID: 25217891; PMCID: PMC4182146.
      Citations: 1     Fields:    Translation:HumansCells
    886. Burger JA, Keating MJ, Wierda WG, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Zacharian G, Huang X, Kantarjian H, Garg N, O'Brien S, Hartmann E, Nogueras-Gonz?lez GM, Rosenwald A. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014 Sep; 15(10):1090-9. PMID: 25150798; PMCID: PMC4174348.
      Citations: 131     Fields:    Translation:HumansCTClinical Trials
    887. Zabriskie MS, Eide CA, Tantravahi SK, Estrada J, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Druker BJ, Deininger MW, O'Hare T, Vellore NA, Nicolini FE, Hern?ndez-Boluda JC, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Baron R. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014 Sep 08; 26(3):428-442. PMID: 25132497; PMCID: PMC4160372.
      Citations: 131     Fields:    Translation:HumansCells
    888. Walter RB, Othus M, Burnett AK, Kantarjian HM, Ossenkoppele GJ, Hills RK, Ravandi F, Pabst T, Evans A, Pierce SR, Vekemans MC, Appelbaum FR, Estey EH, L?wenberg B. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia. 2015 Feb; 29(2):312-20. PMID: 25113226; PMCID: PMC4318722.
      Citations: 59     Fields:    Translation:Humans
    889. Mak PY, Mak DH, Ruvolo V, Jacamo R, Kornblau SM, Kantarjian H, Andreeff M, Carter BZ. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia. Br J Haematol. 2014 Nov; 167(3):376-84. PMID: 25079338; PMCID: PMC4357400.
      Citations: 15     Fields:    Translation:HumansCells
    890. Benton CB, Thomas DA, Yang H, Ravandi F, Rytting M, O'Brien S, Franklin AR, Borthakur G, Dara S, Kwari M, Pierce SR, Jabbour E, Kantarjian H, Garcia-Manero G. Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 Nov; 167(3):356-65. PMID: 25066676; PMCID: PMC4198465.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    891. Gambacorti-Passerini C, Cortes JE, Lipton JH, Dmoszynska A, Wong RS, Rossiev V, Pavlov D, Gogat Marchant K, Khattry N, Kantarjian HM, Duvilli? L, Br?mmendorf TH. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol. 2014 Oct; 89(10):947-53. PMID: 24944159; PMCID: PMC4305212.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    892. Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014 Oct; 89(10):964-8. PMID: 24990142; PMCID: PMC4431614.
      Citations: 19     Fields:    Translation:Humans
    893. Jabbour E, Garcia-Manero G, Cornelison AM, Cortes JE, Ravandi F, Daver N, Kadia T, Teng A, Kantarjian H. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leuk Lymphoma. 2015 Feb; 56(2):390-4. PMID: 24844364; PMCID: PMC4297591.
      Citations: 2     Fields:    Translation:Humans
    894. Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-M?nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 01; 120(23):3660-8. PMID: 25042398; PMCID: PMC4239168.
      Citations: 29     Fields:    Translation:Humans
    895. Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH, Nogueras Gonz?lez GM. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Feb; 15(2):110-4. PMID: 25107338; PMCID: PMC4294996.
      Citations: 15     Fields:    Translation:Humans
    896. Jain P, Lee HJ, Qiao W, Wierda W, Benjamini O, Burger J, Ferrajoli A, Estrov Z, Kantarjian H, Keating M, O'Brien S. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer. 2014 Nov 15; 120(22):3494-501. PMID: 25043749; PMCID: PMC4221361.
      Citations: 3     Fields:    Translation:Humans
    897. Sekeres MA, Giagounidis A, Kantarjian H, Mufti GJ, Fenaux P, Jia C, Yang AS, Platzbecker U. Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes. Br J Haematol. 2014 Nov; 167(3):337-45. PMID: 25039607.
      Citations: 6     Fields:    Translation:Humans
    898. Steensma DP, Kantarjian HM. Reply to J.S. Abrams et al. J Clin Oncol. 2014 Aug 10; 32(23):2516. PMID: 25002713.
      Citations:    Fields:    Translation:Humans
    899. Daver N, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res. 2014 Sep; 38(9):1126-9. PMID: 25047979; PMCID: PMC4157096.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    900. Ma H, Mallampati S, Lu Y, Sun B, Wang E, Leng X, Gong Y, Shen H, Yin CC, Jones D, Amin HM, You MJ, Zweidler-McKay P, Ma Y, Kantarjian HM, Arlinghaus RB, Glassman A, Sun X. The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblastic leukemia. Haematologica. 2014 Oct; 99(10):1591-8. PMID: 24997151; PMCID: PMC4181255.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    901. Jain P, Ok CY, Konoplev S, Patel KP, Jorgensen J, Estrov Z, Luthra R, Kantarjian H, Ravandi F. Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity? J Clin Oncol. 2016 Mar 01; 34(7):e57-60. PMID: 24982452.
      Citations: 5     Fields:    Translation:Humans
    902. DiNardo CD, Tang G, Pemmaraju N, Wang SA, Pike A, Garcia-Manero G, Cortes J, Bueso-Ramos C, Kantarjian HM. Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation. Clin Lymphoma Myeloma Leuk. 2015 Jan; 15(1):47-51. PMID: 25081372; PMCID: PMC4849878.
      Citations: 4     Fields:    Translation:HumansCells
    903. Frolova O, Benito J, Brooks C, Wang RY, Korchin B, Rowinsky EK, Cortes J, Kantarjian H, Andreeff M, Frankel AE, Konopleva M. SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. Br J Haematol. 2014 Sep; 166(6):862-74. PMID: 24942980; PMCID: PMC4146738.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    904. Mathisen MS, Kantarjian HM, Cortes J, Jabbour EJ. Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. Blood Rev. 2014 Sep; 28(5):179-87. PMID: 24984571.
      Citations: 12     Fields:    Translation:Humans
    905. Lee E, Merchan B, Kantarjian HM, Bravo GM, Garc?a-Manero G. Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution. Br J Haematol. 2014 Sep; 166(5):646-59. PMID: 24903747; PMCID: PMC5553700.
      Citations: 14     Fields:    Translation:HumansAnimals
    906. Wodarz D, Garg N, Komarova NL, Benjamini O, Keating MJ, Wierda WG, Kantarjian H, James D, O'Brien S, Burger JA. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood. 2014 Jun 26; 123(26):4132-5. PMID: 24829205; PMCID: PMC4123432.
      Citations: 39     Fields:    Translation:HumansCellsCTClinical Trials
    907. Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G, Quint?s-Cardama A. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):401-10. PMID: 24875590; PMCID: PMC4167474.
      Citations: 21     Fields:    Translation:Humans
    908. Kantarjian H, Steensma D, Rius Sanjuan J, Elshaug A, Light D. High cancer drug prices in the United States: reasons and proposed solutions. J Oncol Pract. 2014 Jul; 10(4):e208-11. PMID: 24803662.
      Citations: 33     Fields:    Translation:Humans
    909. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014 May; 89(5):547-56. PMID: 24729196.
      Citations: 70     Fields:    Translation:Humans
    910. Chae YK, Dimou A, Pierce S, Kantarjian H, Andreeff M. The effect of calcium channel blockers on the outcome of acute myeloid leukemia. Leuk Lymphoma. 2014 Dec; 55(12):2822-9. PMID: 24628293; PMCID: PMC4213321.
      Citations: 12     Fields:    Translation:Humans
    911. Gambacorti-Passerini C, Kim DW, Turkina AG, Masszi T, Assouline S, Durrant S, Kantarjian HM, Khoury HJ, Zaritskey A, Shen ZX, Jin J, Vellenga E, Pasquini R, Mathews V, Cervantes F, Besson N, Turnbull K, Leip E, Kelly V, Cortes JE, Br?mmendorf TH. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol. 2014 Jul; 89(7):732-42. PMID: 24711212; PMCID: PMC4173127.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    912. Pemmaraju N, Kantarjian H, Andreeff M, Cortes J, Ravandi F. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opin Investig Drugs. 2014 Jul; 23(7):943-54. PMID: 24749672; PMCID: PMC4109297.
      Citations: 16     Fields:    Translation:HumansAnimals
    913. Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer. 2014 Jul 15; 120(14):2142-9. PMID: 24737502; PMCID: PMC4124083.
      Citations: 58     Fields:    Translation:Humans
    914. Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Hu K, Woodard P, Yang AS, Kantarjian HM. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer. 2014 Jun 15; 120(12):1838-46. PMID: 24706489; PMCID: PMC4298760.
      Citations: 33     Fields:    Translation:Humans
    915. Ghanem H, Garcia-Manero G, Faderl S, Ravandi F, Cortes J, Katragadda L, O'Brien S, Daver N, Pierce S, Kadia T, Kantarjian H, Jabbour E. Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. Ther Adv Hematol. 2014 Apr; 5(2):29-34. PMID: 24688752; PMCID: PMC3949300.
      Citations: 1     
    916. Rozovski U, Li P, Harris D, Ohanian M, Kantarjian H, Estrov Z. Interleukin-7 receptor-a gene mutations are not detected in adult T-cell acute lymphoblastic leukemia. Cancer Med. 2014 Jun; 3(3):550-4. PMID: 24678068; PMCID: PMC4101745.
      Citations: 4     Fields:    Translation:HumansCells
    917. Kantarjian HM, Steensma DP, Light DW. The Patient Protection and Affordable Care Act: Is it good or bad for oncology? Cancer. 2014 Jun 01; 120(11):1600-3. PMID: 24643748.
      Citations:    Fields:    Translation:Humans
    918. Jabbour E, Daver N, Champlin R, Mathisen M, Oran B, Ciurea S, Khouri I, Cornelison AM, Ghanem H, Cardenas-Turanzas M, Popat U, Ravandi F, Giralt S, Garcia-Manero G, Cortes J, Kantarjian H, de Lima M. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol. 2014 Apr; 89(4):395-8. PMID: 24375514; PMCID: PMC4140180.
      Citations: 15     Fields:    Translation:HumansCells
    919. Benjamini O, Dumlao TL, Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Jorgensen J, Luthra R, Garris R, Thomas D, Kebriaei P, Champlin R, Jabbour E, Burger J, Cortes J, Ravandi F. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014 Mar; 89(3):282-7. PMID: 24779033; PMCID: PMC4196860.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    920. Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res. 2014 Apr 15; 20(8):2226-35. PMID: 24583795; PMCID: PMC3989412.
      Citations: 37     Fields:    Translation:HumansCellsCTClinical Trials
    921. Shah NP, Cortes JE, Schiffer CA, le Coutre P, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H, Healey D, Cunningham M, Saglio G, Guilhot F, Br?mmendorf TH. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014 Apr 10; 123(15):2317-24. PMID: 24569263; PMCID: PMC4915794.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    922. Daver N, Naqvi K, Jabbour E, Kadia T, DiNardo C, Cardenas-Turanzas M, Pierce S, Nguyen KT, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. Am J Hematol. 2014 May; 89(5):509-16. PMID: 24458781; PMCID: PMC4221257.
      Citations: 10     Fields:    Translation:Humans
    923. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, Gattoni E, Pieri L, Guglielmelli P, Elena C, He S, Contel N, Mookerjee B, Sandor V, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014 Feb 15; 120(4):513-20. PMID: 24258498; PMCID: PMC4231215.
      Citations: 62     Fields:    Translation:HumansCellsCTClinical Trials
    924. Hughes TP, Kantarjian HM, Cervantes F, Niederwieser D, Rosti G, Ossenkoppele G, Lobo C, Shibayama H, Fan X, Menssen HD, Kemp C, Larson RA, Saglio G, Hochhaus A, Guilhot F, le Coutre PD. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica. 2014 Jul; 99(7):1204-11. PMID: 24532039; PMCID: PMC4077082.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    925. Zhang L, Singh RR, Patel KP, Stingo F, Routbort M, You MJ, Miranda RN, Garcia-Manero G, Kantarjian HM, Medeiros LJ, Luthra R, Khoury JD. BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS. Am J Hematol. 2014 May; 89(5):499-504. PMID: 24446311; PMCID: PMC4207363.
      Citations: 17     Fields:    Translation:HumansCells
    926. Arthur C, Delaunay J, Mazur G, Thomas XG, Wierzbowska A, Ravandi F, Berrak E, Jones M, Li Y, Kantarjian HM, Mayer J. Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics. BMC Cancer. 2014 Feb 06; 14:69. PMID: 24498872; PMCID: PMC3928608.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    927. Cortes JE, Talpaz M, Kantarjian H. Ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2014 02 06; 370(6):577. PMID: 24499221.
      Citations: 7     Fields:    Translation:Humans
    928. DiNardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi F. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma. 2014 Aug; 55(8):1925-9. PMID: 24138309; PMCID: PMC4139917.
      Citations: 26     Fields:    Translation:Humans
    929. Tsimberidou AM, Keating MJ, Jabbour EJ, Ravandi-Kashani F, O'Brien S, Estey E, Bekele N, Plunkett WK, Kantarjian H, Borthakur G. A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):395-400.e1. PMID: 24637132; PMCID: PMC4387892.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    930. Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul; 28(7):1543-5. PMID: 24487412; PMCID: PMC4091714.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    931. Bryan J, Kantarjian H, Prescott H, Jabbour E. Clofarabine in the treatment of myelodysplastic syndromes. Expert Opin Investig Drugs. 2014 Feb; 23(2):255-63. PMID: 24410313.
      Citations: 1     Fields:    Translation:HumansAnimals
    932. Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver N, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur G. Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):163-71. PMID: 24461514; PMCID: PMC4167660.
      Citations: 5     Fields:    Translation:HumansCells
    933. Zhou Y, Slack R, Jorgensen JL, Wang SA, Rondon G, de Lima M, Shpall E, Popat U, Ciurea S, Alousi A, Qazilbash M, Hosing C, O'Brien S, Thomas D, Kantarjian H, Medeiros LJ, Champlin RE, Kebriaei P. The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):319-26. PMID: 24548609; PMCID: PMC5614489.
      Citations: 23     Fields:    Translation:Humans
    934. Choi S, Kantarjian H, Jabbour E, Huang X, Cortes J, Quint?s-Cardama A. Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):327-334.e8. PMID: 24594142; PMCID: PMC4099320.
      Citations: 6     Fields:    Translation:Humans
    935. DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia. 2014 Apr; 28(4):958-61. PMID: 24492324; PMCID: PMC3981947.
      Citations: 19     Fields:    Translation:Humans
    936. Steensma DP, Kantarjian HM. Impact of cancer research bureaucracy on innovation, costs, and patient care. J Clin Oncol. 2014 Feb 10; 32(5):376-8. PMID: 24395852.
      Citations: 14     Fields:    Translation:Humans
    937. Kurzrock R, Kantarjian H, Stewart DJ. A cancer trial scandal and its regulatory backlash. Nat Biotechnol. 2014 Jan; 32(1):27-31. PMID: 24406925.
      Citations: 4     Fields:    Translation:Humans
    938. Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Mongay L, Mone M, Ortmann CE, Kantarjian HM, Radich JP, Hughes TP, Cortes JE, Guilhot F. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Int J Hematol. 2014; 99(5):616-24. PMID: 24658916.
      Citations: 17     Fields:    Translation:Humans
    939. Kantarjian HM. Charging what the market will bear is inappropriate. Clin Adv Hematol Oncol. 2014 Jan; 12(1):63. PMID: 25129904.
      Citations:    Fields:    Translation:Humans
    940. Jain N, O'Brien S, Thomas D, Kantarjian H. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia. Front Biosci (Elite Ed). 2014 01 01; 6(1):40-5. PMID: 24389139.
      Citations: 6     Fields:    Translation:Humans
    941. Zwelling L, Kantarjian HM. Obamacare: why should we care? J Oncol Pract. 2014 Jan; 10(1):12-4. PMID: 24443729.
      Citations:    Fields:    Translation:Humans
    942. Delaunay J, Mazur G, Minden M, Wierzbowska A, Jones MM, Berrak E, Kantarjian HM. Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia. Leuk Res Rep. 2014; 3(1):17-20. PMID: 24596676; PMCID: PMC3939385.
      Citations:    
    943. Mathisen MS, Kantarjian HM, Jabbour EJ. Emerging drugs for acute lymphocytic leukemia. Expert Opin Emerg Drugs. 2014 Mar; 19(1):37-50. PMID: 24354521.
      Citations: 2     Fields:    Translation:Humans
    944. Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther. 2013; 7:13-21. PMID: 24368888; PMCID: PMC3869911.
      Citations: 23     
    945. Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Porkka K, Martinelli G, Durrant S, Leip E, Kelly V, Turnbull K, Besson N, Gambacorti-Passerini C, Br?mmendorf TH. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014 Feb 27; 123(9):1309-18. PMID: 24345751; PMCID: PMC4467890.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    946. Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):231-8. PMID: 24440659; PMCID: PMC4182922.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    947. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG, D?hner H, M?schen M. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014 Mar; 4(3):362-75. PMID: 24346116; PMCID: PMC3975047.
      Citations: 288     Fields:    Translation:HumansAnimalsCells
    948. Hughes TP, Saglio G, Kantarjian HM, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A, Guilhot F. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014 Feb 27; 123(9):1353-60. PMID: 24335106; PMCID: PMC4624459.
      Citations: 90     Fields:    Translation:HumansCells
    949. Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res. 2014 Mar; 38(3):316-22. PMID: 24374145; PMCID: PMC4414320.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    950. Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):155-162.e1. PMID: 24332214; PMCID: PMC3959284.
      Citations: 15     Fields:    Translation:Humans
    951. Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Chuah C, Pavlovsky C, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A, Boqu? C, Mayer J. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014 Jan 23; 123(4):494-500. PMID: 24311723; PMCID: PMC4190618.
      Citations: 146     Fields:    Translation:HumansCTClinical Trials
    952. Kantarjian H, Steensma D, Light D. Should oncologists support the Affordable Care Act? Lancet Oncol. 2013 Dec; 14(13):1258-9. PMID: 24275127.
      Citations:    Fields:    Translation:Humans
    953. Jabbour EJ, Cortes JE, Kantarjian HM. Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Rev Anticancer Ther. 2013 Dec; 13(12):1433-52. PMID: 24236822; PMCID: PMC4181370.
      Citations: 13     Fields:    Translation:Humans
    954. Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR, Fang Z, Nguyen M, Pierce S, Wei Y, Parmar S, Cortes J, Kantarjian H, Garcia-Manero G. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014 Jun; 28(6):1280-8. PMID: 24270737; PMCID: PMC4032802.
      Citations: 274     Fields:    Translation:HumansCells
    955. Jabbour E, Ghanem H, Huang X, Ravandi F, Garcia-Manero G, O'Brien S, Faderl S, Pierce S, Choi S, Verstovsek S, Brandt M, Cortes J, Kantarjian H. Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):93-7. PMID: 24447728; PMCID: PMC4098769.
      Citations: 6     Fields:    Translation:HumansCells
    956. Foran J, Ravandi F, Wierda W, Garcia-Manero G, Verstovsek S, Kadia T, Burger J, Yule M, Langford G, Lyons J, Ayrton J, Lock V, Borthakur G, Cortes J, Kantarjian H. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):223-30. PMID: 24355079; PMCID: PMC4096861.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    957. Arana Yi C, Jeyakumar G, Medina P, Cortes J, Pierce S, Bueso-Ramos C, Kantarjian H, Verstovsek S. Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers. Leuk Res. 2014 Jan; 38(1):91-4. PMID: 24284333; PMCID: PMC4406374.
      Citations: 2     Fields:    Translation:Humans
    958. Jabbour EJ, Hughes TP, Kantarjian HM, Hochhaus A, Cort?s JE. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma. 2014 Jul; 55(7):1451-62. PMID: 24050507; PMCID: PMC4186697.
      Citations: 14     Fields:    Translation:Humans
    959. Jain N, Khoury JD, Pemmaraju N, Kollipara P, Kantarjian H, Verstovsek S. Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement. Blood. 2013 Nov 07; 122(19):3387-8. PMID: 24203930.
      Citations: 1     Fields:    Translation:Humans
    960. Jain P, Romo CG, Khoury HJ, Kantarjian H, Cortes J. Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts. Haematologica. 2013 Nov; 98(11):e141-2. PMID: 24186316; PMCID: PMC3815188.
      Citations: 1     Fields:    Translation:HumansCells
    961. Benton CB, Ravandi F, Andreeff M, Kadia T, Ruvolo V, Qiu P, Wheeler DA, Garcia-Manero G, Cortes J, Kantarjian HM, Konopleva M. Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations. Leuk Lymphoma. 2014 Jun; 55(6):1431-4. PMID: 24033106; PMCID: PMC4105975.
      Citations: 2     Fields:    Translation:HumansCells
    962. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, PACE Investigators, M?ller MC. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov 07; 369(19):1783-96. PMID: 24180494; PMCID: PMC3886799.
      Citations: 353     Fields:    Translation:HumansCTClinical Trials
    963. Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, Terebelo HR, Ortega GL, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O'Neill P, Erickson-Viitanen S, Leopold L, Sandor V, Levy RS, Kantarjian HM, Verstovsek S. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013 Oct 29; 6(1):81. PMID: 24283202; PMCID: PMC4176265.
      Citations: 33     Fields:    Translation:HumansCellsCTClinical Trials
    964. Karjalainen K, Pasqualini R, Cortes JE, Kornblau SM, Lichtiger B, O'Brien S, Kantarjian HM, Sidman RL, Arap W, Koivunen E. Design, development, and validation of a high-throughput drug-screening assay for targeting of human leukemia. Cancer. 2014 Feb 15; 120(4):589-602. PMID: 24496871; PMCID: PMC4457455.
      Citations:    Fields:    Translation:Humans
    965. Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia. 2014 Apr; 28(4):973-5. PMID: 24157581.
      Citations: 19     Fields:    Translation:Humans
    966. Lu H, Kojima K, Battula VL, Korchin B, Shi Y, Chen Y, Spong S, Thomas DA, Kantarjian H, Lock RB, Andreeff M, Konopleva M. Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth. Ann Hematol. 2014 Mar; 93(3):485-492. PMID: 24154679; PMCID: PMC3948212.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    967. Strati P, Kantarjian H, Thomas D, O'Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi F, Cortes J. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer. 2014 Feb 01; 120(3):373-80. PMID: 24151050; PMCID: PMC3946911.
      Citations: 17     Fields:    Translation:Humans
    968. Luthra R, Patel KP, Reddy NG, Haghshenas V, Routbort MJ, Harmon MA, Barkoh BA, Kanagal-Shamanna R, Ravandi F, Cortes JE, Kantarjian HM, Medeiros LJ, Singh RR. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014 Mar; 99(3):465-73. PMID: 24142997; PMCID: PMC3943309.
      Citations: 77     Fields:    Translation:Humans
    969. Jain P, Kantarjian H, Estey E, Pierce S, Cortes J, Lopez-Berestein G, Ravandi F. Single-agent liposomal all-trans-retinoic Acid as initial therapy for acute promyelocytic leukemia: 13-year follow-up data. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):e47-9. PMID: 24128595; PMCID: PMC4103408.
      Citations: 7     Fields:    Translation:Humans
    970. Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma. 2014 Jun; 55(6):1337-44. PMID: 24004182; PMCID: PMC4143910.
      Citations: 16     Fields:    Translation:Humans
    971. Jabbour E, Cortes J, Ravandi F, O'Brien S, Kantarjian H. Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol. 2013 Oct; 50(4):271-83. PMID: 24246694; PMCID: PMC4098770.
      Citations: 13     Fields:    Translation:Humans
    972. Kantarjian HM, Silver RT, Komrokji RS, Mesa RA, Tacke R, Harrison CN. Ruxolitinib for myelofibrosis--an update of its clinical effects. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):638-45. PMID: 24238036; PMCID: PMC5556922.
      Citations: 8     Fields:    Translation:Humans
    973. Thomas XG, Arthur C, Delaunay J, Jones M, Berrak E, Kantarjian HM. A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):68-72. PMID: 24220616.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    974. Nazha A, Romo CG, Kantarjian H, Cortes J. The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia. Haematologica. 2013 Oct; 98(10):e131. PMID: 24091930; PMCID: PMC3789475.
      Citations: 6     Fields:    Translation:HumansCells
    975. Takahashi K, Patel KP, Kantarjian H, Luthra R, Pierce S, Cortes J, Verstovsek S. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood. 2013 Nov 28; 122(23):3784-6. PMID: 24068492; PMCID: PMC3952679.
      Citations: 8     Fields:    Translation:Humans
    976. le Coutre PD, Kantarjian HM, Baccarani M, Erben P, Reiter A, McCulloch T, Fan X, Novick S, Giles FJ, Hochhaus A. Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. J Cancer Res Clin Oncol. 2013 Dec; 139(12):1985-93. PMID: 24057647; PMCID: PMC5556980.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    977. Yilmaz M, Kantarjian H, Jabbour E, O'Brien S, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger J, Pierce S, Quintas-Cardama A, Cortes J. Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):693-9. PMID: 24060289; PMCID: PMC3835390.
      Citations: 4     Fields:    Translation:Humans
    978. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013 Dec; 98(12):1865-71. PMID: 24038026; PMCID: PMC3856961.
      Citations: 71     Fields:    Translation:Humans
    979. Falchi L, Kantarjian HM, Wang X, Verma D, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE, Quint?s-Cardama A. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013 Dec; 88(12):1024-9. PMID: 23913852; PMCID: PMC3849405.
      Citations: 28     Fields:    Translation:Humans
    980. Konoplev S, Lin P, Yin CC, Lin E, Kantarjian HM, Andreeff M, Medeiros LJ, Konopleva M, Nogueras Gonz?lez GM. CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):686-92. PMID: 24035716; PMCID: PMC4206258.
      Citations: 8     Fields:    Translation:HumansCells
    981. Benjamini O, Kantarjian H, Rios MB, Jabbour E, O'Brien S, Jain P, Cardenas-Turanzas M, Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Quintas-Cardama A, Cortes J. Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk Lymphoma. 2014 Dec; 55(12):2879-86. PMID: 23927391; PMCID: PMC4127158.
      Citations: 13     Fields:    Translation:Humans
    982. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6. PMID: 23877926; PMCID: PMC4110914.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    983. Nazha A, Bueso-Ramos C, Estey E, Faderl S, O'Brien S, Fernandez MH, Nguyen M, Koller C, Freireich E, Beran M, Pierce S, Keating M, Cortes J, Kantarjian H, Ravandi F. The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia. Front Oncol. 2013; 3:218. PMID: 24032106; PMCID: PMC3764477.
      Citations: 14     
    984. Light DW, Kantarjian H. Market spiral pricing of cancer drugs. Cancer. 2013 Nov 15; 119(22):3900-2. PMID: 24002792.
      Citations: 25     Fields:    Translation:Humans
    985. Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013 Oct 10; 31(29):3681-7. PMID: 24002496; PMCID: PMC3804291.
      Citations: 159     Fields:    Translation:HumansCellsCTClinical Trials
    986. Rytting M, Triche L, Thomas D, O'Brien S, Kantarjian H. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014 Feb; 61(2):369-72. PMID: 24000241; PMCID: PMC5042143.
      Citations: 21     Fields:    Translation:Humans
    987. Chakhachiro ZI, Zuo Z, Aladily TN, Kantarjian HM, Cortes JE, Alayed K, Nguyen MH, Medeiros LJ, Bueso-Ramos C. CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias. Am J Clin Pathol. 2013 Sep; 140(3):370-8. PMID: 23955456.
      Citations: 6     Fields:    Translation:Humans
    988. Freireich EJ, Kantarjian H, Keating MJ. Retrospect of hematological malignancies 2012. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S271. PMID: 24290211.
      Citations:    Fields:    Translation:Humans
    989. Kantarjian H, Zwelling L. Cancer drug prices and the free-market forces. Cancer. 2013 Nov 15; 119(22):3903-5. PMID: 24037953.
      Citations: 4     Fields:    Translation:Humans
    990. Ghanem H, Cornelison AM, Garcia-Manero G, Kantarjian H, Ravandi F, Kadia T, Cortes J, O'Brien S, Brandt M, Borthakur G, Jabbour E. Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S289-94. PMID: 23969308; PMCID: PMC4120258.
      Citations: 1     Fields:    Translation:Humans
    991. Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S276-81. PMID: 23969309; PMCID: PMC4101888.
      Citations: 3     Fields:    Translation:Humans
    992. Cherry M, Cardenas-Turanzas M, Pham H, Kantarjian H, Cortes J, Pierce S, Zhou L, Verstovsek S. Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. Leuk Res. 2013 Nov; 37(11):1472-6. PMID: 23993426; PMCID: PMC3818458.
      Citations: 2     Fields:    Translation:Humans
    993. Zheng W, Medeiros LJ, Young KH, Goswami M, Powers L, Kantarjian HH, Thomas DA, Cortes JE, Wang SA. CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. Leuk Lymphoma. 2014 Mar; 55(3):624-7. PMID: 23937105; PMCID: PMC4188389.
      Citations: 12     Fields:    Translation:Humans
    994. Kantarjian H, Hochhaus A. The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. J Cancer Res Clin Oncol. 2013 Dec; 139(12):1971-84. PMID: 23942795; PMCID: PMC3825579.
      Citations: 22     Fields:    Translation:Humans
    995. Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res. 2013 Nov; 37(11):1461-7. PMID: 23993427; PMCID: PMC4205589.
      Citations: 21     Fields:    Translation:HumansCellsCTClinical Trials
    996. Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H, Levy R, Siulnik A, Gupta V, Khan M, DiPersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica. 2014 Feb; 99(2):292-8. PMID: 23911705; PMCID: PMC3912959.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    997. Takahashi K, Pemmaraju N, Strati P, Nogueras-Gonzalez G, Ning J, Bueso-Ramos C, Luthra R, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood. 2013 Oct 17; 122(16):2807-11; quiz 2920. PMID: 23896412; PMCID: PMC3798995.
      Citations: 17     Fields:    Translation:Humans
    998. Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):515-29. PMID: 23890944; PMCID: PMC4160831.
      Citations: 34     Fields:    Translation:Humans
    999. Daver N, Shastri A, Kadia T, Quintas-Cardama A, Jabbour E, Konopleva M, O'Brien S, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res. 2013 Nov; 37(11):1440-4. PMID: 23890523; PMCID: PMC4232180.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    1000. DiNardo CD, Gharibyan V, Yang H, Wei Y, Pierce S, Kantarjian HM, Garcia-Manero G, Rytting M. Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with acute lymphocytic leukemia. Am J Hematol. 2013 Sep; 88(9):784-9. PMID: 23757320; PMCID: PMC3947930.
      Citations: 7     Fields:    Translation:HumansCells
    1001. Nazha A, Kantarjian H, Cortes J, Quint?s-Cardama A. Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia. Expert Opin Pharmacother. 2013 Oct; 14(14):1977-86. PMID: 23875628.
      Citations: 4     Fields:    Translation:HumansAnimals
    1002. Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol. 2013 Oct; 88(10):831-7. PMID: 23760779; PMCID: PMC3923606.
      Citations: 21     Fields:    Translation:HumansCellsCTClinical Trials
    1003. Heinrichs S, Conover LF, Bueso-Ramos CE, Kilpivaara O, Stevenson K, Neuberg D, Loh ML, Wu WS, Rodig SJ, Garcia-Manero G, Kantarjian HM, Look AT. MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. Elife. 2013 Jul 16; 2:e00825. PMID: 23878725; PMCID: PMC3713455.
      Citations: 17     Fields:    Translation:Humans
    1004. Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013 Aug 15; 122(7):1214-21. PMID: 23836561; PMCID: PMC3976223.
      Citations: 77     Fields:    Translation:HumansCells
    1005. Ostronoff F, Othus M, Kantarjian HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM, Petersdorf SH, Godwin JE, Willman CL, Pierce SA, List AF, Sandhu RK, Walter RB, Stirewalt DL, Appelbaum FR, Estey EH. A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia. Br J Haematol. 2013 Oct; 163(1):130-2. PMID: 23829510; PMCID: PMC4128010.
      Citations:    Fields:    Translation:HumansCells
    1006. Nazha A, Kantarjian H, Jain P, Romo C, Jabbour E, Quintas-Cardama A, Luthra R, Abruzzo L, Borthakur G, Ravandi F, Pierce S, O'Brien S, Cortes J. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica. 2013 Nov; 98(11):1686-8. PMID: 23812943; PMCID: PMC3815167.
      Citations: 8     Fields:    Translation:Humans
    1007. Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ, Chronic Lymphocytic Leukemia Research Consortium. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):568-74. PMID: 23810245; PMCID: PMC4180513.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    1008. Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Martinelli G, Mayer J, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Baccarani M, Guilhot F, Mahon FX, M?ller MC, Sau?ele S, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 08; 122(6):872-84. PMID: 23803709; PMCID: PMC4915804.
      Citations: 652     Fields:    Translation:Humans
    1009. Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O'Brien S, Kornblau SM, Kantarjian HM, Gao H, Ferrajoli A. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood. 2013 Aug 01; 122(5):734-7. PMID: 23801633; PMCID: PMC4123325.
      Citations: 24     Fields:    Translation:HumansCellsCTClinical Trials
    1010. Mathisen MS, Kantarjian H, Thomas D, O'Brien S, Jabbour E. Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates. Leuk Lymphoma. 2013 Dec; 54(12):2592-600. PMID: 23547835; PMCID: PMC5681222.
      Citations: 6     Fields:    Translation:Humans
    1011. Jabbour E, Kantarjian H, O'Brien S, Kadia T, Malik A, Welch MA, Teng A, Cortes J, Ravandi F, Garcia-Manero G. Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):592-6. PMID: 23790798; PMCID: PMC4120256.
      Citations: 2     Fields:    Translation:Humans
    1012. Kantarjian HM, O'Brien S, Cortes J. Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):530-3. PMID: 23790799; PMCID: PMC3775965.
      Citations: 36     Fields:    Translation:Humans
    1013. Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S, Quint?s-Cardama A. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a. Blood. 2013 Aug 08; 122(6):893-901. PMID: 23782935; PMCID: PMC3739035.
      Citations: 87     Fields:    Translation:HumansCTClinical Trials
    1014. Williams LA, Garcia Gonzalez AG, Ault P, Mendoza TR, Sailors ML, Williams JL, Huang F, Nazha A, Kantarjian HM, Cleeland CS, Cortes JE. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013 Aug 01; 122(5):641-7. PMID: 23777764; PMCID: PMC3731927.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    1015. Cortes JE, Nicolini FE, Wetzler M, Lipton JH, Akard L, Craig A, Nanda N, Benichou AC, Leonoudakis J, Khoury HJ, Hochhaus A, Baccarani M, Kantarjian HM. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):584-91. PMID: 23787123; PMCID: PMC3775895.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    1016. Wei Y, Dimicoli S, Bueso-Ramos C, Chen R, Yang H, Neuberg D, Pierce S, Jia Y, Zheng H, Wang H, Wang X, Nguyen M, Wang SA, Ebert B, Bejar R, Levine R, Abdel-Wahab O, Kleppe M, Ganan-Gomez I, Kantarjian H, Garcia-Manero G. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia. 2013 Sep; 27(9):1832-40. PMID: 23765228; PMCID: PMC4011663.
      Citations: 68     Fields:    Translation:HumansCells
    1017. Eghtedar A, Kantarjian H, Jabbour E, O'Brien S, Burton E, Garcia-Manero G, Verstovsek S, Ravandi F, Borthakur G, Konopleva M, Quintas-Cardama A, Cortes J. Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):477-84. PMID: 23770156; PMCID: PMC3752280.
      Citations: 9     Fields:    Translation:Humans
    1018. Pemmaraju N, Tanaka MF, Ravandi F, Lin H, Baladandayuthapani V, Rondon G, Giralt SA, Chen J, Pierce S, Cortes J, Kantarjian H, Champlin RE, De Lima M, Qazilbash MH. Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):485-92. PMID: 23769669; PMCID: PMC4112369.
      Citations: 11     Fields:    Translation:Humans
    1019. Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J, Pierce S, Erba H, Faderl S, Appelbaum FR, Estey E. Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson. Leukemia. 2014 Feb; 28(2):289-92. PMID: 23760400; PMCID: PMC4457325.
      Citations: 56     Fields:    Translation:Humans
    1020. Daver N, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quint?s-Cardama A. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):435-40. PMID: 23763915; PMCID: PMC4114766.
      Citations: 12     Fields:    Translation:Humans
    1021. Wetzler M, Thomas DA, Wang ES, Shepard R, Ford LA, Heffner TL, Parekh S, Andreeff M, O'Brien S, Kantarjian HM. Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):430-4. PMID: 23763920; PMCID: PMC3737573.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    1022. Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clin Pharmacol. 2013; 5:85-97. PMID: 23788844; PMCID: PMC3684141.
      Citations: 32     
    1023. Cardenas-Turanzas M, Ravandi-Kashani F, Cortes JE, Jabbour E, Faderl S, Pierce SA, Kantarjian H. Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):579-83. PMID: 23763918; PMCID: PMC4341913.
      Citations:    Fields:    Translation:Humans
    1024. Kantarjian HM, Sekeres MA, Ribrag V, Rousselot P, Garcia-Manero G, Jabbour EJ, Owen K, Stockman PK, Oliver SD. Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):559-67. PMID: 23763917; PMCID: PMC3775947.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    1025. Nicolini FE, Khoury HJ, Akard L, Rea D, Kantarjian H, Baccarani M, Leonoudakis J, Craig A, Benichou AC, Cortes J. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica. 2013 Jul; 98(7):e78-9. PMID: 23753022; PMCID: PMC3696599.
      Citations: 11     Fields:    Translation:Humans
    1026. Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3. PMID: 23774633.
      Citations: 25     Fields:    Translation:Humans
    1027. Kantarjian H, Stewart DJ, Zwelling L. Cancer research in the United States: dying by a thousand paper cuts. Cancer. 2013 Nov 01; 119(21):3742-5. PMID: 23744791.
      Citations: 2     Fields:    Translation:Humans
    1028. Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N, Berdeja JG, Nadeem A, Kassalow L, Kantarjian H. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013 Jul 10; 31(20):2548-53. PMID: 23733767; PMCID: PMC4878053.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    1029. Jain P, Kantarjian H, Cortes J. Chronic myeloid leukemia: overview of new agents and comparative analysis. Curr Treat Options Oncol. 2013 Jun; 14(2):127-43. PMID: 23572291.
      Citations: 16     Fields:    Translation:Humans
    1030. Murphy DM, Bejar R, Stevenson K, Neuberg D, Shi Y, Cubrich C, Richardson K, Eastlake P, Garcia-Manero G, Kantarjian H, Ebert BL, Mike Makrigiorgos G. NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. Leukemia. 2013 Oct; 27(10):2077-81. PMID: 23708912; PMCID: PMC3967719.
      Citations: 31     Fields:    Translation:Humans
    1031. Daver N, Vega-Ruiz A, Kantarjian HM, Estrov Z, Ferrajoli A, Kornblau S, Verstovsek S, Garcia-Manero G, Cortes JE. A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. Eur J Cancer Care (Engl). 2013 Sep; 22(5):605-11. PMID: 23701251; PMCID: PMC3745781.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    1032. Shah NP, Talpaz M, Deininger MW, Mauro MJ, Flinn IW, Bixby D, Lustgarten S, Gozgit JM, Clackson T, Turner CD, Haluska FG, Kantarjian H, Cortes JE. Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. Br J Haematol. 2013 Aug; 162(4):548-52. PMID: 23691988; PMCID: PMC3866040.
      Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
    1033. Santos FP, Tam CS, Kantarjian H, Cortes J, Thomas D, Pollock R, Verstovsek S. Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma. 2014 Jan; 55(1):121-7. PMID: 23573823; PMCID: PMC3874259.
      Citations: 14     Fields:    Translation:Humans
    1034. Attieh Y, Geng QR, Dinardo CD, Zheng H, Jia Y, Fang ZH, Yang H, Wei Y, Kantarjian H, Garcia-Manero G, Ga??n-G?mez I. Low frequency of H3.3 mutations and upregulated DAXX expression in MDS. Blood. 2013 May 09; 121(19):4009-11. PMID: 23660862.
      Citations: 10     Fields:    Translation:HumansCells
    1035. Ravandi F, Cortes J, Kantarjian H. Is there a standard induction regimen for patients with AML? Lancet Oncol. 2013 Jun; 14(7):565-6. PMID: 23664706; PMCID: PMC4111562.
      Citations:    Fields:    Translation:Humans
    1036. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium--the just price. J Clin Oncol. 2013 Oct 01; 31(28):3600-4. PMID: 23650428; PMCID: PMC3782152.
      Citations: 87     Fields:    Translation:Humans
    1037. Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K, Triche TJ, Laird PW, Baty JD, Fulton LL, Fulton R, Heath SE, Kalicki-Veizer J, Kandoth C, Klco JM, Koboldt DC, Kanchi KL, Kulkarni S, Lamprecht TL, Larson DE, Lin L, Lu C, McLellan MD, McMichael JF, Payton J, Schmidt H, Spencer DH, Tomasson MH, Wallis JW, Wartman LD, Watson MA, Welch J, Wendl MC, Ally A, Balasundaram M, Birol I, Butterfield Y, Chiu R, Chu A, Chuah E, Chun HJ, Corbett R, Dhalla N, Guin R, He A, Hirst C, Hirst M, Holt RA, Jones S, Karsan A, Lee D, Li HI, Marra MA, Mayo M, Moore RA, Mungall K, Parker J, Pleasance E, Plettner P, Schein J, Stoll D, Swanson L, Tam A, Thiessen N, Varhol R, Wye N, Zhao Y, Gabriel S, Getz G, Sougnez C, Zou L, Leiserson MD, Vandin F, Wu HT, Applebaum F, Baylin SB, Akbani R, Broom BM, Chen K, Motter TC, Nguyen K, Weinstein JN, Zhang N, Ferguson ML, Adams C, Black A, Bowen J, Gastier-Foster J, Grossman T, Lichtenberg T, Wise L, Davidsen T, Demchok JA, Shaw KR, Sheth M, Sofia HJ, Yang L, Downing JR, Eley G. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013 05 30; 368(22):2059-74. PMID: 23634996; PMCID: PMC3767041.
      Citations: 2081     Fields:    Translation:HumansCells
    1038. Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, York S, Ravandi F, Garris R, Kwari M, Faderl S, Cortes J, Champlin R, O'Brien S. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 01; 119(15):2728-36. PMID: 23633004; PMCID: PMC3720844.
      Citations: 95     Fields:    Translation:HumansCTClinical Trials
    1039. Farroni JS, Zwelling L, Cortes J, Kantarjian H. Saving Medicare through patient-centered changes--the case of injectables. N Engl J Med. 2013 Apr 25; 368(17):1572-3. PMID: 23614583.
      Citations: 1     Fields:    Translation:Humans
    1040. Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Cortes J, Quint?s-Cardama A. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013 Jun 13; 121(24):4867-74. PMID: 23620574; PMCID: PMC3743466.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    1041. Sonnichsen D, Dorer DJ, Cortes J, Talpaz M, Deininger MW, Shah NP, Kantarjian HM, Bixby D, Mauro MJ, Flinn IW, Litwin J, Turner CD, Haluska FG. Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. Cancer Chemother Pharmacol. 2013 Jun; 71(6):1599-607. PMID: 23609479; PMCID: PMC3668123.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    1042. Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013 Jun 06; 121(23):4655-62. PMID: 23613521; PMCID: PMC3674666.
      Citations: 158     Fields:    Translation:HumansCellsCTClinical Trials
    1043. Kantarjian HM, Martinelli G, Jabbour EJ, Ando K, Bay JO, Wei A, Papayannidis C, Owen K, Pike L, Schmitt N, Stockman PK, Giagounidis A, SPARK-AML1 Investigators, Quint?s-Cardama A, Gr?pper S. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer. 2013 Jul 15; 119(14):2611-9. PMID: 23605952; PMCID: PMC4132839.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    1044. Sever M, Pierce S, Zhou L, Kantarjian H, Verstovsek S, Quint?s-Cardama A. Significance of cytogenetic abnormalities in patients with polycythemia vera. Leuk Lymphoma. 2013 Dec; 54(12):2667-70. PMID: 23488603; PMCID: PMC3815965.
      Citations: 10     Fields:    Translation:Humans
    1045. Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Kantarjian H, Shacham S, Kauffman M, Andreeff M. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013 May 16; 121(20):4166-74. PMID: 23564911; PMCID: PMC3656451.
      Citations: 112     Fields:    Translation:HumansCells
    1046. Kantarjian H, Wilson W, Ravandi F, Estey E. Decitabine in older adults with acute myeloid leukemia: why was the dream broken? J Clin Oncol. 2013 May 10; 31(14):1795-6. PMID: 23547076.
      Citations: 7     Fields:    Translation:Humans
    1047. Bhamidipati PK, Kantarjian H, Cortes J, Cornelison AM, Jabbour E. Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol. 2013 Apr; 4(2):103-17. PMID: 23610618; PMCID: PMC3629755.
      Citations: 34     
    1048. Agrawal V, Woo JH, Borthakur G, Kantarjian H, Frankel AE. Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia. Protein Pept Lett. 2013 Apr; 20(4):392-402. PMID: 23016580.
      Citations: 16     Fields:    Translation:HumansCells
    1049. Wei Y, Chen R, Dimicoli S, Bueso-Ramos C, Neuberg D, Pierce S, Wang H, Yang H, Jia Y, Zheng H, Fang Z, Nguyen M, Ganan-Gomez I, Ebert B, Levine R, Kantarjian H, Garcia-Manero G. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia. 2013 Nov; 27(11):2177-86. PMID: 23538751; PMCID: PMC4476310.
      Citations: 45     Fields:    Translation:HumansCells
    1050. Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S, Garcia-Manero G, Pierce S, Luthra R, Cardenas-Turanzas M, Estrov Z, Ravandi F, Cortes J. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol. 2013 Jun; 161(5):659-666. PMID: 23530930; PMCID: PMC4068703.
      Citations: 11     Fields:    Translation:HumansCells
    1051. Al-Kali A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G, Quint?s-Cardama A. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9. PMID: 23512829; PMCID: PMC4089101.
      Citations: 13     Fields:    Translation:Humans
    1052. Saglio G, Larson RA, Kim DW, Etienne G, Rosti G, De Souza C, Kurokawa M, Kalaycio ME, Hoenekopp A, Fan X, Shou Y, Kantarjian HM, Hughes TP, Hochhaus A. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2013 May 02; 121(18):3703-8. PMID: 23502220; PMCID: PMC4915803.
      Citations: 41     Fields:    Translation:HumansCellsCTClinical Trials
    1053. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol. 2013 May; 161(4):508-16. PMID: 23480528; PMCID: PMC4055021.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    1054. Cortes J, Digumarti R, Parikh PM, Wetzler M, Lipton JH, Hochhaus A, Craig AR, Benichou AC, Nicolini FE, Kantarjian HM, Omacetaxine 203 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol. 2013 May; 88(5):350-4. PMID: 23468307; PMCID: PMC5558840.
      Citations: 22     Fields:    Translation:HumansCellsCTClinical Trials
    1055. Jain P, Sargent RL, Konoplev SN, Benjamini O, Kantarjian H, Kadia T. Multiple recurrent extra-medullary relapses of high-grade diffuse large B-cell lymphoma presenting in acute leukemic phase. Am J Hematol. 2013 May; 88(5):433-4. PMID: 23460270; PMCID: PMC5578614.
      Citations: 2     Fields:    Translation:Humans
    1056. Cortes J, Feldman E, Yee K, Rizzieri D, Advani AS, Charman A, Spruyt R, Toal M, Kantarjian H. Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study. Lancet Oncol. 2013 Apr; 14(4):354-62. PMID: 23453583; PMCID: PMC5557006.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    1057. Nazha A, Estrov Z, Cortes J, Bueso-Ramos CE, Kantarjian H, Verstovsek S. Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma. 2013 Nov; 54(11):2537-9. PMID: 23343175; PMCID: PMC4135587.
      Citations: 6     Fields:    Translation:Humans
    1058. Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun W, Sandor V, Levy RS, Kantarjian HM, Verstovsek S. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013 Apr 01; 31(10):1285-92. PMID: 23423753; PMCID: PMC4979167.
      Citations: 81     Fields:    Translation:HumansCTClinical Trials
    1059. Kantarjian H, Pierce S, Cortes J, Verstovsek S, Quint?s-Cardama A. Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):315-318.e2. PMID: 23391717; PMCID: PMC3901422.
      Citations: 10     Fields:    Translation:Humans
    1060. Takahashi K, Cortes J, Pierce S, Abruzzo L, Kantarjian H, Verstovsek S. Chromosome 5q deletion is extremely rare in patients with myelofibrosis. Leuk Res. 2013 May; 37(5):552-5. PMID: 23391517; PMCID: PMC4408989.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    1061. Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol. 2013 Mar; 88(3):198-200. PMID: 23345254; PMCID: PMC4085133.
      Citations: 3     Fields:    Translation:Humans
    1062. Sever M, Cortes J, Kantarjian H, Verstovsek S, Quint?s-Cardama A. Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis. Leuk Lymphoma. 2013 Sep; 54(9):1959-64. PMID: 23278641; PMCID: PMC5127201.
      Citations: 3     Fields:    Translation:HumansCells
    1063. Walter RB, Othus M, Burnett AK, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KG, Ravandi F, Evans A, Pierce SR, Appelbaum FR, Estey EH, L?wenberg B. Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood. 2013 Mar 28; 121(13):2424-31. PMID: 23325837; PMCID: PMC3612855.
      Citations: 31     Fields:    Translation:Humans
    1064. Jabbour E, Kantarjian H, Ghanem H, O'Brien S, Quintas-Cardama A, Garcia-Manero G, Cardenas M, Cortes J. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):302-6. PMID: 23318257; PMCID: PMC4160838.
      Citations: 4     Fields:    Translation:Humans
    1065. Kebriaei P, Wilhelm K, Ravandi F, Brandt M, de Lima M, Ciurea S, Worth L, O'Brien S, Thomas D, Champlin RE, Kantarjian H. Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):296-301. PMID: 23313065; PMCID: PMC4102410.
      Citations: 17     Fields:    Translation:Humans
    1066. Zheng W, Medeiros LJ, Hu Y, Powers L, Cortes JE, Ravandi-Kashani F, Kantarjian HH, Wang SA. CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):307-14. PMID: 23313069; PMCID: PMC4188388.
      Citations: 7     Fields:    Translation:Humans
    1067. Mathisen MS, Kantarjian H, Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, Borthakur G, Cortes JE, Quint?s-Cardama A. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):139-43. PMID: 23276886; PMCID: PMC4114759.
      Citations:    Fields:    Translation:Humans
    1068. Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, O'Brien S, Fullmer A, Cortes JE, Wierda W, Kantarjian H. Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):131-8. PMID: 23260600; PMCID: PMC4098775.
      Citations: 6     Fields:    Translation:Humans
    1069. Bhatt VR, Kantarjian H, Cortes JE, Ravandi F, Borthakur G. Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):153-8. PMID: 23266036; PMCID: PMC3854973.
      Citations: 8     Fields:    Translation:Humans
    1070. Chen Y, Wang H, Kantarjian H, Cortes J. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma. 2013 Jul; 54(7):1411-7. PMID: 23121646; PMCID: PMC5525971.
      Citations: 39     Fields:    Translation:Humans
    1071. Lee HJ, Daver N, Kantarjian HM, Verstovsek S, Ravandi F. The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia. Clin Cancer Res. 2013 Jan 15; 19(2):327-35. PMID: 23209034.
      Citations: 18     Fields:    Translation:HumansCells
    1072. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012 Nov 29; 367(22):2075-88. PMID: 23190221; PMCID: PMC3777383.
      Citations: 272     Fields:    Translation:HumansCTClinical Trials
    1073. O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, Ben-Yehuda D, Stock W, Coutre S, Douer D, Heffner LT, Larson M, Seiter K, Smith S, Assouline S, Kuriakose P, Maness L, Nagler A, Rowe J, Schaich M, Shpilberg O, Yee K, Schmieder G, Silverman JA, Thomas D, Deitcher SR, Kantarjian H. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013 Feb 20; 31(6):676-83. PMID: 23169518; PMCID: PMC4979201.
      Citations: 51     Fields:    Translation:HumansCellsCTClinical Trials
    1074. Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, Chen SC, Su X, Ogden SK, Dang J, Wu G, Gupta V, Andersson AK, Pounds S, Shi L, Easton J, Barbato MI, Mulder HL, Manne J, Wang J, Rusch M, Ranade S, Ganti R, Parker M, Ma J, Radtke I, Ding L, Cazzaniga G, Biondi A, Kornblau SM, Ravandi F, Kantarjian H, Nimer SD, Ley TJ, Ballerini P, Shurtleff S, Tomizawa D, Adachi S, Hayashi Y, Tawa A, Shih LY, Liang DC, Rubnitz JE, Pui CH, Mardis ER, Wilson RK, Downing JR, D?hner K, D?hner H. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell. 2012 Nov 13; 22(5):683-97. PMID: 23153540; PMCID: PMC3547667.
      Citations: 97     Fields:    Translation:HumansAnimalsCells
    1075. Ottmann OG, Larson RA, Kantarjian HM, le Coutre PD, Baccarani M, Hochhaus A, Kim DW, Fan X, Novick S, Giles FJ. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia. Leukemia. 2013 Jun; 27(6):1411-3. PMID: 23138184.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    1076. Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia. 2013 Apr; 27(4):836-42. PMID: 23135353; PMCID: PMC4181539.
      Citations: 22     Fields:    Translation:HumansCells
    1077. Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 2013 Apr; 27(4):907-13. PMID: 23174881; PMCID: PMC4140185.
      Citations: 7     Fields:    Translation:Humans
    1078. Strati P, Cortes J, Faderl S, Kantarjian H, Verstovsek S. Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):287-91. PMID: 23123105; PMCID: PMC4445419.
      Citations: 13     Fields:    Translation:Humans
    1079. Zhou Y, Jorgensen JL, Wang SA, Ravandi F, Cortes J, Kantarjian HM, Medeiros LJ, Konoplev S. Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia. Am J Clin Pathol. 2012 Nov; 138(5):744-50. PMID: 23086776.
      Citations: 6     Fields:    Translation:Humans
    1080. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol. 2012 Nov; 87(11):1037-45. PMID: 23090888.
      Citations: 50     Fields:    Translation:Humans
    1081. Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013 Jan; 88(1):56-9. PMID: 23115106; PMCID: PMC4085099.
      Citations: 31     Fields:    Translation:HumansCells
    1082. Branford S, Kim DW, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, M?ller MC. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol. 2012 Dec 10; 30(35):4323-9. PMID: 23109697; PMCID: PMC4979159.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    1083. Kantarjian HM, Larson RA, Deering KL, Mauro MJ, Cort?s JE. Current practices in the management of chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):48-54. PMID: 23103085; PMCID: PMC3645375.
      Citations: 3     Fields:    Translation:Humans
    1084. Jabbour E, Morris V, Kantarjian H, Yin CC, Burton E, Cortes J. Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2012 Oct 18; 120(16):3382-3. PMID: 23086624; PMCID: PMC4195445.
      Citations: 8     Fields:    Translation:Humans
    1085. Ravandi F, Liu-Dumlao T, Brandt M, Faderl S, Pierce S, Borthakur G, Garcia-Manero G, Cortes J, Kantarjian H, Quint?s-Cardama A. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012 Dec 06; 120(24):4840-5. PMID: 23071272; PMCID: PMC3952725.
      Citations: 81     Fields:    Translation:HumansCells
    1086. Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012 Nov; 13(11):1096-104. PMID: 23075701; PMCID: PMC4004358.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    1087. Giles FJ, Yin OQ, Sallas WM, le Coutre PD, Woodman RC, Ottmann OG, Baccarani M, Kantarjian HM. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. Eur J Clin Pharmacol. 2013 Apr; 69(4):813-23. PMID: 23052406.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    1088. Jin L, Tabe Y, Lu H, Borthakur G, Miida T, Kantarjian H, Andreeff M, Konopleva M. Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer Lett. 2013 Feb 01; 329(1):45-58. PMID: 23036488; PMCID: PMC3572533.
      Citations: 8     Fields:    Translation:HumansCells
    1089. Liu-Dumlao T, Kantarjian H, Thomas DA, O'Brien S, Ravandi F. Philadelphia-positive acute lymphoblastic leukemia: current treatment options. Curr Oncol Rep. 2012 Oct; 14(5):387-94. PMID: 22669492; PMCID: PMC4199301.
      Citations: 32     Fields:    Translation:Humans
    1090. Ghanem H, Kantarjian H, Ohanian M, Jabbour E. The role of clofarabine in acute myeloid leukemia. Leuk Lymphoma. 2013 Apr; 54(4):688-98. PMID: 22957815; PMCID: PMC5681218.
      Citations: 20     Fields:    Translation:HumansAnimals
    1091. Benjamini O, Jain P, Estrov Z, Kantarjian HM, Verstovsek S. Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. Blood. 2012 Sep 27; 120(13):2768-9. PMID: 23019204; PMCID: PMC4081400.
      Citations: 12     Fields:    Translation:Humans
    1092. Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA, Burnett AK, Kantarjian HM. Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol. 2012 Nov 10; 30(32):3921-3. PMID: 22987091; PMCID: PMC4874205.
      Citations: 38     Fields:    Translation:Humans
    1093. Daver N, Nazha A, Kantarjian HM, Haltom R, Ravandi F. Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):86-9. PMID: 22981963; PMCID: PMC4084644.
      Citations: 4     Fields:    Translation:Humans
    1094. Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF. Randomized, dose-escalation study of the p38a MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia. 2013 Apr; 27(4):977-80. PMID: 23032694.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    1095. Cortes JE, Kim DW, Kantarjian HM, Dyagil I, Griskevicius L, Malhotra H, Powell C, Countouriotis AM, Gambacorti-Passerini C, Br?mmendorf TH, Gogat K. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012 Oct 01; 30(28):3486-92. PMID: 22949154; PMCID: PMC4979199.
      Citations: 154     Fields:    Translation:HumansCTClinical Trials
    1096. Mathisen MS, Jabbour E, Kantarjian HM. Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies. Oncology (Williston Park). 2012 Sep; 26(9):851-9. PMID: 23061343.
      Citations: 4     Fields:    Translation:Humans
    1097. Hoehn D, Medeiros LJ, Kantarjian HM, Cortes JE, Wang X, Bueso-Ramos CE. Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia. Hum Pathol. 2012 Dec; 43(12):2354-9. PMID: 22939577.
      Citations: 4     Fields:    Translation:Humans
    1098. Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE, Kantarjian H, Omacetaxine 202 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012 Sep 27; 120(13):2573-80. PMID: 22896000; PMCID: PMC4916583.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    1099. Kantarjian H, Thomas D, Wayne AS, O'Brien S. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol. 2012 Nov 01; 30(31):3876-83. PMID: 22891271; PMCID: PMC3478578.
      Citations: 33     Fields:    Translation:Humans
    1100. Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE. Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica. 2013 Feb; 98(2):217-21. PMID: 22875630; PMCID: PMC3561428.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    1101. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, Raza A, Kantarjian H, Levine RL, Neuberg D, Garcia-Manero G, Ebert BL. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012 Sep 20; 30(27):3376-82. PMID: 22869879; PMCID: PMC3438234.
      Citations: 186     Fields:    Translation:Humans
    1102. Frolova O, Samudio I, Benito JM, Jacamo R, Kornblau SM, Markovic A, Schober W, Lu H, Qiu YH, Buglio D, McQueen T, Pierce S, Shpall E, Konoplev S, Thomas D, Kantarjian H, Lock R, Andreeff M, Konopleva M. Regulation of HIF-1a signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther. 2012 Aug; 13(10):858-70. PMID: 22785211; PMCID: PMC3414410.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    1103. Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood. 2012 Sep 27; 120(13):2679-89. PMID: 22826565; PMCID: PMC3460689.
      Citations: 62     Fields:    Translation:HumansAnimalsCells
    1104. Becker PS, Kantarjian HM, Appelbaum FR, Storer B, Pierce S, Shan J, Faderl S, Estey EH. Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia. Haematologica. 2013 Jan; 98(1):114-8. PMID: 22801963; PMCID: PMC3533672.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    1105. Konoplev S, Yin CC, Kornblau SM, Kantarjian HM, Konopleva M, Andreeff M, Lu G, Zuo Z, Luthra R, Medeiros LJ, Bueso-Ramos CE. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma. 2013 Jan; 54(1):138-44. PMID: 22691121; PMCID: PMC3925981.
      Citations: 31     Fields:    Translation:HumansCells
    1106. Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013 Jan; 27(1):107-12. PMID: 22763385.
      Citations: 72     Fields:    Translation:HumansCTClinical Trials
    1107. Cheng X, Golemovic M, Zingaro R, Gao MZ, Freireich EJ, Andreeff M, Kantarjian HM, Verstovsek S, Quint?s-Cardama A. The organic arsenic derivative GMZ27 induces PML-RARa-independent apoptosis in myeloid leukemia cells. Anticancer Res. 2012 Jul; 32(7):2871-80. PMID: 22753750; PMCID: PMC5166574.
      Citations:    Fields:    Translation:HumansAnimalsCells
    1108. Verma S, Greaves WO, Ravandi F, Reddy N, Bueso-Ramos CE, O'Brien S, Thomas DA, Kantarjian H, Medeiros LJ, Luthra R, Patel KP. Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay. Am J Clin Pathol. 2012 Jul; 138(1):153-6. PMID: 22706871; PMCID: PMC5465956.
      Citations: 16     Fields:    Translation:Humans
    1109. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Sol? F, Pfeilst?cker M. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012 Sep 20; 120(12):2454-65. PMID: 22740453; PMCID: PMC4425443.
      Citations: 831     Fields:    Translation:Humans
    1110. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 09; 120(6):1202-9. PMID: 22718840; PMCID: PMC4081158.
      Citations: 82     Fields:    Translation:Humans
    1111. Chen Y, Kantarjian H, Wang H, Cortes J, Ravandi F. Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. Cancer. 2012 Dec 01; 118(23):5811-8. PMID: 22707337; PMCID: PMC4180246.
      Citations: 25     Fields:    Translation:Humans
    1112. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Minden M, Arthur C, Lys?k D. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012 Jul 20; 30(21):2670-7. PMID: 22689805; PMCID: PMC4874148.
      Citations: 396     Fields:    Translation:HumansCTClinical Trials
    1113. Warren M, Luthra R, Yin CC, Ravandi F, Cortes JE, Kantarjian HM, Medeiros LJ, Zuo Z. Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients. Mod Pathol. 2012 Oct; 25(10):1405-12. PMID: 22684224.
      Citations: 17     Fields:    Translation:Humans
    1114. Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012 Nov; 26(11):2428-31. PMID: 22665218; PMCID: PMC3981542.
      Citations: 20     Fields:    Translation:Humans
    1115. Chacar C, Jabbour E, Ravandi F, Borthakur G, Kadia T, Estrov Z, Rios MB, Cortes J, Kantarjian H. Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):197-200. PMID: 22578814; PMCID: PMC4050633.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    1116. Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, O'Brien S, Broglio K, Ensor J, Escalante C, Andreeff M, Kantarjian H, Lavis V, Yeung SC. A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):355-62. PMID: 22658895; PMCID: PMC3974971.
      Citations: 15     Fields:    Translation:Humans
    1117. Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes J, Kantarjian HM, Mills GB, Andreeff M, Kornblau SM. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood. 2012 Jul 05; 120(1):173-80. PMID: 22645176; PMCID: PMC3390955.
      Citations: 49     Fields:    Translation:HumansCells
    1118. Singh RR, Bains A, Patel KP, Rahimi H, Barkoh BA, Paladugu A, Bisrat T, Ravandi-Kashani F, Cortes JE, Kantarjian HM, Medeiros LJ, Luthra R. Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis. J Mol Diagn. 2012 Jul; 14(4):336-45. PMID: 22642896; PMCID: PMC5707199.
      Citations: 12     Fields:    Translation:Humans
    1119. Yin OQ, Giles FJ, Baccarani M, le Coutre P, Chiparus O, Gallagher N, Saglio G, Hughes TP, Hochhaus A, Kantarjian HM, Larson RA. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012 Aug; 70(2):345-50. PMID: 22623211; PMCID: PMC5557057.
      Citations: 6     Fields:    Translation:Humans
    1120. Jabbour E, Saglio G, Radich J, Kantarjian H. Adherence to BCR-ABL inhibitors: issues for CML therapy. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):223-9. PMID: 22633166; PMCID: PMC4428159.
      Citations: 12     Fields:    Translation:Humans
    1121. Kantarjian H, Cortes J, Quint?s-Cardama A. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):337-40. PMID: 22633167.
      Citations: 45     Fields:    Translation:Humans
    1122. Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood. 2012 Aug 16; 120(7):1390-7. PMID: 22613793; PMCID: PMC4916560.
      Citations: 46     Fields:    Translation:Humans
    1123. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE, Gallagher NJ, Saglio G, Kantarjian HM. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012 Oct; 26(10):2197-203. PMID: 22699418.
      Citations: 140     Fields:    Translation:Humans
    1124. Borthakur G, Kantarjian H, Patel KP, Ravandi F, Qiao W, Faderl S, Kadia T, Luthra R, Pierce S, Cortes JE. Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer. 2012 Dec 01; 118(23):5819-22. PMID: 22605576; PMCID: PMC4184417.
      Citations: 7     Fields:    Translation:HumansCells
    1125. Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012 Jul 10; 30(20):2492-9. PMID: 22585697; PMCID: PMC4874149.
      Citations: 66     Fields:    Translation:HumansCTClinical Trials
    1126. Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol. 2012 Jun 20; 30(18):2204-10. PMID: 22585696; PMCID: PMC4879705.
      Citations: 71     Fields:    Translation:HumansCTClinical Trials
    1127. Chen Y, Kantarjian H, Estrov Z, Faderl S, Ravandi F, Rey K, Cortes J, Borthakur G. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):341-4. PMID: 22579233; PMCID: PMC4103411.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    1128. Kadia TM, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G, Pierce S, Cortes J, Ravandi F. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer. 2012 Nov 15; 118(22):5550-9. PMID: 22569880; PMCID: PMC3416961.
      Citations: 19     Fields:    Translation:HumansCells
    1129. Ohanian M, Cortes J, Kantarjian H, Jabbour E. Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother. 2012 May; 13(7):927-38. PMID: 22519766.
      Citations: 21     Fields:    Translation:Humans
    1130. Ravandi F, Kantarjian H. Haematological cancer: Gemtuzumab ozogamicin in acute myeloid leukaemia. Nat Rev Clin Oncol. 2012 May 01; 9(6):310-1. PMID: 22547217.
      Citations: 3     Fields:    Translation:Humans
    1131. Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, Cortes J, Kantarjian HM, DeAngelo DJ, Huntsman-Labed A, Dutreix C, del Corral A, Giles F. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012 Sep; 26(9):2061-8. PMID: 22627678; PMCID: PMC4118284.
      Citations: 114     Fields:    Translation:HumansCTClinical Trials
    1132. Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica. 2012 Aug; 97(8):1242-5. PMID: 22532519; PMCID: PMC3409823.
      Citations: 19     Fields:    Translation:HumansCells
    1133. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51. PMID: 22534616; PMCID: PMC3859239.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    1134. Kantarjian H, Estrov Z, Borthakur G, Cortes J, Verstovsek S, Quint?s-Cardama A. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res. 2012 Sep; 36(9):1124-7. PMID: 22475363; PMCID: PMC4152772.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    1135. Kantarjian H. Monoclonal antibodies in adult acute lymphoblastic leukemia. Hematology. 2012 Apr; 17 Suppl 1:S52-4. PMID: 22507779.
      Citations:    Fields:    Translation:Humans
    1136. Jabbour EJ, Kantarjian H, Eliasson L, Cornelison AM, Marin D. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol. 2012 Jul; 87(7):687-91. PMID: 22473898.
      Citations: 21     Fields:    Translation:Humans
    1137. Zhang SJ, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A, Hricik T, Heguy A, Hedvat C, Kantarjian H, Levine RL, Abdel-Wahab O, Verstovsek S, G?nen M. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012 May 10; 119(19):4480-5. PMID: 22431577; PMCID: PMC3362363.
      Citations: 95     Fields:    Translation:HumansCells
    1138. Jabbour E, Cortes J, Nazha A, O'Brien S, Quintas-Cardama A, Pierce S, Garcia-Manero G, Kantarjian H. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood. 2012 May 10; 119(19):4524-6. PMID: 22431574; PMCID: PMC3362365.
      Citations: 27     Fields:    Translation:Humans
    1139. Tanaka MF, Kantarjian H, Cortes J, Ohanian M, Jabbour E. Treatment options for chronic myeloid leukemia. Expert Opin Pharmacother. 2012 Apr; 13(6):815-28. PMID: 22429140.
      Citations: 4     Fields:    Translation:Humans
    1140. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17; 119(20):4614-8. PMID: 22422826; PMCID: PMC4081383.
      Citations: 85     Fields:    Translation:HumansCellsCTClinical Trials
    1141. Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C, Kantarjian H, Huh Y, Ravandi F. Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leuk Lymphoma. 2012 Sep; 53(9):1839-41. PMID: 22303899; PMCID: PMC4120044.
      Citations: 5     Fields:    Translation:Humans
    1142. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 01; 366(9):799-807. PMID: 22375971; PMCID: PMC4822164.
      Citations: 737     Fields:    Translation:HumansCTClinical Trials
    1143. Kantarjian H, Cortes J, Quint?s-Cardama A. Bosutinib for the treatment of chronic myeloid leukemia in chronic phase. Drugs Today (Barc). 2012 Mar; 48(3):177-88. PMID: 22462037.
      Citations: 2     Fields:    Translation:HumansAnimals
    1144. Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Ravandi F, Jabbour E, Shan J, Cortes J. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer. 2012 Jun 15; 118(12):3116-22. PMID: 22370904; PMCID: PMC3370116.
      Citations: 11     Fields:    Translation:Humans
    1145. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, Zaritskey A, Countouriotis A, Besson N, Leip E, Kelly V, Br?mmendorf TH. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012 Apr 12; 119(15):3403-12. PMID: 22371878; PMCID: PMC4916559.
      Citations: 106     Fields:    Translation:HumansCTClinical Trials
    1146. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012 May; 157(3):312-20. PMID: 22360602; PMCID: PMC3924750.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    1147. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien S. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012 Apr; 13(4):403-11. PMID: 22357140.
      Citations: 136     Fields:    Translation:HumansCTClinical Trials
    1148. Liu X, Kantarjian H, Plunkett W. Sapacitabine for cancer. Expert Opin Investig Drugs. 2012 Apr; 21(4):541-55. PMID: 22329458; PMCID: PMC3366487.
      Citations: 10     Fields:    Translation:HumansAnimals
    1149. Yamazaki J, Taby R, Vasanthakumar A, Macrae T, Ostler KR, Shen L, Kantarjian HM, Estecio MR, Jelinek J, Godley LA, Issa JP. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics. 2012 Feb; 7(2):201-7. PMID: 22395470; PMCID: PMC3335912.
      Citations: 56     Fields:    Translation:HumansCells
    1150. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012 Jun 15; 118(12):3123-7. PMID: 22294282; PMCID: PMC3342429.
      Citations: 95     Fields:    Translation:Humans
    1151. Link MP, Hagerty K, Kantarjian HM. Chemotherapy drug shortages in the United States: genesis and potential solutions. J Clin Oncol. 2012 Mar 01; 30(7):692-4. PMID: 22291078.
      Citations: 16     Fields:    Translation:Humans
    1152. Fava C, Kantarjian H, Cortes J. Molecular resistance: an early indicator for treatment change? Clin Lymphoma Myeloma Leuk. 2012 Apr; 12(2):79-87. PMID: 22285607; PMCID: PMC5539978.
      Citations: 1     Fields:    Translation:Humans
    1153. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012 Sep 15; 118(18):4471-7. PMID: 22282348; PMCID: PMC3907176.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    1154. Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O'Brien S, Cortes J. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica. 2012 Jul; 97(7):1029-35. PMID: 22271898; PMCID: PMC3396674.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    1155. Tong WG, Kadia T, Borthakur G, Jabbour E, Ravandi F, Faderl S, Wierda W, Pierce S, Shan J, Bueso-Ramos C, Kantarjian H, Garcia-Manero G, Quint?s-Cardama A. Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system. Cancer. 2012 Sep 15; 118(18):4462-70. PMID: 22252728; PMCID: PMC3913560.
      Citations: 13     Fields:    Translation:Humans
    1156. Eghtedar A, Borthakur G, Ravandi F, Jabbour E, Cortes J, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. Am J Hematol. 2012 Mar; 87(3):317-8. PMID: 22228403; PMCID: PMC4221258.
      Citations: 3     Fields:    Translation:HumansCells
    1157. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012 Mar 01; 119(9):1981-7. PMID: 22228624; PMCID: PMC3311242.
      Citations: 108     Fields:    Translation:Humans
    1158. Westin JR, Kantarjian H, Kurzrock R. Treatment of chronic myelogenous leukemia as a paradigm for solid tumors: how targeted agents in newly diagnosed disease transformed outcomes. Am Soc Clin Oncol Educ Book. 2012; 179-85. PMID: 24451731.
      Citations: 2     Fields:    
    1159. Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, Kantarjian HM, le Coutre PD. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2012 May; 68(5):723-33. PMID: 22207416; PMCID: PMC5557053.
      Citations: 25     Fields:    Translation:Humans
    1160. Tang G, Zuo Z, Thomas DA, Lin P, Liu D, Hu Y, Kantarjian HM, Bueso-Ramos C, Medeiros LJ, Wang SA. Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related? Haematologica. 2012 Jun; 97(6):919-25. PMID: 22207681; PMCID: PMC3366660.
      Citations: 20     Fields:    Translation:Humans
    1161. Giles FJ, Kantarjian HM, le Coutre PD, Baccarani M, Mahon FX, Blakesley RE, Gallagher NJ, Gillis K, Goldberg SL, Larson RA, Hochhaus A, Ottmann OG. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia. 2012 May; 26(5):959-62. PMID: 22157807.
      Citations: 25     Fields:    Translation:Humans
    1162. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Wang J, Kim DW, Ogura M, Pavlovsky C, Junghanss C, Milone JH, Nicolini FE, Robak T, Van Droogenbroeck J, Vellenga E, Bradley-Garelik MB, Zhu C, Hochhaus A, Undurraga MS, Ipi?a JJ. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012 Feb 02; 119(5):1123-9. PMID: 22160483; PMCID: PMC4916556.
      Citations: 195     Fields:    Translation:HumansCTClinical Trials
    1163. Khoury HJ, Garcia-Manero G, Borthakur G, Kadia T, Foudray MC, Arellano M, Langston A, Bethelmie-Bryan B, Rush S, Litwiler K, Karan S, Simmons H, Marcus AI, Ptaszynski M, Kantarjian H. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer. 2012 Jul 15; 118(14):3556-64. PMID: 22139909; PMCID: PMC4984525.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    1164. Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, Blakesley R, Shou Y, Gallagher NJ, Baccarani M, Cortes J, Kantarjian HM, le Coutre PD. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia. 2012 Jun; 26(6):1189-94. PMID: 22076466.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    1165. Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly M, Pierce S, Kantarjian H, Garcia-Manero G. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol. 2012 Jan; 87(1):127-9. PMID: 22072492; PMCID: PMC4085038.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    1166. Al-Kali A, Konoplev S, Lin E, Kadia T, Faderl S, Ravandi F, Ayoubi M, Brandt M, Cortes JE, Kantarjian H, Borthakur G. Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients. Haematologica. 2012 Feb; 97(2):235-40. PMID: 22058194; PMCID: PMC3269483.
      Citations: 4     Fields:    Translation:Humans
    1167. Kantarjian H, Cortes J, Santos FP, Quint?s-Cardama A. Evolution of therapies for chronic myelogenous leukemia. Cancer J. 2011 Nov-Dec; 17(6):465-76. PMID: 22157290; PMCID: PMC3243359.
      Citations: 20     Fields:    Translation:HumansAnimals
    1168. Jabbour E, Saglio G, Hughes TP, Kantarjian H. Suboptimal responses in chronic myeloid leukemia: implications and management strategies. Cancer. 2012 Mar 01; 118(5):1181-91. PMID: 22038681; PMCID: PMC3412948.
      Citations: 11     Fields:    Translation:Humans
    1169. Mak DH, Wang RY, Schober WD, Konopleva M, Cortes J, Kantarjian H, Andreeff M, Carter BZ. Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia. 2012 Apr; 26(4):788-94. PMID: 22033489; PMCID: PMC3598156.
      Citations: 19     Fields:    Translation:HumansCells
    1170. Claxton D, Erba HP, Faderl S, Arellano M, Lyons RM, Kovacsovics T, Gabrilove J, Huebner D, Gandhi PJ, Kantarjian H, CLASSIC II Investigators. Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. Leuk Lymphoma. 2012 Mar; 53(3):435-40. PMID: 21877883; PMCID: PMC5556977.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    1171. Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian H. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer. 2012 May 15; 118(10):2665-73. PMID: 22020636; PMCID: PMC4060157.
      Citations: 22     Fields:    Translation:Humans
    1172. Jabbour E, Parikh SA, Kantarjian H, Cortes J. Chronic myeloid leukemia: mechanisms of resistance and treatment. Hematol Oncol Clin North Am. 2011 Oct; 25(5):981-95, v. PMID: 22054730; PMCID: PMC4428141.
      Citations: 16     Fields:    Translation:Humans
    1173. Jabbour E, Kantarjian HM, O'Brien S, Shan J, Garcia-Manero G, Rios MB, Cortes JE, Quint?s-Cardama A. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol. 2011 Nov 10; 29(32):4260-5. PMID: 21990394; PMCID: PMC3221527.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    1174. Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, Martinelli G, Amadori S, Berman E, Sonneveld P, Jongen-Lavrencic M, Rigaudeau S, Stockman P, Goudie A, Faderl S, Jabbour E, Kantarjian H, L?wenberg B. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood. 2011 Dec 01; 118(23):6030-6. PMID: 21976672; PMCID: PMC4186639.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    1175. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller CA, Burger JA, Lerner S, Schlette E, Abruzzo L, Kantarjian HM, Keating MJ. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol. 2011 Nov 01; 29(31):4088-95. PMID: 21969505; PMCID: PMC4876352.
      Citations: 43     Fields:    Translation:Humans
    1176. Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011 Nov 20; 29(33):4417-23. PMID: 21969499; PMCID: PMC3221524.
      Citations: 116     Fields:    Translation:Humans
    1177. Kadia TM, Jabbour E, Kantarjian H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol. 2011 Oct; 38(5):682-92. PMID: 21943675; PMCID: PMC4098768.
      Citations: 28     Fields:    Translation:Humans
    1178. Wood SM, Meyers CA, Faderl S, Kantarjian HM, Pierce SA, Garcia-Manero G. Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome. Am J Hematol. 2011 Nov; 86(11):950-2. PMID: 21919036.
      Citations: 2     Fields:    Translation:Humans
    1179. Mathisen MS, O'Brien S, Thomas D, Cortes J, Kantarjian H, Ravandi F. Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2011 Sep; 6(3):187-94. PMID: 21660654; PMCID: PMC4201047.
      Citations: 6     Fields:    Translation:HumansCells
    1180. Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z, Ravandi F, Faderl S, Kantarjian H, Garcia-Manero G. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood. 2011 Oct 27; 118(17):4690-3. PMID: 21868570; PMCID: PMC4081364.
      Citations: 30     Fields:    Translation:Humans
    1181. Cortes JE, Kantarjian HM, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C, Br?mmendorf TH. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011 Oct 27; 118(17):4567-76. PMID: 21865346; PMCID: PMC4916618.
      Citations: 141     Fields:    Translation:HumansCTClinical Trials
    1182. Kebriaei P, Saliba R, Rondon G, Chiattone A, Luthra R, Anderlini P, Andersson B, Shpall E, Popat U, Jones R, Worth L, Ravandi F, Thomas D, O'Brien S, Kantarjian H, de Lima M, Giralt S, Champlin R. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant. 2012 Apr; 18(4):584-92. PMID: 21867666; PMCID: PMC4102408.
      Citations: 29     Fields:    Translation:HumansCells
    1183. Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S, Shan J, Hendrie PC, Pagel JM, Shustov AR, Stirewalt DL, Faderl S, Harrington E, Estey EH. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol. 2011 Oct; 155(2):182-9. PMID: 21848522; PMCID: PMC4834701.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    1184. Qin T, Castoro R, El Ahdab S, Jelinek J, Wang X, Si J, Shu J, He R, Zhang N, Chung W, Kantarjian HM, Issa JP. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One. 2011; 6(8):e23372. PMID: 21858090; PMCID: PMC3157379.
      Citations: 52     Fields:    Translation:HumansCells
    1185. Lee TS, Kantarjian H, Ma W, Yeh CH, Giles F, Albitar M. Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modeling. PLoS One. 2011; 6(8):e23396. PMID: 21858098; PMCID: PMC3157383.
      Citations: 7     Fields:    Translation:HumansCells
    1186. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011 Sep; 12(9):841-51. PMID: 21856226.
      Citations: 174     Fields:    Translation:HumansCellsCTClinical Trials
    1187. Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, O'Brien S, Cortes J. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood. 2011 Oct 20; 118(16):4353-8. PMID: 21846902; PMCID: PMC3291487.
      Citations: 34     Fields:    Translation:Humans
    1188. Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Zweidler-McKay PA, Campana D, Borthakur G, Bueso-Ramos C, Shpall E, Thomas DA, Jordan CT, Kantarjian H, Wilson WR, Lock R, Andreeff M, Konopleva M. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One. 2011; 6(8):e23108. PMID: 21853076; PMCID: PMC3154919.
      Citations: 60     Fields:    Translation:HumansAnimalsCells
    1189. Cortes J, Quintas-Cardama A, Jabbour E, O'Brien S, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Burton E, Shan J, Kantarjian H. The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint? Clin Lymphoma Myeloma Leuk. 2011 Oct; 11(5):421-6. PMID: 21831744; PMCID: PMC3215673.
      Citations: 8     Fields:    Translation:Humans
    1190. Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Koller C, Challagundla P, York S, Brandt M, Luthra R, Burger J, Thomas D, Keating M, Kantarjian H. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood. 2011 Oct 06; 118(14):3818-23. PMID: 21821712; PMCID: PMC4081440.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    1191. Santos FP, Kantarjian H, McConkey D, O'Brien S, Faderl S, Borthakur G, Ferrajoli A, Wright J, Cortes J. Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase. Clin Lymphoma Myeloma Leuk. 2011 Aug; 11(4):355-60. PMID: 21816374; PMCID: PMC4405186.
      Citations: 10     Fields:    Translation:HumansCells
    1192. Al-Kali A, Cortes J, Faderl S, Jones D, Abril C, Pierce S, Brandt M, Kantarjian H, Ravandi F. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2011 Aug; 11(4):361-6. PMID: 21816375; PMCID: PMC4101692.
      Citations: 16     Fields:    Translation:Humans
    1193. Jabbour E, Kantarjian H, O'Brien S, Shan J, Quintas-Cardama A, Faderl S, Garcia-Manero G, Ravandi F, Rios MB, Cortes J. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2011 Oct 27; 118(17):4541-6; quiz 4759. PMID: 21803854; PMCID: PMC3291489.
      Citations: 47     Fields:    Translation:Humans
    1194. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, Lannutti BJ, Burger JA. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011 Sep 29; 118(13):3603-12. PMID: 21803855; PMCID: PMC4916562.
      Citations: 242     Fields:    Translation:HumansCellsCTClinical Trials
    1195. Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, Chen J, Qazilbash M, Kebriaei P, Konopleva M, Andreeff M, Cortes J, McCue D, Kantarjian H, Champlin RE, de Lima M. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1874-7. PMID: 21767516; PMCID: PMC4061979.
      Citations: 36     Fields:    Translation:Humans
    1196. Lancet JE, Ravandi F, Ricklis RM, Cripe LD, Kantarjian HM, Giles FJ, List AF, Chen T, Allen RS, Fox JA, Michelson GC, Karp JE. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia. 2011 Dec; 25(12):1808-14. PMID: 21760592; PMCID: PMC4576993.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    1197. Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. Cancer. 2012 Feb 01; 118(3):848-55. PMID: 21751205; PMCID: PMC3919032.
      Citations: 7     Fields:    Translation:Humans
    1198. Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer. 2012 Feb 01; 118(3):722-8. PMID: 21751197; PMCID: PMC4180241.
      Citations: 12     Fields:    Translation:Humans
    1199. Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Faderl S, Garcia-Manero G, Borthakur G, Cortes J. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol. 2011 Aug 10; 29(23):3173-8. PMID: 21747082; PMCID: PMC4874216.
      Citations: 26     Fields:    Translation:Humans
    1200. Jelinek J, Gharibyan V, Estecio MR, Kondo K, He R, Chung W, Lu Y, Zhang N, Liang S, Kantarjian HM, Cortes JE, Issa JP. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS One. 2011; 6(7):e22110. PMID: 21760961; PMCID: PMC3132778.
      Citations: 52     Fields:    Translation:HumansCells
    1201. Gibbons DL, Pricl S, Kantarjian H, Cortes J, Quint?s-Cardama A. The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer. 2012 Jan 15; 118(2):293-9. PMID: 21732333; PMCID: PMC6896214.
      Citations: 24     Fields:    Translation:Humans
    1202. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL, Nilsson B. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011 Jun 30; 364(26):2496-506. PMID: 21714648; PMCID: PMC3159042.
      Citations: 591     Fields:    Translation:HumansCells
    1203. Cortes J, Kantarjian H, Ball ED, Dipersio J, Kolitz JE, Fernandez HF, Goodman M, Borthakur G, Baer MR, Wetzler M. Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012 Jan 15; 118(2):418-27. PMID: 21717444; PMCID: PMC4977021.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    1204. Shihadeh F, Reed V, Faderl S, Medeiros LJ, Mazloom A, Hadziahmetovic M, Kantarjian H, Allen P, Ballas L, Pierce S, Dabaja B. Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease. Cancer. 2012 Jan 01; 118(1):112-7. PMID: 21692072.
      Citations: 27     Fields:    Translation:Humans
    1205. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood. 2011 Aug 25; 118(8):2085-93. PMID: 21670470; PMCID: PMC4123326.
      Citations: 25     Fields:    Translation:HumansCellsCTClinical Trials
    1206. Tang M, Gonen M, Quintas-Cardama A, Cortes J, Kantarjian H, Field C, Hughes TP, Branford S, Michor F. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood. 2011 Aug 11; 118(6):1622-31. PMID: 21653938; PMCID: PMC3156048.
      Citations: 24     Fields:    Translation:HumansCells
    1207. Naqvi K, Verstovsek S, Kantarjian H, Ravandi F. A potential role of ruxolitinib in leukemia. Expert Opin Investig Drugs. 2011 Aug; 20(8):1159-66. PMID: 21635221; PMCID: PMC4143907.
      Citations: 7     Fields:    Translation:HumansCells
    1208. Fullmer A, Kantarjian H, Cortes J, Jabbour E. Dasatinib for the treatment of chronic myeloid leukemia. Expert Rev Hematol. 2011 Jun; 4(3):253-60. PMID: 21668392.
      Citations:    Fields:    Translation:Humans
    1209. Jabbour E, Thomas D, Kantarjian H, Zhou L, Pierce S, Cortes J, Verstovsek S. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood. 2011 Jul 28; 118(4):899-902. PMID: 21622644; PMCID: PMC4186644.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    1210. Freireich EJ, Kantarjian H, Verstovsek S, Cort?s JE. Retrospect of hematologic malignancies 2010. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S1. PMID: 22035736.
      Citations:    Fields:    Translation:Humans
    1211. Kantarjian HM, Quint?s-Cardama A, Cortes JE. Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications. Cancer. 2011 Dec 01; 117(23):5261-70. PMID: 21598241; PMCID: PMC4181589.
      Citations: 8     Fields:    Translation:Humans
    1212. Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ, Laille E, Giordano H, Sakoian S, Jabbour E, Kantarjian H, Skikne B. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011 Jun 20; 29(18):2521-7. PMID: 21576646; PMCID: PMC3675699.
      Citations: 88     Fields:    Translation:HumansCellsCTClinical Trials
    1213. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol. 2011 Jun 20; 29(18):2507-13. PMID: 21555694; PMCID: PMC4874214.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    1214. Naqvi K, Garcia-Manero G, Sardesai S, Oh J, Vigil CE, Pierce S, Lei X, Shan J, Kantarjian HM, Suarez-Almazor ME. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol. 2011 Jun 01; 29(16):2240-6. PMID: 21537048; PMCID: PMC3107743.
      Citations: 45     Fields:    Translation:Humans
    1215. Bryan J, Kantarjian H, Garcia-Manero G, Jabbour E. Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opin Drug Metab Toxicol. 2011 May; 7(5):661-72. PMID: 21500965.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    1216. Cornelison AM, Kantarjian H, Cortes J, Jabbour E. Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S101-10. PMID: 22035738; PMCID: PMC4428283.
      Citations: 5     Fields:    Translation:Humans
    1217. Kantarjian H, Shan J, Jabbour E, Abruzzo LV, Verstovsek S, Garcia-Manero G, O'Brien S, Cortes J, Quint?s-Cardama A. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Cancer. 2011 Nov 15; 117(22):5085-93. PMID: 21523765; PMCID: PMC4324753.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    1218. Schanz J, Steidl C, Fonatsch C, Tuechler H, Valent P, Hildebrandt B, Giagounidis A, Aul C, Stauder R, Krieger O, Garcia-Manero G, Kantarjian H, Germing U, Haase D, Estey E, Pfeilst?cker M, N?sslinger T, L?bbert M. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol. 2011 May 20; 29(15):1963-70. PMID: 21519021; PMCID: PMC4874202.
      Citations: 54     Fields:    Translation:Humans
    1219. Manshouri T, Estrov Z, Burger J, Zhang Y, Livun A, Knez L, Harris D, Creighton CJ, Kantarjian HM, Verstovsek S, Quint?s-Cardama A. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res. 2011 Jun 01; 71(11):3831-40. PMID: 21512135; PMCID: PMC4067142.
      Citations: 49     Fields:    Translation:HumansAnimalsCells
    1220. Dayyani F, Mougalian SS, Naqvi K, Shan J, Ravandi F, Cortes J, Weinberg J, Jabbour E, Faderl S, Wierda W, Thomas D, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Prediction model for mortality after intracranial hemorrhage in patients with leukemia. Am J Hematol. 2011 Jul; 86(7):546-9. PMID: 21509801; PMCID: PMC4712950.
      Citations: 7     Fields:    Translation:Humans
    1221. Kantarjian HM, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthukar G, Faderl S, Garcia-Manero G, Kadia T, Sankhala K, Odenike O, Altman JK, Minden M. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Invest New Drugs. 2012 Jun; 30(3):1107-15. PMID: 21494838; PMCID: PMC4205950.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    1222. Al Ameri A, Jabbour E, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Shan J, Pierce S, Cortes J, Kantarjian H. Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. Clin Lymphoma Myeloma Leuk. 2011 Apr; 11(2):237-41. PMID: 21575929; PMCID: PMC4120264.
      Citations: 5     Fields:    Translation:Humans
    1223. Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas DA, Cortes J, Borthakur G, Pardanani AD, Estrov Z, Verstovsek S. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011 Nov 01; 117(21):4869-4877. PMID: 21480207; PMCID: PMC4160798.
      Citations: 22     Fields:    Translation:Humans
    1224. Cortes JE, Hochhaus A, le Coutre PD, Rosti G, Pinilla-Ibarz J, Jabbour E, Gillis K, Woodman RC, Blakesley RE, Giles FJ, Kantarjian HM, Baccarani M. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood. 2011 May 26; 117(21):5600-6. PMID: 21467546; PMCID: PMC4186645.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    1225. Konoplev S, Jorgensen JL, Thomas DA, Lin E, Burger J, Kantarjian HM, Andreeff M, Medeiros LJ, Konopleva M. Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia. Cancer. 2011 Oct 15; 117(20):4689-95. PMID: 21456010.
      Citations: 25     Fields:    Translation:HumansCells
    1226. Prescott H, Kantarjian H, Cortes J, Ravandi F. Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. Expert Opin Emerg Drugs. 2011 Sep; 16(3):407-23. PMID: 21417961; PMCID: PMC4122233.
      Citations: 3     Fields:    Translation:HumansAnimals
    1227. Kantarjian H, Cortes J. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. J Clin Oncol. 2011 Apr 20; 29(12):1512-6. PMID: 21422414; PMCID: PMC4979098.
      Citations: 8     Fields:    Translation:Humans
    1228. Thomas DA, O'Brien S, Faderl S, Manning JT, Romaguera J, Fayad L, Hagemeister F, Medeiros J, Cortes J, Kantarjian H. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases? Curr Hematol Malig Rep. 2011 Mar; 6(1):58-66. PMID: 21191675; PMCID: PMC4394740.
      Citations: 10     Fields:    Translation:Humans
    1229. Mathisen MS, Kantarjian HM, Cortes J, Jabbour E. Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica. 2011 Mar; 96(3):347-9. PMID: 21357713; PMCID: PMC3046262.
      Citations: 6     Fields:    Translation:HumansCells
    1230. Jaso J, Thomas DA, Cunningham K, Jorgensen JL, Kantarjian HM, Medeiros LJ, Wang SA. Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Cancer. 2011 Sep 01; 117(17):4009-17. PMID: 21365622; PMCID: PMC5548124.
      Citations: 13     Fields:    Translation:HumansCells
    1231. Kantarjian H, Garcia-Manero G, Ravandi F, Santos FP. The search for better prognostic models in myelodysplastic syndromes. Curr Hematol Malig Rep. 2011 Mar; 6(1):13-21. PMID: 21136214; PMCID: PMC4206196.
      Citations: 2     Fields:    Translation:Humans
    1232. Kantarjian H, O'Brien S, Jabbour E, Borthakur G, Ravandi F, Verstovsek S, Shan J, Cortes J, Quint?s-Cardama A. Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica. 2011 Jun; 96(6):918-21. PMID: 21357704; PMCID: PMC3105655.
      Citations: 6     Fields:    Translation:Humans
    1233. Pemmaraju N, Kantarjian H, Ravandi F, Cortes J. FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era? Cancer. 2011 Aug 01; 117(15):3293-304. PMID: 21319142; PMCID: PMC4316826.
      Citations: 20     Fields:    Translation:HumansAnimals
    1234. Kantarjian HM, Baccarani M, Jabbour E, Saglio G, Cortes JE. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clin Cancer Res. 2011 Apr 01; 17(7):1674-83. PMID: 21307148.
      Citations: 19     Fields:    Translation:Humans
    1235. Yang H, Fang Z, Wei Y, Hu Y, Calin GA, Kantarjian HM, Garcia-Manero G. Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. Am J Hematol. 2011 Feb; 86(2):237-8. PMID: 21264920; PMCID: PMC3652683.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    1236. Kantarjian H, Cortes J, Verstovsek S, Quint?s-Cardama A. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011 Feb; 10(2):127-40. PMID: 21283107.
      Citations: 114     Fields:    Translation:HumansAnimals
    1237. Faderl S, Thomas DA, O'Brien S, Ravandi F, Garcia-Manero G, Borthakur G, Ferrajoli A, Verstovsek S, Ayoubi M, Rytting M, Feliu J, Kantarjian HM. Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):54-9. PMID: 21454191.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    1238. Fullmer A, Kantarjian H, Cortes J, Jabbour E. New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Leuk Lymphoma. 2011 Feb; 52 Suppl 1:81-91. PMID: 21299461; PMCID: PMC5681224.
      Citations: 7     Fields:    Translation:Humans
    1239. Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Wiktor-Jedrzejczak W, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011 Mar 24; 117(12):3294-301. PMID: 21270442; PMCID: PMC3069671.
      Citations: 167     Fields:    Translation:Humans
    1240. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011 Mar 17; 117(11):3016-24. PMID: 21245487; PMCID: PMC4123386.
      Citations: 71     Fields:    Translation:HumansCTClinical Trials
    1241. Kantarjian H, Schiffer C, Burnett A. Hematologic malignancies: where do we stand in 2011? J Clin Oncol. 2011 Feb 10; 29(5):473-4. PMID: 21220610.
      Citations:    Fields:    Translation:Humans
    1242. Cortes J, Hochhaus A, Hughes T, Kantarjian H. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol. 2011 Feb 10; 29(5):524-31. PMID: 21220597; PMCID: PMC4979134.
      Citations: 33     Fields:    Translation:HumansCells
    1243. Carter BZ, Mak DH, Morris SJ, Borthakur G, Estey E, Byrd AL, Konopleva M, Kantarjian H, Andreeff M. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis. 2011 Jan; 16(1):67-74. PMID: 20938744; PMCID: PMC3376026.
      Citations: 24     Fields:    Translation:HumansCellsCTClinical Trials
    1244. Mattiuzzi GN, Cortes JE, Blamble DA, Bekele BN, Xiao L, Cabanillas M, Borthakur G, O'Brien S, Kantarjian H. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer. 2010 Dec 15; 116(24):5659-66. PMID: 21218459; PMCID: PMC4185295.
      Citations: 12     Fields:    Translation:Humans
    1245. Jabbour E, Cortes J, Santos FP, Jones D, O'Brien S, Rondon G, Popat U, Giralt S, Kebriaei P, Jones RB, Kantarjian H, Champlin R, de Lima M. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2011 Mar 31; 117(13):3641-7. PMID: 21156844; PMCID: PMC4186643.
      Citations: 23     Fields:    Translation:HumansCells
    1246. Al-Kali A, Verstovsek S, Kantarjian H, Luthra R, Cortes J. Competing cell clones in myeloproliferative neoplasm. Blood. 2010 Dec 02; 116(23):5074-5. PMID: 21127188; PMCID: PMC4916558.
      Citations: 1     Fields:    Translation:HumansCells
    1247. Saglio G, Kantarjian H, Holyoake T, Ranganathan A, Panel at the Third Global Workshop on Chronic Myeloid Leukemia, Cort?s JE. Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2010 Dec; 10(6):443-51. PMID: 21156461.
      Citations: 1     Fields:    Translation:Humans
    1248. Santos FP, Kantarjian H, Cortes J, Quintas-Cardama A. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Curr Opin Investig Drugs. 2010 Dec; 11(12):1450-65. PMID: 21154127.
      Citations: 17     Fields:    Translation:Humans
    1249. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. CCL3 (MIP-1a) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood. 2011 Feb 03; 117(5):1662-9. PMID: 21115978; PMCID: PMC3318778.
      Citations: 61     Fields:    Translation:Humans
    1250. Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 2011 May 01; 117(9):1800-11. PMID: 21509757; PMCID: PMC4180713.
      Citations: 29     Fields:    Translation:Humans
    1251. Santos FP, Jones D, Qiao W, Cortes JE, Ravandi F, Estey EE, Verma D, Kantarjian H, Borthakur G. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer. 2011 May 15; 117(10):2145-55. PMID: 21523727; PMCID: PMC4184429.
      Citations: 38     Fields:    Translation:Humans
    1252. Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, Blakesley R, Baccarani M, Cortes J, le Coutre PD. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011 Jan 27; 117(4):1141-5. PMID: 21098399; PMCID: PMC4916554.
      Citations: 113     Fields:    Translation:HumansCTClinical Trials
    1253. Ma W, Kantarjian H, Zhang K, Zhang X, Wang X, Chen C, Donahue AC, Zhang Z, Yeh CH, O'Brien S, Garcia-Manero G, Caporaso N, Landgren O, Albitar M. Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome. BMC Med Genet. 2010 Nov 16; 11:163. PMID: 21078205; PMCID: PMC2992491.
      Citations: 7     Fields:    Translation:HumansCells
    1254. Rytting M, Ravandi F, Estey E, Cortes J, Faderl S, Garcia-Manero G, Jeha S, Ouzounian S, Pierce S, Kantarjian H. Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. Cancer. 2010 Nov 15; 116(22):5272-8. PMID: 20665501; PMCID: PMC5434864.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    1255. Fullmer A, Kantarjian H, Cortes J, Jabbour E. Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia. Expert Opin Pharmacother. 2010 Dec; 11(18):3065-72. PMID: 21073351.
      Citations: 2     Fields:    Translation:HumansAnimals
    1256. Karjalainen K, Jaalouk DE, Bueso-Ramos CE, Zurita AJ, Kuniyasu A, Eckhardt BL, Marini FC, Lichtiger B, O'Brien S, Kantarjian HM, Cortes JE, Koivunen E, Arap W, Pasqualini R. Targeting neuropilin-1 in human leukemia and lymphoma. Blood. 2011 Jan 20; 117(3):920-7. PMID: 21063027; PMCID: PMC3298438.
      Citations: 33     Fields:    Translation:HumansCells
    1257. Kantarjian H, O'Brien S. Questions regarding frontline therapy of acute myeloid leukemia. Cancer. 2010 Nov 01; 116(21):4896-901. PMID: 20623787.
      Citations: 14     Fields:    Translation:Humans
    1258. Carter BZ, Qiu YH, Zhang N, Coombes KR, Mak DH, Thomas DA, Ravandi F, Kantarjian HM, Koller E, Andreeff M, Kornblau SM. Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood. 2011 Jan 20; 117(3):780-7. PMID: 21041716; PMCID: PMC3035072.
      Citations: 27     Fields:    Translation:HumansCells
    1259. Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB, Cortes J. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood. 2011 Feb 10; 117(6):1822-7. PMID: 21030554; PMCID: PMC4081281.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    1260. Santos FP, Alvarado Y, Kantarjian H, Verma D, O'Brien S, Mattiuzzi G, Ravandi F, Borthakur G, Cortes J. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer. 2011 Mar 01; 117(5):982-91. PMID: 20960502; PMCID: PMC4324729.
      Citations: 5     Fields:    Translation:Humans
    1261. Jabbour E, Kantarjian H, Ravandi F, Garcia-Manero G, Estrov Z, Verstovsek S, O'Brien S, Faderl S, Thomas DA, Wright JJ, Cortes J. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2011 Mar 15; 117(6):1236-44. PMID: 20960519; PMCID: PMC4061136.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    1262. Cortes J, Kantarjian HM, Quint?s-Cardama A. Monitoring molecular response in chronic myeloid leukemia. Cancer. 2011 Mar 15; 117(6):1113-22. PMID: 20960522; PMCID: PMC4969001.
      Citations: 4     Fields:    Translation:Humans
    1263. Ma W, Kantarjian H, Zhang X, Wang X, Estrov Z, O'Brien S, Albitar M. Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance. Leuk Res. 2011 Apr; 35(4):526-33. PMID: 20951430; PMCID: PMC4051750.
      Citations: 6     Fields:    Translation:Humans
    1264. Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, Faderl S, Verstovsek S, Mathews S, Andreeff M, Cortes JE. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 2011 Jan; 96(1):62-8. PMID: 20952518; PMCID: PMC3012766.
      Citations: 89     Fields:    Translation:HumansCTClinical Trials
    1265. Jabbour E, Cortes J, Kantarjian H. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. Cancer. 2011 Mar 01; 117(5):897-906. PMID: 20945321; PMCID: PMC4428165.
      Citations: 12     Fields:    Translation:HumansAnimals
    1266. Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer. 2011 Mar 01; 117(5):992-1000. PMID: 20945323.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    1267. Ravandi F, Cortes J, Faderl S, O'Brien S, Garcia-Manero G, Verstovsek S, Santos FP, Shan J, Brandt M, de Lima M, Pierce S, Kantarjian H. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood. 2010 Dec 23; 116(26):5818-23; quiz 6153. PMID: 20923968; PMCID: PMC4081278.
      Citations: 36     Fields:    Translation:Humans
    1268. Agrawal M, Garg RJ, Cortes J, Kantarjian H, Verstovsek S, Quintas-Cardama A. Experimental therapeutics for patients with myeloproliferative neoplasias. Cancer. 2011 Feb 15; 117(4):662-76. PMID: 20922795.
      Citations: 5     Fields:    Translation:Humans
    1269. Kantarjian H, Cortes J, Quint?s-Cardama A. Third-generation tyrosine kinase inhibitors and beyond. Semin Hematol. 2010 Oct; 47(4):371-80. PMID: 20875554.
      Citations: 5     Fields:    Translation:Humans
    1270. Thomas D, O'Brien S, Faderl S, Ravandi F, Jabbour E, Pierce S, Cortes J, Kantarjian H. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. Cancer. 2010 Oct 01; 116(19):4580-9. PMID: 20572037; PMCID: PMC4458382.
      Citations: 5     Fields:    Translation:Humans
    1271. Jabbour E, Kantarjian H, Cortes J. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one? Semin Hematol. 2010 Oct; 47(4):344-53. PMID: 20875551.
      Citations: 5     Fields:    Translation:Humans
    1272. Cortes J, Jones D, Ravandi F, Garcia-Manero G, Verstovsek S, Koller C, Hiteshew J, Shan J, O'Brien S, Kantarjian H, Quint?s-Cardama A. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer. 2011 Feb 01; 117(3):572-80. PMID: 20886606; PMCID: PMC4312759.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    1273. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16; 363(12):1117-27. PMID: 20843246; PMCID: PMC5187954.
      Citations: 489     Fields:    Translation:HumansCTClinical Trials
    1274. Al-Kali A, Kantarjian H, Shan J, Bassett R, Borthakur G, Jabbour E, Verstovsek S, O'Brien S, Cortes J, Quint?s-Cardama A. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer. 2011 Jan 15; 117(2):327-35. PMID: 20845478; PMCID: PMC4327987.
      Citations: 10     Fields:    Translation:Humans
    1275. Parikh SA, Bhusal Y, Faderl SH, Wierda WG, O'Brien S, Kantarjian H, Adachi JA, Burger JA. The great imitator: systemic nocardiosis mimicking Richter's transformation in relapsed chronic lymphocytic leukemia. J Clin Oncol. 2010 Dec 10; 28(35):e732-4. PMID: 20823404.
      Citations: 4     Fields:    Translation:Humans
    1276. Agrawal M, Garg RJ, Kantarjian H, Cortes J. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy? Curr Oncol Rep. 2010 Sep; 12(5):302-13. PMID: 20640942.
      Citations: 9     Fields:    Translation:Humans
    1277. Lahoti A, Kantarjian H, Salahudeen AK, Ravandi F, Cortes JE, Faderl S, O'Brien S, Wierda W, Mattiuzzi GN. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer. 2010 Sep 01; 116(17):4063-8. PMID: 20564156; PMCID: PMC4181579.
      Citations: 31     Fields:    Translation:Humans
    1278. Dayyani F, Kantarjian H, O'Brien S, Pierce S, Jones D, Faderl S, Garcia-Manero G, Cortes J, Ravandi F. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer. 2011 Jan 01; 117(1):110-5. PMID: 20803607; PMCID: PMC4287232.
      Citations: 13     Fields:    Translation:Humans
    1279. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Jabbour E, Garcia-Manero G, Pierce S, Shan J, Cortes J, O'Brien S. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 2010 Dec 15; 116(24):5568-74. PMID: 20737576; PMCID: PMC4332768.
      Citations: 45     Fields:    Translation:Humans
    1280. Zuo Z, Jones D, Yao H, Thomas DA, O'Brien S, Ravandi F, Kantarjian HM, Abruzzo LV, Medeiros LJ, Chen SS, Luthra R. A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Mod Pathol. 2010 Nov; 23(11):1524-34. PMID: 20729815.
      Citations: 1     Fields:    Translation:HumansCells
    1281. Jabbour E, Garcia-Manero G, Batty N, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP, Kantarjian H. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010 Aug 15; 116(16):3830-4. PMID: 20564137; PMCID: PMC4295788.
      Citations: 83     Fields:    Translation:Humans
    1282. Ma W, Kantarjian H, Zhang X, Wang X, Zhang Z, Yeh CH, O'Brien S, Giles F, Bruey JM, Albitar M. JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms. PLoS One. 2010 Aug 13; 5(8):e12165. PMID: 20730051; PMCID: PMC2921382.
      Citations: 6     Fields:    Translation:HumansCells
    1283. Parikh SA, Kantarjian H, Schimmer A, Walsh W, Asatiani E, El-Shami K, Winton E, Verstovsek S. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug; 10(4):285-9. PMID: 20709666.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    1284. Velev N, Cortes J, Champlin R, Jones D, Rondon G, Giralt S, Borthakur G, Kantarjian HM, De Lima M. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer. 2010 Aug 01; 116(15):3631-7. PMID: 20564073.
      Citations: 13     Fields:    Translation:Humans
    1285. Apostolidou E, Kantarjian H, Thomas D, Burger I, Borthakur G, Verstovsek S. Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug; 10(4):281-4. PMID: 20709665.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    1286. Bashir Q, De Lima MJ, McMannis JD, Garcia-Manero G, Shpall E, Kantarjian H, Cortes JE, O'Brien SM, Jones D, Qazilbash M, Wei W, Giralt SA, Champlin RE, Hosing C. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leuk Lymphoma. 2010 Aug; 51(8):1478-84. PMID: 20658954; PMCID: PMC4188823.
      Citations: 3     Fields:    Translation:HumansCells
    1287. Bryan J, Jabbour E, Prescott H, Garcia-Manero G, Issa JP, Kantarjian H. Current and future management options for myelodysplastic syndromes. Drugs. 2010 Jul 30; 70(11):1381-94. PMID: 20614946.
      Citations: 7     Fields:    Translation:HumansCells
    1288. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010 Nov 25; 116(22):4422-9. PMID: 20668231; PMCID: PMC4081299.
      Citations: 148     Fields:    Translation:Humans
    1289. Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):3880-9. PMID: 20660823; PMCID: PMC2940403.
      Citations: 127     Fields:    Translation:HumansCellsCTClinical Trials
    1290. Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, Garcia-Manero G, Hu K, Franklin JL, Berger DP. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010 Oct 28; 116(17):3163-70. PMID: 20631375; PMCID: PMC3324162.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    1291. Bryan J, Jabbour E, Prescott H, Kantarjian H. Thrombocytopenia in patients with myelodysplastic syndromes. Semin Hematol. 2010 Jul; 47(3):274-80. PMID: 20620439; PMCID: PMC4428284.
      Citations: 10     Fields:    Translation:Humans
    1292. Jones D, Chen SS, Jabbour E, Rios MB, Kantarjian H, Cortes J. Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. Blood. 2010 Jul 01; 115(26):5428-9. PMID: 20595523.
      Citations: 4     Fields:    Translation:Humans
    1293. Tong WG, Kantarjian H, O'Brien S, Faderl S, Ravandi F, Borthakur G, Shan J, Pierce S, Rios MB, Cortes J. Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Cancer. 2010 Jul 01; 116(13):3152-9. PMID: 20564631; PMCID: PMC4314210.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    1294. Jabbour E, Cortes J, Kantarjian H. Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. Core Evid. 2010 Jun 15; 4:207-13. PMID: 20694077; PMCID: PMC2899790.
      Citations: 10     
    1295. Santos FP, Kantarjian H, Fava C, O'Brien S, Garcia-Manero G, Ravandi F, Wierda W, Thomas D, Shan J, Cortes J. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol. 2010 Aug; 150(3):303-12. PMID: 20553275; PMCID: PMC4105000.
      Citations: 16     Fields:    Translation:Humans
    1296. Tong WG, Estrov Z, Wang Y, O'Brien S, Faderl S, Harris DM, Van Pham Q, Hazan-Halevy I, Liu Z, Koch P, Kantarjian H, Keating MJ, Ferrajoli A. The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells. Invest New Drugs. 2011 Dec; 29(6):1206-12. PMID: 20533075; PMCID: PMC4230707.
      Citations: 7     Fields:    Translation:HumansCells
    1297. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M, Huguet F, Boqu? C. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010 Jun 17; 362(24):2260-70. PMID: 20525995.
      Citations: 506     Fields:    Translation:HumansCTClinical Trials
    1298. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun 17; 362(24):2251-9. PMID: 20525993.
      Citations: 523     Fields:    Translation:HumansCTClinical Trials
    1299. Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A, Goldberg S, Kam GL, Jagasia M, Mendrek W, Fischer T, Facon T, Marin D, Mueller MC, Shou Y, Gallagher NJ, Larson RA, Mahon FX, Baccarani M, Cortes J, Kantarjian HM, D?nzinger U. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. 2010 Jul; 24(7):1299-301. PMID: 20520639; PMCID: PMC3078756.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    1300. Faderl S, Bueso-Ramos C, Liu Z, Pal A, Bornmann W, Ciurea DV, Harris D, Hazan-Halevy I, Kantarjian HM, Estrov Z. Kit inhibitor APcK110 extends survival in an AML xenograft mouse model. Invest New Drugs. 2011 Oct; 29(5):1094-7. PMID: 20517635; PMCID: PMC4251765.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    1301. Jabbour E, Fullmer A, Kantarjian H, Cort?s JE. Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective. Clin Lymphoma Myeloma Leuk. 2010 Jun; 10 Suppl 1:S6-13. PMID: 20529808.
      Citations: 2     Fields:    Translation:Humans
    1302. Kantarjian H, le Coutre P, Cortes J, Pinilla-Ibarz J, Nagler A, Hochhaus A, Kimura S, Ottmann O. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer. 2010 Jun 01; 116(11):2665-72. PMID: 20310049; PMCID: PMC2876208.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    1303. Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G, Koller C, Borthakur G, Cortes J. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer. 2010 Jun 01; 116(11):2673-81. PMID: 20499401; PMCID: PMC4216809.
      Citations: 23     Fields:    Translation:Humans
    1304. Batty GN, Kantarjian H, Issa JP, Jabbour E, Santos FP, McCue D, Garcia-Manero G, Pierce S, O'Brien S, Ravandi F, Cort?s JE. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk. 2010 Jun; 10(3):205-10. PMID: 20511166; PMCID: PMC3726276.
      Citations: 6     Fields:    Translation:Humans
    1305. Kantarjian H, Quint?s-Cardama A, Cort?s JE. Applying cytogenetic and molecular information in the clinic: implications for the treatment of chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2010 Jun; 10 Suppl 1:S14-9. PMID: 20529803.
      Citations:    Fields:    Translation:Humans
    1306. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010 Jul; 150(2):200-8. PMID: 20528872.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    1307. Tsao T, Kornblau S, Safe S, Watt JC, Ruvolo V, Chen W, Qiu Y, Coombes KR, Ju Z, Abdelrahim M, Schober W, Ling X, Kardassis D, Meyer C, Schimmer A, Kantarjian H, Andreeff M, Konopleva M. Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia. Cancer Res. 2010 Jun 15; 70(12):4949-60. PMID: 20501850; PMCID: PMC3727426.
      Citations: 22     Fields:    Translation:HumansCellsCTClinical Trials
    1308. Liu X, Wang Y, Benaissa S, Matsuda A, Kantarjian H, Estrov Z, Plunkett W. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC. Blood. 2010 Sep 09; 116(10):1737-46. PMID: 20479284; PMCID: PMC2947394.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    1309. Jabbour E, Thomas D, Cortes J, Kantarjian HM, O'Brien S. Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer. 2010 May 15; 116(10):2290-300. PMID: 20209620.
      Citations: 27     Fields:    Translation:Humans
    1310. Sampat K, Rossi A, Garcia-Gutierrez V, Cortes J, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of pericardial effusions in patients with leukemia. Cancer. 2010 May 15; 116(10):2366-71. PMID: 20209609; PMCID: PMC3833724.
      Citations: 8     Fields:    Translation:Humans
    1311. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010 Sep 23; 116(12):2070-7. PMID: 20466853; PMCID: PMC4081177.
      Citations: 121     Fields:    Translation:HumansCTClinical Trials
    1312. Samudio IJ, Duvvuri S, Clise-Dwyer K, Watt JC, Mak D, Kantarjian H, Yang D, Ruvolo V, Borthakur G. Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells. Leuk Lymphoma. 2010 May; 51(5):911-919. PMID: 20423286; PMCID: PMC4122268.
      Citations: 7     Fields:    Translation:HumansCells
    1313. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, Faderl S, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010 May 01; 116(9):2174-9. PMID: 20162709; PMCID: PMC3753205.
      Citations: 43     Fields:    Translation:Humans
    1314. Verma D, Kantarjian H, Faderl S, O'Brien S, Pierce S, Vu K, Freireich E, Keating M, Cortes J, Ravandi F. Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. Leuk Lymphoma. 2010 May; 51(5):778-82. PMID: 20196624; PMCID: PMC4086357.
      Citations: 24     Fields:    Translation:Humans
    1315. Chandra P, Luthra R, Zuo Z, Yao H, Ravandi F, Reddy N, Garcia-Manero G, Kantarjian H, Jones D. Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases. Am J Clin Pathol. 2010 May; 133(5):686-93. PMID: 20395514.
      Citations: 8     Fields:    Translation:HumansCells
    1316. Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol. 2010 Jul; 150(1):72-82. PMID: 20456355; PMCID: PMC4124904.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    1317. Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V, Ravandi F. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood. 2010 Aug 12; 116(6):886-92. PMID: 20427701; PMCID: PMC2924226.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    1318. Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010 Jun 01; 28(16):2755-60. PMID: 20421540; PMCID: PMC4872315.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    1319. Manshouri T, Estrov Z, Harris D, Zhang Y, Gaikwad A, Kantarjian HM, Verstovsek S, Quint?s-Cardama A. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. Invest New Drugs. 2011 Oct; 29(5):818-26. PMID: 20372971; PMCID: PMC4170651.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    1320. Bruey JM, Kantarjian H, Ma W, Estrov Z, Yeh C, Donahue A, Sanders H, O'Brien S, Keating M, Albitar M. Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia. Leuk Res. 2010 Oct; 34(10):1320-4. PMID: 20362333; PMCID: PMC4108997.
      Citations: 7     Fields:    Translation:HumansCells
    1321. Abdool A, Yeh CH, Kantarjian H, O'Brien S, Bruey J, Giles F, Albitar M. Circulating CD33 and its clinical value in acute leukemia. Exp Hematol. 2010 Jun; 38(6):462-71. PMID: 20362641.
      Citations: 6     Fields:    Translation:HumansCells
    1322. Kantarjian HM, Cortes J, Hochhaus A, La Ros?e P. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer. 2010 Mar 15; 116(6):1419-30. PMID: 20120030.
      Citations: 19     Fields:    Translation:Humans
    1323. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10; 28(11):1856-62. PMID: 20212254; PMCID: PMC2930809.
      Citations: 154     Fields:    Translation:HumansCTClinical Trials
    1324. Fullmer A, O'Brien S, Kantarjian H, Jabbour E. Emerging therapy for the treatment of acute lymphoblastic leukemia. Expert Opin Emerg Drugs. 2010 Mar; 15(1):1-11. PMID: 20055690.
      Citations: 1     Fields:    Translation:Humans
    1325. Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, Kantarjian HM. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 2010 Mar 01; 116(5):1165-76. PMID: 20101737; PMCID: PMC5345568.
      Citations: 80     Fields:    Translation:HumansCells
    1326. Amin HM, Kantarjian H, Verstovsek S, Quint?s-Cardama A. Treatment of aggressive systemic mastocytosis with daclizumab. Leuk Lymphoma. 2010 Mar; 51(3):540-2. PMID: 20038223.
      Citations: 3     Fields:    Translation:Humans
    1327. Walter RB, Kantarjian HM, Huang X, Pierce SA, Sun Z, Gundacker HM, Ravandi F, Faderl SH, Tallman MS, Appelbaum FR, Estey EH. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J Clin Oncol. 2010 Apr 01; 28(10):1766-71. PMID: 20159819; PMCID: PMC2849766.
      Citations: 71     Fields:    Translation:Humans
    1328. Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S, Quint?s-Cardama A. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010 Apr 15; 115(15):3109-17. PMID: 20130243; PMCID: PMC3953826.
      Citations: 306     Fields:    Translation:HumansAnimalsCells
    1329. Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Lambert A, Matloub Y, Hochhaus A, M?ller MC. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010 Feb; 95(2):232-40. PMID: 20139391; PMCID: PMC2817025.
      Citations: 84     Fields:    Translation:HumansCTClinical Trials
    1330. Jones D, Yao H, Romans A, Dando C, Pierce S, Borthakur G, Hamilton A, Bueso-Ramos C, Ravandi F, Garcia-Manero G, Kantarjian H. Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias. Genes Chromosomes Cancer. 2010 Feb; 49(2):182-91. PMID: 19908318; PMCID: PMC4161977.
      Citations: 11     Fields:    Translation:HumansCells
    1331. Ghanem H, Jabbour E, Faderl S, Ghandhi V, Plunkett W, Kantarjian H. Clofarabine in leukemia. Expert Rev Hematol. 2010 Feb; 3(1):15-22. PMID: 21082931.
      Citations: 9     Fields:    Translation:Humans
    1332. Parikh SA, Kantarjian HM, Richie MA, Cortes JE, Verstovsek S. Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. Leuk Lymphoma. 2010 Feb; 51(2):269-74. PMID: 20038218; PMCID: PMC4184061.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    1333. Abdel-Karim I, Plunkett WK, O'Brien S, Giles F, Thomas D, Faderl S, Ravandi F, Rios MB, Du M, Schneck KB, Chen VJ, Lin BK, Nicol SJ, Kantarjian HM. A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia. Invest New Drugs. 2011 Apr; 29(2):323-31. PMID: 20091088; PMCID: PMC4204658.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    1334. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Garcia-Manero G, Shan J, Pierce S, Cortes J, O'Brien S. Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk Lymphoma. 2010 Mar; 51(3):475-80. PMID: 20078325; PMCID: PMC4086446.
      Citations: 5     Fields:    Translation:Humans
    1335. Dimov ND, Medeiros LJ, Kantarjian HM, Cortes JE, Chang KS, Bueso-Ramos CE, Ravandi F. Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients. Cancer. 2010 Jan 15; 116(2):369-76. PMID: 19950129; PMCID: PMC4180261.
      Citations: 10     Fields:    Translation:Humans
    1336. Wang SA, Jabbar K, Lu G, Chen SS, Galili N, Vega F, Jones D, Raza A, Kantarjian H, Garcia-Manero G, McDonnell TJ, Medeiros LJ. Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. Leukemia. 2010 Apr; 24(4):740-7. PMID: 20072149.
      Citations: 8     Fields:    Translation:HumansCells
    1337. Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine RL, Verstovsek S. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010 Jan 15; 70(2):447-52. PMID: 20068184; PMCID: PMC2947340.
      Citations: 123     Fields:    Translation:Humans
    1338. Burger JA, Velev NS, Jabbour EJ, Wierda WG, Ravandi F, Cortes JE, Kantarjian H, Nieto YL, Shpall EJ, Jorgensen JL. Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells. Leukemia. 2010 Mar; 24(3):666-8. PMID: 20054352; PMCID: PMC10405622.
      Citations:    Fields:    Translation:HumansCells
    1339. Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F. Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther. 2010 Jan; 10(1):9-22. PMID: 20014881.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    1340. Al Ameri A, Koller C, Kantarjian H, Ravandi F, Verstovsek S, Borthakur G, Pierce S, Mattiuzzi G. Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer. 2010 Jan 01; 116(1):93-7. PMID: 19862814.
      Citations: 4     Fields:    Translation:Humans
    1341. Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma. 2010 Jan; 51(1):73-8. PMID: 20017599; PMCID: PMC2876330.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    1342. Hasserjian RP, Zuo Z, Garcia C, Tang G, Kasyan A, Luthra R, Abruzzo LV, Kantarjian HM, Medeiros LJ, Wang SA. Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood. 2010 Mar 11; 115(10):1985-92. PMID: 20040759; PMCID: PMC2942006.
      Citations: 33     Fields:    Translation:Humans
    1343. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010 Feb 01; 28(4):605-13. PMID: 20038729; PMCID: PMC2815995.
      Citations: 121     Fields:    Translation:HumansCells
    1344. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H, Andreeff M. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest. 2010 Jan; 120(1):142-56. PMID: 20038799; PMCID: PMC2799198.
      Citations: 315     Fields:    Translation:HumansAnimalsCells
    1345. Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M, Petersdorf S, Shami PJ, Yeager AM, Eckert S, Abichandani R, Faderl S. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. 2010 Feb 01; 28(4):549-55. PMID: 20026805.
      Citations: 70     Fields:    Translation:HumansCTClinical Trials
    1346. Ravandi F, Issa JP, Garcia-Manero G, O'Brien S, Pierce S, Shan J, Borthakur G, Verstovsek S, Faderl S, Cortes J, Kantarjian H. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 2009 Dec 15; 115(24):5746-51. PMID: 19795507; PMCID: PMC2794953.
      Citations: 35     Fields:    Translation:HumansCells
    1347. Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010 Jan 20; 28(3):437-44. PMID: 20008626.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    1348. Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, Borthakur G, Walker B, Zhao W, Shan J, Kantarjian H. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010 Jan 20; 28(3):398-404. PMID: 20008620; PMCID: PMC2815702.
      Citations: 88     Fields:    Translation:Humans
    1349. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010 Jan 20; 28(3):392-7. PMID: 20008621; PMCID: PMC2815701.
      Citations: 93     Fields:    Translation:Humans
    1350. Cortes JE, Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova E, De Souza C, Rudoltz M, Yu R, Krahnke T, Kantarjian HM, Radich JP, Hughes TP, Guilhot F. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010 Jan 20; 28(3):424-30. PMID: 20008622; PMCID: PMC4979244.
      Citations: 96     Fields:    Translation:HumansCTClinical Trials
    1351. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek S. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010 Feb 11; 115(6):1131-6. PMID: 20008298; PMCID: PMC4081385.
      Citations: 78     Fields:    Translation:HumansCTClinical Trials
    1352. Mattiuzzi GN, Cortes J, Alvarado G, Verstovsek S, Koller C, Pierce S, Blamble D, Faderl S, Xiao L, Hernandez M, Kantarjian H. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer. 2011 Jan; 19(1):19-26. PMID: 19956980.
      Citations: 16     Fields:    Translation:Humans
    1353. Chen W, Konoplev S, Medeiros LJ, Koeppen H, Leventaki V, Vadhan-Raj S, Jones D, Kantarjian HM, Falini B, Bueso-Ramos CE. Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation. Cancer. 2009 Dec 01; 115(23):5481-9. PMID: 19672946; PMCID: PMC3378048.
      Citations: 16     Fields:    Translation:HumansCells
    1354. Thomas DA, Kantarjian HM, Stock W, Heffner LT, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Pierce S, Lu B, Deitcher SR, O'Brien S. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer. 2009 Dec 01; 115(23):5490-8. PMID: 19708032; PMCID: PMC4458381.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    1355. Kantarjian H, Cortes J, Quint?s-Cardama A. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer. 2009 Dec 01; 115(23):5382-93. PMID: 19739234.
      Citations: 36     Fields:    Translation:Humans
    1356. Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Westwood R, Green SR, Chiao JH, Boone PA, Cortes J, Plunkett W. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol. 2010 Jan 10; 28(2):285-91. PMID: 19933907; PMCID: PMC3340938.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    1357. Tanaka C, Yin OQ, Sethuraman V, Smith T, Wang X, Grouss K, Kantarjian H, Giles F, Ottmann OG, Galitz L, Schran H. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther. 2010 Feb; 87(2):197-203. PMID: 19924121.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    1358. Kantarjian H, O'Brien S, Ravandi F, Borthakur G, Faderl S, Bueso-Ramos C, Abruzzo L, Pierce S, Shan J, Issa JP, Garcia-Manero G. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer. 2009 Nov 15; 115(22):5202-9. PMID: 19691096; PMCID: PMC2783477.
      Citations: 11     Fields:    Translation:HumansCells
    1359. Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol. 2010 Feb; 148(3):386-93. PMID: 19895616; PMCID: PMC4476391.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    1360. Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R, European LeukemiaNet, Baccarani M, Guilhot F. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009 Dec 10; 27(35):6041-51. PMID: 19884523; PMCID: PMC4979100.
      Citations: 393     Fields:    Translation:Humans
    1361. Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O'Brien S, Koller C, Pierce S, Brandt M, Kennedy D, Cortes J, Beran M. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res. 2010 Jun; 34(6):752-6. PMID: 19878996; PMCID: PMC4082769.
      Citations: 49     Fields:    Translation:Humans
    1362. Konoplev S, Huang X, Drabkin HA, Koeppen H, Jones D, Kantarjian HM, Garcia-Manero G, Chen W, Medeiros LJ, Bueso-Ramos CE. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. Cancer. 2009 Oct 15; 115(20):4737-44. PMID: 19637342; PMCID: PMC4199225.
      Citations: 12     Fields:    Translation:HumansCells
    1363. Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S, Quint?s-Cardama A. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009 Nov 10; 27(32):5418-24. PMID: 19826111; PMCID: PMC4881362.
      Citations: 126     Fields:    Translation:HumansCTClinical Trials
    1364. Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10; 27(32):5425-30. PMID: 19805674; PMCID: PMC4881363.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    1365. Sampat K, Kantarjian H, Borthakur G. Clofarabine: emerging role in leukemias. Expert Opin Investig Drugs. 2009 Oct; 18(10):1559-64. PMID: 19715446.
      Citations: 2     Fields:    Translation:Humans
    1366. Thomas DA, O'Brien S, Kantarjian HM. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009 Oct; 23(5):949-71, v. PMID: 19825447; PMCID: PMC4458386.
      Citations: 17     Fields:    Translation:Humans
    1367. Jabbour E, Hochhaus A, Cortes J, Kantarjian HM, La Ros?e P. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia. 2010 Jan; 24(1):6-12. PMID: 19798095.
      Citations: 28     Fields:    Translation:Humans
    1368. Yeh CH, Tseng R, Hannah A, Estrov Z, Estey E, Kantarjian H, Albitar M. Clinical correlation of circulating heat shock protein 70 in acute leukemia. Leuk Res. 2010 May; 34(5):605-9. PMID: 19800118; PMCID: PMC4127889.
      Citations: 13     Fields:    Translation:Humans
    1369. Thomas DA, Ravandi F, Keating M, Kantarjian HM. Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy. Leuk Lymphoma. 2009 Oct; 50 Suppl 1:27-31. PMID: 19814695; PMCID: PMC4109291.
      Citations:    Fields:    Translation:Humans
    1370. Tam CS, Kantarjian H, Cortes J, Lynn A, Pierce S, Zhou L, Keating MJ, Thomas DA, Verstovsek S. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009 Nov 20; 27(33):5587-93. PMID: 19786661; PMCID: PMC4979081.
      Citations: 36     Fields:    Translation:Humans
    1371. Kantarjian H, Pasquini R, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP, L?vy V. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009 Sep 15; 115(18):4136-47. PMID: 19536906; PMCID: PMC5345391.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    1372. Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H, Ravandi F. Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia. 2009 Dec; 23(12):2275-80. PMID: 19741728; PMCID: PMC4217206.
      Citations: 27     Fields:    Translation:Humans
    1373. Lee TS, Ma W, Zhang X, Kantarjian H, Albitar M. Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations. BMC Struct Biol. 2009 Sep 10; 9:58. PMID: 19744331; PMCID: PMC2749040.
      Citations: 10     Fields:    Translation:HumansCells
    1374. Garg RJ, Kantarjian H, O'Brien S, Faderl S, Estrov Z, Cortes J, Quint?s-Cardama A. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009 Nov 12; 114(20):4361-8. PMID: 19729517; PMCID: PMC3952810.
      Citations: 49     Fields:    Translation:HumansCTClinical Trials
    1375. Armistead PM, de Lima M, Pierce S, Qiao W, Wang X, Thall PF, Giralt S, Ravandi F, Kantarjian H, Champlin R, Estey E. Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1431-8. PMID: 19822303; PMCID: PMC4067765.
      Citations: 22     Fields:    Translation:Humans
    1376. De Souza Santos FP, Kantarjian H, O'Brien S, Faderl S, Awais A, Borthakur G, Cortes J, Quint?s-Cardama A. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer. 2009 Sep 01; 115(17):3935-43. PMID: 19517473; PMCID: PMC4386888.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    1377. Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, Cohen EN, Ebarb T, Scheinberg DA, Cortes J. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer. 2009 Sep 01; 115(17):3924-34. PMID: 19536894; PMCID: PMC5534348.
      Citations: 24     Fields:    Translation:HumansCellsCTClinical Trials
    1378. Jabbour E, Fava C, Kantarjian H. Advances in the biology and therapy of patients with chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009 Sep; 22(3):395-407. PMID: 19959090.
      Citations: 11     Fields:    Translation:Humans
    1379. Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM, Andreeff M, Carter BZ. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther. 2009 Sep; 8(9):2509-16. PMID: 19723894; PMCID: PMC2754862.
      Citations: 17     Fields:    Translation:HumansCells
    1380. Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek S, Quint?s-Cardama A. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009 Oct 01; 27(28):4760-6. PMID: 19720904; PMCID: PMC4879697.
      Citations: 52     Fields:    Translation:HumansCTClinical Trials
    1381. Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A, McDougall K, Albitar M, Radich J, Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) Trial Study Group. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol. 2009 Oct 01; 27(28):4754-9. PMID: 19720924; PMCID: PMC4979200.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    1382. Sever M, Kantarjian H, Pierce S, Jain N, Estrov Z, Cortes J, Verstovsek S. Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation. Int J Hematol. 2009 Nov; 90(4):522-525. PMID: 19728024; PMCID: PMC4209590.
      Citations: 4     Fields:    Translation:Humans
    1383. Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Shan J, Cortes J. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer. 2009 Aug 15; 115(16):3709-18. PMID: 19517462; PMCID: PMC4388415.
      Citations: 37     Fields:    Translation:Humans
    1384. Bruey JM, Kantarjian H, Estrov Z, Zhang Z, Ma W, Albitar F, Abdool A, Thomas D, Yeh C, O'Brien S, Albitar M. Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia. Leuk Res. 2010 Feb; 34(2):173-6. PMID: 19679351; PMCID: PMC4132892.
      Citations: 4     Fields:    Translation:Humans
    1385. Kantarjian H, Cortes J, Quint?s-Cardama A. Imatinib and beyond--exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol. 2009 Sep; 6(9):535-43. PMID: 19652654.
      Citations: 50     Fields:    Translation:Humans
    1386. Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 Sep 20; 27(27):4563-9. PMID: 19652059; PMCID: PMC4979191.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    1387. Cole S, Kantarjian H, Ault P, Cort?s JE. Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature. Clin Lymphoma Myeloma. 2009 Aug; 9(4):324-7. PMID: 19717385.
      Citations: 14     Fields:    Translation:Humans
    1388. Rytting ME, Kantarjian H, Albitar M. Acute lymphoblastic leukemia with Burkitt-like morphologic features and high myeloperoxidase activity. Am J Clin Pathol. 2009 Aug; 132(2):182-5; quiz 306. PMID: 19605811.
      Citations: 3     Fields:    Translation:Humans
    1389. Radich J, Branford S, Kantarjian HM, Hanfstein B, Rousselot P, Kim DW, Lipton JH, Bleickardt E, Lambert A, Hughes TP, Hochhaus A, M?ller MC. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia. 2009 Sep; 23(9):1628-33. PMID: 19641527.
      Citations: 11     Fields:    Translation:HumansCells
    1390. Borthakur G, Lin E, Jain N, Estey EE, Cortes JE, O'Brien S, Faderl S, Ravandi F, Pierce S, Kantarjian H. Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer. 2009 Jul 15; 115(14):3217-21. PMID: 19441109; PMCID: PMC4184418.
      Citations: 22     Fields:    Translation:Humans
    1391. Fullmer A, O'Brien S, Kantarjian H, Jabbour E. Novel therapies for relapsed acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2009 Jul; 4(3):148-56. PMID: 20425428; PMCID: PMC4572835.
      Citations: 4     Fields:    Translation:Humans
    1392. Cortes JE, O'Brien S, Ravandi F, Borthakur G, Liu D, Bleickardt E, Chen TT, Kantarjian HM, Quint?s-Cardama A. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer. 2009 Jul 01; 115(13):2912-21. PMID: 19402171; PMCID: PMC4176768.
      Citations: 16     Fields:    Translation:Humans
    1393. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood. 2009 Sep 03; 114(10):2037-43. PMID: 19567878; PMCID: PMC4186638.
      Citations: 37     Fields:    Translation:HumansCells
    1394. Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, Rios MB, Cortes J. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood. 2009 Sep 10; 114(11):2232-5. PMID: 19531657; PMCID: PMC4828071.
      Citations: 51     Fields:    Translation:Humans
    1395. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009 Aug 10; 27(23):3842-8. PMID: 19528372; PMCID: PMC4879689.
      Citations: 108     Fields:    Translation:HumansCTClinical Trials
    1396. Issa JP, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res. 2009 Jun 15; 15(12):3938-46. PMID: 19509174; PMCID: PMC2732562.
      Citations: 179     Fields:    Translation:HumansCells
    1397. Zhang WW, Cortes JE, Yao H, Zhang L, Reddy NG, Jabbour E, Kantarjian HM, Jones D. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol. 2009 Aug 01; 27(22):3642-9. PMID: 19506164; PMCID: PMC2799062.
      Citations: 26     Fields:    Translation:Humans
    1398. Kantarjian H, Ravandi F, O'Brien S, Thomas D, Vidal-Senmache G, Wierda W, Kornblau S, Cortes J, Quint?s-Cardama A. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer. 2009 Jun 01; 115(11):2482-90. PMID: 19280591; PMCID: PMC4180711.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    1399. Kantarjian HM, Shan J, Jones D, O'Brien S, Rios MB, Jabbour E, Cortes J. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol. 2009 Aug 01; 27(22):3659-63. PMID: 19487383; PMCID: PMC2799063.
      Citations: 23     Fields:    Translation:HumansCells
    1400. Nussenzveig RH, Cortes J, Sever M, Ault P, Manshouri T, Bueso-Ramos C, Prchal JT, Kantarjian H, Verstovsek S, Quint?s-Cardama A. Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. Int J Hematol. 2009 Jul; 90(1):58-63. PMID: 19484334; PMCID: PMC4378576.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    1401. Golemovic M, Manshouri T, Orsolic N, Duzkale H, Johansen M, Freireich EJ, Kantarjian H, Zingaro RA, Verstovsek S, Quint?s-Cardama A. MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells. Invest New Drugs. 2010 Aug; 28(4):402-12. PMID: 19468689; PMCID: PMC4378574.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    1402. Carter BZ, Mak DH, Woessner R, Gross S, Schober WD, Estrov Z, Kantarjian H, Andreeff M. Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia. 2009 Oct; 23(10):1755-62. PMID: 19458629; PMCID: PMC3593228.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    1403. Ma W, Kantarjian H, Bekele B, Donahue AC, Zhang X, Zhang ZJ, O'Brien S, Estey E, Estrov Z, Cortes J, Keating M, Giles F, Albitar M. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res. 2009 Jun 01; 15(11):3820-6. PMID: 19458051; PMCID: PMC4091712.
      Citations: 20     Fields:    Translation:Humans
    1404. Garg R, Kantarjian H, Thomas D, Faderl S, Ravandi F, Lovshe D, Pierce S, O'Brien S. Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy. Cancer. 2009 May 15; 115(10):2147-54. PMID: 19298009; PMCID: PMC4199455.
      Citations: 7     Fields:    Translation:HumansCells
    1405. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009 Jul 02; 114(1):144-7. PMID: 19420352; PMCID: PMC2710942.
      Citations: 313     Fields:    Translation:Humans
    1406. Albitar M, Potts SJ, Giles FJ, O'Brien S, Jilani I, Donahue AC, Estey EH, Kantarjian H. Proteomics-based prediction of clinical response in acute myeloid leukemia. Exp Hematol. 2009 Jul; 37(7):784-90. PMID: 19422784.
      Citations: 3     Fields:    Translation:Humans
    1407. Han X, Kantarjian H, Cortes J, Quint?s-Cardama A. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009 Jul 09; 114(2):261-3. PMID: 19414863; PMCID: PMC3952950.
      Citations: 66     Fields:    Translation:Humans
    1408. Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, de Padua L, Shpall EJ, Champlin R, de Lima M. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009 May 01; 115(9):1899-905. PMID: 19235255; PMCID: PMC4086213.
      Citations: 70     Fields:    Translation:Humans
    1409. Silver RT, Cortes J, Waltzman R, Mone M, Kantarjian H. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica. 2009 May; 94(5):743-4. PMID: 19407320; PMCID: PMC2675690.
      Citations: 11     Fields:    Translation:Humans
    1410. Kantarjian H, Cortes JE, Pavlovsky C. First-line therapy for chronic myeloid leukemia: Past, present, and future. Am J Hematol. 2009 May; 84(5):287-93. PMID: 19306355.
      Citations: 15     Fields:    Translation:Humans
    1411. Heinrichs S, Kulkarni RV, Bueso-Ramos CE, Levine RL, Loh ML, Li C, Neuberg D, Kornblau SM, Issa JP, Gilliland DG, Garcia-Manero G, Kantarjian HM, Estey EH, Look AT. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia. 2009 Sep; 23(9):1605-13. PMID: 19387468; PMCID: PMC2950785.
      Citations: 30     Fields:    Translation:Humans
    1412. Faderl S, Pal A, Bornmann W, Albitar M, Maxwell D, Van Q, Peng Z, Harris D, Liu Z, Hazan-Halevy I, Kantarjian HM, Estrov Z. Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells. Cancer Res. 2009 May 01; 69(9):3910-7. PMID: 19383925; PMCID: PMC4220548.
      Citations: 9     Fields:    Translation:HumansCells
    1413. Kantarjian H, Cortes J, Kim DW, Dorlhiac-Llacer P, Pasquini R, DiPersio J, Radich JP, Khoury HJ, Khoroshko N, Bradley-Garelik MB, Zhu C, Tallman MS, M?ller MC. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009 Jun 18; 113(25):6322-9. PMID: 19369231; PMCID: PMC4916944.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    1414. Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, Kornblau S, O'Brien S, Cortes J, Quint?s-Cardama A. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009 Jun 18; 113(25):6315-21. PMID: 19369233; PMCID: PMC3953080.
      Citations: 66     Fields:    Translation:HumansCells
    1415. Lee TS, Ma W, Zhang X, Giles F, Kantarjian H, Albitar M. Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations. Cancer. 2009 Apr 15; 115(8):1692-700. PMID: 19195039.
      Citations: 18     Fields:    Translation:Cells
    1416. Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy. Oncologist. 2009 May; 14(5):489-96. PMID: 19365094.
      Citations: 4     Fields:    Translation:Humans
    1417. Vega-Ruiz A, Faderl S, Estrov Z, Pierce S, Cortes J, Kantarjian H, Ravandi F. Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience. Int J Hematol. 2009 May; 89(4):489-496. PMID: 19340529; PMCID: PMC4199302.
      Citations: 24     Fields:    Translation:Humans
    1418. Kantarjian HM, Cortes JE, Quint?s-Cardama A. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009 Apr; 16(2):122-31. PMID: 19337198.
      Citations: 80     Fields:    Translation:Humans
    1419. Verma D, Fava C, Kantarjian H, Cortes J. Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia. Am J Hematol. 2009 Apr; 84(4):256-7. PMID: 19260121.
      Citations: 1     Fields:    Translation:HumansCells
    1420. Kantarjian HM. Introduction: targeting different pathways to prevent tumor cell development. Semin Oncol. 2009 Apr; 36(2 Suppl 1):S1-5. PMID: 19393830.
      Citations:    Fields:    Translation:Humans
    1421. Ma W, Kantarjian H, Yeh CH, Zhang ZJ, Cortes J, Albitar M. BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. Acta Haematol. 2009; 121(1):27-31. PMID: 19332983; PMCID: PMC2790522.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    1422. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, Bass A, Marubayashi S, Heguy A, Garcia-Manero G, Kantarjian H, Offit K, Stone RM, Gilliland DG, Klein RJ, Levine RL. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009 Apr; 41(4):455-9. PMID: 19287384; PMCID: PMC3676425.
      Citations: 142     Fields:    Translation:Humans
    1423. Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood. 2009 May 21; 113(21):5058-63. PMID: 19282457; PMCID: PMC4081366.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    1424. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009 Sep; 33(9):1199-203. PMID: 19250674; PMCID: PMC4419687.
      Citations: 73     Fields:    Translation:Humans
    1425. Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H, Ravandi F. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia. 2009 Jul; 23(7):1297-302. PMID: 19242494; PMCID: PMC4217203.
      Citations: 19     Fields:    Translation:HumansAnimalsCTClinical Trials
    1426. Ma W, Kantarjian H, Zhang X, Yeh CH, Zhang ZJ, Verstovsek S, O'Brien S, Giles F, Albitar M. Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biology. Int J Lab Hematol. 2010 Feb; 32(1 Pt 2):95-102. PMID: 19254349.
      Citations: 3     Fields:    Translation:Humans
    1427. Samanta AK, Chakraborty SN, Wang Y, Kantarjian H, Sun X, Hood J, Perrotti D, Arlinghaus RB. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene. 2009 Apr 09; 28(14):1669-81. PMID: 19234487; PMCID: PMC2841483.
      Citations: 57     Fields:    Translation:HumansAnimalsCells
    1428. Kantarjian HM, O'Brien S. Insurance policies in the United States may explain part of the outcome differences of adolescents and young adults with acute lymphoblastic leukemia treated on adult versus pediatric regimens. Blood. 2009 Feb 19; 113(8):1861; author reply 1862. PMID: 19228933.
      Citations: 2     Fields:    Translation:Humans
    1429. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol. 2009 Apr 01; 27(10):1637-43. PMID: 19224852; PMCID: PMC4890649.
      Citations: 28     Fields:    Translation:Humans
    1430. Fava C, Kantarjian H, Cortes J, Jabbour E. Development and targeted use of nilotinib in chronic myeloid leukemia. Drug Des Devel Ther. 2009 Feb 06; 2:233-43. PMID: 19920910; PMCID: PMC2761189.
      Citations: 7     Fields:    
    1431. Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Luthra R, Kantarjian HM, Verstovsek S, Quint?s-Cardama A. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009 Nov; 33(11):1481-4. PMID: 19193436; PMCID: PMC4184059.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    1432. Jabbour E, Cortes JE, Kantarjian HM. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc. 2009 02; 84(2):161-9. PMID: 19181650; PMCID: PMC2664587.
      Citations: 12     Fields:    Translation:Humans
    1433. Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, Krahnke T, Cortes J, Druker BJ, International Randomized Study of Interferon and STI571 (IRIS) Investigators. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 2009 Feb 01; 115(3):551-60. PMID: 19117345; PMCID: PMC4445370.
      Citations: 31     Fields:    
    1434. Jabbour E, Cortes J, Kantarjian H. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol. 2009 Jan; 4(1):3-10. PMID: 19343297.
      Citations: 16     Fields:    Translation:Humans
    1435. De Padua Silva L, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S, Davisson J, Garcia-Manero G, Champlin R, Issa JP, Ravandi F. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant. 2009 Jun; 43(11):839-43. PMID: 19151791.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    1436. Tsimberidou AM, Tam C, Abruzzo LV, O'Brien S, Wierda WG, Lerner S, Kantarjian HM, Keating MJ. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer. 2009 Jan 15; 115(2):373-80. PMID: 19117034; PMCID: PMC4404627.
      Citations: 40     Fields:    Translation:HumansCells
    1437. Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ, Thomas DA, Pierce S, Kantarjian H, Verstovsek S. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood. 2009 Apr 30; 113(18):4171-8. PMID: 19131547; PMCID: PMC4828077.
      Citations: 27     Fields:    Translation:HumansCells
    1438. Freireich EJ, Kantarjian H, Keating MJ. Leukemia research, 2008. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S178. PMID: 19778837.
      Citations:    Fields:    Translation:Humans
    1439. Fava C, Kantarjian H, Jabbour E, Cort?s JE. Standard management of patients with chronic myeloid leukemia. Clin Lymphoma Myeloma. 2009; 9 Suppl 4:S382-90. PMID: 20007107.
      Citations: 1     Fields:    Translation:Humans
    1440. Garcia-Manero G, Yang H, Kuang SQ, O'Brien S, Thomas D, Kantarjian H. Epigenetics of acute lymphocytic leukemia. Semin Hematol. 2009 Jan; 46(1):24-32. PMID: 19100365; PMCID: PMC3833728.
      Citations: 25     Fields:    Translation:HumansCells
    1441. Tefferi A, Levine RL, Kantarjian H. Oncogenic signals as treatment targets in classic myeloproliferative neoplasms. Biol Blood Marrow Transplant. 2009 Jan; 15(1 Suppl):114-9. PMID: 19147089.
      Citations: 1     Fields:    Translation:HumansCells
    1442. Ma W, Kantarjian H, Zhang X, Jilani I, Sheikholeslami MR, Donahue AC, Ravandi F, Estey E, O'Brien S, Keating M, Giles FJ, Albitar M. Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications. Cancer Biomark. 2009; 5(1):51-8. PMID: 19242062.
      Citations: 6     Fields:    Translation:HumansCells
    1443. Jabbour E, Kantarjian H, Cort?s JE. Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S272-9. PMID: 19778852.
      Citations: 5     Fields:    Translation:Humans
    1444. Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer. 2009 Jan 01; 115(1):101-6. PMID: 19090005; PMCID: PMC4180242.
      Citations: 7     Fields:    Translation:Humans
    1445. Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S, Cort?s JE. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S261-5. PMID: 19778850.
      Citations: 5     Fields:    Translation:Humans
    1446. Apostolidou E, Kantarjian HM, Verstovsek S. JAK2 inhibitors: A reality? A hope? Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S340-5. PMID: 19778862.
      Citations: 4     Fields:    Translation:Humans
    1447. Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A, Ravandi F, Ault P, Bueso-Ramos C, Cortes JE, Quint?s-Cardama A. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. 2009 Jan 01; 15(1):368-73. PMID: 19118067; PMCID: PMC4822510.
      Citations: 19     Fields:    Translation:HumansCells
    1448. Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S, Strom S, Freireich EJ, Medeiros LJ, Kantarjian HM, Keating MJ. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol. 2009 Feb 20; 27(6):904-10. PMID: 19114699; PMCID: PMC4979239.
      Citations: 71     Fields:    Translation:Humans
    1449. Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood. 2009 Feb 26; 113(9):1892-8. PMID: 19109226; PMCID: PMC2651008.
      Citations: 4     Fields:    Translation:HumansCells
    1450. Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, Yee K, Ravandi F, Giles F, Schuh A, Gupta V, Andreeff M, Koller C, Chang H, Kamel-Reid S, Berger M, Viallet J, Borthakur G. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res. 2008 Dec 15; 14(24):8295-301. PMID: 19088047.
      Citations: 85     Fields:    Translation:HumansCTClinical Trials
    1451. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009 Feb 01; 27(4):504-10. PMID: 19075265; PMCID: PMC4881307.
      Citations: 119     Fields:    Translation:Humans
    1452. Ma W, Kantarjian H, Zhang X, Yeh CH, Zhang ZJ, Verstovsek S, Albitar M. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn. 2009 Jan; 11(1):49-53. PMID: 19074595; PMCID: PMC2607565.
      Citations: 24     Fields:    Translation:HumansCells
    1453. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, Wierda WG, Faderl S, Garcia-Manero G, Verstovsek S, Rios MB, Cortes J. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood. 2009 Mar 05; 113(10):2154-60. PMID: 19060245; PMCID: PMC4081392.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    1454. Lee TS, Ma W, Zhang X, Giles F, Cortes J, Kantarjian H, Albitar M. BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Mol Cancer Ther. 2008 Dec; 7(12):3834-41. PMID: 19056677.
      Citations: 21     Fields:    Translation:HumansCells
    1455. Lin KI, Tam CS, Keating MJ, Wierda WG, O'Brien S, Lerner S, Coombes KR, Schlette E, Ferrajoli A, Barron LL, Kipps TJ, Rassenti L, Faderl S, Kantarjian H, Abruzzo LV. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood. 2009 Apr 02; 113(14):3168-71. PMID: 19050308; PMCID: PMC4916943.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    1456. Verstovsek S, Freireich E, Kantarjian H, Chen YW, Zingaro R, Quint?s-Cardama A. Chemical and clinical development of darinaparsin, a novel organic arsenic derivative. Anticancer Agents Med Chem. 2008 Dec; 8(8):904-9. PMID: 19075572.
      Citations: 5     Fields:    Translation:HumansAnimals
    1457. Mori S, Cortes J, Kantarjian H, Zhang W, Andreef M, Ravandi F. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma. 2008 Dec; 49(12):2246-55. PMID: 19052971; PMCID: PMC4086439.
      Citations: 27     Fields:    Translation:HumansCells
    1458. O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G, Kantarjian HM. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008 Dec 01; 113(11):3186-91. PMID: 18846563; PMCID: PMC4188532.
      Citations: 55     Fields:    Translation:Humans
    1459. Borthakur G, Kantarjian H, Wang X, Plunkett WK, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer. 2008 Dec 01; 113(11):3181-5. PMID: 18932257; PMCID: PMC4126078.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    1460. Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer. 2008 Nov 15; 113(10):2734-41. PMID: 18973182.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    1461. Jain N, Cortes J, Manshouri T, Luthra R, Garcia-Manero G, Kantarjian H, Verstovsek S, Quint?s-Cardama A. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res. 2009 Jun; 33(6):837-9. PMID: 19013640; PMCID: PMC4422052.
      Citations: 11     Fields:    Translation:Humans
    1462. Ye D, Garcia-Manero G, Kantarjian HM, Xiao L, Vadhan-Raj S, Fernandez MH, Nguyen MH, Medeiros LJ, Bueso-Ramos CE. Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. J Hematop. 2009 Mar; 2(1):2-8. PMID: 19669217; PMCID: PMC2713495.
      Citations: 17     
    1463. Kantarjian H. Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O]. Clin Adv Hematol Oncol. 2008 Nov; 6(11):797-9. PMID: 19194361.
      Citations:    Fields:    Translation:Humans
    1464. Sekeres MA, Schoonen WM, Kantarjian H, List A, Fryzek J, Paquette R, Maciejewski JP. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008 Nov 05; 100(21):1542-51. PMID: 18957672; PMCID: PMC2579314.
      Citations: 86     Fields:    Translation:Humans
    1465. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer. 2008 Oct 15; 113(8):2090-6. PMID: 18756533; PMCID: PMC4163782.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    1466. O'Brien S, Thomas DA, Ravandi F, Faderl S, Pierce S, Kantarjian H. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008 Oct 15; 113(8):2097-101. PMID: 18720356; PMCID: PMC4199453.
      Citations: 32     Fields:    Translation:Humans
    1467. Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, Coombes KR, Mills GB. Functional proteomic profiling of AML predicts response and survival. Blood. 2009 Jan 01; 113(1):154-64. PMID: 18840713; PMCID: PMC2951831.
      Citations: 132     Fields:    Translation:HumansCells
    1468. Kantarjian H, O'Brien S, Cortes J, Wierda W, Faderl S, Garcia-Manero G, Issa JP, Estey E, Keating M, Freireich EJ. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer. 2008 Oct 01; 113(7 Suppl):1933-52. PMID: 18798533; PMCID: PMC4392892.
      Citations: 36     Fields:    Translation:Humans
    1469. Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, Kurzrock R. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer. 2008 Oct 01; 113(7):1605-13. PMID: 18683214.
      Citations: 41     Fields:    Translation:Humans
    1470. Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S, Kantarjian HM, Estey E. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009 Jan 01; 113(1):28-36. PMID: 18827183; PMCID: PMC2614639.
      Citations: 59     Fields:    Translation:Humans
    1471. Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2008 Dec 15; 112(13):4839-42. PMID: 18818391; PMCID: PMC4186640.
      Citations: 23     Fields:    Translation:Humans
    1472. Jones D, Luthra R, Cortes J, Thomas D, O'Brien S, Bueso-Ramos C, Hai S, Ravandi F, de Lima M, Kantarjian H, Jorgensen JL. BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. Blood. 2008 Dec 15; 112(13):5190-2. PMID: 18809762; PMCID: PMC2597614.
      Citations: 14     Fields:    Translation:Humans
    1473. Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, List A, Fenaux P, Sanz G, Issa JP, Freireich EJ, Garcia-Manero G. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008 Sep 15; 113(6):1351-61. PMID: 18618511; PMCID: PMC4188533.
      Citations: 160     Fields:    Translation:HumansCells
    1474. Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J. The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 2008 Sep 15; 113(6):1338-43. PMID: 18629842.
      Citations: 2     Fields:    Translation:Humans
    1475. Tsimberidou AM, Kantarjian HM, Wen S, Keating MJ, O'Brien S, Brandt M, Pierce S, Freireich EJ, Medeiros LJ, Estey E. Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer. 2008 Sep 15; 113(6):1370-8. PMID: 18623376; PMCID: PMC2574728.
      Citations: 67     Fields:    Translation:HumansCTClinical Trials
    1476. Jones D, Thomas D, Yin CC, O'Brien S, Cortes JE, Jabbour E, Breeden M, Giles FJ, Zhao W, Kantarjian HM. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer. 2008 Sep 01; 113(5):985-94. PMID: 18615627; PMCID: PMC4204653.
      Citations: 48     Fields:    Translation:Humans
    1477. Yeh CH, Tseng R, Zhang Z, Cortes J, O'Brien S, Giles F, Hannah A, Estrov Z, Keating M, Kantarjian H, Albitar M. Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. Leuk Res. 2009 Feb; 33(2):212-7. PMID: 18715642; PMCID: PMC4163801.
      Citations: 9     Fields:    Translation:Humans
    1478. Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, Wierda W, Keating MJ, Kantarjian HM. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009 Jun 18; 113(25):6330-7. PMID: 18703706; PMCID: PMC2943753.
      Citations: 58     Fields:    Translation:Humans
    1479. Jabbour E, El Ahdab S, Cortes J, Kantarjian H. Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. Expert Opin Investig Drugs. 2008 Jul; 17(7):1127-36. PMID: 18549348.
      Citations: 3     Fields:    Translation:HumansAnimals
    1480. Verma D, Kantarjian H, Jain N, Cortes J. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. Leuk Lymphoma. 2008 Jul; 49(7):1399-402. PMID: 18452066.
      Citations: 8     Fields:    Translation:Humans
    1481. El Kinge AR, Hatoum HA, Mahfouz RA, Otrock ZK, Jabbour E, Kantarjian H, Bazarbachi A. Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia. Leuk Res. 2009 Apr; 33(4):565-6. PMID: 18571231.
      Citations: 1     Fields:    Translation:Humans
    1482. Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, Cortes JA, Champlin RE, Ciurea SE, Manshouri T, Pierce SM, Kantarjian HM, Verstovsek S. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood. 2008 Sep 01; 112(5):1628-37. PMID: 18566326; PMCID: PMC2518875.
      Citations: 56     Fields:    Translation:Humans
    1483. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008 Sep 01; 112(5):1638-45. PMID: 18565853; PMCID: PMC4081352.
      Citations: 67     Fields:    Translation:Humans
    1484. Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008 Jun 15; 14(12):3906-15. PMID: 18559612; PMCID: PMC5018899.
      Citations: 57     Fields:    Translation:HumansCellsCTClinical Trials
    1485. Garcia-Manero G, Stoltz ML, Ward MR, Kantarjian H, Sharma S. A pilot pharmacokinetic study of oral azacitidine. Leukemia. 2008 Sep; 22(9):1680-4. PMID: 18548103.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    1486. Shah NP, Kantarjian HM, Kim DW, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A, R?a D. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008 Jul 01; 26(19):3204-12. PMID: 18541900.
      Citations: 161     Fields:    Translation:HumansCTClinical Trials
    1487. Kroeger H, Jelinek J, He R, Kondo K, Chung W, Zhang L, Shen L, Kantarjian HM, Bueso-Ramos CE, Issa JP, Est?cio MR. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood. 2008 Aug 15; 112(4):1366-73. PMID: 18523155; PMCID: PMC2515110.
      Citations: 61     Fields:    Translation:HumansCells
    1488. Yanada M, Borthakur G, Ravandi F, Bueso-Ramos C, Kantarjian H, Estey E. Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. Haematologica. 2008 Aug; 93(8):1263-5. PMID: 18519513.
      Citations: 10     Fields:    Translation:Humans
    1489. Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008 Jun; 112(11):2341-51. PMID: 18398832; PMCID: PMC4784235.
      Citations: 84     Fields:    Translation:Humans
    1490. Manshouri T, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, Cortes JE, Kantarjian HM, Verstovsek S, Quint?s-Cardama A. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 2008 Jun; 99(6):1265-73. PMID: 18482053; PMCID: PMC4829954.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    1491. Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE, Minden M. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008 Aug 15; 112(4):981-9. PMID: 18495956; PMCID: PMC4081529.
      Citations: 102     Fields:    Translation:HumansCellsCTClinical Trials
    1492. Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F, Shan J, Cortes J. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood. 2008 Aug 01; 112(3):516-8. PMID: 18492956; PMCID: PMC4082324.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    1493. Jabbour E, Cortes JE, Kantarjian HM. Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. Cancer. 2008 May 15; 112(10):2112-8. PMID: 18348294; PMCID: PMC5141579.
      Citations: 14     Fields:    Translation:Humans
    1494. Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, Bornmann W, Kantarjian H, Viallet J, Samudio I, Andreeff M. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 2008 May 01; 68(9):3413-20. PMID: 18451169; PMCID: PMC4096127.
      Citations: 117     Fields:    Translation:HumansAnimalsCells
    1495. Samudio I, Kurinna S, Ruvolo P, Korchin B, Kantarjian H, Beran M, Dunner K, Kondo S, Andreeff M, Konopleva M. Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells. Mol Cancer Ther. 2008 May; 7(5):1130-9. PMID: 18483301; PMCID: PMC2396196.
      Citations: 27     Fields:    Translation:HumansCells
    1496. Lee TS, Potts SJ, Kantarjian H, Cortes J, Giles F, Albitar M. Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. Cancer. 2008 Apr 15; 112(8):1744-53. PMID: 18338744.
      Citations: 15     Fields:    Translation:HumansCells
    1497. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008 Aug 15; 112(4):975-80. PMID: 18411418; PMCID: PMC3952498.
      Citations: 247     Fields:    Translation:HumansCTClinical Trials
    1498. Tong W, Manshouri T, Vega F, Lennon PA, Cools J, Gilliland DG, Lee F, Cortes J, Kantarjian H, Garcia-Manero G, Quint?s-Cardama A. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia. 2008 Jun; 22(6):1117-24. PMID: 18401417.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    1499. Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Ezzeddine R, Countouriotis AM, Kantarjian HM, Hochhaus A, M?ller MC. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008 Jun; 22(6):1200-6. PMID: 18401416.
      Citations: 124     Fields:    Translation:Humans
    1500. Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Cortes J. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood. 2008 Jul 01; 112(1):53-5. PMID: 18403620; PMCID: PMC4081375.
      Citations: 41     Fields:    Translation:Humans
    1501. Yanada M, Borthakur G, Garcia-Manero G, Ravandi F, Faderl S, Pierce S, Kantarjian H, Estey E. Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia. Leuk Res. 2008 Oct; 32(10):1505-9. PMID: 18405972; PMCID: PMC4182927.
      Citations: 10     Fields:    Translation:Humans
    1502. Tong W, Kantarjian H, Thomas D, Ravandi F, Kornblau S, Manshouri T, Cortes JE, Garcia-Manero G, Verstovsek S, Quint?s-Cardama A. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia. 2008 May; 22(5):965-70. PMID: 18385750; PMCID: PMC4369783.
      Citations: 42     Fields:    Translation:HumansCellsCTClinical Trials
    1503. Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, Issa JP, Kantarjian H. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma. 2008 Apr; 49(4):690-5. PMID: 18398735; PMCID: PMC3702160.
      Citations: 38     Fields:    Translation:HumansCellsCTClinical Trials
    1504. Ma W, Kantarjian H, Zhang X, Sun W, Buller AM, Jilani I, Schwartz JG, Giles F, Albitar M. Higher detection rate of JAK2 mutation using plasma. Blood. 2008 Apr 01; 111(7):3906-7. PMID: 18362222.
      Citations: 9     Fields:    Translation:Humans
    1505. Yu Z, Sun B, Kantarjian HM, Keating MJ, Amin HM, Sun X. Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators. Leuk Lymphoma. 2008 Apr; 49(4):751-6. PMID: 18398743.
      Citations: 2     Fields:    Translation:HumansCells
    1506. Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E. Relapse and death during first remission in acute myeloid leukemia. Haematologica. 2008 Apr; 93(4):633-4. PMID: 18379012.
      Citations: 7     Fields:    Translation:Humans
    1507. Vega-Ruiz A, O'Brien S, Cortes J, Kebriaei P, Thomas D, Kantarjian H, Ravandi F. Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate. Leuk Res. 2008 Sep; 32(9):1468-71. PMID: 18355919; PMCID: PMC4086363.
      Citations:    Fields:    Translation:Humans
    1508. Ma W, Kantarjian H, O'Brien S, Jilani I, Zhang X, Estrov Z, Ferrajoli A, Keating M, Giles F, Albitar M. Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer. 2008 Mar 15; 112(6):1306-12. PMID: 18224667.
      Citations: 15     Fields:    Translation:HumansCells
    1509. Fabbri M, Garzon R, Andreeff M, Kantarjian HM, Garcia-Manero G, Calin GA. MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia. 2008 Jun; 22(6):1095-105. PMID: 18323801.
      Citations: 63     Fields:    Translation:Humans
    1510. Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R, Rosti G, Apperley JF. The effects of imatinib on pregnancy outcome. Blood. 2008 Jun 15; 111(12):5505-8. PMID: 18322153; PMCID: PMC4916938.
      Citations: 90     Fields:    Translation:Humans
    1511. Kantarjian H, Quint?s-Cardama A, Cort?s JE. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma. 2008 Mar; 8 Suppl 3:S82-8. PMID: 19254885.
      Citations: 8     Fields:    Translation:Humans
    1512. Faderl S, Gandhi V, Kantarjian HM. Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia. Curr Opin Hematol. 2008 Mar; 15(2):101-7. PMID: 18300755.
      Citations: 4     Fields:    Translation:Humans
    1513. Cortes J, Kantarjian H. Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia. J Natl Compr Canc Netw. 2008 Mar; 6 Suppl 2:S22-S30. PMID: 18397678.
      Citations: 5     Fields:    Translation:Humans
    1514. Kantarjian H, Cortes J. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices. J Natl Compr Canc Netw. 2008 Mar; 6 Suppl 2:S37-42; quiz S43-S44. PMID: 18397680.
      Citations: 3     Fields:    Translation:Humans
    1515. Tefferi A, Kantarjian H. Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement. Am J Hematol. 2008 Mar; 83(3):175-7. PMID: 18181199.
      Citations:    Fields:    Translation:Humans
    1516. Jabbour E, Kantarjian H, Cort?s JE. Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules. Clin Lymphoma Myeloma. 2008 Mar; 8 Suppl 3:S75-81. PMID: 19254884.
      Citations:    Fields:    Translation:HumansCells
    1517. Jabbour E, Kantarjian HM, Koller C, Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer. 2008 Mar 01; 112(5):1089-95. PMID: 18186499.
      Citations: 11     Fields:    Translation:Humans
    1518. Gibbons DL, Kantarjian H, Talpaz M, Donato N, Cortes J, Quint?s-Cardama A. Sequencing of subcloned PCR products facilitates earlier detection of BCR-ABL1(T315I) and other mutants compared to direct sequencing of the ABL1 kinase domain. Leukemia. 2008 Apr; 22(4):885-8. PMID: 18305550.
      Citations: 1     Fields:    Translation:Humans
    1519. Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008 Feb 15; 112(4):837-45. PMID: 18085610.
      Citations: 41     Fields:    Translation:HumansCells
    1520. Tsimberidou AM, Kantarjian HM, Wen S, O'Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ, Keating MJ, Estey EH. The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients. Clin Cancer Res. 2008 Feb 01; 14(3):721-30. PMID: 18245532.
      Citations: 22     Fields:    Translation:Humans
    1521. Verstovsek S, Manshouri T, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z, Quint?s-Cardama A. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res. 2008 Feb 01; 14(3):788-96. PMID: 18245540.
      Citations: 31     Fields:    Translation:HumansCells
    1522. Kurzrock R, Kantarjian HM, Blascovich MA, Bucher C, Verstovsek S, Wright JJ, Pilat SR, Cortes JE, Estey EH, Giles FJ, Beran M, Sebti SM. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. Clin Cancer Res. 2008 Jan 15; 14(2):509-14. PMID: 18223226.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    1523. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, Flomenberg N, Marcucci G, Calin GA, Kornblau SM, Kantarjian H, Bloomfield CD, Andreeff M, Croce CM. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008 Mar 15; 111(6):3183-9. PMID: 18187662; PMCID: PMC2265455.
      Citations: 285     Fields:    Translation:HumansCells
    1524. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10; 26(2):196-203. PMID: 18182662.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    1525. Jilani I, Wei C, Bekele BN, Zhang ZJ, Keating M, Wierda W, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien SM, Giles FJ, Albitar M. Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int J Lab Hematol. 2009 Feb; 31(1):97-105. PMID: 18190591; PMCID: PMC4163781.
      Citations: 10     Fields:    Translation:Humans
    1526. Jin L, Tabe Y, Konoplev S, Xu Y, Leysath CE, Lu H, Kimura S, Ohsaka A, Rios MB, Calvert L, Kantarjian H, Andreeff M, Konopleva M. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther. 2008 Jan; 7(1):48-58. PMID: 18202009.
      Citations: 77     Fields:    Translation:HumansCells
    1527. Jabbour E, Cortes JE, Ghanem H, O'Brien S, Kantarjian HM. Targeted therapy in chronic myeloid leukemia. Expert Rev Anticancer Ther. 2008 Jan; 8(1):99-110. PMID: 18095887.
      Citations: 17     Fields:    Translation:Humans
    1528. Jilani I, Kantarjian H, Faraji H, Gorre M, Cortes J, Ottmann O, Bhalla K, O'Brien S, Giles F, Albitar M. An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. Leuk Res. 2008 Jun; 32(6):936-43. PMID: 18155764.
      Citations: 4     Fields:    Translation:HumansCells
    1529. Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E. Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission. Cancer. 2007 Dec 15; 110(12):2756-60. PMID: 17948909.
      Citations: 9     Fields:    Translation:Humans
    1530. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, Huang X, Kantarjian H. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008 Mar; 22(3):538-43. PMID: 18079733.
      Citations: 101     Fields:    Translation:Humans
    1531. Atallah E, Nussenzveig R, Yin CC, Bueso-Ramos C, Tam C, Manshouri T, Pierce S, Kantarjian H, Verstovsek S. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. Leukemia. 2008 Jun; 22(6):1295-8. PMID: 18059483.
      Citations: 11     Fields:    Translation:Humans
    1532. Kantarjian HM. Purine Nucleosidase Phosphorylase (PNP): A novel target in leukemias and lymphomas. Semin Oncol. 2007 Dec; 34(6 Suppl 5):S1-2. PMID: 18086341.
      Citations:    Fields:    Translation:Humans
    1533. Borthakur G, Lin E, Faderl S, Ferrajoli A, Wierda W, Giles F, Browning ML, Kantarjian H, Keating M, O'Brien S. Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies. Cancer. 2007 Dec 01; 110(11):2478-83. PMID: 17960607.
      Citations: 2     Fields:    Translation:HumansCells
    1534. Kantarjian H, Verstovsek S, Quint?s-Cardama A. Treatment of systemic mastocytosis with denileukin diftitox. Am J Hematol. 2007 Dec; 82(12):1124. PMID: 17665501.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    1535. Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W, Estrov Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res. 2007 Dec 01; 67(23):11291-9. PMID: 18056455.
      Citations: 63     Fields:    Translation:HumansCells
    1536. Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JP. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood. 2008 Feb 15; 111(4):2382-4. PMID: 18055864; PMCID: PMC2234065.
      Citations: 32     Fields:    Translation:HumansCellsCTClinical Trials
    1537. Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood. 2008 Feb 15; 111(4):1774-80. PMID: 18055868.
      Citations: 45     Fields:    Translation:Humans
    1538. Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, Kwong YL, Baccarani M, Hughes T, Martinelli G, Radich JP, Zheng M, Shou Y, Kantarjian H, le Coutre P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008 Feb 15; 111(4):1834-9. PMID: 18048643.
      Citations: 82     Fields:    Translation:HumansCTClinical Trials
    1539. O'Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, O'Neal B, Kantarjian H, Keating M. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008 Feb 15; 111(4):1816-9. PMID: 18039954.
      Citations: 23     Fields:    Translation:HumansCells
    1540. Cortes J, Garcia-Manero G, O'Brien S, Jones D, Faderl S, Ebarb T, Giles F, Thomas D, Kantarjian H, Quint?s-Cardama A. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer. 2007 Nov 01; 110(9):2000-6. PMID: 17849425.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    1541. Jabbour E, Cortes J, Giles F, Kantarjian H. Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment. Cancer J. 2007 Nov-Dec; 13(6):357-65. PMID: 18032972.
      Citations: 2     Fields:    Translation:Humans
    1542. Bareng J, Jilani I, Gorre M, Kantarjian H, Giles F, Hannah A, Albitar M. A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry. Leuk Lymphoma. 2007 Nov; 48(11):2189-95. PMID: 17926180.
      Citations: 12     Fields:    Translation:HumansCells
    1543. Ravandi F, Burnett AK, Agura ED, Kantarjian HM. Progress in the treatment of acute myeloid leukemia. Cancer. 2007 Nov 01; 110(9):1900-10. PMID: 17786921.
      Citations: 29     Fields:    Translation:Humans
    1544. Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Richie MA, Beran M, Giles F, Verstovsek S. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer. 2007 Nov 01; 110(9):2012-8. PMID: 17849460.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    1545. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008 Feb 01; 111(3):1060-6. PMID: 17962510.
      Citations: 198     Fields:    Translation:HumansCellsCTClinical Trials
    1546. Gibbons DL, Cortes J, Bobadilla D, Slovak ML, Kantarjian H, Abruzzo LV, Quint?s-Cardama A. Association of 3q21q26 syndrome and late-appearing Philadelphia chromosome in acute myeloid leukemia. Leukemia. 2008 Apr; 22(4):877-8. PMID: 17928880.
      Citations: 1     Fields:    Translation:HumansCells
    1547. Kantarjian H, Cortes J, Quint?s-Cardama A. Tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med. 2007 Oct 11; 357(15):1557; author reply 1557-8. PMID: 17933034.
      Citations: 4     Fields:    Translation:Humans
    1548. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Gambacorti C, Stone RM, Goldman J, Fischer T, O'Brien SG, Reiffers JJ, Mone M, Krahnke T, Talpaz M, Kantarjian HM. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood. 2008 Feb 01; 111(3):1039-43. PMID: 17932248.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    1549. Tsimberidou AM, Wen S, O'Brien S, McLaughlin P, Wierda WG, Ferrajoli A, Faderl S, Manning J, Lerner S, Mai CV, Rodriguez AM, Hess M, Do KA, Freireich EJ, Kantarjian HM, Medeiros LJ, Keating MJ. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2007 Oct 10; 25(29):4648-56. PMID: 17925562.
      Citations: 21     Fields:    Translation:Humans
    1550. Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S. Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct; 48(10):1922-30. PMID: 17852710.
      Citations: 25     Fields:    Translation:HumansAnimals
    1551. Kantarjian H, Cortes J, Quint?s-Cardama A. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov. 2007 Oct; 6(10):834-48. PMID: 17853901.
      Citations: 91     Fields:    Translation:HumansAnimalsCells
    1552. Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M, Stone R, Fischer T, Kantarjian H, Niederwieser D, Gambacorti-Passerini C, So C, Gathmann I, Goldman JM, Smith D, Druker BJ, Guilhot F. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer. 2007 Oct 01; 110(7):1509-19. PMID: 17702093.
      Citations: 34     Fields:    Translation:Humans
    1553. Tam CS, O'Brien S, Lerner S, Khouri I, Ferrajoli A, Faderl S, Browning M, Tsimberidou AM, Kantarjian H, Wierda WG. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma. 2007 Oct; 48(10):1931-9. PMID: 17917961.
      Citations: 27     Fields:    Translation:Humans
    1554. Jilani I, Kantarjian H, Gorre M, Cortes J, Ottmann O, Bhalla K, Giles FJ, Albitar M. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy. Leuk Res. 2008 Apr; 32(4):643-9. PMID: 17900686.
      Citations: 7     Fields:    Translation:HumansCells
    1555. Cortes J, Jabbour E, Daley GQ, O'Brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P, Kantarjian H. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer. 2007 Sep 15; 110(6):1295-302. PMID: 17623836.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    1556. Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N, Wierda WG, Jones D. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007 Dec 01; 110(12):4005-11. PMID: 17785585.
      Citations: 89     Fields:    Translation:HumansCells
    1557. Kantarjian H, O'brien S, Borthakur G, Bruzzi J, Munden R, Cortes J, Quint?s-Cardama A. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007 Sep 01; 25(25):3908-14. PMID: 17761974.
      Citations: 114     Fields:    Translation:HumansCTClinical Trials
    1558. Kalac M, Vrhovac R, Kantarjian H, Verstovsek S, Quint?s-Cardama A. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer. 2007 Sep 01; 110(5):955-64. PMID: 17654661.
      Citations: 6     Fields:    Translation:HumansCells
    1559. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007 Nov 15; 110(10):3540-6. PMID: 17715389.
      Citations: 220     Fields:    Translation:HumansCTClinical Trials
    1560. Kantarjian H, Abruzzo LV, Cortes J, Quint?s-Cardama A. Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy. Leukemia. 2007 Nov; 21(11):2394-6. PMID: 17690707.
      Citations: 3     Fields:    Translation:Humans
    1561. Atallah E, Cortes J, O'Brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ, Kantarjian H. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood. 2007 Nov 15; 110(10):3547-51. PMID: 17673605.
      Citations: 33     Fields:    Translation:Humans
    1562. Radomska H, Chang JS, Konopleva M, Kobayashi S, Levantini E, Suh N, Di Ruscio A, Voso MT, Watt JC, Santhanam R, Kantarjian H, Andreeff M, Sporn MB, Perrotti D, Berdel WE, Serve H, Tenen DG, Koschmieder S, D'Al? F, Sch?neich C, Sargin B, M?ller-Tidow C. CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood. 2007 Nov 15; 110(10):3695-705. PMID: 17671235; PMCID: PMC2077317.
      Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
    1563. Torres HA, Aguilera EA, Mattiuzzi GN, Cabanillas ME, Rohatgi N, Sepulveda CA, Kantarjian HM, Jiang Y, Safdar A, Raad II, Chemaly RF. Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia. Haematologica. 2007 Sep; 92(9):1216-23. PMID: 17666367.
      Citations: 20     Fields:    Translation:HumansCells
    1564. Plimack ER, Kantarjian HM, Issa JP. Decitabine and its role in the treatment of hematopoietic malignancies. Leuk Lymphoma. 2007 Aug; 48(8):1472-81. PMID: 17701577.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    1565. Jabbour E, Cortes J, Kantarjian H, Giralt S, Andersson BS, Giles F, Shpall E, Kebriaei P, Champlin R, de Lima M. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer. 2007 Jul 15; 110(2):340-4. PMID: 17559140.
      Citations: 16     Fields:    Translation:Humans
    1566. Jabbour E, Kantarjian HM, Abruzzo LV, O'Brien S, Garcia-Manero G, Verstovsek S, Shan J, Rios MB, Cortes J. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2007 Oct 15; 110(8):2991-5. PMID: 17625066.
      Citations: 35     Fields:    Translation:Humans
    1567. Singer JB, Shou Y, Giles F, Kantarjian HM, Hsu Y, Robeva AS, Rae P, Weitzman A, Meyer JM, Dugan M, Ottmann OG. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia. 2007 Nov; 21(11):2311-5. PMID: 17611564.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    1568. Thomas DA, O'Brien S, Cortes J, Kantarjian H. New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia. Curr Hematol Malig Rep. 2007 Jul; 2(3):183-9. PMID: 20425368.
      Citations: 1     Fields:    Translation:Humans
    1569. Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi F. Biphenotypic acute leukaemia: a case series. Br J Haematol. 2007 Jul; 138(2):213-6. PMID: 17593028.
      Citations: 15     Fields:    Translation:Humans
    1570. Ravandi F, Faderl S, Kebriaei P, Kantarjian H. Modern treatment programs for adults with acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2007 Jul; 2(3):169-75. PMID: 20425366.
      Citations:    Fields:    Translation:HumansCells
    1571. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007 Oct 01; 110(7):2302-8. PMID: 17596541.
      Citations: 146     Fields:    Translation:HumansCellsCTClinical Trials
    1572. Yanada M, Huang X, Garcia-Manero G, O'brien S, Ravandi F, Borthakur G, Faderl S, Issa JP, Kantarjian H, Estey E. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome. Br J Haematol. 2007 Aug; 138(4):555-7. PMID: 17593249.
      Citations: 1     Fields:    Translation:Humans
    1573. Sun X, Zhang W, Ramdas L, Stivers DN, Jones DM, Kantarjian HM, Estey EH, Vadhan-Raj S, Medeiros LJ, Bueso-Ramos CE. Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping. Mod Pathol. 2007 Aug; 20(8):811-20. PMID: 17571080.
      Citations: 9     Fields:    Translation:HumansCells
    1574. Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. Current and emerging treatment options in chronic myeloid leukemia. Cancer. 2007 Jun 01; 109(11):2171-81. PMID: 17431887.
      Citations: 30     Fields:    Translation:Humans
    1575. Beran M, Wen S, Shen Y, Onida F, Jelinek J, Cortes J, Giles F, Kantarjian H. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma. 2007 Jun; 48(6):1150-60. PMID: 17577778.
      Citations: 19     Fields:    Translation:Humans
    1576. Pan J, Manshouri T, Cortes J, Kantarjian H, Verstovsek S, Quint?s-Cardama A. Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406. Cancer Sci. 2007 Aug; 98(8):1223-5. PMID: 17517053.
      Citations: 3     Fields:    Translation:HumansCells
    1577. Pan J, Manshouri T, Giles FJ, Lamb P, Tefferi A, Cortes J, Kantarjian H, Verstovsek S, Quint?s-Cardama A. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia. 2007 Jul; 21(7):1395-404. PMID: 17495975.
      Citations: 14     Fields:    Translation:HumansCells
    1578. Mughal T, Cortes J, Cross NC, Donato N, Hantschel O, Jabbour E, Kantarjian H, Melo JV, Skorski T, Silver RT, Goldman JM. Chronic myeloid leukemia--some topical issues. Leukemia. 2007 Jul; 21(7):1347-52. PMID: 17495971.
      Citations: 3     Fields:    Translation:Humans
    1579. Kantarjian H, Giles F, List A, Lyons R, Sekeres MA, Pierce S, Deuson R, Leveque J. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007 May 01; 109(9):1705-14. PMID: 17366593.
      Citations: 59     Fields:    Translation:Humans
    1580. Jabbour E, Cortes J, Kantarjian H. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. Expert Opin Investig Drugs. 2007 May; 16(5):679-87. PMID: 17461740.
      Citations: 11     Fields:    Translation:HumansAnimals
    1581. Jabbour E, Cortes J, Kantarjian H. Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs? Oncology (Williston Park). 2007 May; 21(6):653-62; discussion 663-4, 667-8. PMID: 17564324.
      Citations: 1     Fields:    Translation:Humans
    1582. Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007 Aug 15; 110(4):1233-7. PMID: 17449798.
      Citations: 65     Fields:    Translation:Humans
    1583. Kantarjian H, O'Brien S, Talpaz M, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Rios MB, Shan J, Giles F, Cortes J. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer. 2007 Apr 15; 109(8):1556-60. PMID: 17342766.
      Citations: 29     Fields:    Translation:Humans
    1584. Soupir CP, Vergilio JA, Dal Cin P, Muzikansky A, Kantarjian H, Jones D, Hasserjian RP. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol. 2007 Apr; 127(4):642-50. PMID: 17369142.
      Citations: 46     Fields:    Translation:Humans
    1585. Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, Faderl SH, Laddie NM, Garcia-Manero G, Cortes JE. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer. 2007 Apr 01; 109(7):1355-9. PMID: 17326049.
      Citations: 25     Fields:    Translation:Humans
    1586. Kantarjian HM, Cortes J, Hochhaus A, Baccarani M, Lokey L, Guilhot F. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns. Cancer. 2007 Apr 01; 109(7):1365-75. PMID: 17326047.
      Citations: 10     Fields:    Translation:Humans
    1587. Kantarjian H, Cortes J, Quint?s-Cardama A. The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia. Leuk Lymphoma. 2007 Apr; 48(4):802-4. PMID: 17454640.
      Citations:    Fields:    Translation:HumansCells
    1588. Kantarjian HM. Therapy for elderly patients with acute myeloid leukemia: a problem in search of solutions. Cancer. 2007 Mar 15; 109(6):1007-10. PMID: 17279580.
      Citations: 8     Fields:    Translation:Humans
    1589. Konoplev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X, Xiao L, Andreeff M, Konopleva M, Medeiros LJ. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer. 2007 Mar 15; 109(6):1152-6. PMID: 17315232.
      Citations: 66     Fields:    Translation:Humans
    1590. Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE, Issa JP. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007 Mar 15; 109(6):1133-7. PMID: 17315156; PMCID: PMC2952542.
      Citations: 60     Fields:    Translation:Humans
    1591. Jabbour E, Kantarjian H, Cortes J. Clinical activity of tipifarnib in hematologic malignancies. Expert Opin Investig Drugs. 2007 Mar; 16(3):381-92. PMID: 17302532.
      Citations: 3     Fields:    Translation:HumansAnimals
    1592. Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'brien S, Verstovsek S, Cortes J, Morris GM, Garcia-Manero G, Issa JP. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer. 2007 Mar 01; 109(5):899-906. PMID: 17236224.
      Citations: 42     Fields:    Translation:HumansCellsCTClinical Trials
    1593. Heidel F, Cortes J, Aulitzky W, Letvak L, Kindler T, Huber C, Kantarjian H, Fischer T, R?cker FG, D?hner H. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. Cancer. 2007 Mar 01; 109(5):907-14. PMID: 17285599.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    1594. Borthakur G, O'Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, Kantarjian HM, Lerner S, Keating MJ. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. Br J Haematol. 2007 Mar; 136(6):800-5. PMID: 17341265.
      Citations: 23     Fields:    Translation:Humans
    1595. Jabbour E, Cortes J, O'Brien S, Rios MB, Giles F, Kantarjian H. Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. Clin Lymphoma Myeloma. 2007 Mar; 7 Suppl 2:S51-7. PMID: 17382013.
      Citations:    Fields:    Translation:Humans
    1596. Atallah E, Kantarjian H, Cortes J. Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. Clin Lymphoma Myeloma. 2007 Mar; 7 Suppl 3:S105-12. PMID: 17382019.
      Citations: 6     Fields:    Translation:Humans
    1597. Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K, Estey E, Kantarjian H, Garcia-Manero G, Issa JP. RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res. 2007 Mar 01; 67(5):1997-2005. PMID: 17332327.
      Citations: 35     Fields:    Translation:HumansCells
    1598. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, Hellmann A, Zaritsky A, Golenkov A, Radich J, Hughes T, Countouriotis A, Shah N. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007 Jun 15; 109(12):5143-50. PMID: 17317857.
      Citations: 107     Fields:    Translation:HumansCTClinical Trials
    1599. Aribi A, Borthakur G, Ravandi F, Shan J, Davisson J, Cortes J, Kantarjian H. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer. 2007 Feb 15; 109(4):713-7. PMID: 17219444.
      Citations: 47     Fields:    Translation:Humans
    1600. Kantarjian HM, Giles F, Cortes J, Quint?s-Cardama A. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res. 2007 Feb 15; 13(4):1089-97. PMID: 17317816.
      Citations: 27     Fields:    Translation:Humans
    1601. Chemaly RF, Torres HA, Aguilera EA, Mattiuzzi G, Cabanillas M, Kantarjian H, Gonzalez V, Safdar A, Raad II. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis. 2007 Apr 01; 44(7):964-7. PMID: 17342649.
      Citations: 19     Fields:    Translation:Humans
    1602. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007 Jun 01; 109(11):4679-85. PMID: 17299097.
      Citations: 119     Fields:    Translation:Humans
    1603. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian H. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007 Feb; 136(4):624-7. PMID: 17223919.
      Citations: 90     Fields:    Translation:Humans
    1604. Kantarjian HM. Recent experience with decitabine in MDS. Clin Adv Hematol Oncol. 2007 Feb; 5(2):140. PMID: 17344803.
      Citations: 2     Fields:    Translation:Humans
    1605. Ma W, Tseng R, Gorre M, Jilani I, Keating M, Kantarjian H, Cortes J, O'Brien S, Giles F, Albitar M. Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia. Haematologica. 2007 Feb; 92(2):170-5. PMID: 17296565.
      Citations: 6     Fields:    Translation:HumansCells
    1606. Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Giles F, Thomas D, Wierda W, Cortes J, Quint?s-Cardama A. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma. 2007 Feb; 48(2):283-9. PMID: 17325887.
      Citations: 8     Fields:    Translation:Humans
    1607. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer. 2007 Feb; 7(2):118-29. PMID: 17251918.
      Citations: 131     Fields:    Translation:HumansCells
    1608. Safdar A, Rodriguez G, Rolston KV, O'Brien S, Khouri IF, Shpall EJ, Keating MJ, Kantarjian HM, Champlin RE, Raad II, Kontoyiannis DP. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Feb; 39(3):157-64. PMID: 17245424.
      Citations: 15     Fields:    Translation:Humans
    1609. Jeha S, Kantarjian H. Clofarabine for the treatment of acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2007 Feb; 7(2):113-8. PMID: 17288522.
      Citations: 11     Fields:    Translation:HumansAnimals
    1610. Raza A, Mufti GJ, Aul C, Germing U, Kantarjian H, Cripe L, De Porre P, Kurzrock R, Fenaux P, Kerstens R. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood. 2007 May 15; 109(10):4158-63. PMID: 17264294.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    1611. Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007 Jan 15; 109(2):265-73. PMID: 17133405.
      Citations: 43     Fields:    Translation:HumansCells
    1612. Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J, Quint?s-Cardama A. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 2007 Jan 15; 109(2):248-55. PMID: 17154172.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    1613. Albitar M, Johnson M, Do KA, Day A, Jilani I, Pierce S, Estey E, Kantarjian H, Keating M, Verstovsek S, O'brien S, Giles FJ. Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy. Leukemia. 2007 Mar; 21(3):480-8. PMID: 17215857.
      Citations: 6     Fields:    Translation:Humans
    1614. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, Levine R, Le Bousse-Kerdiles MC, Wadleigh M, Campbell PJ, Silver RT, Vannucchi AM, Deeg HJ, Gisslinger H, Thomas D, Odenike O, Solberg LA, Gotlib J, Hexner E, Nimer SD, Kantarjian H, Orazi A, Vardiman JW, Thiele J, Tefferi A, International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007 Jun; 31(6):737-40. PMID: 17210175.
      Citations: 85     Fields:    Translation:Humans
    1615. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007 Apr 15; 109(8):3214-8. PMID: 17209054.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    1616. Jabbour E, Cortes J, O'Brien S, Giles F, Kantarjian H. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hematol. 2007 Jan; 44(1 Suppl 1):S25-31. PMID: 17292738.
      Citations: 7     Fields:    Translation:Humans
    1617. Alvarez RH, Kantarjian H, Cortes JE. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol. 2007 Jan; 44(1 Suppl 1):S4-14. PMID: 17292736.
      Citations: 12     Fields:    Translation:Humans
    1618. Atallah E, Kantarjian H, Cortes J. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med. 2007 Jan; 13(1):14; author reply 15-6. PMID: 17206119.
      Citations: 8     Fields:    Translation:Humans
    1619. Jabbour E, Kantarjian H. Introduction: chronic myelogenous leukemia (CML). Semin Hematol. 2007 Jan; 44(1 Suppl 1):S1-3. PMID: 17292735.
      Citations: 5     Fields:    Translation:Humans
    1620. Atallah E, Kantarjian H, Garcia-Manero G. The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opin Pharmacother. 2007 Jan; 8(1):65-73. PMID: 17163808.
      Citations: 8     Fields:    Translation:HumansCells
    1621. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006 Dec 19; 145(12):913-23. PMID: 17179059.
      Citations: 73     Fields:    Translation:Humans
    1622. Druker BJ, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, IRIS Investigators, Guilhot F. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 Dec 07; 355(23):2408-17. PMID: 17151364.
      Citations: 1171     Fields:    Translation:Humans
    1623. Ravandi F, Jilani I, Estey E, Kantarjian H, Dey A, Aguilar C, Jitkaroon C, Giles F, O'Brien S, Keating M, Albitar M. Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML). Leuk Res. 2007 Jun; 31(6):791-7. PMID: 17156841.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    1624. Giles F, Rizzieri D, Karp J, Vey N, Ravandi F, Faderl S, Khan KD, Verhoef G, Wijermans P, Advani A, Roboz G, Kantarjian H, Bilgrami SF, Ferrant A, Daenen SM, Karsten V, Cahill A, Albitar M, Mufti G, O'Brien S. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol. 2007 Jan 01; 25(1):25-31. PMID: 17146105.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    1625. Roboz GJ, Giles FJ, Ritchie EK, Allen-Bard S, Curcio TJ, Wilkes MA, Park SL, Kantarjian HM, Faderl S, Ravandi F, Kelner MJ, Feldman EJ. Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia. J Clin Oncol. 2007 Jan 01; 25(1):10-5. PMID: 17146106.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    1626. Kantarjian H, Cortes J, Quint?s-Cardama A. Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib. Future Oncol. 2006 Dec; 2(6):655-65. PMID: 17155893.
      Citations: 5     Fields:    Translation:Humans
    1627. Verstovsek S, Kantarjian H, Tefferi A, Quint?s-Cardama A. Experimental therapy in myelofibrosis with myeloid metaplasia. Expert Opin Investig Drugs. 2006 Dec; 15(12):1555-63. PMID: 17107281.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    1628. Ahmed B, Estey E, Manning J, David C, Keating MJ, Kantarjian H, Tsimberidou AM. Anaplastic large cell lymphoma with involvement of the pancreas presenting as panniculitis in a patient with a history of acute myeloid leukemia--case report and review of the literature. Haematologica. 2006 Dec; 91(12 Suppl):ECR55. PMID: 17194661.
      Citations: 3     Fields:    Translation:Humans
    1629. Verstovsek S, Giles F, Perez N, Ravandi-Kashani F, Beran M, Freireich E, Kantarjian H, Quint?s-Cardama A. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia? Hematol Oncol. 2006 Dec; 24(4):181-8. PMID: 16783836.
      Citations: 21     Fields:    Translation:Humans
    1630. Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP, Hochhaus A. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007 Mar 15; 109(6):2303-9. PMID: 17138817.
      Citations: 173     Fields:    Translation:HumansCTClinical Trials
    1631. Han X, Garcia-Manero G, McDonnell TJ, Lozano G, Medeiros LJ, Xiao L, Rosner G, Nguyen M, Fernandez M, Valentin-Vega YA, Barboza J, Jones DM, Rassidakis GZ, Kantarjian HM, Bueso-Ramos CE. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol. 2007 Jan; 20(1):54-62. PMID: 17143258.
      Citations: 25     Fields:    Translation:HumansCells
    1632. Vaklavas C, Tefferi A, Butterfield J, Ketterling R, Verstovsek S, Kantarjian H, Pardanani A. 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leuk Res. 2007 May; 31(5):691-4. PMID: 17095087.
      Citations: 12     Fields:    Translation:HumansCells
    1633. Tsimberidou AM, Kantarjian H, Keating MJ, Estey E. Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide? Leuk Lymphoma. 2006 Nov; 47(11):2282-8. PMID: 17107899.
      Citations: 4     Fields:    Translation:Humans
    1634. Zhao W, Claxton DF, Medeiros LJ, Lu D, Vadhan-Raj S, Kantarjian HM, Nguyen MH, Bueso-Ramos CE. Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22). Am J Surg Pathol. 2006 Nov; 30(11):1436-44. PMID: 17063086.
      Citations: 2     Fields:    Translation:HumansCells
    1635. Jabbour E, Cortes J, Kantarjian H. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr Opin Oncol. 2006 Nov; 18(6):578-83. PMID: 16988578.
      Citations: 4     Fields:    Translation:Humans
    1636. Alvarez RH, Kantarjian HM, Cortes JE. The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer. 2006 Oct 15; 107(8):1918-29. PMID: 16986126.
      Citations: 45     Fields:    Translation:HumansCells
    1637. Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, Giralt S. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007 Feb 15; 109(4):1395-400. PMID: 17038533.
      Citations: 87     Fields:    Translation:Humans
    1638. Aribi A, Huh Y, Keating M, O'brien S, Ferrajoli A, Faderl S, Wierda W, Kantarjian H, Ravandi F. T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. Leuk Res. 2007 Jul; 31(7):939-45. PMID: 17045649.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    1639. Quintas-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Giles F, Ravandi F, Faderl S, Pierce S, Shan J, Verstovsek S, Cortes J. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer. 2006 Oct 01; 107(7):1525-9. PMID: 16955510.
      Citations: 5     Fields:    Translation:HumansAnimalsCTClinical Trials
    1640. Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S. Novel approaches in the treatment of systemic mastocytosis. Cancer. 2006 Oct 01; 107(7):1429-39. PMID: 16948123.
      Citations: 12     Fields:    Translation:Humans
    1641. Thomas DA, Ravandi F, Kantarjian H. Monoclonal antibody therapy for hairy cell leukemia. Hematol Oncol Clin North Am. 2006 Oct; 20(5):1125-36. PMID: 16990112.
      Citations: 3     Fields:    Translation:Humans
    1642. Jilani I, Keating M, Day A, William W, Kantarjian H, O'brien S, Giles FJ, Albitar M. Simplified sensitive method for the detection of B-cell clonality in lymphoid malignancies. Clin Lab Haematol. 2006 Oct; 28(5):325-31. PMID: 16999724.
      Citations: 8     Fields:    Translation:HumansCells
    1643. Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, Giles F, Talpaz M, Cortes J. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood. 2007 Jan 15; 109(2):497-9. PMID: 16990591.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    1644. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood. 2007 Jan 15; 109(2):500-2. PMID: 16990603.
      Citations: 93     Fields:    Translation:HumansCells
    1645. Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE, Keating MJ. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer. 2006 Sep 15; 107(6):1294-302. PMID: 16902984.
      Citations: 28     Fields:    Translation:Humans
    1646. Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc. 2006 Sep; 81(9):1241-57. PMID: 16970222.
      Citations: 99     Fields:    Translation:HumansCells
    1647. Chen W, Rassidakis GZ, Li J, Routbort M, Jones D, Kantarjian H, Medeiros LJ, Bueso-Ramos CE. High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations ("cuplike" nuclei). Blood. 2006 Sep 01; 108(5):1783-4. PMID: 16926303.
      Citations: 6     Fields:    Translation:HumansCells
    1648. Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P. Dasatinib. Nat Rev Drug Discov. 2006 Sep; 5(9):717-8. PMID: 17001803.
      Citations: 45     Fields:    Translation:HumansCells
    1649. Arana-Yi C, Giles F, Thomas D, Carrasco-Yalan A, Cortes J, Kantarjian H, Verstovsek S, Quint?s-Cardama A. Advances in the therapy of chronic idiopathic myelofibrosis. Oncologist. 2006 Sep; 11(8):929-43. PMID: 16951397.
      Citations: 5     Fields:    Translation:Humans
    1650. Onciu M, Schlette E, Zhou Y, Raimondi SC, Giles FJ, Kantarjian HM, Medeiros LJ, Ribeiro RC, Pui CH, Sandlund JT. Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma. Cancer. 2006 Sep 01; 107(5):1084-92. PMID: 16862570.
      Citations: 10     Fields:    Translation:Humans
    1651. Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML, Gundacker HM, Kim HT, Dewald GW, Kantarjian HM, Pierce SR, Estey EH. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol. 2006 Oct; 135(2):165-73. PMID: 16939487.
      Citations: 81     Fields:    Translation:Humans
    1652. Ma W, Kantarjian H, Jilani I, Gorre M, Bhalla K, Ottmann O, Giles F, Albitar M. Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA. Leukemia. 2006 Nov; 20(11):1989-91. PMID: 16932346.
      Citations: 4     Fields:    Translation:Humans
    1653. Pan J, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ, Verstovsek S, Quint?s-Cardama A. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood. 2007 Jan 01; 109(1):315-22. PMID: 16912224.
      Citations: 23     Fields:    Translation:HumansCells
    1654. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006 Aug 01; 12(15):4628-35. PMID: 16899611.
      Citations: 121     Fields:    Translation:HumansCTClinical Trials
    1655. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9. PMID: 16882711; PMCID: PMC1895437.
      Citations: 180     Fields:    Translation:HumansCellsCTClinical Trials
    1656. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 01; 109(1):52-7. PMID: 16882708.
      Citations: 243     Fields:    Translation:HumansCells
    1657. Oki Y, Jelinek J, Beran M, Verstovsek S, Kantarjian HM, Issa JP. Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica. 2006 Aug; 91(8):1147-8. PMID: 16870548.
      Citations: 8     Fields:    Translation:HumansCells
    1658. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006 Oct; 20(10):1767-73. PMID: 16855631.
      Citations: 120     Fields:    Translation:HumansCells
    1659. Levis M, Brown P, Smith BD, Stine A, Pham R, Stone R, Deangelo D, Galinsky I, Giles F, Estey E, Kantarjian H, Cohen P, Wang Y, Roesel J, Karp JE, Small D. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006 Nov 15; 108(10):3477-83. PMID: 16857987; PMCID: PMC1895426.
      Citations: 97     Fields:    Translation:HumansCells
    1660. Sheikholeslami MR, Jilani I, Keating M, Uyeji J, Chen K, Kantarjian H, O'Brien S, Giles F, Albitar M. Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis. Cytometry B Clin Cytom. 2006 Jul 15; 70(4):270-5. PMID: 16906585.
      Citations: 6     Fields:    Translation:HumansCells
    1661. Faderl S, Ferrajoli A, Harris D, Van Q, Kantarjian HM, Estrov Z. Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk Res. 2007 Jan; 31(1):91-5. PMID: 16828865.
      Citations: 18     Fields:    Translation:HumansCells
    1662. Orsolic N, Golemovic M, Scappini B, Manshouri T, Chandra J, Basic I, Giles F, Kantarjian H, Verstovsek S, Quint?s-Cardama A. Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Cancer Sci. 2006 Sep; 97(9):952-60. PMID: 16822295.
      Citations: 7     Fields:    Translation:HumansCells
    1663. Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006 Jul 01; 107(1):125-35. PMID: 16700034.
      Citations: 20     Fields:    Translation:Humans
    1664. Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W, Ferrajoli A, Kornblau S, Jabbour E, Shan J, O'brien S, Albitar M, Kantarjian H. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol. 2006 Jul; 134(1):58-60. PMID: 16803568.
      Citations: 6     Fields:    Translation:Humans
    1665. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 2006 Jul 01; 66(13):6468-72. PMID: 16818614.
      Citations: 67     Fields:    Translation:HumansAnimalsCells
    1666. Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood. 2006 Oct 15; 108(8):2811-3. PMID: 16809614.
      Citations: 38     Fields:    Translation:Humans
    1667. Verstovsek S, Akin C, Manshouri T, Huynh L, Manley P, Tefferi A, Cortes J, Giles FJ, Kantarjian H, Quint?s-Cardama A. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res. 2006 Nov; 30(11):1365-70. PMID: 16797704.
      Citations: 18     Fields:    Translation:HumansCells
    1668. Abruzzo LV, Giles FJ, Jorgensen J, Cortes J, Sarriera JE, Kantarjian H, Verstovsek S, Quint?s-Cardama A. A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome. Leukemia. 2006 Sep; 20(9):1638-40. PMID: 16791272.
      Citations:    Fields:    Translation:Humans
    1669. Ma W, Kantarjian H, Verstovsek S, Jilani I, Gorre M, Giles F, Cortes J, O'Brien S, Keating M, Albitar M. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour. Br J Haematol. 2006 Aug; 134(3):341-3. PMID: 16787500.
      Citations: 2     Fields:    Translation:Humans
    1670. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15; 354(24):2542-51. PMID: 16775235.
      Citations: 382     Fields:    Translation:HumansCTClinical Trials
    1671. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15; 354(24):2531-41. PMID: 16775234.
      Citations: 553     Fields:    Translation:HumansCTClinical Trials
    1672. Safdar A, Rodriguez GH, Lichtiger B, Dickey BF, Kontoyiannis DP, Freireich EJ, Shpall EJ, Raad II, Kantarjian HM, Champlin RE. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer. 2006 Jun 15; 106(12):2664-71. PMID: 16691620.
      Citations: 20     Fields:    Translation:HumansCells
    1673. Tsimberidou AM, Tirado-Gomez M, Andreeff M, O'Brien S, Kantarjian H, Keating M, Lopez-Berestein G, Estey E. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leuk Lymphoma. 2006 Jun; 47(6):1062-8. PMID: 16840198.
      Citations: 17     Fields:    Translation:Humans
    1674. Razzouk BI, Estey E, Pounds S, Lensing S, Pierce S, Brandt M, Rubnitz JE, Ribeiro RC, Rytting M, Pui CH, Kantarjian H, Jeha S. Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. Cancer. 2006 Jun 01; 106(11):2495-502. PMID: 16639734.
      Citations: 20     Fields:    Translation:Humans
    1675. Kantarjian HM, Giles F, Verstovsek S, Quint?s-Cardama A. Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. Semin Thromb Hemost. 2006 Jun; 32(4 Pt 2):409-16. PMID: 16810616.
      Citations: 4     Fields:    Translation:HumansCells
    1676. Ma W, Jilani I, Gorre M, Keating M, Chan H, Tseng R, Kantarjian H, O'Brien S, Giles FJ, Albitar M. Plasma as a source of mRNA for determining IgV(H) mutation status in patients with chronic lymphocytic leukaemia. Br J Haematol. 2006 Jun; 133(6):690-2. PMID: 16704448.
      Citations: 1     Fields:    Translation:HumansCells
    1677. Tsimberidou AM, Estey E, Kantarjian H, Keating MJ, Pierce S, Garcia-Manero G. Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia. Leukemia. 2006 Aug; 20(8):1452-3. PMID: 16728980.
      Citations: 2     Fields:    Translation:HumansCells
    1678. Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, Wen S, Do KA, Smith SC, Lerner S, Freireich EJ, Keating MJ. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006 May 20; 24(15):2343-51. PMID: 16710033.
      Citations: 70     Fields:    Translation:Humans
    1679. Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R, European LeukemiaNet, Baccarani M, Guilhot F. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006 Sep 15; 108(6):1809-20. PMID: 16709930.
      Citations: 308     Fields:    Translation:HumansCells
    1680. Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006 Sep 15; 108(6):1835-40. PMID: 16709931.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    1681. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, Kantarjian HM, Garcia-Manero G, Issa JP. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res. 2006 May 15; 66(10):5495-503. PMID: 16707479.
      Citations: 114     Fields:    Translation:HumansCells
    1682. Hock BD, McKenzie JL, Patton NW, Drayson M, Taylor K, Wakeman C, Kantarjian H, Giles F, Albitar M. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer. 2006 May 15; 106(10):2148-57. PMID: 16598754.
      Citations: 15     Fields:    Translation:Humans
    1683. Verstovsek S, Giles FJ, Manshouri T, Huynh L, Manley P, Cortes J, Tefferi A, Kantarjian H, Quint?s-Cardama A. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res. 2006 Dec; 30(12):1499-505. PMID: 16682077.
      Citations: 13     Fields:    Translation:HumansCells
    1684. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg LA, Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NC, Gilliland DG, Kantarjian H, IWG for Myelofibrosis Research and Treatment (IWG-MRT). International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006 Sep 01; 108(5):1497-503. PMID: 16675707.
      Citations: 116     Fields:    Translation:Humans
    1685. Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'Brien SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer. 2006 May 01; 106(9):1974-84. PMID: 16583431.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    1686. Kantarjian HM, Cortes J. New strategies in chronic myeloid leukemia. Int J Hematol. 2006 May; 83(4):289-93. PMID: 16757426.
      Citations: 9     Fields:    Translation:Humans
    1687. Yin CC, Cortes J, Barkoh B, Hayes K, Kantarjian H, Jones D. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy. Cancer. 2006 Apr 15; 106(8):1730-8. PMID: 16532439.
      Citations: 12     Fields:    Translation:HumansCells
    1688. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R, Shen L, Nimer SD, Leavitt R, Raza A, Saba H. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006 Apr 15; 106(8):1794-803. PMID: 16532500.
      Citations: 524     Fields:    Translation:HumansCellsCTClinical Trials
    1689. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006 Aug 15; 108(4):1158-64. PMID: 16609064.
      Citations: 67     Fields:    Translation:HumansCTClinical Trials
    1690. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006 Jul 15; 108(2):419-25. PMID: 16609072.
      Citations: 504     Fields:    Translation:Humans
    1691. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, de Lima M. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006 Aug 15; 108(4):1421-3. PMID: 16601247.
      Citations: 29     Fields:    Translation:Humans
    1692. Albitar M, Potts SJ, Giles FJ, O'Brien S, Keating M, Thomas D, Clarke C, Jilani I, Aguilar C, Estey E, Kantarjian H. Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia. Cancer. 2006 Apr 01; 106(7):1587-94. PMID: 16518825.
      Citations: 11     Fields:    Translation:Humans
    1693. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 01; 106(7):1569-80. PMID: 16502413.
      Citations: 156     Fields:    Translation:HumansCTClinical Trials
    1694. Giles F, Verstovsek S, Faderl S, Vey N, Karp J, Roboz G, Khan KD, Cooper M, Bilgrami SF, Ferrant A, Daenen S, Karsten V, Cahill A, Albitar M, Kantarjian H, O'Brien S, Feldman E. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leuk Res. 2006 Dec; 30(12):1591-5. PMID: 16574225.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    1695. Koller C, Bekele BN, Zhou X, Park C, Estrov Z, O'Brien S, Keating M, Jilani I, Giles FJ, Kantarjian HM, Albitar M. Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia. Blood. 2006 Aug 01; 108(3):1001-6. PMID: 16551975.
      Citations: 4     Fields:    Translation:Humans
    1696. Albitar M, Vose JM, Johnson MM, Do KA, Day A, Jilani I, Kantarjian H, Keating M, O'Brien SM, Verstovsek S, Armitage JO, Giles FJ. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease. Leuk Res. 2007 Feb; 31(2):139-45. PMID: 16545870.
      Citations: 11     Fields:    Translation:Humans
    1697. Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Rios MB, Shan J, Kantarjian HM. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006 Mar 15; 106(6):1306-15. PMID: 16463391.
      Citations: 25     Fields:    Translation:Humans
    1698. Beran M, Shen Y, Onida F, Wen S, Kantarjian H, Estey E. Prognostic significance of monocytosis in patients with myeloproliferative disorders. Leuk Lymphoma. 2006 Mar; 47(3):417-23. PMID: 16396764.
      Citations: 5     Fields:    Translation:HumansCells
    1699. Kantarjian H, Beran M, Cortes J, O'Brien S, Giles F, Pierce S, Shan J, Plunkett W, Keating M, Estey E. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer. 2006 Mar 01; 106(5):1099-109. PMID: 16435387.
      Citations: 26     Fields:    Translation:Humans
    1700. Kantarjian H, O'brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006 Mar 01; 106(5):1090-8. PMID: 16435386.
      Citations: 203     Fields:    Translation:Humans
    1701. Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006 Jun 15; 107(12):4658-62. PMID: 16497968.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    1702. Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clin Proc. 2006 Feb; 81(2):247-60. PMID: 16471082.
      Citations: 31     Fields:    Translation:Humans
    1703. Tsimberidou AM, Giles FJ, Estey E, O'Brien S, Keating MJ, Kantarjian HM. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol. 2006 Feb; 132(4):398-409. PMID: 16412015.
      Citations: 16     Fields:    Translation:HumansCells
    1704. Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M, Cortes J. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2006 Mar 01; 24(7):1204-8. PMID: 16446320.
      Citations: 53     Fields:    Translation:HumansCells
    1705. Wierda W, O'brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer. 2006 Jan 15; 106(2):337-45. PMID: 16353201.
      Citations: 16     Fields:    Translation:Humans
    1706. Borthakur G, Kantarjian H, Daley G, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Faderl S, Sugrue M, Cortes J. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer. 2006 Jan 15; 106(2):346-52. PMID: 16342165.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    1707. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006 Jul 01; 108(1):45-51. PMID: 16403905.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    1708. Thomas DA, Sarris AH, Cortes J, Faderl S, O'Brien S, Giles FJ, Garcia-Manero G, Rodriguez MA, Cabanillas F, Kantarjian H. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer. 2006 Jan 01; 106(1):120-7. PMID: 16331634.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    1709. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006 May 01; 107(9):3469-73. PMID: 16373661.
      Citations: 114     Fields:    Translation:HumansCTClinical Trials
    1710. Yee KW, Jabbour E, Kantarjian HM, Giles FJ. Clinical experience with decitabine in North American patients with myelodysplastic syndrome. Ann Hematol. 2005 Dec; 84 Suppl 1:18-24. PMID: 16273408.
      Citations: 2     Fields:    Translation:Humans
    1711. Kantarjian H. Trends in the management of chronic myelogenous leukemia. J Natl Compr Canc Netw. 2005 Nov; 3 Suppl 1:S41-5. PMID: 16280112.
      Citations:    Fields:    Translation:Humans
    1712. Giles FJ, Cortes JE, Kantarjian HM. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. Curr Mol Med. 2005 Nov; 5(7):615-23. PMID: 16305488.
      Citations: 10     Fields:    Translation:Humans
    1713. Merzianu M, Medeiros LJ, Cortes J, Yin C, Lin P, Jones D, Glassman A, Kantarjian H, Huh Y. inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases. Am J Clin Pathol. 2005 Nov; 124(5):807-14. PMID: 16203287.
      Citations: 10     Fields:    Translation:HumansCells
    1714. Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res. 2005 Nov 01; 11(21):7817-24. PMID: 16278404.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    1715. Jabbour EJ, Faderl S, Kantarjian HM. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2005 Nov; 80(11):1517-27. PMID: 16295033.
      Citations: 24     Fields:    Translation:Humans
    1716. Ravandi F, O'Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, Wierda W, Garcia-Manero G, Thomas D, Koller C, Verstovsek S, Giles F, Cortes J, Herling M, Kantarjian H, Keating M. T-cell prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2005 Nov; 6(3):234-9. PMID: 16354329.
      Citations: 12     Fields:    Translation:HumansCells
    1717. Ravandi F, Kantarjian H, Jones D, Dearden C, Keating M, O'Brien S. Mature T-cell leukemias. Cancer. 2005 Nov 01; 104(9):1808-18. PMID: 16136598.
      Citations: 6     Fields:    Translation:HumansCells
    1718. Gao H, Lee BN, Talpaz M, Donato NJ, Cortes JE, Kantarjian HM, Reuben JM. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia. 2005 Nov; 19(11):1905-11. PMID: 16151467.
      Citations: 23     Fields:    Translation:HumansCells
    1719. Jabbour E, Kantarjian H, O'Brien S, Rios MB, Abruzzo L, Verstovsek S, Garcia-Manero G, Cortes J. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood. 2006 Jan 15; 107(2):480-2. PMID: 16195326.
      Citations: 17     Fields:    Translation:Humans
    1720. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2005 Sep 15; 11(18):6615-24. PMID: 16166440.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    1721. Verstovsek S, Golemovic M, Kantarjian H, Manshouri T, Estrov Z, Manley P, Sun T, Arlinghaus RB, Alland L, Dugan M, Cortes J, Giles F, Beran M. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer. 2005 Sep 15; 104(6):1230-6. PMID: 16078266.
      Citations: 14     Fields:    Translation:HumansCells
    1722. Patel SP, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovek S, Kantarjian H, Estey E. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia. Leuk Res. 2006 Mar; 30(3):362-3. PMID: 16168477.
      Citations: 3     Fields:    Translation:Humans
    1723. Cortes J, Kantarjian H. New targeted approaches in chronic myeloid leukemia. J Clin Oncol. 2005 Sep 10; 23(26):6316-24. PMID: 16155014.
      Citations: 2     Fields:    Translation:Humans
    1724. Amin HM, Yang Y, Shen Y, Estey EH, Giles FJ, Pierce SA, Kantarjian HM, O'Brien SM, Jilani I, Albitar M. Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias. Leukemia. 2005 Sep; 19(9):1567-72. PMID: 16049515.
      Citations: 9     Fields:    Translation:Humans
    1725. Talpaz M, Rakhit A, Rittweger K, O'Brien S, Cortes J, Fettner S, Hooftman L, Kantarjian H. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin Cancer Res. 2005 Sep 01; 11(17):6247-55. PMID: 16144928.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    1726. Gandhi V, Kilpatrick JM, Plunkett W, Ayres M, Harman L, Du M, Bantia S, Davisson J, Wierda WG, Faderl S, Kantarjian H, Thomas D. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. 2005 Dec 15; 106(13):4253-60. PMID: 16131572; PMCID: PMC1895256.
      Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
    1727. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood. 2006 Feb 01; 107(3):880-4. PMID: 16123215.
      Citations: 23     Fields:    Translation:HumansCells
    1728. Faderl S, Do KA, Johnson MM, Keating M, O'brien S, Jilani I, Ferrajoli A, Ravandi-Kashani F, Aguilar C, Dey A, Thomas DA, Giles FJ, Kantarjian HM, Albitar M. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood. 2005 Dec 15; 106(13):4303-7. PMID: 16123221.
      Citations: 16     Fields:    Translation:Humans
    1729. Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Faderl S, Wierda W, Rios MB, Shan J, Cortes J. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer. 2005 Aug 15; 104(4):777-80. PMID: 15971197.
      Citations: 1     Fields:    Translation:Humans
    1730. Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer. 2005 Aug 01; 104(3):541-6. PMID: 15977212.
      Citations: 4     Fields:    Translation:Humans
    1731. Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005 Aug 01; 104(3):547-54. PMID: 15973664.
      Citations: 23     Fields:    Translation:Humans
    1732. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005 Nov 15; 106(10):3370-3. PMID: 16037387; PMCID: PMC1895065.
      Citations: 104     Fields:    Translation:Humans
    1733. Kantarjian HM, Issa JP. Decitabine dosing schedules. Semin Hematol. 2005 Jul; 42(3 Suppl 2):S17-22. PMID: 16015500.
      Citations: 11     Fields:    Translation:Humans
    1734. Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, Dugan M, Alland L, Griffin JD, Arlinghaus RB, Sun T, Kantarjian H, Beran M, Mestan J. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005 Jul 01; 11(13):4941-7. PMID: 16000593.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    1735. Issa JP, Kantarjian HM. Introduction: emerging role of epigenetic therapy: focus on decitabine. Semin Hematol. 2005 Jul; 42(3 Suppl 2):S1-2. PMID: 16015499.
      Citations: 6     Fields:    Translation:Humans
    1736. Faderl S, Kantarjian HM. Drug insight: emerging new drugs in the treatment of myelodysplastic syndromes. Nat Clin Pract Oncol. 2005 Jul; 2(7):348-55. PMID: 16075794.
      Citations:    Fields:    Translation:Humans
    1737. Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Rios MB, Shan J, Cortes J. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leuk Lymphoma. 2005 Jul; 46(7):993-7. PMID: 16019549.
      Citations: 4     Fields:    Translation:Humans
    1738. Saba R, Jabbour E, Giles F, Cortes J, Talpaz M, O'Brien S, Freireich EJ, Garcia-Manero G, Kantarjian H, Verstovsek S. Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. Cancer. 2005 Jun 15; 103(12):2551-7. PMID: 15861412.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    1739. Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian HM. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. Cancer. 2005 May 15; 103(10):1985-95. PMID: 15803490.
      Citations: 22     Fields:    Translation:Humans
    1740. Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Shan J, Rios MB, Champlin R, de Lima M, Cortes J. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. Cancer. 2005 May 15; 103(10):2099-108. PMID: 15830345.
      Citations: 25     Fields:    Translation:Humans
    1741. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005 Jun 10; 23(17):3948-56. PMID: 15883410.
      Citations: 88     Fields:    Translation:HumansCellsCTClinical Trials
    1742. Issa JP, Kantarjian H. Azacitidine. Nat Rev Drug Discov. 2005 05; Suppl:S6-7. PMID: 15962522.
      Citations: 19     Fields:    Translation:HumansCells
    1743. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005 May 01; 11(9):3425-32. PMID: 15867244.
      Citations: 93     Fields:    Translation:HumansCTClinical Trials
    1744. Bueso-Ramos C, Xu Y, McDonnell TJ, Brisbay S, Pierce S, Kantarjian H, Rosner G, Garcia-Manero G. Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. J Clin Oncol. 2005 Jun 10; 23(17):3932-9. PMID: 15851765.
      Citations: 11     Fields:    Translation:HumansCells
    1745. Issa JP, Kantarjian HM, Kirkpatrick P. Azacitidine. Nat Rev Drug Discov. 2005 Apr; 4(4):275-6. PMID: 15861567.
      Citations: 47     Fields:    Translation:HumansCells
    1746. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res. 2005 Jun; 29(6):649-52. PMID: 15863204.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    1747. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad II. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005 Apr 15; 191(8):1350-60. PMID: 15776383.
      Citations: 172     Fields:    Translation:HumansAnimals
    1748. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20; 23(18):4070-8. PMID: 15767647.
      Citations: 131     Fields:    Translation:Humans
    1749. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20; 23(18):4079-88. PMID: 15767648.
      Citations: 264     Fields:    Translation:HumansCTClinical Trials
    1750. Tefferi A, Dewald GW, Litzow ML, Cortes J, Mauro MJ, Talpaz M, Kantarjian HM. Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. Mayo Clin Proc. 2005 Mar; 80(3):390-402. PMID: 15757021.
      Citations: 6     Fields:    Translation:HumansCells
    1751. Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol. 2005 Apr 20; 23(12):2805-12. PMID: 15728224.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    1752. Canalli AA, Yang H, Jeha S, Hoshino K, Sanchez-Gonzalez B, Brandt M, Pierce S, Kantarjian H, Issa JP, Garcia-Manero G. Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. Leuk Res. 2005 Aug; 29(8):881-5. PMID: 15978938.
      Citations: 5     Fields:    Translation:HumansCells
    1753. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res. 2005 Jul; 29(7):739-48. PMID: 15927669.
      Citations: 55     Fields:    Translation:HumansCells
    1754. Estey E, Koller C, Tsimberidou AM, O'Brien S, Beran M, Cortes J, Tirado-Gomez M, Lopez-Berestein G, Kantarjian H. Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid. Blood. 2005 Feb 01; 105(3):1366-7. PMID: 15659618.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    1755. Patel HS, Kantarjian HM, Bueso-Ramos CE, Medeiros LJ, Haidar MA. Frequent deletions at 12q14.3 chromosomal locus in adult acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2005 Jan; 42(1):87-94. PMID: 15495192.
      Citations: 3     Fields:    Translation:HumansCells
    1756. Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, Camitta B, Pui CH. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005 Jan; 19(1):34-8. PMID: 15510203.
      Citations: 33     Fields:    Translation:Humans
    1757. Hennessy BT, Thomas DA, Giles FJ, Kantarjian H, Verstovsek S. New approaches in the treatment of myelofibrosis. Cancer. 2005 Jan 01; 103(1):32-43. PMID: 15565565.
      Citations: 3     Fields:    Translation:Humans
    1758. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004 Dec 15; 101(12):2788-801. PMID: 15481055.
      Citations: 176     Fields:    Translation:HumansCTClinical Trials
    1759. Jilani I, Keating M, Giles FJ, O'Brien S, Kantarjian HM, Albitar M. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. Leuk Res. 2004 Dec; 28(12):1255-62. PMID: 15475065.
      Citations: 4     Fields:    Translation:Humans
    1760. Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Rios MB, Hayes K, Glassman A, Bekele BN, Zhou X, Cortes J. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood. 2005 Mar 15; 105(6):2281-6. PMID: 15572595.
      Citations: 21     Fields:    Translation:HumansCellsCTClinical Trials
    1761. Hennessy B, Giles F, Cortes J, O'brien S, Ferrajoli A, Ossa G, Garcia-Manero G, Faderl S, Kantarjian H, Verstovsek S. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. Am J Hematol. 2004 Nov; 77(3):209-14. PMID: 15495258.
      Citations: 9     Fields:    Translation:Humans
    1762. Sun X, Amin HM, Freireich EJ, Keating MJ, Kantarjian HM, Koller CA, O'Brien SM, Giles F, Albitar M. Hairy cell leukemia with large cells: long disease course with adequate response to therapy. Leukemia. 2004 Nov; 18(11):1912-4. PMID: 15385931.
      Citations:    Fields:    Translation:Humans
    1763. Jabbour E, Kantarjian H, Cortes J. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk Lymphoma. 2004 Nov; 45(11):2187-95. PMID: 15512806.
      Citations: 5     Fields:    Translation:HumansCells
    1764. Konopleva M, Tsao T, Estrov Z, Lee RM, Wang RY, Jackson CE, McQueen T, Monaco G, Munsell M, Belmont J, Kantarjian H, Sporn MB, Andreeff M. The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res. 2004 Nov 01; 64(21):7927-35. PMID: 15520199.
      Citations: 55     Fields:    Translation:HumansCells
    1765. Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb 01; 105(3):940-7. PMID: 15486072.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    1766. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood. 2004 Oct 01; 104(7):2204-5. PMID: 15377577.
      Citations: 79     Fields:    Translation:Humans
    1767. Cooper T, Kantarjian H, Plunkett W, Gandhi V. Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. Nucleosides Nucleotides Nucleic Acids. 2004 Oct; 23(8-9):1417-23. PMID: 15571270.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    1768. Hachem RY, Kontoyiannis DP, Boktour MR, Afif C, Cooksley C, Bodey GP, Chatzinikolaou I, Perego C, Kantarjian HM, Raad II. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer. 2004 Oct 01; 101(7):1594-600. PMID: 15378491.
      Citations: 28     Fields:    Translation:HumansAnimals
    1769. Tsimberidou AM, Estey E, Whitman GJ, Dryden MJ, Ratnam S, Pierce S, Faderl S, Giles F, Kantarjian HM, Garcia-Manero G. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res. 2004 Sep; 28(9):991-4. PMID: 15234578.
      Citations: 8     Fields:    Translation:Humans
    1770. Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O'Brien S, Cortes J, Thomas D, Rassenti LZ, Kipps TJ, Kantarjian HM, Keating M. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004 Sep 01; 101(5):999-1008. PMID: 15329909.
      Citations: 25     Fields:    Translation:HumansCells
    1771. Hanna H, Benjamin R, Chatzinikolaou I, Alakech B, Richardson D, Mansfield P, Dvorak T, Munsell MF, Darouiche R, Kantarjian H, Raad I. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J Clin Oncol. 2004 Aug 01; 22(15):3163-71. PMID: 15284269.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    1772. Bueso-Ramos CE, Cortes J, Talpaz M, O'Brien S, Giles F, Rios MB, Medeiros LJ, Kantarjian H. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer. 2004 Jul 15; 101(2):332-6. PMID: 15241831.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    1773. Faderl S, Kantarjian HM. Novel therapies for myelodysplastic syndromes. Cancer. 2004 Jul 15; 101(2):226-41. PMID: 15241818.
      Citations: 12     Fields:    Translation:Humans
    1774. Esmaeli B, Diba R, Ahmadi MA, Saadati HG, Faustina MM, Shepler TR, Talpaz M, Fraunfelder R, Rios MB, Kantarjian H. Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec). Eye (Lond). 2004 Jul; 18(7):760-2. PMID: 14739914.
      Citations: 6     Fields:    Translation:Humans
    1775. Verstovsek S, Giles FJ, O'Brien S, Faderl S, Kantarjian HM, Keating MJ, Albitar M. Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia. Leuk Res. 2004 Jul; 28(7):707-11. PMID: 15158092.
      Citations: 2     Fields:    Translation:HumansCells
    1776. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-Zeichner L. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004 Jul 15; 39(2):199-205. PMID: 15307029.
      Citations: 171     Fields:    Translation:Humans
    1777. Quintas-Cardama A, Kantarjian H, O'Brien S, Garcia-Manero G, Rios MB, Talpaz M, Cortes J. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer. 2004 Jun 15; 100(12):2592-7. PMID: 15197801.
      Citations: 11     Fields:    Translation:Humans
    1778. Tsimberidou AM, Keating MJ, Giles FJ, Wierda WG, Ferrajoli A, Lerner S, Beran M, Andreeff M, Kantarjian HM, O'Brien S. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer. 2004 Jun 15; 100(12):2583-91. PMID: 15197800.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    1779. Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, Faderl S, Thomas D, Garcia-Manero G, Rios MB, Shan J, Jones D, Talpaz M. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004 Oct 01; 104(7):1979-88. PMID: 15198956.
      Citations: 31     Fields:    Translation:HumansCells
    1780. Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ, Kantarjian H. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004 Sep 15; 104(6):1624-30. PMID: 15178574.
      Citations: 82     Fields:    Translation:HumansCTClinical Trials
    1781. Ault P, Kantarjian H, Welch MA, Giles F, Rios MB, Cortes J. Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia. Leuk Res. 2004 Jun; 28(6):613-8. PMID: 15120938.
      Citations: 3     Fields:    Translation:Humans
    1782. Cortes J, O'Brien S, Quintas A, Giles F, Shan J, Rios MB, Talpaz M, Kantarjian H. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer. 2004 Jun 01; 100(11):2396-402. PMID: 15160343.
      Citations: 9     Fields:    Translation:Humans
    1783. Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, Bierman PJ, O'Brien SM, Kantarjian HM, Armitage JO, Albitar M. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res. 2004 Jun; 28(6):595-604. PMID: 15120936.
      Citations: 15     Fields:    Translation:HumansCells
    1784. Tsimberidou AM, Medina J, Cortes J, Rios A, Bonnie G, Faderl S, Kantarjian H, Garcia-Manero G. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leuk Res. 2004 Jun; 28(6):657-60. PMID: 15120945.
      Citations: 4     Fields:    Translation:Humans
    1785. Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM. Accelerated and blastic phases of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004 Jun; 18(3):753-74, xii. PMID: 15271404.
      Citations: 12     Fields:    Translation:HumansCells
    1786. Cortes JE, O'Brien SM, Giles F, Alvarez RH, Talpaz M, Kantarjian HM. Investigational strategies in chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004 Jun; 18(3):619-39, ix. PMID: 15271396.
      Citations: 1     Fields:    Translation:HumansCells
    1787. Beran M, Luthra R, Kantarjian H, Estey E. FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype. Leuk Res. 2004 Jun; 28(6):547-50. PMID: 15120929.
      Citations: 14     Fields:    Translation:HumansCells
    1788. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, Ruiz SL, Patel G, Guerciolini R, Wright J, Kantarjian H. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 2004 May 15; 10(10):3371-6. PMID: 15161691.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    1789. Cortes J, Kantarjian H. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders. Cancer. 2004 May 15; 100(10):2064-78. PMID: 15139047.
      Citations: 5     Fields:    Translation:HumansCells
    1790. Sanders KE, Ha CS, Cortes-Franco JE, Koller CA, Kantarjian HM, Cox JD. The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia. Cancer. 2004 May 15; 100(10):2176-80. PMID: 15139061.
      Citations: 12     Fields:    Translation:Humans
    1791. Giles F, Thomas D, Garcia-Manero G, Faderl S, Cortes J, Verstovsek S, Ferrajoli A, Jeha S, Beran M, Koller C, Andreeff M, Cahill A, Clairmont C, Sznol M, Kantarjian H. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res. 2004 May 01; 10(9):2908-17. PMID: 15131024.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    1792. Hu Q, Dey AL, Yang Y, Shen Y, Jilani IB, Estey EH, Kantarjian HM, Giles FJ, Albitar M. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer. 2004 May 01; 100(9):1884-91. PMID: 15112269.
      Citations: 20     Fields:    Translation:Humans
    1793. Tsao AS, Kantarjian H, Thomas D, Giles F, Cortes J, Garcia-Manero G, Huh Y, Yang Y, Shen Y, Albitar M, Estey E. C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. Leuk Res. 2004 Apr; 28(4):373-8. PMID: 15109537.
      Citations: 6     Fields:    Translation:Humans
    1794. Giles FJ, Kantarjian H, Cortes J. Novel therapies for patients with chronic myeloid leukemia. Expert Rev Anticancer Ther. 2004 Apr; 4(2):271-82. PMID: 15056057.
      Citations:    Fields:    Translation:HumansAnimalsCells
    1795. Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM, Estey E, Beran M. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia. Leuk Res. 2004 Apr; 28(4):353-7. PMID: 15109534.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    1796. Giles FJ, Tallman MS, Garcia-Manero G, Cortes JE, Thomas DA, Wierda WG, Verstovsek S, Hamilton M, Barrett E, Albitar M, Kantarjian HM. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer. 2004 Apr 01; 100(7):1449-58. PMID: 15042679.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    1797. El-Zimaity MM, Kantarjian H, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Verstovsek S, Thomas D, Ferrajoli A, Hayes K, Nebiyou Bekele B, Zhou X, Rios MB, Glassman AB, Cortes JE. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol. 2004 Apr; 125(2):187-95. PMID: 15059141.
      Citations: 31     Fields:    Translation:HumansCells
    1798. Scappini B, Gatto S, Onida F, Ricci C, Divoky V, Wierda WG, Andreeff M, Dong L, Hayes K, Verstovsek S, Kantarjian HM, Beran M. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer. 2004 Apr 01; 100(7):1459-71. PMID: 15042680.
      Citations: 17     Fields:    Translation:HumansCells
    1799. Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, De Porre P, Kantarjian HM. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol. 2004 Apr 01; 22(7):1287-92. PMID: 15051776.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    1800. Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O'Brien SM. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer. 2004 Mar 15; 100(6):1179-85. PMID: 15022284.
      Citations: 70     Fields:    Translation:Humans
    1801. Raad I, Hachem R, Hanna H, Afif C, Escalante C, Kantarjian H, Rolston K. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother. 2004 Apr; 53(4):646-9. PMID: 14998986.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    1802. Orsolic N, Giles FJ, Gourdeau H, Golemovic M, Beran M, Cortes J, Freireich EJ, Kantarjian H, Verstovsek S. Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation. Br J Haematol. 2004 Mar; 124(6):727-38. PMID: 15009060.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    1803. Kantarjian H, Cortes J. Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group. Leukemia. 2004 Mar; 18(3):650. PMID: 14737079.
      Citations: 1     Fields:    Translation:Humans
    1804. Bueso-Ramos CE, Rocha FC, Shishodia S, Medeiros LJ, Kantarjian HM, Vadhan-Raj S, Estrov Z, Smith TL, Nguyen MH, Aggarwal BB. Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. Hum Pathol. 2004 Feb; 35(2):246-53. PMID: 14991544.
      Citations: 21     Fields:    Translation:Humans
    1805. Ravandi F, Kantarjian H, Giles F, Cortes J. New agents in acute myeloid leukemia and other myeloid disorders. Cancer. 2004 Feb 01; 100(3):441-54. PMID: 14745859.
      Citations: 9     Fields:    Translation:Humans
    1806. Mattiuzzi GN, Kantarjian H, O'Brien S, Kontoyiannis DP, Giles F, Zhou X, Lim J, Bekele BN, Faderl S, Cortes J, Pierce S, Leitz GJ, Raad I, Estey E. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004 Feb 01; 100(3):568-73. PMID: 14745874.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    1807. Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, Kontoyiannis D, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004 Feb 01; 100(3):581-9. PMID: 14745876.
      Citations: 10     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    1808. Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, Shishodia S, Albitar M, Hayes K, Kantarjian H, Talpaz M, Shishodin S. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 2004 Jan 15; 64(2):672-7. PMID: 14744784.
      Citations: 70     Fields:    Translation:HumansCells
    1809. Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM, Dauses T, Allebach J, Small D. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004 May 15; 103(10):3669-76. PMID: 14726387.
      Citations: 215     Fields:    Translation:HumansCellsCTClinical Trials
    1810. Sneed TB, Kantarjian HM, Talpaz M, O'Brien S, Rios MB, Bekele BN, Zhou X, Resta D, Wierda W, Faderl S, Giles F, Cortes JE. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. 2004 Jan 01; 100(1):116-21. PMID: 14692031.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    1811. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, Cooper M, Hannah A, Garcia-Manero G, Faderl S, Kantarjian H, Cherrington J, Albitar M, Giles FJ. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):88-95. PMID: 14734456.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    1812. Kantarjian H, O'Brien S, Cortes J, Giles F, Shan J, Rios MB, Faderl S, Verstovsek S, Garcia-Manero G, Wierda W, Kornblau S, Ferrajoli A, Keating M, Talpaz M. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):68-75. PMID: 14734453.
      Citations: 12     Fields:    Translation:Humans
    1813. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004 Apr 15; 103(8):2873-8. PMID: 15070658.
      Citations: 91     Fields:    Translation:HumansCells
    1814. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer. 2003 Dec 15; 98(12):2636-42. PMID: 14669283.
      Citations: 18     Fields:    Translation:HumansCells
    1815. Gandhi V, Kantarjian H, Faderl S, Bonate P, Du M, Ayres M, Rios MB, Keating MJ, Plunkett W. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res. 2003 Dec 15; 9(17):6335-42. PMID: 14695132.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    1816. O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, Koller CA, Ferrajoli A, Browning M, Lerner S, Albitar M, Keating MJ. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003 Dec 15; 98(12):2657-63. PMID: 14669286.
      Citations: 41     Fields:    Translation:HumansCellsCTClinical Trials
    1817. Giles FJ, Feldman EJ, Roboz GJ, Larson RA, Mamus SW, Cortes JE, Verstovsek S, Faderl S, Talpaz M, Beran M, Albitar M, O'Brien SM, Kantarjian HM. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk Res. 2003 Dec; 27(12):1091-6. PMID: 12921945.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    1818. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2003 Dec 01; 98(11):2483-7. PMID: 14635084.
      Citations: 20     Fields:    Translation:HumansCells
    1819. Hennessy BT, Garcia-Manero G, Kantarjian HM, Giles FJ. DNA methylation in haematological malignancies: the role of decitabine. Expert Opin Investig Drugs. 2003 Dec; 12(12):1985-93. PMID: 14640942.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    1820. Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, Bierman PJ, O'Brien SM, Keating MJ, Kantarjian HM, Armitage JO, Albitar M. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol. 2003 Dec; 123(5):850-7. PMID: 14632776.
      Citations: 15     Fields:    Translation:HumansCells
    1821. Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, Wright LP, Samson T, Cahill A, Lambert P, Plunkett W, Sznol M, DiPersio JF, Gandhi V. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res. 2003 Dec; 27(12):1077-83. PMID: 12921943.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    1822. Yang AS, Estecio MR, Garcia-Manero G, Kantarjian HM, Issa JP. Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation". Science. 2003 Nov 14; 302(5648):1153; author reply 1153. PMID: 14615517.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    1823. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004 Mar 01; 103(5):1635-40. PMID: 14604977.
      Citations: 270     Fields:    Translation:HumansCellsCTClinical Trials
    1824. Thomas DA, Estey E, Giles FJ, Faderl S, Cortes J, Keating M, O'Brien S, Albitar M, Kantarjian H. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol. 2003 Nov; 123(3):436-41. PMID: 14617002.
      Citations: 8     Fields:    Translation:Humans
    1825. Medina J, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Rios MB, Hayes K, Cortes J. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer. 2003 Nov 01; 98(9):1905-11. PMID: 14584073.
      Citations: 30     Fields:    Translation:Humans
    1826. Yazji S, Giles FJ, Tsimberidou AM, Estey EH, Kantarjian HM, O'Brien SA, Kurzrock R. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia. 2003 Nov; 17(11):2101-6. PMID: 12931212.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    1827. Rogers A, Joe Y, Manshouri T, Dey A, Jilani I, Giles F, Estey E, Freireich E, Keating M, Kantarjian H, Albitar M. Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. Blood. 2004 Apr 01; 103(7):2799-801. PMID: 14576069.
      Citations: 18     Fields:    Translation:HumansCells
    1828. Drummond MW, Holyoake TL. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003 Oct 15; 98(8):1776-7; author reply 1777-8. PMID: 14534900.
      Citations:    Fields:    Translation:Humans
    1829. Jeha S, Gandhi V, Chan KW, McDonald L, Ramirez I, Madden R, Rytting M, Brandt M, Keating M, Plunkett W, Kantarjian H. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004 Feb 01; 103(3):784-9. PMID: 14551141.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    1830. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004 Jun 15; 103(12):4396-407. PMID: 14551133.
      Citations: 172     Fields:    Translation:HumansCTClinical Trials
    1831. Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H, Giles FJ. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res. 2003 Oct; 27(10):887-91. PMID: 12860007.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    1832. Marin D, Goldman JM, Olavarria E, Apperley JF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood. 2003 Oct 01; 102(7):2702-3; author reply 2703-4. PMID: 14504074.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    1833. Lee JN, Giles F, Huh YO, Manshouri T, O'Brien S, Kantarjian HM, Keating MJ, Albitar M. Molecular differences between small and large cells in patients with chronic lymphocytic leukemia. Eur J Haematol. 2003 Oct; 71(4):235-42. PMID: 12950231.
      Citations: 4     Fields:    Translation:HumansCells
    1834. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003 Oct 01; 98(7):1337-54. PMID: 14508819.
      Citations: 57     Fields:    Translation:HumansCells
    1835. Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S, Albitar M, Kantarjian H, Estey E, Giles FJ. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res. 2003 Oct; 27(10):893-7. PMID: 12860008.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    1836. Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, Verstovsek S, Faderl S, Rios MB, Talpaz M. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Cancer. 2003 Oct 01; 98(7):1430-7. PMID: 14508830.
      Citations: 4     Fields:    Translation:HumansCells
    1837. Tsimberidou AM, Giles FJ, Kantarjian HM, Keating MJ, O'Brien SM. Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease. Leuk Lymphoma. 2003 Oct; 44(10):1719-25. PMID: 14692524.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    1838. Beran M, O'Brien S, Thomas DA, Tran HT, Cortes-Franco JE, Giles F, Estey E, Kantarjian HM. Phase I study of oral topotecan in hematological malignancies. Clin Cancer Res. 2003 Sep 15; 9(11):4084-91. PMID: 14519630.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    1839. Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003 Sep 15; 98(6):1105-13. PMID: 12973833.
      Citations: 23     Fields:    Translation:Humans
    1840. Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, Thomas DA, Ferrajoli A, Keating MJ, O'Brien S, Kantarjian HM, Giles FJ. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol. 2003 Dec; 52(6):449-52. PMID: 13680159.
      Citations: 4     Fields:    Translation:Humans
    1841. O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer. 2003 Sep 01; 98(5):888-93. PMID: 12942553.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    1842. Raad II, Escalante C, Hachem RY, Hanna HA, Husni R, Afif C, Boktour MR, Whimbey EE, Kontoyiannis D, Jacobson K, Kantarjian H, Levett LM, Rolston KV. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer. 2003 Sep 01; 98(5):1039-47. PMID: 12942573.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    1843. Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF, Wright JJ, Freireich EJ, Talpaz M, Sebti SM. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood. 2003 Dec 15; 102(13):4527-34. PMID: 12947010.
      Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
    1844. Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, Kantarjian HM. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer. 2003 Aug 01; 98(3):437-57. PMID: 12879460.
      Citations: 22     Fields:    Translation:Humans
    1845. Gatto S, Scappini B, Pham L, Onida F, Milella M, Ball G, Ricci C, Divoky V, Verstovsek S, Kantarjian HM, Keating MJ, Cortes-Franco JE, Beran M. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica. 2003 Aug; 88(8):853-63. PMID: 12935973.
      Citations: 19     Fields:    Translation:HumansCells
    1846. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 2003 Aug 01; 98(3):522-8. PMID: 12879469.
      Citations: 61     Fields:    Translation:Humans
    1847. Jilani I, O'Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, Naeem S, Verstovsek S, Kantarjian H, Giles F, Keating M, Albitar M. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood. 2003 Nov 15; 102(10):3514-20. PMID: 12893761.
      Citations: 37     Fields:    Translation:HumansCells
    1848. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, Champlin R, Kantarjian H, Bodey GP, Raad II. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003 Jul 15; 98(2):292-9. PMID: 12872348.
      Citations: 50     Fields:    Translation:Humans
    1849. Estey EH, Thall PF, Wang X, Verstovsek S, Cortes J, Kantarjian HM. Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML. Blood. 2003 Nov 01; 102(9):3097-9. PMID: 12842982.
      Citations: 5     Fields:    Translation:HumansCells
    1850. Verstovsek S, Lunin S, Kantarjian H, Manshouri T, Faderl S, Cortes J, Giles F, Albitar M. Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. Leuk Res. 2003 Jul; 27(7):661-9. PMID: 12681367.
      Citations: 3     Fields:    Translation:Humans
    1851. Champlin RE, Kantarjian H. Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia. Clin Adv Hematol Oncol. 2003 Jul; 1(7):398-400. PMID: 16258420.
      Citations:    Fields:    Translation:Humans
    1852. Kantarjian H, O'Brien S, Cortes J, Giles F, Thomas D, Kornblau S, Shan J, Beth Rios M, Keating M, Freireich E, Talpaz M. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer. 2003 Jul 01; 98(1):81-5. PMID: 12833459.
      Citations: 13     Fields:    Translation:Humans
    1853. Torres HA, Bodey GP, Rolston KV, Kantarjian HM, Raad II, Kontoyiannis DP. Infections in patients with aplastic anemia: experience at a tertiary care cancer center. Cancer. 2003 Jul 01; 98(1):86-93. PMID: 12833460.
      Citations: 23     Fields:    Translation:Humans
    1854. Konopleva M, Cheng SC, Cortes JE, Hayes KJ, Pierce SA, Andreeff M, Giles FJ, O'Brien S, Kantarjian HM, Estey EH. Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts. Haematologica. 2003 Jul; 88(7):733-6. PMID: 12857550.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    1855. Thomas DA, O'Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, Cortes J, Kantarjian HM. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003 Dec 01; 102(12):3906-11. PMID: 12816862.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    1856. Garcia-Manero G, Talpaz M, Giles FJ, Cortes J, Faderl S, O'Brien S, Thomas D, Verstovsek S, Beth Rios M, Shan J, Ferrajoli A, Wierda W, Kantarjian HM. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. Cancer. 2003 Jun 15; 97(12):3010-6. PMID: 12784336.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    1857. Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, Giles F, Faderl S, O'Brien S, Jeha S, Davis J, Shaked Z, Craig A, Keating M, Plunkett W, Freireich EJ. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003 Oct 01; 102(7):2379-86. PMID: 12791647.
      Citations: 80     Fields:    Translation:HumansCTClinical Trials
    1858. Giles FJ, Shi GG, Cortes JE, Thomas D, Keating AR, Kantarjian HM, Keating MJ, O'Brien SM. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol. 2003 Sep; 52(3):223-8. PMID: 12783199.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    1859. Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A, Kantarjian H. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer. 2003 Jun 01; 97(11):2760-6. PMID: 12767088.
      Citations: 19     Fields:    Translation:Humans
    1860. Estey E, Giles F, Cortes J, Beran M, Verstovsek S, Garcia-Manero G, Faderl S, Kantarjian H. Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML. Leuk Res. 2003 Jun; 27(6):475-9. PMID: 12648505.
      Citations:    Fields:    Translation:HumansCells
    1861. Tsimberidou AM, Kantarjian HM, Estey E, Cortes JE, Verstovsek S, Faderl S, Thomas DA, Garcia-Manero G, Ferrajoli A, Manning JT, Keating MJ, Albitar M, O'Brien S, Giles FJ. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia. 2003 Jun; 17(6):1100-3. PMID: 12764375.
      Citations: 85     Fields:    Translation:HumansCells
    1862. Tsimberidou AM, Colburn DE, Welch MA, Cortes JE, Verstovsek S, O'Brien SM, Albitar M, Kantarjian HM, Giles FJ. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol. 2003 Sep; 52(3):229-34. PMID: 12783207.
      Citations: 1     Fields:    Translation:Humans
    1863. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med. 2003 May 20; 138(10):819-30. PMID: 12755554.
      Citations: 86     Fields:    Translation:HumansAnimalsCells
    1864. Gatto S, Ball G, Onida F, Kantarjian HM, Estey EH, Beran M. Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). Blood. 2003 Sep 01; 102(5):1622-5. PMID: 12738677.
      Citations: 11     Fields:    Translation:Humans
    1865. Verstovsek S, Manshouri T, Smith FO, Giles FJ, Cortes J, Estey E, Kantarjian H, Keating M, Jeha S, Albitar M. Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia. Cancer. 2003 May 01; 97(9):2212-7. PMID: 12712473.
      Citations: 10     Fields:    Translation:Humans
    1866. Giles FJ, Kantarjian HM, Cortes JE, Garcia-Manero G, Verstovsek S, Faderl S, Thomas DA, Ferrajoli A, O'Brien S, Wathen JK, Xiao LC, Berry DA, Estey EH. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol. 2003 May 01; 21(9):1722-7. PMID: 12721247.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    1867. Giles FJ, Bekele BN, O'Brien S, Cortes JE, Verstovsek S, Balerdi M, Yared M, Zhou X, Kantarjian HM, Keating MJ, Thall P, Albitar M. A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. Br J Haematol. 2003 May; 121(4):578-85. PMID: 12752098.
      Citations: 6     Fields:    Translation:Humans
    1868. Kantarjian H, Talpaz M, O'Brien S, Giles F, Rios MB, White K, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Kornblau S, Cortes J. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003 May 01; 97(9):2225-8. PMID: 12712475.
      Citations: 4     Fields:    Translation:Humans
    1869. Amin HM, Jilani I, Estey EH, Keating MJ, Dey AL, Manshouri T, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Giles FJ, Albitar M. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood. 2003 Sep 01; 102(5):1866-8. PMID: 12730116.
      Citations: 8     Fields:    Translation:HumansCells
    1870. Thomas MB, Koller C, Yang Y, Shen Y, O'Brien S, Kantarjian H, Davis J, Estey E. Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia. Leukemia. 2003 May; 17(5):990-3. PMID: 12750721.
      Citations: 5     Fields:    Translation:Humans
    1871. Tsimberidou AM, Waddelow T, Kantarjian HM, Albitar M, Giles FJ. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. Leuk Res. 2003 May; 27(5):375-80. PMID: 12620287.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    1872. Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S, Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer. 2003 May 01; 97(9):2218-24. PMID: 12712474.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    1873. Giles FJ, Cooper MA, Silverman L, Karp JE, Lancet JE, Zangari M, Shami PJ, Khan KD, Hannah AL, Cherrington JM, Thomas DA, Garcia-Manero G, Albitar M, Kantarjian HM, Stopeck AT. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. Cancer. 2003 Apr 15; 97(8):1920-8. PMID: 12673719.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    1874. Ibrahim S, Jilani I, O'Brien S, Rogers A, Manshouri T, Giles F, Faderl S, Thomas D, Kantarjian H, Keating M, Albitar M. Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia. Cancer. 2003 Apr 15; 97(8):1914-9. PMID: 12673718.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    1875. Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, Aggarwal BB. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood. 2003 Aug 01; 102(3):987-95. PMID: 12689943.
      Citations: 87     Fields:    Translation:HumansCells
    1876. Apostolidou E, Estey E, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Tsimberidou A, Kantarjian H, Giles FJ. Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. Leuk Res. 2003 Apr; 27(4):301-4. PMID: 12531220.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    1877. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003 Apr 01; 97(7):1711-20. PMID: 12655528.
      Citations: 35     Fields:    Translation:Humans
    1878. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27; 348(13):1201-14. PMID: 12660384.
      Citations: 399     Fields:    Translation:HumansCells
    1879. Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, Estrov Z. Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood. 2003 Jul 15; 102(2):630-7. PMID: 12663443.
      Citations: 19     Fields:    Translation:HumansCells
    1880. Duzkale H, Jilani I, Orsolic N, Zingaro RA, Golemovic M, Giles FJ, Kantarjian H, Albitar M, Freireich EJ, Verstovsek S. In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines. Cancer Chemother Pharmacol. 2003 May; 51(5):427-32. PMID: 12736761.
      Citations: 5     Fields:    Translation:HumansCells
    1881. Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, Hong W, Cortes JE, Verstovsek S, Albitar M, O'Brien SM, Kantarjian HM, Karp JE. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug 01; 102(3):795-801. PMID: 12649163.
      Citations: 34     Fields:    Translation:HumansCellsCTClinical Trials
    1882. Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol. 2003 Mar 15; 21(6):1050-6. PMID: 12637470.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    1883. Tsimberidou A, Estey E, Cortes J, Thomas D, Faderl S, Verstovsek S, Garcia-Manero G, Keating M, Albitar M, O'Brien S, Kantarjian H, Giles F. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer. 2003 Mar 15; 97(6):1481-7. PMID: 12627513.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    1884. Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003 Mar 15; 21(6):1167-73. PMID: 12637486.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    1885. Cortes J, Giles F, O'Brien S, Thomas D, Garcia-Manero G, Rios MB, Faderl S, Verstovsek S, Ferrajoli A, Freireich EJ, Talpaz M, Kantarjian H. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood. 2003 Jul 01; 102(1):83-6. PMID: 12637317.
      Citations: 43     Fields:    Translation:Humans
    1886. O'Brien SG, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, IRIS Investigators, Guilhot F. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003 Mar 13; 348(11):994-1004. PMID: 12637609.
      Citations: 945     Fields:    Translation:HumansCTClinical Trials
    1887. de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian H. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer. 2003 Mar 01; 97(5):1242-7. PMID: 12599231.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    1888. Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Faderl S, Giles FJ, Keating M, Albitar M. Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia. Cancer. 2003 Mar 01; 97(5):1248-52. PMID: 12599232.
      Citations: 1     Fields:    Translation:Humans
    1889. Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O'Brien S, Keating M, Estey E. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2003 Mar 01; 97(5):1234-41. PMID: 12599230.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    1890. Faderl S, Lotan R, Kantarjian HM, Harris D, Van Q, Estrov Z. N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL). Leuk Res. 2003 Mar; 27(3):259-66. PMID: 12537979.
      Citations: 12     Fields:    Translation:HumansCells
    1891. Mattiuzzi GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J, Kontoyiannis D, Giles FJ, Raad I, Verstovsek S, Ferrajoli A, Kantarjian HM. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res. 2003 Mar; 9(3):976-80. PMID: 12631595.
      Citations: 30     Fields:    Translation:HumansCells
    1892. Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, Rios MB, Letvak L, Kaled ES, Kantarjian H. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003 Jun 15; 101(12):4714-6. PMID: 12595304.
      Citations: 33     Fields:    Translation:HumansCellsCTClinical Trials
    1893. Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S, Keating MJ, Freireich EJ, Talpaz M. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003 Feb 15; 97(4):1033-41. PMID: 12569603.
      Citations: 59     Fields:    Translation:HumansCells
    1894. Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, Imai K, Kantarjian HM, Issa JP, Garcia-Manero G. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood. 2003 May 15; 101(10):4131-6. PMID: 12586619.
      Citations: 42     Fields:    Translation:HumansCells
    1895. Garcia-Manero G, Jeha S, Daniel J, Williamson J, Albitar M, Kantarjian HM, Issa JP. Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia. Cancer. 2003 Feb 01; 97(3):695-702. PMID: 12548613.
      Citations: 17     Fields:    Translation:HumansCells
    1896. Wierda WG, Johnson MM, Do KA, Manshouri T, Dey A, O'Brien S, Giles FJ, Kantarjian H, Thomas D, Faderl S, Lerner S, Keating M, Albitar M. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br J Haematol. 2003 Feb; 120(3):452-6. PMID: 12580959.
      Citations: 23     Fields:    Translation:Humans
    1897. Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003 May 15; 101(10):3794-800. PMID: 12560227.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    1898. Lu D, Nounou R, Beran M, Estey E, Manshouri T, Kantarjian H, Keating MJ, Albitar M. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 2003 Jan 15; 97(2):441-9. PMID: 12518368.
      Citations: 5     Fields:    Translation:HumansCells
    1899. Mattiuzzi GN, Estey E, Raad I, Giles F, Cortes J, Shen Y, Kontoyiannis D, Koller C, Munsell M, Beran M, Kantarjian H. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer. 2003 Jan 15; 97(2):450-6. PMID: 12518369.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    1900. Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003 May 01; 101(9):3413-5. PMID: 12522009.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    1901. O'Brien SM, Kantarjian H, Radich J. Update: chronic myelogenous leukemia clinical practice guidelines. J Natl Compr Canc Netw. 2003 Jan; 1 Suppl 1:S29-40. PMID: 19795574.
      Citations: 1     Fields:    Translation:Humans
    1902. Jilani I, Estey E, Manshuri T, Caligiuri M, Keating M, Giles F, Thomas D, Kantarjian H, Albitar M. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA. Leukemia. 2003 Jan; 17(1):114-9. PMID: 12529667.
      Citations: 9     Fields:    Translation:HumansCells
    1903. Kantarjian HM, Talpaz M, Cortes J, O'Brien S, Faderl S, Thomas D, Giles F, Rios MB, Shan J, Arlinghaus R. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 2003 Jan; 9(1):160-6. PMID: 12538464.
      Citations: 14     Fields:    Translation:Humans
    1904. Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin Hematol. 2003 Jan; 40(1):79-86. PMID: 12563614.
      Citations: 16     Fields:    Translation:Humans
    1905. Thomas DA, Cortes J, Kantarjian HM. New agents in the treatment of acute lymphocytic leukaemia. Best Pract Res Clin Haematol. 2002 Dec; 15(4):771-90. PMID: 12617876.
      Citations: 2     Fields:    Translation:Humans
    1906. Manshouri T, Do KA, Wang X, Giles FJ, O'Brien SM, Saffer H, Thomas D, Jilani I, Kantarjian HM, Keating MJ, Albitar M. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003 Apr 01; 101(7):2507-13. PMID: 12446458.
      Citations: 45     Fields:    Translation:HumansCells
    1907. Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z, Kantarjian H, Giles FJ. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol. 2003 Jan; 51(1):81-6. PMID: 12497210.
      Citations: 11     Fields:    Translation:Humans
    1908. Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol. 2003 Jan; 51(1):87-90. PMID: 12497211.
      Citations: 8     Fields:    Translation:Humans
    1909. Cortes J, Tsimberidou AM, Alvarez R, Thomas D, Beran M, Kantarjian H, Estey E, Giles FJ. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol. 2002 Dec; 50(6):497-500. PMID: 12451477.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    1910. Tsao AS, Kantarijian H, Talpaz M. STI-571 in chronic myelogenous leukaemia. Br J Haematol. 2002 Oct; 119(1):15-24. PMID: 12358949.
      Citations: 4     Fields:    Translation:HumansCells
    1911. Kurzrock R, Cortes J, Kantarjian H. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. Semin Hematol. 2002 Oct; 39(4 Suppl 3):20-4. PMID: 12447848.
      Citations: 7     Fields:    Translation:HumansAnimals
    1912. Giles F, Garcia-Manero G, Cortes J, Thomas D, Kantarjian H, Estey E. Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy. Haematologica. 2002 Oct; 87(10):1114-6. PMID: 12368170.
      Citations: 1     Fields:    Translation:Humans
    1913. Jilani I, Estey E, Huh Y, Joe Y, Manshouri T, Yared M, Giles F, Kantarjian H, Cortes J, Thomas D, Keating M, Freireich E, Albitar M. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol. 2002 Oct; 118(4):560-6. PMID: 12375643.
      Citations: 36     Fields:    Translation:HumansCells
    1914. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Shan J, Rios MB, Cortes J. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003 Jan 15; 101(2):473-5. PMID: 12393385.
      Citations: 64     Fields:    Translation:HumansCTClinical Trials
    1915. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 2002 Sep; 26(9):881-4. PMID: 12127565.
      Citations: 22     Fields:    Translation:Humans
    1916. Keating MJ, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M, Lerner S, Kantarjian H. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002 Sep; 43(9):1755-62. PMID: 12685828.
      Citations: 42     Fields:    Translation:Humans
    1917. Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, De Lima M, Garcia-Manero G, Champlin R, Arlinghaus R, Talpaz M. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2002 Sep 01; 100(5):1590-5. PMID: 12176876.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    1918. Lai R, O'Brien S, Maushouri T, Rogers A, Kantarjian H, Keating M, Albitar M. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer. 2002 Sep 01; 95(5):1071-5. PMID: 12209693.
      Citations: 22     Fields:    Translation:Humans
    1919. Esmaeli B, Prieto VG, Butler CE, Kim SK, Ahmadi MA, Kantarjian HM, Talpaz M. Severe periorbital edema secondary to STI571 (Gleevec). Cancer. 2002 Aug 15; 95(4):881-7. PMID: 12209733.
      Citations: 15     Fields:    Translation:Humans
    1920. Garcia-Manero G, Faderl S, Giles F, Thomas D, Cortes J, O'Brien S, Davis J, Kantarjian HM, Estey E. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Haematologica. 2002 Aug; 87(8):804-7. PMID: 12161355.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    1921. Albitar M, Manshouri T, Shen Y, Liu D, Beran M, Kantarjian HM, Rogers A, Jilani I, Lin CW, Pierce S, Freireich EJ, Estey EH. Myelodysplastic syndrome is not merely "preleukemia". Blood. 2002 Aug 01; 100(3):791-8. PMID: 12130488.
      Citations: 21     Fields:    Translation:HumansCells
    1922. Germing U, Strupp C, Aivado M, Gattermann N. New prognostic parameters for chronic myelomonocytic leukemia. Blood. 2002 Jul 15; 100(2):731-2; author reply 732-3. PMID: 12123232.
      Citations: 18     Fields:    Translation:Humans
    1923. Giles FJ, Cortes JE, Thomas DA, Garcia-Manero G, Faderl S, Jeha S, De Jager RL, Kantarjian HM. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res. 2002 Jul; 8(7):2134-41. PMID: 12114413.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    1924. Kantarjian HM, Cortes JE, Rowe JM, Kurzrock R. Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies. Semin Hematol. 2002 Jul; 39(3 Suppl 2):36-8. PMID: 12214292.
      Citations:    Fields:    Translation:Humans
    1925. Ravandi F, Cortes J, Estrov Z, Thomas D, Giles FJ, Huh YO, Pierce S, O'Brien S, Faderl S, Kantarjian HM. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res. 2002 Jul; 26(7):643-9. PMID: 12008081.
      Citations: 19     Fields:    Translation:HumansCells
    1926. Verstovsek S, Estey E, Manshouri T, Giles FJ, Cortes J, Beran M, Rogers A, Keating M, Kantarjian H, Albitar M. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol. 2002 Jul; 118(1):151-6. PMID: 12100142.
      Citations: 12     Fields:    Translation:Humans
    1927. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res. 2002 Jul; 8(7):2177-87. PMID: 12114418.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    1928. Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002 Jul; 8(7):2167-76. PMID: 12114417.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    1929. Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee MS, Kantarjian HM, Issa JP. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res. 2002 Jul; 8(7):2217-24. PMID: 12114423.
      Citations: 44     Fields:    Translation:HumansCells
    1930. Cortes JE, Kurzrock R, Kantarjian HM. Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. Semin Hematol. 2002 Jul; 39(3 Suppl 2):26-30. PMID: 12214290.
      Citations:    Fields:    Translation:Humans
    1931. Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M, Pierce SA, Thomas DA, Kantarjian HM. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood. 2002 Jun 15; 99(12):4343-9. PMID: 12036860.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    1932. Lin CW, Manshouri T, Jilani I, Neuberg D, Patel K, Kantarjian H, Andreeff M, Estrov Z, Beran M, Keating M, Estey E, Albitar M. Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. Leuk Res. 2002 Jun; 26(6):551-9. PMID: 12007503.
      Citations: 11     Fields:    Translation:HumansCells
    1933. Atallah E, Talpaz M, O'brien S, Rios MB, Guo JQ, Arlinghaus R, Fernandes-Reese S, Kantarjian H. Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. Cancer. 2002 Jun 01; 94(11):2996-9. PMID: 12115389.
      Citations: 4     Fields:    Translation:HumansCells
    1934. Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O'Brien S, Garcia-Manero G, Manshouri T, Albitar M. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2002 Jun; 16(6):1045-52. PMID: 12040436.
      Citations: 31     Fields:    Translation:Humans
    1935. Rex JH, Anaissie EJ, Boutati E, Estey E, Kantarjian H. Systemic antifungal prophylaxis reduces invasive fungal in acute myelogenous leukemia: a retrospective review of 833 episodes of neutropenia in 322 adults. Leukemia. 2002 Jun; 16(6):1197-9. PMID: 12040453.
      Citations: 1     Fields:    Translation:Humans
    1936. Estey EH, Giles FJ, Beran M, O'Brien S, Pierce SA, Faderl SH, Cortes JE, Kantarjian HM. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood. 2002 Jun 01; 99(11):4222-4. PMID: 12010830.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    1937. Dabaja BS, Ha CS, Thomas DA, Wilder RB, Gopal R, Cortes J, Bueso-Ramos C, Hess MA, Cox JD, Kantarjian HM. The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. Cancer. 2002 May 15; 94(10):2738-44. PMID: 12173345.
      Citations: 11     Fields:    Translation:Humans
    1938. Scappini B, Onida F, Kantarjian HM, Dong L, Verstovsek S, Keating MJ, Beran M. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer. 2002 May 15; 94(10):2653-62. PMID: 12173333.
      Citations: 5     Fields:    Translation:Cells
    1939. Kantarjian HM. Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience. J Clin Oncol. 2002 May 15; 20(10):2415-6. PMID: 12011118.
      Citations: 2     Fields:    Translation:Humans
    1940. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002 May 15; 99(10):3547-53. PMID: 11986206.
      Citations: 56     Fields:    Translation:HumansCellsCTClinical Trials
    1941. Verstovsek S, Lin H, Kantarjian H, Saglio G, De Micheli D, Pane F, Garcia-Manero G, Intrieri M, Rotoli B, Salvatore F, Guo JQ, Talpaz M, Specchia G, Pizzolo G, Liberati AM, Cortes J, Quackenbush RC, Arlinghaus RB. Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer. 2002 May 01; 94(9):2416-25. PMID: 12015767.
      Citations: 14     Fields:    Translation:HumansCells
    1942. Lee WI, Kantarjian H, Glassman A, Talpaz M, Lee MS. Quantitative measurement of BCR/abl transcripts using real-time polymerase chain reaction. Ann Oncol. 2002 May; 13(5):781-8. PMID: 12075749.
      Citations: 6     Fields:    Translation:HumansCells
    1943. O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer. 2002 Apr 01; 94(7):2024-32. PMID: 11932905.
      Citations: 11     Fields:    Translation:Humans
    1944. Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, Keating MJ, Giles FJ. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma. 2002 Apr; 43(4):767-72. PMID: 12153163.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    1945. Garcia-Manero G, Talpaz M, Kantarjian HM. Current therapy of chronic myelogenous leukemia. Intern Med. 2002 Apr; 41(4):254-64. PMID: 11993784.
      Citations: 1     Fields:    Translation:Humans
    1946. Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Giles FJ, Rogers A, Albitar M. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood. 2002 Mar 15; 99(6):2265-7. PMID: 11877311.
      Citations: 18     Fields:    Translation:Humans
    1947. DiRaimondo F, Albitar M, Huh Y, O'Brien S, Montillo M, Tedeschi A, Kantarjian H, Lerner S, Giustolisi R, Keating M. The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease. Cancer. 2002 Mar 15; 94(6):1721-30. PMID: 11920534.
      Citations: 9     Fields:    Translation:Humans
    1948. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002 Mar 15; 99(6):1928-37. PMID: 11877262.
      Citations: 183     Fields:    Translation:HumansCellsCTClinical Trials
    1949. Verstovsek S, Kantarjian H, Manshouri T, O'Brien S, Faderl S, Talpaz M, Cortes J, Albitar M. Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia. Cancer. 2002 Mar 01; 94(5):1517-21. PMID: 11920509.
      Citations: 6     Fields:    Translation:Humans
    1950. Cortes J, Thomas D, Rios A, Koller C, O'Brien S, Jeha S, Faderl S, Kantarjian H. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002 Mar 01; 94(5):1492-9. PMID: 11920506.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    1951. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E, International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002 Feb 28; 346(9):645-52. PMID: 11870241.
      Citations: 427     Fields:    Translation:HumansCellsCTClinical Trials
    1952. Surapaneni UR, Cortes JE, Thomas D, O'Brien S, Giles FJ, Koller C, Faderl S, Kantarjian H. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer. 2002 Feb 01; 94(3):773-9. PMID: 11857312.
      Citations: 29     Fields:    Translation:Humans
    1953. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, Glassman AB, Albitar M, Kwari MI, Beran M. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002 Feb 01; 99(3):840-9. PMID: 11806985.
      Citations: 124     Fields:    Translation:HumansCells
    1954. Weiser MA, O'Brien S, Thomas DA, Pierce SA, Lam TP, Kantarjian HM. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen. Cancer. 2002 Jan 15; 94(2):285-91. PMID: 11900213.
      Citations: 2     Fields:    Translation:HumansCells
    1955. Faderl S, Gandhi V, Kantarjian H, Plunkett W. New nucleoside analogues in clinical development. Cancer Chemother Biol Response Modif. 2002; 20:37-58. PMID: 12703199.
      Citations: 1     Fields:    Translation:HumansAnimals
    1956. Lai R, Estey E, Shen Y, Despa S, Kantarjian H, Beran M, Maushouri T, Quackenbuch RC, Keating M, Albitar M. Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome. Cancer. 2002 Jan 01; 94(1):14-7. PMID: 11815955.
      Citations: 9     Fields:    Translation:Humans
    1957. Raad I, Hanna H, Osting C, Hachem R, Umphrey J, Tarrand J, Kantarjian H, Bodey GP. Masking of neutropenic patients on transport from hospital rooms is associated with a decrease in nosocomial aspergillosis during construction. Infect Control Hosp Epidemiol. 2002 Jan; 23(1):41-3. PMID: 11868892.
      Citations: 9     Fields:    Translation:HumansAnimals
    1958. Estey EH, Thall PF, Cortes JE, Giles FJ, O'Brien S, Pierce SA, Wang X, Kantarjian HM, Beran M. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood. 2001 Dec 15; 98(13):3575-83. PMID: 11739159.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    1959. Scappini B, Onida F, Kantarjian HM, Dong L, Verstovsek S, Keating MJ, Beran M. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells. Clin Cancer Res. 2001 Dec; 7(12):3884-93. PMID: 11751479.
      Citations: 5     Fields:    Translation:HumansCells
    1960. Kantarjian HM, Shan J, Smith T, Talpaz M, Kozuch P, Rios MB, Cortes J, Giles FJ, O'Brien S. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. Cancer. 2001 Nov 15; 92(10):2501-7. PMID: 11745182.
      Citations: 3     Fields:    Translation:Humans
    1961. Faderl S, Estrov Z, Kantarjian HM, Harris D, Van Q, Fokt I, Przewloka T, Godlewski C, Woynarowski JM, Priebe W. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res. 2001 Nov-Dec; 21(6A):3777-84. PMID: 11911247.
      Citations: 2     Fields:    Translation:HumansCells
    1962. Beran M, Shen Y, Kantarjian H, O'Brien S, Koller CA, Giles FJ, Cortes J, Thomas DA, Faderl S, Despa S, Estey EH. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer. 2001 Oct 15; 92(8):1999-2015. PMID: 11596013.
      Citations: 25     Fields:    Translation:Humans
    1963. Kantarjian HM, Talpaz M. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Semin Oncol. 2001 Oct; 28(5 Suppl 17):9-18. PMID: 11740802.
      Citations: 7     Fields:    Translation:Humans
    1964. Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O'Brien SM. Homoharringtonine: history, current research, and future direction. Cancer. 2001 Sep 15; 92(6):1591-605. PMID: 11745238.
      Citations: 50     Fields:    Translation:Humans
    1965. Talpaz M, O'Brien S, Rose E, Gupta S, Shan J, Cortes J, Giles FJ, Faderl S, Kantarjian HM. Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 2001 Sep 15; 98(6):1708-13. PMID: 11535501.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    1966. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Dahlberg S, Ellison R, Warrell RP, Coutr? S. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001 Sep 15; 19(18):3852-60. PMID: 11559723.
      Citations: 201     Fields:    Translation:HumansCTClinical Trials
    1967. Aboul-Nasr R, O'Brien S, Freireich EJ, Ginsberg CF, Kantarjian HM, Koller CA, Keating MJ, Albitar M. "T-cell-rich B-cell lymphoproliferative disorder" of the bone marrow. Leuk Lymphoma. 2001 Sep-Oct; 42(5):1023-31. PMID: 11697619.
      Citations:    Fields:    Translation:HumansCells
    1968. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001 Jul 15; 92(2):406-13. PMID: 11466696.
      Citations: 51     Fields:    Translation:Humans
    1969. Estey E, Koller C, Cortes J, Reed P, Freireich E, Giles F, Kantarjian H. Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid. Leuk Lymphoma. 2001 Jul; 42(3):309-16. PMID: 11699395.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    1970. Ibrahim S, Keating M, Do KA, O'Brien S, Huh YO, Jilani I, Lerner S, Kantarjian HM, Albitar M. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001 Jul 01; 98(1):181-6. PMID: 11418478.
      Citations: 71     Fields:    Translation:Humans
    1971. Cortes J, Estey E, O'Brien S, Giles F, Shen Y, Koller C, Beran M, Thomas D, Keating M, Kantarjian H. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer. 2001 Jul 01; 92(1):7-14. PMID: 11443603.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    1972. Dabaja BS, O'Brien SM, Kantarjian HM, Cortes JE, Thomas DA, Albitar M, Schlette ES, Faderl S, Sarris A, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome. Leuk Lymphoma. 2001 Jul; 42(3):329-37. PMID: 11699397.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    1973. Verstovsek S, Estey E, Manshouri T, Keating M, Kantarjian H, Giles FJ, Albitar M. High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome. Leuk Lymphoma. 2001 Jul; 42(3):511-6. PMID: 11699417.
      Citations: 5     Fields:    Translation:HumansCells
    1974. Giles FJ, Shen Y, Kantarjian HM, Korbling MJ, O'Brien S, Anderlini P, Donato M, Pierce S, Keating MJ, Freireich EJ, Estey E. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival. Leuk Lymphoma. 2001 Jun; 42(1-2):67-73. PMID: 11699223.
      Citations: 23     Fields:    Translation:Humans
    1975. Ravandi F, Kantarjian H, Cohen A, Davis M, O'Brien S, Anderlini P, Andersson B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno N, deVos D, Champlin R, Giralt S. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant. 2001 Jun; 27(12):1221-5. PMID: 11548839.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    1976. Ravandi F, Kantarjian HM, Talpaz M, O'Brien S, Faderl S, Giles FJ, Thomas D, Cortes J, Andreeff M, Estrov Z, Rios MB, Albitar M. Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer. 2001 Jun 01; 91(11):1964-72. PMID: 11391574.
      Citations: 8     Fields:    Translation:Humans
    1977. Ravandi F, Hayes K, Cortes J, Albitar M, Glassman A, Talpaz M, Kantarjian HM. Translocation t(17;18)(q10;q10): a new nonrandom chromosomal translocation of clonal evolution in chronic myeloid leukemia. Cancer. 2001 May 01; 91(9):1704-8. PMID: 11335894.
      Citations: 2     Fields:    Translation:HumansCells
    1978. Verstovsek S, Manshouri T, Kantarjian H, Giles FJ, Keating M, Estey E, Albitar M. Highly reproducible detection and semi-quantification of telomerase activity. Biotechniques. 2001 May; 30(5):930-4. PMID: 11355351.
      Citations:    Fields:    Translation:HumansCells
    1979. Di Raimondo F, Giustolisi R, Lerner S, Cacciola E, O'Brien S, Kantarjian H, Keating MJ. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann Oncol. 2001 May; 12(5):621-5. PMID: 11432619.
      Citations: 8     Fields:    Translation:Humans
    1980. Donato NJ, Wu JY, Zhang L, Kantarjian H, Talpaz M. Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood. 2001 May 01; 97(9):2846-53. PMID: 11313280.
      Citations: 7     Fields:    Translation:HumansCells
    1981. O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001 Apr 15; 19(8):2165-70. PMID: 11304768.
      Citations: 125     Fields:    Translation:HumansCTClinical Trials
    1982. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001 Apr 05; 344(14):1031-7. PMID: 11287972.
      Citations: 1251     Fields:    Translation:HumansCellsCTClinical Trials
    1983. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001 Apr 05; 344(14):1038-42. PMID: 11287973.
      Citations: 629     Fields:    Translation:HumansCellsCTClinical Trials
    1984. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med. 2001 Apr 03; 134(7):573-86. PMID: 11281740.
      Citations: 98     Fields:    Translation:HumansCells
    1985. Aguayo A, Manshouri T, O'Brien S, Keating M, Beran M, Koller C, Kantarjian H, Rogers A, Albitar M. Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL). Leuk Res. 2001 Apr; 25(4):279-85. PMID: 11248324.
      Citations: 10     Fields:    Translation:HumansCells
    1986. Ferrajoli A, Manshouri T, Estrov Z, Keating MJ, O'Brien S, Lerner S, Beran M, Kantarjian HM, Freireich EJ, Albitar M. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res. 2001 Apr; 7(4):795-9. PMID: 11309324.
      Citations: 16     Fields:    Translation:Humans
    1987. Giles FJ, Kantarjian H, O'Brien S, Rios MB, Cortes J, Beran M, Koller C, Keating M, Talpaz M. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase. Leuk Lymphoma. 2001 Apr; 41(3-4):309-19. PMID: 11378543.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    1988. Laurent E, Talpaz M, Kantarjian H, Kurzrock R. The BCR gene and philadelphia chromosome-positive leukemogenesis. Cancer Res. 2001 Mar 15; 61(6):2343-55. PMID: 11289094.
      Citations: 30     Fields:    Translation:HumansAnimals
    1989. Tannir NM, Kantarjian H. Idiopathic thrombocytopenic purpura following successful treatment of acute lymphoblastic leukemia. Leuk Lymphoma. 2001 Mar; 41(1-2):217-20. PMID: 11342378.
      Citations:    Fields:    Translation:Humans
    1990. O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, Lerner S, Keating M. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001 Mar 01; 19(5):1414-20. PMID: 11230486.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    1991. Pachmann K, Zhao S, Schenk T, Kantarjian H, El-Naggar AK, Siciliano MJ, Guo JQ, Arlinghaus RB, Andreeff M. Expression of bcr-abl mRNA in individual chronic myelogenous leukaemia cells as determined by in situ amplification. Br J Haematol. 2001 Mar; 112(3):749-59. PMID: 11260080.
      Citations:    Fields:    Translation:HumansCells
    1992. Nguyen Q, Estey E, Raad I, Rolston K, Kantarjian H, Jacobson K, Konoplev S, Ghosh S, Luna M, Tarrand J, Whimbey E. Cytomegalovirus pneumonia in adults with leukemia: an emerging problem. Clin Infect Dis. 2001 Feb 15; 32(4):539-45. PMID: 11181115.
      Citations: 18     Fields:    Translation:Humans
    1993. Kantarjian HM. Adult acute lymphocytic leukemia. Future research directions. Hematol Oncol Clin North Am. 2001 Feb; 15(1):207-11, viii. PMID: 11253607.
      Citations:    Fields:    Translation:HumansCellsPHPublic Health
    1994. Fleming RV, Kantarjian HM, Husni R, Rolston K, Lim J, Raad I, Pierce S, Cortes J, Estey E. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma. 2001 Feb; 40(5-6):511-20. PMID: 11426524.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    1995. Giles FJ, Cortes JE, Baker SD, Thomas DA, O'Brien S, Smith TL, Beran M, Bivins C, Jolivet J, Kantarjian HM. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol. 2001 Feb 01; 19(3):762-71. PMID: 11157029.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    1996. Thomas DA, Kantarjian HM. Lymphoblastic lymphoma. Hematol Oncol Clin North Am. 2001 Feb; 15(1):51-95, vi. PMID: 11253609.
      Citations: 3     Fields:    Translation:Humans
    1997. Faderl S, Gidel C, Kantarjian HM, Manshouri T, Keating M, Albitar M. Loss of heterozygosity on chromosome 5 in adults with acute lymphoblastic leukemia. Leuk Res. 2001 Jan; 25(1):39-43. PMID: 11137559.
      Citations: 6     Fields:    Translation:HumansCells
    1998. Krskov?-Honz?tkov? L, Cerm?k J, Sajdov? J, Star? J, Sedl?cek P, Sieglov? Z. Loss of heterozygosity and heterogeneity of its appearance and persisting in the course of acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2001 Jan; 25(1):45-53. PMID: 11137560.
      Citations:    Fields:    Translation:HumansCells
    1999. Thomas DA, Giles FJ, Cortes J, Albitar M, Kantarjian HM. Antiangiogenic therapy in leukemia. Acta Haematol. 2001; 106(4):190-207. PMID: 11815717.
      Citations: 3     Fields:    Translation:Humans
    2000. Sarriera JE, Albitar M, Estrov Z, Gidel C, Aboul-Nasr R, Manshouri T, Kornblau S, Chang KS, Kantarjian H, Estey E. Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing. Leukemia. 2001 Jan; 15(1):57-61. PMID: 11243400.
      Citations: 7     Fields:    Translation:HumansCells
    2001. Giles F, Cortes J, Garcia-Manero G, Kornblau S, Estey E, Kwari M, Murgo A, Kantarjian H. Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. Invest New Drugs. 2001; 19(1):13-20. PMID: 11291829.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    2002. Kantarjian HM. Adult acute lymphocytic leukemia. Introduction and questions related to current programs. Hematol Oncol Clin North Am. 2000 Dec; 14(6):1205-8, VII. PMID: 11147219.
      Citations:    Fields:    Translation:HumansCells
    2003. Garcia-Manero G, Kantarjian HM. The hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000 Dec; 14(6):1381-96, x-xi. PMID: 11147229.
      Citations: 24     Fields:    Translation:HumansCells
    2004. Rodriguez J, McLaughlin P, Fayad L, Santiago M, Hess M, Rodriguez MA, Romaguera J, Hagemeister F, Kantarjian H, Cabanillas F. Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981. Ann Oncol. 2000 Dec; 11(12):1551-6. PMID: 11205462.
      Citations: 4     Fields:    Translation:Humans
    2005. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of minimal residual disease in leukemia. Int J Oncol. 2000 Dec; 17(6):1277-87. PMID: 11078816.
      Citations: 2     Fields:    Translation:HumansCells
    2006. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL, World Health Organization(WHO) international working group, L?wenberg B. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000 Dec 01; 96(12):3671-4. PMID: 11090046.
      Citations: 198     Fields:    Translation:Humans
    2007. Thomas DA, Kantarjian HM. Current role of thalidomide in cancer treatment. Curr Opin Oncol. 2000 Nov; 12(6):564-73. PMID: 11085456.
      Citations: 7     Fields:    Translation:Humans
    2008. Tannir NM, Talpaz M, Ghazal H, Proothi S, Kantarjian HM. Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia. Leuk Lymphoma. 2000 Nov; 39(5-6):647-50. PMID: 11342349.
      Citations: 5     Fields:    Translation:Humans
    2009. Ibrahim S, Estey EH, Pierce S, Glassman A, Keating M, O'Brien S, Kantarjian HM, Albitar M. 11q23 abnormalities in patients with acute myelogenous leukemia and myelodysplastic syndrome as detected by molecular and cytogenetic analyses. Am J Clin Pathol. 2000 Nov; 114(5):793-7. PMID: 11068555.
      Citations: 11     Fields:    Translation:HumansCells
    2010. Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A, Kornblau SM, Cortes J, Thomas DA, Pierce S, Keating MJ, Estrov Z, Albitar M. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer. 2000 Nov 01; 89(9):1976-82. PMID: 11064355.
      Citations: 34     Fields:    Translation:Humans
    2011. Kantarjian HM, Giles FJ, O'Brien S, Giralt S, Talpaz M. Therapeutic choices in younger patients with chronic myelogenous leukemia. Cancer. 2000 Oct 15; 89(8):1647-58. PMID: 11042556.
      Citations: 2     Fields:    Translation:Humans
    2012. Kantarjian HM, Talpaz M, Smith TL, Cortes J, Giles FJ, Rios MB, Mallard S, Gajewski J, Murgo A, Cheson B, O'Brien S. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol. 2000 Oct 15; 18(20):3513-21. PMID: 11032593.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    2013. Kozuch P, Talpaz M, Faderl S, O'Brien S, Freireich EJ, Kantarjian H. Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha: a synergistic correlation? Cancer. 2000 Oct 01; 89(7):1482-9. PMID: 11013361.
      Citations: 7     Fields:    Translation:Humans
    2014. Faderl S, Kantarjian HM, Talpaz M, O'Brien S. New treatment approaches for chronic myelogenous leukemia. Semin Oncol. 2000 Oct; 27(5):578-86. PMID: 11049024.
      Citations:    Fields:    Translation:HumansCells
    2015. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O'Brien S, Keating M, Freireich E, Albitar M. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000 Sep 15; 96(6):2240-5. PMID: 10979972.
      Citations: 150     Fields:    Translation:Humans
    2016. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000 Sep; 6(9):1018-23. PMID: 10973322.
      Citations: 157     Fields:    Translation:HumansCells
    2017. Talpaz M, Qiu X, Cheng K, Cortes JE, Kantarjian H, Kurzrock R. Autoantibodies to Abl and Bcr proteins. Leukemia. 2000 Sep; 14(9):1661-6. PMID: 10995014.
      Citations:    Fields:    Translation:HumansCells
    2018. Romaguera JE, Khouri IF, Kantarjian HM, Hagemeister FB, Rodriguez MA, McLaughlin P, Sarris AH, Younes A, Rodriguez J, Cabanillas F. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma. 2000 Sep; 39(1-2):77-85. PMID: 10975386.
      Citations: 9     Fields:    Translation:Humans
    2019. Aguayo A, O'Brien S, Keating M, Manshouri T, Gidel C, Barlogie B, Beran M, Koller C, Kantarjian H, Albitar M. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood. 2000 Jul 15; 96(2):768-70. PMID: 10887147.
      Citations: 9     Fields:    Translation:HumansCells
    2020. Albitar M, Beran M, O'Brien S, Kantarjian H, Frieriech E, Keating M, Estey E. Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia. Blood. 2000 Jul 01; 96(1):372-3. PMID: 10939804.
      Citations: 4     Fields:    Translation:Humans
    2021. Saad ED, Thomas DA, O'Brien S, Fuller GN, Medeiros LJ, Forman A, Albitar M, Schomer D, Kantarjian HM, Keating MJ. Progressive multifocal leukoencephalopathy with concurrent Richter's syndrome. Leuk Lymphoma. 2000 Jun; 38(1-2):183-90. PMID: 10811461.
      Citations: 2     Fields:    Translation:HumansCells
    2022. Ravandi-Kashani F, O'Brien S, Manshouri T, Lerner S, Sim S, Dodd K, Kantarjian H, Freireich E, Keating M, Albitar M. Variations in the low levels of cyclin D1/BCL1 have prognostic value in chronic lymphocytic leukemia. Leuk Res. 2000 Jun; 24(6):469-74. PMID: 10781679.
      Citations: 1     Fields:    Translation:HumansCells
    2023. Seong CM, Giralt S, Kantarjian H, Xu J, Swantkowski J, Hayes K, Glassman AB, Khouri I, Korbling M, Thall P, Siciliano MJ, Champlin RE. Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia. J Clin Oncol. 2000 May; 18(9):1831-6. PMID: 10784623.
      Citations: 1     Fields:    Translation:HumansCells
    2024. Reuben JM, Lee BN, Johnson H, Fritsche H, Kantarjian HM, Talpaz M. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha. Clin Cancer Res. 2000 May; 6(5):1671-7. PMID: 10815885.
      Citations: 13     Fields:    Translation:HumansCells
    2025. Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J, Kantarjian H, Andreeff M, May WS. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res. 2000 Apr; 6(4):1401-9. PMID: 10778970.
      Citations: 16     Fields:    Translation:HumansCells
    2026. Huh YO, Smith TL, Collins P, Bueso-Ramos C, Albitar M, Kantarjian HM, Pierce SA, Freireich EJ. Terminal deoxynucleotidyl transferase expression in acute myelogenous leukemia and myelodysplasia as determined by flow cytometry. Leuk Lymphoma. 2000 Apr; 37(3-4):319-31. PMID: 10752983.
      Citations: 5     Fields:    Translation:Humans
    2027. Chung CY, Kantarjian H, Haidar M, Starostik P, Manshouri T, Gidel C, Freireich E, Keating M, Albitar M. Deletions in the 13q14 locus in adult lymphoblastic leukemia: rate of incidence and relevance. Cancer. 2000 Mar 15; 88(6):1359-64. PMID: 10717617.
      Citations: 2     Fields:    Translation:HumansCells
    2028. Keating MJ, Smith TL, Lerner S, O'Brien S, Robertson LE, Kantarjian H, Freireich EJ. Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leuk Lymphoma. 2000 Mar; 37(1-2):71-85. PMID: 10721771.
      Citations: 1     Fields:    Translation:Humans
    2029. Haidar MA, Manshouri T, Keating MJ, Kantarjian HM, Freireich EJ, Mehta K, Albitar M. Downregulation of the p53 tumor suppressor gene and upregulation of the bcl-2 gene in retinoic acid receptor alpha-deficient transgenic mice. Int J Oncol. 2000 Mar; 16(3):561-5. PMID: 10675490.
      Citations: 1     Fields:    Translation:HumansAnimals
    2030. Haidar MA, Kantarjian H, Manshouri T, Chang CY, O'Brien S, Freireich E, Keating M, Albitar M. ATM gene deletion in patients with adult acute lymphoblastic leukemia. Cancer. 2000 Mar 01; 88(5):1057-62. PMID: 10699895.
      Citations: 16     Fields:    Translation:HumansCells
    2031. Giles FJ, Wong GC, Clark SJ, Pierce S, Kantarjian HM, Keating MJ. Oral idarubicin in patients with late chronic phase chronic myelogenous leukemia or chronic myelomonocytic leukemia. Leuk Lymphoma. 2000 Mar; 37(1-2):87-95. PMID: 10721772.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    2032. Kaban K, Kantarjian H, Talpaz M, O'Brien S, Cortes J, Giles FJ, Pierce S, Albitar M. Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy. Cancer. 2000 Feb 01; 88(3):570-6. PMID: 10649249.
      Citations:    Fields:    Translation:HumansCells
    2033. Vey N, Giles FJ, Kantarjian H, Smith TL, Beran M, Jeha S. The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia. Clin Cancer Res. 2000 Feb; 6(2):731-6. PMID: 10690560.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    2034. Cortes J, Estey E, Beran M, O'Brien S, Giles F, Koller C, Keating M, Kantarjian H. Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia. Leuk Lymphoma. 2000 Feb; 36(5-6):479-84. PMID: 10784392.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    2035. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000 Feb; 18(3):547-61. PMID: 10653870.
      Citations: 213     Fields:    Translation:HumansCTClinical Trials
    2036. Keyhani A, Huh YO, Jendiroba D, Pagliaro L, Cortez J, Pierce S, Pearlman M, Estey E, Kantarjian H, Freireich EJ. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. Leuk Res. 2000 Feb; 24(2):153-9. PMID: 10654451.
      Citations: 27     Fields:    Translation:Humans
    2037. Cortes J, Kantarjian HM. Promising approaches in acute leukemia. Invest New Drugs. 2000 Feb; 18(1):57-82. PMID: 10830141.
      Citations:    Fields:    Translation:HumansAnimals
    2038. Faber J, Kantarjian H, Roberts MW, Keating M, Freireich E, Albitar M. Terminal deoxynucleotidyl transferase-negative acute lymphoblastic leukemia. Arch Pathol Lab Med. 2000 Jan; 124(1):92-7. PMID: 10629138.
      Citations: 10     Fields:    Translation:Humans
    2039. Faderl S, Kantarjian HM, Thomas DA, Cortes J, Giles F, Pierce S, Albitar M, Estrov Z. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma. 2000 Jan; 36(3-4):263-73. PMID: 10674898.
      Citations: 32     Fields:    Translation:HumansCells
    2040. Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Tsimberidou AM, Medeiros LJ, Samuels B, Pate O, Oholendt M, Kantarjian H, Burge C, Cabanillas F. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol. 2000 Jan; 11(1):69-72. PMID: 10690390.
      Citations: 30     Fields:    Translation:HumansAnimalsCTClinical Trials
    2041. Rodriguez J, Cortes J, Talpaz M, O'Brien S, Smith TL, Rios MB, Kantarjian H. Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia. Clin Cancer Res. 2000 Jan; 6(1):147-52. PMID: 10656443.
      Citations: 4     Fields:    Translation:Humans
    2042. Kantarjian H, Melo JV, Tura S, Giralt S, Talpaz M. Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies. Hematology Am Soc Hematol Educ Program. 2000; 90-109. PMID: 11701537.
      Citations: 10     Fields:    
    2043. Sacchi S, Kantarjian HM, O'Brien S, Cortes J, Rios MB, Giles FJ, Beran M, Koller CA, Keating MJ, Talpaz M. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999 Dec 15; 86(12):2632-41. PMID: 10594858.
      Citations: 21     Fields:    Translation:Humans
    2044. Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, Giles F, Estrov Z, Barlogie B, Albitar M. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999 Dec 01; 94(11):3717-21. PMID: 10572084.
      Citations: 45     Fields:    Translation:Humans
    2045. Koller CA, Kantarjian HM, Feldman EJ, O'Brien S, Rios MB, Estey E, Keating M. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia. Cancer. 1999 Dec 01; 86(11):2246-51. PMID: 10590364.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    2046. Ravandi F, Cortes J, Albitar M, Arlinghaus R, Qiang Guo J, Talpaz M, Kantarjian HM. Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance. Br J Haematol. 1999 Dec; 107(3):581-6. PMID: 10583263.
      Citations: 11     Fields:    Translation:Humans
    2047. Lin CW, O'Brien S, Faber J, Manshouri T, Romaguera J, Huh YO, Kantarjian H, Keating M, Albitar M. De novo CD5+ Burkitt lymphoma/leukemia. Am J Clin Pathol. 1999 Dec; 112(6):828-35. PMID: 10587706.
      Citations: 3     Fields:    Translation:HumansCells
    2048. Kantarjian HM, Talpaz M, O'Brien S, Manshouri T, Cortes J, Giles F, Rios MB, Croce CM, Albitar M. Significance of FHIT expression in chronic myelogenous leukemia. Clin Cancer Res. 1999 Dec; 5(12):4059-64. PMID: 10632340.
      Citations: 2     Fields:    Translation:HumansCells
    2049. Giles FJ, O'Brien SM, Santini V, Gandhi V, Plunkett W, Seymour JF, Robertson LE, Kantarjian HM, Keating MJ. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma. 1999 Dec; 36(1-2):57-65. PMID: 10613450.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    2050. Partyka S, O'Brien S, Podoloff D, Kantarjian H, Keating MJ. The usefulness of high dose (7-10mci) gallium (67Ga) scanning to diagnose Richter's transformation. Leuk Lymphoma. 1999 Dec; 36(1-2):151-5. PMID: 10613460.
      Citations: 4     Fields:    Translation:Humans
    2051. Faderl S, Thall PF, Kantarjian HM, Talpaz M, Harris D, Van Q, Beran M, Kornblau SM, Pierce S, Estrov Z. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res. 1999 Dec; 5(12):4041-7. PMID: 10632337.
      Citations: 18     Fields:    Translation:HumansCells
    2052. Moravcov? J, N?dvorn?kov? S, Luk?sov? M, Klamov? H. Polymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia. Blood. 1999 Nov 15; 94(10):3609-11. PMID: 10610116.
      Citations:    Fields:    Translation:Humans
    2053. Khouri IF, Lee MS, Romaguera J, Mirza N, Kantarjian H, Korbling M, Albitar M, Giralt S, Samuels B, Anderlini P, Rodriguez J, von Wolff B, Gajewski J, Cabanillas F, Champlin R. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol. 1999 Nov; 10(11):1293-9. PMID: 10631455.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    2054. Sacchi S, Kantarjian HM, Freireich EJ, O'Brien S, Cortes J, Rios MB, Kornblau S, Giles FJ, Koller C, Gajewski J, Talpaz M. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia. Leuk Lymphoma. 1999 Nov; 35(5-6):483-9. PMID: 10609785.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    2055. Estrov Z, Manna SK, Harris D, Van Q, Estey EH, Kantarjian HM, Talpaz M, Aggarwal BB. Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood. 1999 Oct 15; 94(8):2844-53. PMID: 10515888.
      Citations: 22     Fields:    Translation:HumansCells
    2056. Kantarjian H. New developments in the treatment of acute myeloid leukemia: focus on topotecan. Semin Hematol. 1999 Oct; 36(4 Suppl 8):16-25. PMID: 10622225.
      Citations: 1     Fields:    Translation:Humans
    2057. Estey EH, Giles FJ, Kantarjian H, O'Brien S, Cortes J, Freireich EJ, Lopez-Berestein G, Keating M. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood. 1999 Oct 01; 94(7):2230-5. PMID: 10498593.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    2058. Aguayo A, Cortes J, Thomas D, Pierce S, Keating M, Kantarjian H. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer. 1999 Oct 01; 86(7):1203-9. PMID: 10506705.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    2059. Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O'Brien S, Giles FJ, Gajewski J, Pierce S, Keating MJ. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999 Oct 01; 86(7):1216-30. PMID: 10506707.
      Citations: 75     Fields:    Translation:HumansCTClinical Trials
    2060. Beran M, Kantarjian H. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Semin Hematol. 1999 Oct; 36(4 Suppl 8):3-10. PMID: 10622223.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    2061. Beran M, Estey E, O'Brien S, Cortes J, Koller CA, Giles FJ, Kornblau S, Andreeff M, Vey N, Pierce SR, Hayes K, Wong GC, Keating M, Kantarjian H. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol. 1999 Sep; 17(9):2819-30. PMID: 10561358.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    2062. Ravandi-Kashani F, Cortes J, Cohen P, Talpaz M, O'Brien S, Markowitz A, Kantarjian H. Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leuk Lymphoma. 1999 Sep; 35(1-2):109-18. PMID: 10512168.
      Citations: 4     Fields:    Translation:Humans
    2063. Cortes J, Fayad L, O'Brien S, Keating M, Kantarjian H. Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity. Clin Cancer Res. 1999 Sep; 5(9):2491-7. PMID: 10499624.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    2064. Faderl S, Estrov Z, Kantarjian HM, Thomas D, Cortes J, Manshouri T, Chan CC, Hays KJ, Pierce S, Albitar M. The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia. Cytokines Cell Mol Ther. 1999 Sep; 5(3):159-63. PMID: 10641574.
      Citations: 4     Fields:    Translation:HumansCells
    2065. Giles FJ, Kantarjian HM, Cortes J, Thomas DA, Talpaz M, Manshouri T, Albitar M. Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance. Cancer. 1999 Sep 01; 86(5):805-13. PMID: 10463979.
      Citations: 9     Fields:    Translation:Humans
    2066. Starostik P, O'Brien S, Chung CY, Haidar M, Manshouri T, Kantarjian H, Freireich E, Keating M, Albitar M. The prognostic significance of 13q14 deletions in chronic lymphocytic leukemia. Leuk Res. 1999 Sep; 23(9):795-801. PMID: 10475618.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    2067. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood. 1999 Sep 01; 94(5):1517-36. PMID: 10477676.
      Citations: 52     Fields:    Translation:Humans
    2068. Lion T. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making. Blood. 1999 Aug 15; 94(4):1486-8. PMID: 10484639.
      Citations:    Fields:    Translation:Humans
    2069. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999 Aug 03; 131(3):207-19. PMID: 10428738.
      Citations: 73     Fields:    Translation:HumansCells
    2070. Seong D, Kantarjian HM, Albitar M, Arlinghaus R, Xu J, Talpaz M, Rios MB, Guo JQ, O'Brien S, Siciliano M. Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization. Ann Oncol. 1999 Aug; 10(8):955-9. PMID: 10509158.
      Citations: 9     Fields:    Translation:HumansCells
    2071. Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, Hagemeister FB, Cabanillas FF, Murphy S, Keating MJ, Kantarjian H. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999 Aug; 17(8):2461-70. PMID: 10561310.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    2072. Wilhelm M, O'Brien S, Rios MB, Estey E, Keating MJ, Plunkett W, Sorenson M, Kantarjian HM. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase. Leuk Lymphoma. 1999 Aug; 34(5-6):511-8. PMID: 10492074.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    2073. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999 Jul 15; 341(3):164-72. PMID: 10403855.
      Citations: 297     Fields:    Translation:HumansCells
    2074. Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff M. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res. 1999 Jul; 5(7):1758-66. PMID: 10430080.
      Citations: 24     Fields:    Translation:Humans
    2075. Faderl S, Kantarjian HM, Manshouri T, Chan CY, Pierce S, Hays KJ, Cortes J, Thomas D, Estrov Z, Albitar M. The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia. Clin Cancer Res. 1999 Jul; 5(7):1855-61. PMID: 10430092.
      Citations: 5     Fields:    Translation:HumansCells
    2076. Ravandi-Kashani F, Cortes J, Talpaz M, Kantarjian HM. Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect? Cancer. 1999 Jun 15; 85(12):2583-8. PMID: 10375106.
      Citations: 9     Fields:    Translation:Humans
    2077. O'Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreeff M, Giralt S, Cheson B, Keating M, Freireich E, Rios MB, Talpaz M. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood. 1999 Jun 15; 93(12):4149-53. PMID: 10361112.
      Citations: 17     Fields:    Translation:HumansCells
    2078. Dabaja BS, Faderl S, Thomas D, Cortes J, O'Brien S, Nasr F, Pierce S, Hayes K, Glassman A, Keating M, Kantarjian HM. Deletions and losses in chromosomes 5 or 7 in adult acute lymphocytic leukemia: incidence, associations and implications. Leukemia. 1999 Jun; 13(6):869-72. PMID: 10360374.
      Citations: 2     Fields:    Translation:HumansCells
    2079. Aboul-Nasr R, Estey EH, Kantarjian HM, Freireich EJ, Andreeff M, Johnson BJ, Albitar M. Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens. Am J Clin Pathol. 1999 Jun; 111(6):753-8. PMID: 10361510.
      Citations: 6     Fields:    Translation:HumansCells
    2080. Weinkauff R, Estey EH, Starostik P, Hayes K, Huh YO, Hirsch-Ginsberg C, Andreeff M, Keating M, Kantarjian HM, Freireich EJ, Albitar M. Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia. Am J Clin Pathol. 1999 Jun; 111(6):733-40. PMID: 10361507.
      Citations: 16     Fields:    Translation:HumansCells
    2081. Estey EH, Thall PF, Reed P, Kantarjian H, Beran M, Pierce S, Keating MJ. Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy. Leukemia. 1999 Jun; 13(6):850-4. PMID: 10360371.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    2082. Patmasiriwat P, Fraizer G, Kantarjian H, Saunders GF. WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia. Leukemia. 1999 Jun; 13(6):891-900. PMID: 10360378.
      Citations: 10     Fields:    Translation:Humans
    2083. Vey N, Kantarjian H, Tran H, Beran M, O'Brien S, Bivins C, Giles F, Cortes J, Cheson B, Arbuck S, Estey E. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia. Ann Oncol. 1999 May; 10(5):577-83. PMID: 10416008.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    2084. Faderl S, Talpaz M, Kantarjian HM, Estrov Z. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood. 1999 May 01; 93(9):2755-9. PMID: 10216068.
      Citations: 7     Fields:    Translation:Humans
    2085. Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999 Apr 15; 93(8):2478-84. PMID: 10194425.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    2086. Cortes JE, Kantarjian HM, O'Brien S, Giles F, Keating MJ, Freireich EJ, Estey EH. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer. 1999 Apr 01; 85(7):1506-13. PMID: 10193940.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    2087. Issa JP, Kantarjian H, Mohan A, O'Brien S, Cortes J, Pierce S, Talpaz M. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood. 1999 Mar 15; 93(6):2075-80. PMID: 10068681.
      Citations: 9     Fields:    Translation:HumansCells
    2088. Faderl S, Kantarjian HM, Talpaz M. Chronic myelogenous leukemia: update on biology and treatment. Oncology (Williston Park). 1999 Feb; 13(2):169-80; discussion 181, 184. PMID: 10079468.
      Citations: 20     Fields:    Translation:HumansCells
    2089. Albitar M, Chang KS, Pierce S, Kantarjian H, Estey E. The short form of PML-RARalpha fusion transcript is associated with poor survival. Leuk Res. 1999 Jan; 23(1):89-92. PMID: 9933141.
      Citations: 2     Fields:    Translation:Humans
    2090. Cortes J, O'Brien S, Estey E, Giles F, Keating M, Kantarjian H. Phase I study of liposomal daunorubicin in patients with acute leukemia. Invest New Drugs. 1999; 17(1):81-7. PMID: 10555126.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    2091. Vey N, Kantarjian H, Beran M, O'Brien S, Cortes J, Koller C, Estey E. Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study. Invest New Drugs. 1999; 17(1):89-95. PMID: 10555127.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    2092. Kantarjian HM, O'Brien S, Smith TL, Rios MB, Cortes J, Beran M, Koller C, Giles FJ, Andreeff M, Kornblau S, Giralt S, Keating MJ, Talpaz M. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol. 1999 Jan; 17(1):284-92. PMID: 10458244.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    2093. Aguayo A, Cortes JE, Kantarjian HM, Beran M, Gandhi V, Plunkett W, Kurtzberg J, Keating MJ. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. Cancer. 1999 Jan 01; 85(1):58-64. PMID: 9921974.
      Citations: 5     Fields:    Translation:HumansCells
    2094. Albitar M, Manshouri T, Kantarjian H, Keating M, Estrov Z, Faber J, Freireich EJ, Pierce S, Estey E. Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia. Leuk Res. 1999 Jan; 23(1):63-9. PMID: 9933137.
      Citations: 3     Fields:    Translation:Humans
    2095. Jeha S, Kantarjian H, O'Brien S, Vitek L, Beran M. Activity of oral and intravenous 9-aminocamptothecin in SCID mice engrafted with human leukemia. Leuk Lymphoma. 1998 Dec; 32(1-2):159-64. PMID: 10037011.
      Citations: 1     Fields:    Translation:HumansAnimals
    2096. Rodriguez J, Cortes J, Smith T, O'Brien S, Rios MB, Talpaz M, Kantarjian H. Determinants of prognosis in late chronic-phase chronic myelogenous leukemia. J Clin Oncol. 1998 Dec; 16(12):3782-7. PMID: 9850022.
      Citations: 3     Fields:    Translation:Humans
    2097. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998 Dec; 16(12):3803-9. PMID: 9850025.
      Citations: 60     Fields:    Translation:Humans
    2098. Beran M, Estey E, O'Brien SM, Giles FJ, Koller CA, Kornblau S, Keating M, Kantarjian HM. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma. 1998 Nov; 31(5-6):521-31. PMID: 9922042.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    2099. Estrov Z, Thall PF, Talpaz M, Estey EH, Kantarjian HM, Andreeff M, Harris D, Van Q, Walterscheid M, Kornblau SM. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood. 1998 Nov 01; 92(9):3090-7. PMID: 9787143.
      Citations: 45     Fields:    Translation:HumansCells
    2100. Kantarjian HM, Talpaz M. Questions raised by the Benelux CML Study Group: results from the randomized study with hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha2b for chronic myeloid leukemia. Blood. 1998 Oct 15; 92(8):2984-7. PMID: 9763593.
      Citations:    Fields:    Translation:Humans
    2101. Starostik P, Manshouri T, O'Brien S, Freireich E, Kantarjian H, Haidar M, Lerner S, Keating M, Albitar M. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res. 1998 Oct 15; 58(20):4552-7. PMID: 9788599.
      Citations: 12     Fields:    Translation:HumansCells
    2102. Anaissie EJ, Kontoyiannis DP, O'Brien S, Kantarjian H, Robertson L, Lerner S, Keating MJ. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998 Oct 01; 129(7):559-66. PMID: 9758577.
      Citations: 30     Fields:    Translation:Humans
    2103. Cortes J, Talpaz M, O'Brien S, Rios MB, Majlis A, Keating M, Freireich EJ, Kantarjian H. Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. J Clin Oncol. 1998 Oct; 16(10):3279-85. PMID: 9779702.
      Citations: 7     Fields:    Translation:Humans
    2104. Krainick U, Kantarjian H, Broussard S, Talpaz M. Local cutaneous necrotizing lesions associated with interferon injections. J Interferon Cytokine Res. 1998 Oct; 18(10):823-7. PMID: 9809617.
      Citations: 1     Fields:    Translation:Humans
    2105. Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE, Freireich EJ, Estey E, Kantarjian H. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998 Aug 15; 92(4):1165-71. PMID: 9694704.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    2106. Kornblau SM, Andreeff M, Hu SX, Xu HJ, Patel S, Theriault A, Koller C, Kantarjian H, Estey E, Deisseroth AB, Benedict WF. Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study. Clin Cancer Res. 1998 Aug; 4(8):1955-63. PMID: 9717825.
      Citations: 1     Fields:    Translation:HumansCells
    2107. Jendiroba DB, Lichtiger B, Anaissie E, Reddy V, O'Brien S, Kantarjian H, Freireich EJ. Evaluation and comparison of three mobilization methods for the collection of granulocytes. Transfusion. 1998 Aug; 38(8):722-8. PMID: 9709779.
      Citations: 2     Fields:    Translation:HumansCells
    2108. Kantarjian H. New advances in the treatment of hematologic malignancies: focus on topoisomerase I inhibitors. Introduction. Semin Hematol. 1998 Jul; 35(3 Suppl 4):1-2. PMID: 9779875.
      Citations:    Fields:    Translation:Humans
    2109. Gandhi V, Plunkett W, Kantarjian H, Talpaz M, Robertson LE, O'Brien S. Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. J Clin Oncol. 1998 Jul; 16(7):2321-31. PMID: 9667246.
      Citations: 11     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    2110. Beran M, Kantarjian H. Topotecan in the treatment of hematologic malignancies. Semin Hematol. 1998 Jul; 35(3 Suppl 4):26-31. PMID: 9779879.
      Citations: 3     Fields:    Translation:Humans
    2111. Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998 Jul; 4(7):1661-72. PMID: 9676840.
      Citations: 21     Fields:    Translation:HumansCells
    2112. Cortes J, Kantarjian H, O'Brien S, Kurzrock R, Keating M, Talpaz M. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. Leukemia. 1998 Jun; 12(6):860-4. PMID: 9639411.
      Citations: 10     Fields:    Translation:HumansCells
    2113. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 1998 Jun 01; 91(11):3995-4019. PMID: 9596644.
      Citations: 53     Fields:    Translation:Humans
    2114. Englund JA, Champlin RE, Wyde PR, Kantarjian H, Atmar RL, Tarrand J, Yousuf H, Regnery H, Klimov AI, Cox NJ, Whimbey E. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis. 1998 Jun; 26(6):1418-24. PMID: 9636873.
      Citations: 31     Fields:    Translation:HumansCells
    2115. Schenk TM, Keyhani A, Bottcher S, Kliche KO, Goodacre A, Guo JQ, Arlinghaus RB, Kantarjian HM, Andreeff M. Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia. 1998 May; 12(5):666-74. PMID: 9593263.
      Citations: 8     Fields:    Translation:HumansCells
    2116. Randhawa GS, Cui H, Barletta JA, Strichman-Almashanu LZ, Talpaz M, Kantarjian H, Deisseroth AB, Champlin RC, Feinberg AP. Loss of imprinting in disease progression in chronic myelogenous leukemia. Blood. 1998 May 01; 91(9):3144-7. PMID: 9558368.
      Citations: 18     Fields:    Translation:HumansCells
    2117. Seong D, Thall P, Kantarjian HM, Talpaz M, Swantkowski J, Xu J, Shen Y, Glassman A, Ramagli L, Siciliano MJ. Philadelphia chromosome-positive myeloid cells in the peripheral blood of chronic myelogenous leukemia patients: comparison with the frequency detected in cycling cells of the bone marrow. Clin Cancer Res. 1998 Apr; 4(4):861-7. PMID: 9563879.
      Citations:    Fields:    Translation:HumansCells
    2118. Cortes J, Fayad L, Kantarjian H, O'Brien S, Lee MS, Talpaz M. Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia. Leukemia. 1998 Apr; 12(4):455-62. PMID: 9557601.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    2119. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol. 1998 Apr; 16(4):1526-31. PMID: 9552062.
      Citations: 5     Fields:    Translation:Humans
    2120. DeLima M, Albitar M, O'Brien S, Pierce S, Kantarjian H, Andreeff M, Fayad L, Keating M, Estey E. Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia. Am J Med. 1998 Mar; 104(3):246-51. PMID: 9552087.
      Citations: 5     Fields:    Translation:Humans
    2121. Sacchi S, Kantarjian HM, Smith TL, O'Brien S, Pierce S, Kornblau S, Beran M, Keating MJ, Talpaz M. Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia. J Clin Oncol. 1998 Mar; 16(3):882-9. PMID: 9508169.
      Citations:    Fields:    Translation:Humans
    2122. Kantarjian HM, Giles FJ, O'Brien SM, Talpaz M. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin North Am. 1998 Feb; 12(1):31-80. PMID: 9523225.
      Citations: 8     Fields:    Translation:Humans
    2123. Munker R, Kantarjian H, O'Brien S, Keating M, Andreeff M, Estey EH. Phase I study of taxol in refractory acute myelogenous leukemias using a weekly schedule. Acta Haematol. 1998; 99(2):106-8. PMID: 9554461.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    2124. Bueso-Ramos C, O'Brien S, Pierce S, Keating M, Talpaz M, Kantarjian HM, Wilhelm M. Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia. Leukemia. 1998 Jan; 12(1):65-70. PMID: 9436922.
      Citations:    Fields:    Translation:Humans
    2125. Kornblau SM, Kantarjian H, O'Brien S, Andreeff M, Koller CA, Beran M, Keating M, Estey E. CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia. Leuk Lymphoma. 1998 Jan; 28(3-4):371-5. PMID: 9517508.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    2126. Ravandi-Kashani F, Cortes J, Kantarjian H, Talpaz M. Chronic Myeloid Leukemia: Current Guidelines for Diagnosis and Management. Hematology. 1998; 3(4):263-76. PMID: 27413879.
      Citations:    Fields:    
    2127. de Lima M, Strom SS, Keating M, Kantarjian H, Pierce S, O'Brien S, Freireich E, Estey E. Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. Blood. 1997 Dec 15; 90(12):4719-24. PMID: 9389687.
      Citations: 16     Fields:    Translation:Humans
    2128. Beran M, Jeha S, O'Brien S, Estey E, Vitek L, Zurlo MG, Rios MB, Keating M, Kantarjian H. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2377-84. PMID: 9815637.
      Citations: 2     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    2129. Koller CA, Kantarjian HM, Thomas D, O'Brien S, Rios MB, Kornblau S, Murphy S, Keating M. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia. 1997 Dec; 11(12):2039-44. PMID: 9447817.
      Citations: 14     Fields:    Translation:Humans
    2130. Kantarjian HM, Talpaz M, O'Brien S, Kurzrock R, Gutterman J, Keating MJ, McCredie KB, Freireich EJ. Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture. Clin Cancer Res. 1997 Dec; 3(12 Pt 2):2723-33. PMID: 10068280.
      Citations: 2     Fields:    Translation:Humans
    2131. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 1997 Oct 15; 90(8):2969-77. PMID: 9376577.
      Citations: 34     Fields:    Translation:HumansCells
    2132. Dignani MC, Anaissie EJ, Hester JP, O'Brien S, Vartivarian SE, Rex JH, Kantarjian H, Jendiroba DB, Lichtiger B, Andersson BS, Freireich EJ. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia. 1997 Oct; 11(10):1621-30. PMID: 9324280.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    2133. Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia. 1997 Oct; 11(10):1661-4. PMID: 9324286.
      Citations: 31     Fields:    Translation:Humans
    2134. Kantarjian HM, O'Brien SM, Keating M, Beran M, Estey E, Giralt S, Kornblau S, Rios MB, de Vos D, Talpaz M. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia. 1997 Oct; 11(10):1617-20. PMID: 9324279.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    2135. Sacchi S, Kantarjian HM, O'Brien S, Beran M, Koller C, Pierce S, Kornblau S, Estey E, Keating MJ, Talpaz M. Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia. Leukemia. 1997 Oct; 11(10):1610-6. PMID: 9324278.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    2136. O'Brien S, Kantarjian H, Beran M, Koller C, Talpaz M, Lerner S, Keating MJ. Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia. 1997 Oct; 11(10):1631-5. PMID: 9324281.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    2137. Bseiso AW, Kantarjian HM, Guo JQ, Cortes J, Talpaz M, Koller C, AlBitar M, Keating M, Arlinghaus R. Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia. Leukemia. 1997 Sep; 11(9):1583-7. PMID: 9305617.
      Citations:    Fields:    Translation:Humans
    2138. Giles FJ, Kantarjian HM. Biology and treatment of chronic myelogenous leukemia. Oncology (Williston Park). 1997 Sep; 11(9):1295-300; discussion 1302-10. PMID: 9306419.
      Citations: 1     Fields:    Translation:HumansCells
    2139. Spector N, Pulcheri W, Nucci M, Maiolino A. Comparing an apple to a fruit salad. J Clin Oncol. 1997 Aug; 15(8):3021-2. PMID: 9256146.
      Citations:    Fields:    Translation:Humans
    2140. Rodriguez-Monge EJ, Cortes JE, O'Brien S, Talpaz M, Kantarjian HM. Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia. Cancer. 1997 Aug 01; 80(3):396-400. PMID: 9241073.
      Citations:    Fields:    Translation:HumansCells
    2141. Cortes J, Kantarjian H, O'Brien S, Beran M, Estey E, Keating M, Talpaz M. A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Leukemia. 1997 Jul; 11(7):929-32. PMID: 9204970.
      Citations: 2     Fields:    Translation:Humans
    2142. Bouvet M, Babiera GV, Termuhlen PM, Hester JP, Kantarjian HM, Pollock RE. Splenectomy in the accelerated or blastic phase of chronic myelogenous leukemia: a single-institution, 25-year experience. Surgery. 1997 Jul; 122(1):20-5. PMID: 9225910.
      Citations: 2     Fields:    Translation:Humans
    2143. Giralt S, Estey E, Albitar M, van Besien K, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Keating M, Kantarjian H, Champlin R, Rond?n G, K?rbling M. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15; 89(12):4531-6. PMID: 9192777.
      Citations: 150     Fields:    Translation:HumansCTClinical Trials
    2144. Cortes J, Kantarjian H, Talpaz M, O'Brien S, Beran M, Koller C, Keating M. Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine. Leukemia. 1997 Jun; 11(6):788-91. PMID: 9177428.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    2145. Cortes J, Kantarjian HM, Giralt S, Talpaz M. Natural history and staging of chronic myelogenous leukaemia. Baillieres Clin Haematol. 1997 Jun; 10(2):277-90. PMID: 9376664.
      Citations: 4     Fields:    Translation:Humans
    2146. Talpaz M, Kantarjian HM, O'Brien S, Kurzrock R. The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia. Baillieres Clin Haematol. 1997 Jun; 10(2):291-305. PMID: 9376665.
      Citations:    Fields:    Translation:Humans
    2147. Fayad L, Kantarjian H, O'Brien S, Seong D, Albitar M, Keating M, Talpaz M. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia. 1997 May; 11(5):767-71. PMID: 9180306.
      Citations: 7     Fields:    Translation:HumansCells
    2148. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol. 1997 May; 15(5):1796-802. PMID: 9164187.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    2149. Seong D, Giralt S, Fischer H, Hayes K, Glassman A, Arlinghaus R, Xu J, Kantarjian H, Siciliano M, Champlin R. Usefulness of detection of minimal residual disease by 'hypermetaphase' fluorescent in situ hybridization after allogeneic BMT for chronic myelogenous leukemia. Bone Marrow Transplant. 1997 Mar; 19(6):565-70. PMID: 9085736.
      Citations:    Fields:    Translation:Humans
    2150. Kantarjian HM, O'Brien SM, Estey E, Giralt S, Beran M, Rios MB, Keating M, de Vos D, Talpaz M. Decitabine studies in chronic and acute myelogenous leukemia. Leukemia. 1997 Mar; 11 Suppl 1:S35-6. PMID: 9130691.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    2151. Gisslinger H, Kurzrock R, Wetzler M, Tucker S, Kantarjian H, Robertson B, Talpaz M. Apoptosis in chronic myelogenous leukemia: studies of stage-specific differences. Leuk Lymphoma. 1997 Mar; 25(1-2):121-33. PMID: 9130620.
      Citations: 1     Fields:    Translation:HumansCells
    2152. Giralt S, Davis M, O'Brien S, van Besien K, Champlin R, de Vos D, Kantarjian H. Studies of decitabine with allogeneic progenitor cell transplantation. Leukemia. 1997 Mar; 11 Suppl 1:S32-4. PMID: 9130690.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    2153. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol. 1997 Feb; 15(2):483-90. PMID: 9053469.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    2154. Bseiso AW, Kantarjian H, Estey E. Myelodysplastic syndrome following successful therapy of acute promyelocytic leukemia. Leukemia. 1997 Jan; 11(1):168-9. PMID: 9001434.
      Citations: 6     Fields:    Translation:Humans
    2155. Sacchi S, Cortes J, Kantarjian H, Talpaz M. Effects of interferon-alpha therapy on lymphocyte subpopulations in patients with chronic myeloid leukemia. Hematopathol Mol Hematol. 1997-1998; 11(1):41-7. PMID: 9439979.
      Citations:    Fields:    Translation:HumansCells
    2156. Kantarjian HM, O'Brien S, Pierce S, Keating MJ, Freireich EJ, Estey EH, Wilhelm M. Pneumonia during remission induction chemotherapy in patients with AML or MDS. Leukemia. 1996 Dec; 10(12):1870-3. PMID: 8946924.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    2157. Keating MJ, O'Brien S, McLaughlin P, Dimopoulos M, Gandhi V, Plunkett W, Lerner S, Kantarjian H, Estey E. Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther. 1996 Dec; 38 Suppl 2:S83-91. PMID: 9137961.
      Citations: 3     Fields:    Translation:Humans
    2158. Guo JQ, Lian J, Glassman A, Talpaz M, Kantarjian H, Deisseroth AB, Arlinghaus RB. Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients. Am J Clin Pathol. 1996 Oct; 106(4):442-8. PMID: 8853030.
      Citations: 1     Fields:    Translation:HumansCells
    2159. O'Brien S, Kantarjian H, Talpaz M. Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha. Leuk Lymphoma. 1996 Oct; 23(3-4):247-52. PMID: 9031105.
      Citations: 3     Fields:    Translation:Humans
    2160. Beran M, Kantarjian H, O'Brien S, Koller C, al-Bitar M, Arbuck S, Pierce S, Moore M, Abbruzzese JL, Andreeff M, Keating M, Estey E. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 1996 Oct 01; 88(7):2473-9. PMID: 8839838.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    2161. Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996 Oct; 10(10):1563-9. PMID: 8847890.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    2162. Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood. 1996 Jul 15; 88(2):756. PMID: 8695828.
      Citations: 31     Fields:    Translation:Humans
    2163. Patmasiriwat P, Fraizer GC, Claxton D, Kantarjian H, Saunders GF. Expression pattern of WT1 and GATA-1 in AML with chromosome 16q22 abnormalities. Leukemia. 1996 Jul; 10(7):1127-33. PMID: 8683991.
      Citations: 3     Fields:    Translation:HumansCells
    2164. Ghaddar HM, Pierce S, Kantarjian HM, Freireich EJ, Keating MJ, Estey EH. Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Leuk Lymphoma. 1996 Jun; 22(1-2):71-6. PMID: 8724530.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    2165. Dimopoulos MA, Weber D, Kantarjian H, Delasalle KB, Alexanian R. HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol. 1996 Jun; 52(2):77-81. PMID: 8638645.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    2166. Anderlini P, Ghaddar HM, Smith TL, Pierce S, Kantarjian HM, O'Brien S, Keating MJ, Freireich EJ, Estey EH. Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. Leukemia. 1996 Jun; 10(6):964-9. PMID: 8667653.
      Citations: 5     Fields:    Translation:Humans
    2167. Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med. 1996 May; 100(5):555-70. PMID: 8644769.
      Citations: 19     Fields:    Translation:Humans
    2168. Khouri IF, Kantarjian HM, Talpaz M, Giralt S, Rios MO, Hester JP, Champlin RE, Deisseroth AB. Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience. Bone Marrow Transplant. 1996 May; 17(5):775-9. PMID: 8733697.
      Citations: 1     Fields:    Translation:Humans
    2169. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M. Treatment of myelogenous leukemia: current status and investigational options. Blood. 1996 Apr 15; 87(8):3069-81. PMID: 8605319.
      Citations: 19     Fields:    Translation:Humans
    2170. Anderlini P, Luna M, Kantarjian HM, O'Brien S, Pierce S, Keating MJ, Estey EH. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 1996 Apr; 10(4):600-8. PMID: 8618434.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    2171. Kantarjian HM, Estey EH, Keating MA. New chemotherapeutic agents in acute myeloid leukemia. Leukemia. 1996 Apr; 10 Suppl 1:S4-6. PMID: 8618470.
      Citations: 6     Fields:    Translation:Humans
    2172. Anderlini P, Pierce S, Kantarjian H, Estey E. Acute myeloid leukemia-type chemotherapy for myelodysplasia. J Clin Oncol. 1996 Apr; 14(4):1404-5. PMID: 8648402.
      Citations:    Fields:    Translation:Humans
    2173. Cortes J, Kantarjian H, O'Brien S, Robertson LE, Pierce S, Talpaz M. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med. 1996 Apr; 100(4):452-5. PMID: 8610733.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    2174. Jeha S, Luo XN, Beran M, Kantarjian H, Atweh GF. Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells. Cancer Res. 1996 Mar 15; 56(6):1445-50. PMID: 8640838.
      Citations: 18     Fields:    Translation:AnimalsCells
    2175. Estrov Z, Talpaz M, Zipf TF, Kantarjian HM, Ku S, Ouspenskaia MV, Hirsch-Ginsberg C, Huh Y, Yee G, Kurzrock R. Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). J Cell Physiol. 1996 Mar; 166(3):618-30. PMID: 8600166.
      Citations: 9     Fields:    Translation:HumansCells
    2176. Escudier SM, Albitar M, Robertson LE, Andreeff M, Pierce S, Kantarjian HM. Acute lymphoblastic leukemia following preleukemic syndromes in adults. Leukemia. 1996 Mar; 10(3):473-7. PMID: 8642864.
      Citations: 5     Fields:    Translation:Humans
    2177. Kantarjian HM, Beran M, O'Brien S, Robertson L, Siddik Z, Yoshida M, Yang LY, Rios MB, Keating MJ, Meyer M, et al. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia. Leukemia. 1996 Mar; 10(3):396-401. PMID: 8642853.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    2178. van Besien KW, Mehra RC, Giralt SA, Kantarjian HM, Pugh WC, Khouri IF, Moon Y, Williams P, Andersson BS, Przepiorka D, McCarthy PL, Gajewski JL, Deisseroth AB, Cabanillas FF, Champlin R. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med. 1996 Mar; 100(3):299-307. PMID: 8629675.
      Citations: 11     Fields:    Translation:Humans
    2179. Sarris A, Cortes J, Kantarjian H, Pierce S, Smith T, Keating M, Koller C, Kornblau S, O'Brien S, Andreeff M. Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl. Leuk Lymphoma. 1996 Mar; 21(1-2):85-92. PMID: 8907274.
      Citations: 7     Fields:    Translation:Humans
    2180. Escudier SM, Kantarjian HM, Estey EH. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. Leuk Lymphoma. 1996 Feb; 20(5-6):435-9. PMID: 8833399.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    2181. O'Brien S, Jeha S, Kantarjian H, Pisa P, Jin G, Keating M, Beran M. Engraftment of chronic prolymphocytic and T cell leukemia in SCID mice. Leukemia. 1996 Feb; 10(2):338-44. PMID: 8637244.
      Citations:    Fields:    Translation:HumansAnimalsCells
    2182. Wright S, Chucrallah A, Chong YY, Kantarjian H, Keating M, Albitar M. Acute lymphoblastic leukemia with myeloperoxidase activity. Am J Hematol. 1996 Feb; 51(2):147-51. PMID: 8579056.
      Citations: 3     Fields:    Translation:Humans
    2183. O'Brien S, Kantarjian H, Keating MJ. Purine analogs in chronic lymphocytic leukemia and Waldenstr?m's macroglobulinemia. Ann Oncol. 1996; 7 Suppl 6:S27-33. PMID: 9010576.
      Citations: 6     Fields:    Translation:Humans
    2184. Anaissie EJ, Vartivarian S, Bodey GP, Legrand C, Kantarjian H, Abi-Said D, Karl C, Vadhan-Raj S. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. Am J Med. 1996 Jan; 100(1):17-23. PMID: 8579082.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    2185. Pollicardo N, O'Brien S, Estey EH, al-Bitar M, Pierce S, Keating M, Kantarjian HM. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution. Leukemia. 1996 Jan; 10(1):27-31. PMID: 8558933.
      Citations: 5     Fields:    Translation:Humans
    2186. Cortes JE, Kantarjian H, Freireich EJ. Acute lymphocytic leukemia: a comprehensive review with emphasis on biology and therapy. Cancer Treat Res. 1996; 84:291-323. PMID: 8724635.
      Citations: 1     Fields:    Translation:Humans
    2187. Majlis A, Smith TL, Talpaz M, O'Brien S, Rios MB, Kantarjian HM. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol. 1996 Jan; 14(1):196-203. PMID: 8558198.
      Citations: 11     Fields:    Translation:HumansCells
    2188. Smith TL, Lee JJ, Kantarjian HM, Legha SS, Raber MN. Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. J Clin Oncol. 1996 Jan; 14(1):287-95. PMID: 8558210.
      Citations: 13     Fields:    Translation:Humans
    2189. Cortes JE, Kantarjian HM. Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy. Cancer. 1995 Dec 15; 76(12):2393-417. PMID: 8625065.
      Citations: 21     Fields:    Translation:HumansAnimals
    2190. Jeha S, Kantarjian H, O'Brien S, Huh Y, Pisa P, Ordonez N, Beran M. Growth and biologic properties of karyotypically defined subcategories of adult acute lymphocytic leukemia in mice with severe combined immunodeficiency. Blood. 1995 Dec 01; 86(11):4278-85. PMID: 7492788.
      Citations: 2     Fields:    Translation:HumansAnimals
    2191. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Seong D, Lee M, Gajewski J, Van Besien K, Khouri I, Mehra R, Przepiorka D, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R, Rond?n G, K?rbling M. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995 Dec 01; 86(11):4337-43. PMID: 7492795.
      Citations: 30     Fields:    Translation:HumansCells
    2192. O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, Hester J, Rios MB, Andreeff M, Talpaz M. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 1995 Nov 01; 86(9):3322-6. PMID: 7579434.
      Citations: 39     Fields:    Translation:Humans
    2193. Preti HA, Huh YO, O'Brien SM, Andreeff M, Pierce ST, Keating M, Kantarjian HM. Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis. Cancer. 1995 Nov 01; 76(9):1564-70. PMID: 8635059.
      Citations: 7     Fields:    Translation:Humans
    2194. Anderlini P, Benjamin RS, Wong FC, Kantarjian HM, Andreeff M, Kornblau SM, O'Brien S, Mackay B, Ewer MS, Pierce SA, et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol. 1995 Nov; 13(11):2827-34. PMID: 7595745.
      Citations: 29     Fields:    Translation:Humans
    2195. Wetzler M, Kantarjian H, Kurzrock R, Talpaz M. Interferon-alpha therapy for chronic myelogenous leukemia. Am J Med. 1995 Oct; 99(4):402-11. PMID: 7573097.
      Citations: 5     Fields:    Translation:Humans
    2196. Seong DC, Kantarjian HM, Ro JY, Talpaz M, Xu J, Robinson JR, Deisseroth AB, Champlin RE, Siciliano MJ. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood. 1995 Sep 15; 86(6):2343-9. PMID: 7662980.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    2197. Verschraegen CF, Kantarjian HM, Hirsch-Ginsberg C, Lee MS, O'Brien S, Rios MB, Stass SA, Keating M, Talpaz M. The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations. Cancer. 1995 Sep 15; 76(6):992-7. PMID: 8625225.
      Citations: 8     Fields:    Translation:HumansCells
    2198. Chucrallah AE, Stass SA, Huh YO, Albitar M, Kantarjian HM. Adult acute lymphoblastic leukemia at relapse. Cytogenetic, immunophenotypic, and molecular changes. Cancer. 1995 Sep 15; 76(6):985-91. PMID: 8625224.
      Citations: 5     Fields:    Translation:Humans
    2199. Cortes J, O'Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995 Sep 15; 86(6):2091-7. PMID: 7662956.
      Citations: 37     Fields:    Translation:Humans
    2200. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol. 1995 Sep; 13(9):2401-7. PMID: 7666100.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    2201. Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Plunkett W, Keating MJ. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia. 1995 Sep; 9(9):1444-9. PMID: 7658710.
      Citations: 9     Fields:    Translation:Humans
    2202. O'Brien S, Kantarjian H, Beran M, Robertson LE, Koller C, Lerner S, Keating MJ. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy. Blood. 1995 Aug 15; 86(4):1298-300. PMID: 7632936.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    2203. Giralt S, Kantarjian H, Talpaz M. Treatment of chronic myelogenous leukemia. Semin Oncol. 1995 Aug; 22(4):396-404. PMID: 7638636.
      Citations: 1     Fields:    Translation:Humans
    2204. Haidar MA, Cao XB, Manshouri T, Chan LL, Glassman A, Kantarjian HM, Keating MJ, Beran MS, Albitar M. p16INK4A and p15INK4B gene deletions in primary leukemias. Blood. 1995 Jul 01; 86(1):311-5. PMID: 7795238.
      Citations: 12     Fields:    Translation:HumansCells
    2205. Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Keating MJ. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia. 1995 Jun; 9(6):943-5. PMID: 7596181.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    2206. Marlton P, Keating M, Kantarjian H, Pierce S, O'Brien S, Freireich EJ, Estey E. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia. 1995 Jun; 9(6):965-71. PMID: 7596186.
      Citations: 9     Fields:    Translation:HumansCells
    2207. Talpaz M, Kantarjian H, Liang J, Calvert L, Hamer J, Tibbits P, Durett A, Claxton D, Giralt S, Khouri I, et al. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood. 1995 Jun 01; 85(11):3257-63. PMID: 7756658.
      Citations: 3     Fields:    Translation:HumansCells
    2208. Verschraegen CF, Talpaz M, Hirsch-Ginsberg CF, Pherwani R, Rios MB, Stass SA, Kantarjian HM. Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia. Blood. 1995 May 15; 85(10):2705-10. PMID: 7742530.
      Citations:    Fields:    Translation:Humans
    2209. Kantarjian HM, Talpaz M. Interferon-alpha therapy in chronic myelogenous leukemia: questions related to the German randomized trial. Blood. 1995 May 15; 85(10):2998-9, 3000-2. PMID: 7742562.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    2210. Talpaz M, Kantarjian H. Low-dose interferon-alpha in chronic myeloid leukemia. Ann Intern Med. 1995 May 01; 122(9):728-9. PMID: 7702237.
      Citations:    Fields:    Translation:Humans
    2211. Giralt S, Kantarjian H, Talpaz M. The natural history of chronic myelogenous leukemia in the interferon era. Semin Hematol. 1995 Apr; 32(2):152-8. PMID: 7652582.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    2212. Kantarjian HM, Talpaz M, Hester J, Feldman E, Korbling M, Liang J, Rios MB, Smith TL, Calvert L, Deisseroth AB. Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy. J Clin Oncol. 1995 Mar; 13(3):553-9. PMID: 7884415.
      Citations: 3     Fields:    Translation:HumansCells
    2213. O'Brien S, Kantarjian H, Ellis A, Zwelling L, Estey E, Keating M. Topotecan in chronic lymphocytic leukemia. Cancer. 1995 Mar 01; 75(5):1104-8. PMID: 7850708.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    2214. Estey EH, Kantarjian HM, O'Brien S, Kornblau S, Andreeff M, Beran M, Pierce S, Keating M. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cytokines Mol Ther. 1995 Mar; 1(1):21-8. PMID: 9384660.
      Citations: 3     Fields:    Translation:Humans
    2215. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med. 1995 Feb 15; 122(4):254-61. PMID: 7825760.
      Citations: 35     Fields:    Translation:Humans
    2216. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, Michaux JL, Wu Y, DeBlasio A, Miller WH, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood. 1995 Feb 15; 85(4):1083-94. PMID: 7849296.
      Citations: 62     Fields:    Translation:HumansCells
    2217. Cortes JE, Talpaz M, Beran M, O'Brien SM, Rios MB, Stass S, Kantarjian HM. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. Cancer. 1995 Jan 15; 75(2):464-70. PMID: 7812917.
      Citations: 11     Fields:    Translation:Humans
    2218. Hester JP, Dignani MC, Anaissie EJ, Kantarjian HM, O'Brien S, Freireich EJ. Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. J Clin Apher. 1995; 10(4):188-93. PMID: 8770711.
      Citations: 10     Fields:    Translation:HumansCells
    2219. Cortes JE, Kantarjian H, O'Brien S, Keating M, Pierce S, Freireich EJ, Estey E. Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes. Leukemia. 1995 Jan; 9(1):115-7. PMID: 7845005.
      Citations: 9     Fields:    Translation:Humans
    2220. Kantarjian HM, Talpaz M. Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia. Semin Oncol. 1994 Dec; 21(6 Suppl 14):8-13. PMID: 7992099.
      Citations: 1     Fields:    Translation:Humans
    2221. Robertson LE, Estey E, Kantarjian H, Koller C, O'Brien S, Brown B, Keating MJ. Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia. Leukemia. 1994 Dec; 8(12):2047-51. PMID: 7807993.
      Citations: 5     Fields:    Translation:Humans
    2222. Cortes J, O'Brien S, Kantarjian H, Cork A, Stass S, Freireich EJ, Keating M, Pierce S, Estey E. Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes. Leukemia. 1994 Dec; 8(12):2174-8. PMID: 7808007.
      Citations: 7     Fields:    Translation:HumansCells
    2223. Drach D, Estrov Z, Zhao S, Drach J, Cork A, Collins D, Kantarjian H, Andreeff M. Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia. Leuk Lymphoma. 1994 Dec; 16(1-2):79-88. PMID: 7535143.
      Citations: 2     Fields:    Translation:HumansCells
    2224. Dimopoulos MA, Kantarjian H, Weber D, O'Brien S, Estey E, Delasalle K, Rose E, Cabanillas F, Keating M, Alexanian R. Primary therapy of Waldenstr?m's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol. 1994 Dec; 12(12):2694-8. PMID: 7989946.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    2225. Wetzler M, Kurzrock R, Estrov Z, Kantarjian H, Gisslinger H, Underbrink MP, Talpaz M. Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood. 1994 Nov 01; 84(9):3142-7. PMID: 7949186.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    2226. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest. 1994 Oct; 94(4):1383-9. PMID: 7929813; PMCID: PMC295262.
      Citations: 15     Fields:    Translation:HumansCells
    2227. Yang L, Liu Y, Li L, Kantarjian H, Keating M. DNA cross-linking and repair in Cisplatin-resistant human tumor-cells following exposure to a new Cisplatin analog, ci-973. Int J Oncol. 1994 Sep; 5(3):597-602. PMID: 21559619.
      Citations:    Fields:    
    2228. Giralt SA, LeMaistre CF, Vriesendorp HM, Andersson BS, Dimopoulos M, Gajewski J, Van Besien K, Mehra R, Przepiorka D, Khouri I, et al. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Oncol. 1994 Sep; 12(9):1923-30. PMID: 8083714.
      Citations: 8     Fields:    Translation:Humans
    2229. Gandhi V, Du M, Kantarjian HM, Plunkett W. Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia. Leukemia. 1994 Sep; 8(9):1463-8. PMID: 8090026.
      Citations:    Fields:    Translation:HumansCells
    2230. Kantarjian HM, O'Brien S, Smith T, Estey EH, Beran M, Preti A, Pierce S, Keating MJ. Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen. Br J Haematol. 1994 Sep; 88(1):94-100. PMID: 7803263.
      Citations: 13     Fields:    Translation:Humans
    2231. Ghaddar HM, Plunkett W, Kantarjian HM, Pierce S, Freireich EJ, Keating MJ, Estey EH. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia. 1994 Aug; 8(8):1269-74. PMID: 8057660.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    2232. Giralt S, O'Brien S, Weeks E, Luna M, Kantarjian H. Leukemia cutis in acute promyelocytic leukemia: report of three cases after treatment with all-trans retinoic acid. Leuk Lymphoma. 1994 Aug; 14(5-6):453-6. PMID: 7812204.
      Citations: 6     Fields:    Translation:Humans
    2233. Kantarjian HM. Adult acute lymphocytic leukemia: critical review of current knowledge. Am J Med. 1994 Aug; 97(2):176-84. PMID: 8059784.
      Citations: 1     Fields:    Translation:Humans
    2234. O'Brien S, Kurzrock R, Duvic M, Kantarjian H, Stass S, Robertson LE, Estey E, Pierce S, Keating MJ. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood. 1994 Aug 01; 84(3):733-8. PMID: 7913841.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    2235. Preti HA, O'Brien S, Giralt S, Beran M, Pierce S, Kantarjian HM. Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients. Am J Med. 1994 Jul; 97(1):60-5. PMID: 8030658.
      Citations: 13     Fields:    Translation:HumansCells
    2236. Kantarjian HM, Talpaz M, Andersson B, Khouri I, Giralt S, Rios MB, Champlin R, Hester J, Deisseroth AB. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia. Bone Marrow Transplant. 1994 Jul; 14(1):57-61. PMID: 7951120.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    2237. Cortes JE, Kantarjian H, O'Brien S, Robertson LE, Koller C, Hirsh-Ginsberg C, Stass S, Keating M, Estey E. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer. 1994 Jun 15; 73(12):2946-52. PMID: 8199992.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    2238. Preti A, Kantarjian HM. Management of adult acute lymphocytic leukemia: present issues and key challenges. J Clin Oncol. 1994 Jun; 12(6):1312-22. PMID: 8201394.
      Citations: 4     Fields:    Translation:Humans
    2239. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. 1994 May 15; 83(10):3068-76. PMID: 7514051.
      Citations: 26     Fields:    Translation:HumansCells
    2240. Seymour JF, Pierce SA, Kantarjian HM, Keating MJ, Estey EH. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia. 1994 May; 8(5):823-6. PMID: 7514247.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    2241. Bodey GP, Anaissie EJ, Elting LS, Estey E, O'Brien S, Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer. 1994 Apr 15; 73(8):2099-106. PMID: 8156515.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    2242. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol. 1994 Apr; 12(4):671-8. PMID: 7512125.
      Citations: 40     Fields:    Translation:HumansCellsCTClinical Trials
    2243. Kantarjian HM, Deisseroth A, Talpaz M. Chronic myelogenous leukemia--update and future directions. Rev Invest Clin. 1994 Apr; Suppl:118-24. PMID: 7886295.
      Citations:    Fields:    Translation:Humans
    2244. Huh YO, Pugh WC, Kantarjian HM, Stass SA, Cork A, Trujillo JM, Keating MJ. Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody. Am J Clin Pathol. 1994 Mar; 101(3):283-9. PMID: 8135183.
      Citations: 1     Fields:    Translation:HumansCells
    2245. Seymour JF, Kantarjian HM. Hypercalcemia in acute lymphoblastic leukemia. Leuk Res. 1994 Mar; 18(3):231-2. PMID: 8139290.
      Citations: 1     Fields:    Translation:Humans
    2246. Dimopoulos MA, Weber DM, Kantarjian H, Keating M, Alexanian R. 2Chlorodeoxyadenosine therapy of patients with Waldenstr?m macroglobulinemia previously treated with fludarabine. Ann Oncol. 1994 Mar; 5(3):288-9. PMID: 7514439.
      Citations: 5     Fields:    Translation:Humans
    2247. O'Brien S, Kantarjian H, Estey E, Koller C, Robertson B, Beran M, Andreeff M, Pierce S, Keating M. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med. 1994 Feb 03; 330(5):319-22. PMID: 7904047.
      Citations: 6     Fields:    Translation:Humans
    2248. Kantarjian H, Talpaz M, Estey E, Ku S, Kurzrock R. What is the contribution of molecular studies to the diagnosis of BCR-ABL-positive disease in adult acute leukemia? Am J Med. 1994 Feb; 96(2):133-8. PMID: 8109597.
      Citations:    Fields:    Translation:Humans
    2249. Preti A, Kantarjian HM, Estey E, Huh Y, Keating M, Pierce S, Hirsch-Ginsberg C, Yee G, Stass SA. Characteristics and outcome of patients with acute lymphocytic leukemia and myeloperoxidase-positive blasts by electron microscopy. Hematol Pathol. 1994; 8(4):155-67. PMID: 7860434.
      Citations: 1     Fields:    Translation:Humans
    2250. Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Li YY, Gandhi V, et al. The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma. 1994; 14 Suppl 2:11-6. PMID: 7533576.
      Citations: 2     Fields:    Translation:Humans
    2251. Beran M, Pisa P, Kantarjian H, Porwit A, Bjorkholm M. Growth of sensitive and drug-resistant human myeloid leukemia cells in SCID mice. Hematol Pathol. 1994; 8(4):135-54. PMID: 7860433.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    2252. Preti HA, Kantarjian HM. Acute lymphocytic leukemia in adults: an update. Tex Med. 1994 Jan; 90(1):52-9. PMID: 8140553.
      Citations:    Fields:    Translation:Humans
    2253. Keating MJ, Estey E, O'Brien S, Kantarjian H, Robertson LE, Plunkett W. Clinical experience with fludarabine in leukaemia. Drugs. 1994; 47 Suppl 6:39-49. PMID: 7525188.
      Citations: 5     Fields:    Translation:Humans
    2254. Keating MJ, O'Brien S, Plunkett W, Robertson LE, Gandhi V, Estey E, Dimopoulos M, Cabanillas F, Kemena A, Kantarjian H. Fludarabine phosphate: a new active agent in hematologic malignancies. Semin Hematol. 1994 Jan; 31(1):28-39. PMID: 7510070.
      Citations: 5     Fields:    Translation:HumansAnimals
    2255. Use of retroviral markers to identify efficacy of purging and origin of relapse following autologous bone marrow and peripheral blood cell transplantation in indolent B cell neoplasms (follicular non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL) patients). Hum Gene Ther. 1993 Dec; 4(6):821-34. PMID: 8186294.
      Citations:    Fields:    Translation:HumansCells
    2256. Estey EH, Kantarjian H, Keating M. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome. Semin Oncol. 1993 Dec; 20(6 Suppl 8):1-5. PMID: 8290966.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    2257. Quesnel B, Kantarjian H, Bjergaard JP, Brault P, Estey E, Lai JL, Tilly H, Stoppa AM, Archimbaud E, Harousseau JL, et al. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol. 1993 Dec; 11(12):2370-9. PMID: 8246025.
      Citations: 24     Fields:    Translation:HumansCells
    2258. Anaissie EJ, Kontoyiannis DP, Vartivarian S, Kantarjian HM, O'Brien S, Giralt SA, Andersson BS, Karl C, Champlin RE, Bodey GP. Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with SCH 39304. Clin Infect Dis. 1993 Dec; 17(6):1022-31. PMID: 8110925.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    2259. Kantarjian HM, Estey E, O'Brien S, Anaissie E, Beran M, Pierce S, Robertson L, Keating MJ. Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission. Cancer. 1993 Nov 15; 72(10):2950-5. PMID: 7693325.
      Citations: 4     Fields:    Translation:Humans
    2260. Kantarjian HM, Talpaz M. Therapy of chronic myelogenous leukemia. Stem Cells. 1993 Oct; 11 Suppl 3:8-9. PMID: 8298480.
      Citations:    Fields:    Translation:Humans
    2261. Kantarjian H, Guti?rrez de Guzm?n J. [Role of retinoic acid in the treatment of acute promyelocytic leukemia]. Sangre (Barc). 1993 Oct; 38(5):375-8. PMID: 8140499.
      Citations:    Fields:    Translation:HumansCells
    2262. Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Yang LY, Gandhi V, et al. New initiatives with fludarabine monophosphate in hematologic malignancies. Semin Oncol. 1993 Oct; 20(5 Suppl 7):13-20. PMID: 7694371.
      Citations: 1     Fields:    Translation:Humans
    2263. Suki S, Kantarjian H, Gandhi V, Estey E, O'Brien S, Beran M, Rios MB, Plunkett W, Keating M. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer. 1993 Oct 01; 72(7):2155-60. PMID: 8374873.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    2264. Robertson LE, Pugh W, O'Brien S, Kantarjian H, Hirsch-Ginsberg C, Cork A, McLaughlin P, Cabanillas F, Keating MJ. Richter's syndrome: a report on 39 patients. J Clin Oncol. 1993 Oct; 11(10):1985-9. PMID: 8410123.
      Citations: 36     Fields:    Translation:Humans
    2265. Deisseroth AB, Kantarjian H, Talpaz M, Champlin R, Reading C, Hanania EG, Fu S, Randhawa GS, Cha Y, Fang X, et al. Molecular approaches to the diagnosis and treatment of cancer. Stem Cells. 1993 Oct; 11 Suppl 3:129-30. PMID: 7905320.
      Citations:    Fields:    Translation:Humans
    2266. O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, Robertson LE, Lerner S, Keating M. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 1993 Sep 15; 82(6):1695-700. PMID: 8400226.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    2267. Giralt S, Escudier S, Kantarjian H, Deisseroth A, Freireich EJ, Andersson BS, O'Brien S, Andreeff M, Fisher H, Cork A, et al. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med. 1993 Sep 09; 329(11):757-61. PMID: 7688862.
      Citations: 7     Fields:    Translation:Humans
    2268. Di Raimondo F, Giustolisi R, Cacciola E, O'Brien S, Kantarjian H, Robertson LB, Keating MJ. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma. 1993 Sep; 11(1-2):63-8. PMID: 8220155.
      Citations: 6     Fields:    Translation:Humans
    2269. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood. 1993 Aug 01; 82(3):691-703. PMID: 8338938.
      Citations: 43     Fields:    Translation:Humans
    2270. Beran M, Pisa P, O'Brien S, Kurzrock R, Siciliano M, Cork A, Andersson BS, Kohli V, Kantarjian H. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res. 1993 Aug 01; 53(15):3603-10. PMID: 8339266.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    2271. Estrov Z, Talpaz M, Kantarjian HM, Zipf TF, McClain KL, Kurzrock R. Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction. Cancer Res. 1993 Jul 15; 53(14):3289-93. PMID: 8324740.
      Citations:    Fields:    Translation:HumansCells
    2272. Dimopoulos MA, O'Brien S, Kantarjian H, Pierce S, Delasalle K, Barlogie B, Alexanian R, Keating MJ. Fludarabine therapy in Waldenstr?m's macroglobulinemia. Am J Med. 1993 Jul; 95(1):49-52. PMID: 8328496.
      Citations: 13     Fields:    Translation:Humans
    2273. Jaiyesimi IA, Kantarjian HM, Estey EH. Advances in therapy for hairy cell leukemia. A review. Cancer. 1993 Jul 01; 72(1):5-16. PMID: 7685243.
      Citations: 3     Fields:    Translation:Humans
    2274. Giralt SA, Kantarjian HM, Talpaz M, Rios MB, Del Giglio A, Andersson BS, Przepiorka D, Deisseroth AB, Champlin RE. Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol. 1993 Jun; 11(6):1055-61. PMID: 8501491.
      Citations:    Fields:    Translation:Humans
    2275. Ross DW, Brunning RD, Kantarjian HM, Koeffler HP, Ozer H. A proposed staging system for chronic myeloid leukemia. Cancer. 1993 Jun 01; 71(11):3788-91. PMID: 8490930.
      Citations: 1     Fields:    Translation:Humans
    2276. Kemena A, O'Brien S, Kantarjian H, Robertson L, Koller C, Beran M, Estey E, Plunkett W, Lerner S, Keating MJ. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leuk Lymphoma. 1993 Jun; 10(3):187-93. PMID: 8220117.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    2277. Keating MJ, O'Brien S, Kantarjian H, Plunkett W, Estey E, Koller C, Beran M, Freireich EJ. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 1993 Jun 01; 81(11):2878-84. PMID: 8499626.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    2278. Robertson LE, Hall R, Keating MJ, Estey E, Kantarjian HM, McLaughlin P, Hagemeister FB, Plunkett W. High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis. Leuk Lymphoma. 1993 May; 10(1-2):43-8. PMID: 8374522.
      Citations: 3     Fields:    Translation:Humans
    2279. Estrov Z, Kurzrock R, Pocsik E, Pathak S, Kantarjian HM, Zipf TF, Harris D, Talpaz M, Aggarwal BB. Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. J Exp Med. 1993 Mar 01; 177(3):763-74. PMID: 8382256; PMCID: PMC2190931.
      Citations: 19     Fields:    Translation:HumansCells
    2280. Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ, et al. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood. 1993 Mar 01; 81(5):1146-51. PMID: 8382970.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    2281. Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 1993 Mar; 9(4-5):343-50. PMID: 8394169.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    2282. Estrov Z, Markowitz AB, Kurzrock R, Wetzler M, Kantarjian HM, Ferrajoli A, Gutterman JU, Talpaz M. Suppression of chronic myelogenous leukemia colony growth by interleukin-4. Leukemia. 1993 Feb; 7(2):214-20. PMID: 8426475.
      Citations: 4     Fields:    Translation:HumansCells
    2283. Deisseroth AB, Kantarjian H, Talpaz M, Champlin R, Reading C, Andersson B, Claxton D. Use of two retroviral markers to test relative contribution of marrow and peripheral blood autologous cells to recovery after preparative therapy. The University of Texas M.D. Anderson Cancer Center. Division of Medicine. Hum Gene Ther. 1993 Feb; 4(1):71-85. PMID: 8461383.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    2284. Zhao L, Kantarjian HM, Van Oort J, Cork A, Trujillo JM, Liang JC. Detection of residual proliferating leukemic cells by fluorescence in situ hybridization in CML patients in complete remission after interferon treatment. Leukemia. 1993 Feb; 7(2):168-71. PMID: 8426470.
      Citations:    Fields:    Translation:HumansCells
    2285. Dimopoulos MA, Kantarjian H, Estey E, O'Brien S, Delasalle K, Keating MJ, Freireich EJ, Alexanian R. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med. 1993 Feb 01; 118(3):195-8. PMID: 8093333.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    2286. Niesvizky R, Siegel D, Michaeli J. 2-Chlorodeoxyadenosine for multiple myeloma. Blood. 1993 Feb 01; 81(3):868-9. PMID: 7679003.
      Citations: 4     Fields:    Translation:Humans
    2287. Kantarjian HM, Estey EH, Keating MJ. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am. 1993 Feb; 7(1):81-107. PMID: 7680643.
      Citations: 11     Fields:    Translation:Humans
    2288. Kantarjian HM, Talpaz M. Long-term follow-up results of alpha interferon therapy in chronic myelogenous leukemia at M. D. Anderson Cancer Center. Leuk Lymphoma. 1993; 11 Suppl 1:169-74. PMID: 8251891.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    2289. Kurzrock R, Kantarjian H, Wetzler M, Estrov Z, Estey E, Troutman-Worden K, Gutterman JU, Talpaz M. Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. Exp Hematol. 1993 Jan; 21(1):80-5. PMID: 8417962.
      Citations: 6     Fields:    Translation:Humans
    2290. Estey EH, Plunkett W, Kantarjian H, Rios MB, Keating MJ. Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C. Leuk Lymphoma. 1993; 10 Suppl:115-21. PMID: 8481661.
      Citations: 1     Fields:    Translation:Humans
    2291. Estey E, Pierce S, Kantarjian H, O'Brien S, Beran M, Andreeff M, Escudier S, Koller C, Kornblau S, Robertson L, et al. Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leuk Lymphoma. 1993; 11 Suppl 2:59-63. PMID: 7510196.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    2292. Derderian PM, Kantarjian HM, Talpaz M, O'Brien S, Cork A, Estey E, Pierce S, Keating M. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med. 1993 Jan; 94(1):69-74. PMID: 8420302.
      Citations: 11     Fields:    Translation:Humans
    2293. Dimopoulos MA, O'Brien S, Kantarjian H, Estey EE, Keating MJ, Alexanian R. Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues. Leuk Lymphoma. 1993; 11 Suppl 2:105-8. PMID: 7907250.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    2294. Deisseroth AB, Hanania EG, Fu S, Claxton D, Andreeff M, Champlin R, Kavanagh J, Hortobagyi G, Holmes F, Reading C, et al. Genetic therapy of human neoplastic disease. J Hematother. 1993; 2(3):373-5. PMID: 7921999.
      Citations:    Fields:    Translation:HumansAnimalsCells
    2295. Keating MJ, O'Brien S, Kantarjian H, Robertson LB, Koller C, Beran M, Estey E. Nucleoside analogs in treatment of chronic lymphocytic leukemia. Leuk Lymphoma. 1993; 10 Suppl:139-45. PMID: 8097653.
      Citations: 2     Fields:    Translation:Humans
    2296. Keating MJ, O'Brien S, Robertson L, Huh Y, Kantarjian H, Plunkett W. Chronic lymphocytic leukemia--correlation of response and survival. Leuk Lymphoma. 1993; 11 Suppl 2:167-75. PMID: 8124227.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    2297. Lee M, Khouri I, Champlin R, Kantarjian H, Talpaz M, Trujillo J, Freireich E, Deisseroth A, Stass S. Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation. Br J Haematol. 1992 Dec; 82(4):708-14. PMID: 1482658.
      Citations: 3     Fields:    Translation:HumansCells
    2298. Kantarjian HM, Smith T, Estey E, Polyzos A, O'Brien S, Pierce S, Beran M, Feldman E, Keating MJ. Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia. Am J Med. 1992 Dec; 93(6):599-604. PMID: 1466355.
      Citations: 5     Fields:    Translation:Humans
    2299. Keating MJ, O'Brien S, Robertson L, Plunkett W, Kantarjian H, Koller C. New drugs in the treatment of chronic lymphocytic leukemia. Leukemia. 1992 Nov; 6 Suppl 4:140-1. PMID: 1359203.
      Citations: 1     Fields:    Translation:Humans
    2300. Seong DC, Gottlieb K, Suh SP, Sims S, Talpaz M, Kantarjian H, Deisseroth A. Identification of a complex formed between nuclear proteins and the transcriptional enhancer of interferon-inducible genes that is present in the peripheral blood myeloid cells of CML but not normal individuals. J Interferon Res. 1992 Oct; 12(5):323-7. PMID: 1431311.
      Citations:    Fields:    Translation:HumansCells
    2301. Dimopoulos MA, Kantarjian HM, Estey EH, Alexanian R. 2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood. 1992 Sep 15; 80(6):1626. PMID: 1355673.
      Citations: 6     Fields:    Translation:Humans
    2302. Anaissie E, Kontoyiannis DP, Kantarjian H, Elting L, Robertson LE, Keating M. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med. 1992 Sep 15; 117(6):466-9. PMID: 1354425.
      Citations: 11     Fields:    Translation:HumansCells
    2303. O'Brien S, Kantarjian H, Freireich E, Johnston D, Nguyen K, Beran M. CI-973, a new platinum derivative with potential antileukemic activity. Cancer Res. 1992 Aug 01; 52(15):4130-4. PMID: 1638526.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    2304. Dhingra K, Kurzrock R, Kantarjian H, Baine R, Eastman PS, Ku S, Gutterman JU, Talpaz M. Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction. Leukemia. 1992 Aug; 6(8):754-60. PMID: 1640725.
      Citations: 2     Fields:    Translation:HumansCells
    2305. Marin T, Butturini A, Kantarjian H, Sokal J, Mickey MR, Gale R. Survival of children with chronic myeloid leukemia. Am J Pediatr Hematol Oncol. 1992 Aug; 14(3):229-32. PMID: 1510192.
      Citations: 2     Fields:    Translation:Humans
    2306. Robertson LE, Huh YO, Butler JJ, Pugh WC, Hirsch-Ginsberg C, Stass S, Kantarjian H, Keating MJ. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood. 1992 Jul 01; 80(1):29-36. PMID: 1377051.
      Citations: 21     Fields:    Translation:HumansCells
    2307. Freireich EJ, Cork A, Stass SA, McCredie KB, Keating MJ, Estey EH, Kantarjian HM, Trujillo JM. Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia. 1992 Jun; 6(6):500-6. PMID: 1602788.
      Citations: 10     Fields:    Translation:HumansCells
    2308. Saunders PP, Alvarez E, Kantarjian HM. Determination of nicotinamide-adenine dinucleotide and thiazole-4-carboxamide-adenine dinucleotide in human leukocytes by reversed-phase high-performance liquid chromatography. J Chromatogr. 1992 May 20; 577(1):37-41. PMID: 1400744.
      Citations: 1     Fields:    Translation:HumansCells
    2309. Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A, Keating M. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood. 1992 May 01; 79(9):2246-55. PMID: 1571541.
      Citations: 7     Fields:    Translation:Humans
    2310. Kantarjian HM, Keating MJ, Estey EH, O'Brien S, Pierce S, Beran M, Koller C, Feldman E, Talpaz M. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol. 1992 May; 10(5):772-8. PMID: 1569449.
      Citations: 9     Fields:    Translation:Humans
    2311. Lee MS, Kantarjian H, Talpaz M, Freireich EJ, Deisseroth A, Trujillo JM, Stass SA. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood. 1992 Apr 15; 79(8):1920-3. PMID: 1562719.
      Citations: 9     Fields:    Translation:HumansCells
    2312. Etkin M, Filaccio M, Ellerson D, Suh SP, Claxton D, Gaozza E, Brenner M, Moen R, Belmont J, Moore KA, et al. Use of cell-free retroviral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous leukemia patients and from normal individuals. Hum Gene Ther. 1992 Apr; 3(2):137-45. PMID: 1391033.
      Citations:    Fields:    Translation:HumansCells
    2313. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol. 1992 Mar; 10(3):406-13. PMID: 1740680.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    2314. Talpaz M, Chernajovsky Y, Troutman-Worden K, Wetzler M, Kantarjian H, Gutterman JU, Kurzrock R. Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients. Cancer Res. 1992 Mar 01; 52(5):1087-90. PMID: 1737366.
      Citations: 7     Fields:    Translation:Humans
    2315. Kantarjian HM, Talpaz M, Kontoyiannis D, Gutterman J, Keating MJ, Estey EH, O'Brien S, Rios MB, Beran M, Deisseroth A. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 1992 Mar; 10(3):398-405. PMID: 1740679.
      Citations: 6     Fields:    Translation:Humans
    2316. Estey EH, Kurzrock R, Kantarjian HM, O'Brien SM, McCredie KB, Beran M, Koller C, Keating MJ, Hirsch-Ginsberg C, Huh YO, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood. 1992 Feb 15; 79(4):882-7. PMID: 1346577.
      Citations: 11     Fields:    Translation:HumansCells
    2317. Claxton D, Deisseroth A, Talpaz M, Reading C, Kantarjian H, Trujillo J, Stass S, Gooch G, Spitzer G. Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia. Blood. 1992 Feb 15; 79(4):997-1002. PMID: 1371081.
      Citations: 2     Fields:    Translation:HumansCells
    2318. Kantarjian HM, Estey EH, O'Brien S, Anaissie E, Beran M, Rios MB, Keating MJ, Gutterman J. Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia. Blood. 1992 Feb 15; 79(4):876-81. PMID: 1737098.
      Citations: 4     Fields:    Translation:HumansCells
    2319. Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia. Cancer. 1992 Jan 15; 69(2):410-2. PMID: 1370212.
      Citations: 4     Fields:    Translation:Humans
    2320. Estey E, Trujillo JM, Cork A, O'Brien S, Beran M, Kantarjian H, Keating M, Freireich EJ, Stass S. AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes. Hematol Pathol. 1992; 6(1):43-8. PMID: 1601822.
      Citations: 1     Fields:    Translation:HumansCells
    2321. Yuan T, Zhou YQ, Herst CV, Reading C, Ellersen D, Etkin M, Khouri I, Kantarjian H, Talpaz M, Deisseroth A. Molecular approaches to purging of chronic myelogenous leukemia marrow in autologous transplantation. Prog Clin Biol Res. 1992; 377:227-30. PMID: 1438419.
      Citations:    Fields:    Translation:HumansCells
    2322. Keating MJ, Estey E, Kantarjian H, Plunkett W, O'Brien S, Koller C, Beran M, Freireich EJ. Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991. Leukemia. 1992; 6 Suppl 2:78-80. PMID: 1578950.
      Citations: 1     Fields:    Translation:Humans
    2323. Upadhyaya G, Guba SC, Sih SA, Feinberg AP, Talpaz M, Kantarjian HM, Deisseroth AB, Emerson SG. Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest. 1991 Dec; 88(6):2131-6. PMID: 1721627; PMCID: PMC295821.
      Citations: 11     Fields:    Translation:HumansCells
    2324. Talpaz M, Kurzrock R, Kantarjian H, Rothberg J, Saks S, Evans L, Gutterman JU. A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia. Cancer. 1991 Nov 15; 68(10):2125-30. PMID: 1913450.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    2325. Wetzler M, Kurzrock R, Lowe DG, Kantarjian H, Gutterman JU, Talpaz M. Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. Blood. 1991 Nov 01; 78(9):2400-6. PMID: 1932751.
      Citations: 4     Fields:    Translation:HumansCells
    2326. Kantarjian HM, Talpaz M, Dhingra K, Estey E, Keating MJ, Ku S, Trujillo J, Huh Y, Stass S, Kurzrock R. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood. 1991 Nov 01; 78(9):2411-8. PMID: 1932753.
      Citations: 15     Fields:    Translation:HumansCells
    2327. Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer. 1991 Oct 01; 68(7):1536-7. PMID: 1893353.
      Citations: 24     Fields:    Translation:Humans
    2328. Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Interferon alpha in the therapy of CML. Br J Haematol. 1991 Oct; 79 Suppl 1:38-41. PMID: 1931707.
      Citations: 2     Fields:    Translation:Humans
    2329. Kantarjian HM, Talpaz M, Keating MJ, Estey EH, O'Brien S, Beran M, McCredie KB, Gutterman J, Freireich EJ. Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 1991 Sep 15; 68(6):1201-7. PMID: 1873771.
      Citations: 3     Fields:    Translation:Humans
    2330. Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D, Gutterman JU, Talpaz M. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood. 1991 Sep 15; 78(6):1476-84. PMID: 1715791.
      Citations: 14     Fields:    Translation:Humans
    2331. O'Brien S, Kantarjian H, Estey E, Koller C, Beran M, McCredie K, Keating M. Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia. Cancer. 1991 Aug 15; 68(4):691-4. PMID: 1855168.
      Citations: 4     Fields:    Translation:Humans
    2332. Anaissie E, Bodey GP, Kantarjian H, David C, Barnett K, Bow E, Defelice R, Downs N, File T, Karam G, et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med. 1991 Aug; 91(2):142-50. PMID: 1867240.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    2333. Seong D, Sims S, Johnson E, Lyding J, Lopez A, Garovoy M, Talpaz M, Kantarjian H, Lopez-Berestein G, Reading C, et al. Activation of class I HLA expression by TNF-alpha and gamma-interferon is mediated through protein kinase C-dependent pathway in CML cell lines. Br J Haematol. 1991 Jul; 78(3):359-67. PMID: 1908310.
      Citations:    Fields:    Translation:Cells
    2334. Bodey G, Reuben A, Elting L, Kantarjian H, Keating M, Hagemeister F, Koller C, Velasquez W, Papadopoulos N. Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever. Eur J Clin Microbiol Infect Dis. 1991 Jul; 10(7):551-8. PMID: 1915397.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    2335. Kantarjian HM, Talpaz M, LeMaistre CF, Spinolo J, Spitzer G, Yau J, Dicke K, Jagannath S, Deisseroth AB. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia. Cancer. 1991 Jun 15; 67(12):2959-65. PMID: 1675151.
      Citations: 1     Fields:    Translation:HumansCells
    2336. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med. 1991 Apr 01; 114(7):532-8. PMID: 2001086.
      Citations: 45     Fields:    Translation:Humans
    2337. O'Brien S, Witt R, Talpaz M, Kantarjian H. Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission. Cancer. 1991 Apr 01; 67(7):1946-9. PMID: 2004308.
      Citations: 2     Fields:    Translation:Humans
    2338. Dhingra K, Talpaz M, Kantarjian H, Ku S, Rothberg J, Gutterman JU, Kurzrock R. Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression. Leukemia. 1991 Mar; 5(3):191-5. PMID: 2013978.
      Citations: 2     Fields:    Translation:HumansCells
    2339. Estey EH, Kurzrock R, Talpaz M, McCredie KB, O'Brien S, Kantarjian HM, Keating MJ, Deisseroth AB, Gutterman JU. Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol. 1991 Mar; 77(3):291-5. PMID: 2012752.
      Citations: 6     Fields:    Translation:HumansCells
    2340. Kantarjian HM, Schachner J, Keating MJ. Fludarabine therapy in hairy cell leukemia. Cancer. 1991 Mar 01; 67(5):1291-3. PMID: 1991291.
      Citations: 7     Fields:    Translation:Humans
    2341. Kantarjian HM, Childs C, O'Brien S, Huh Y, Beran M, Schachner J, Koller C, Keating MJ. Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia. Am J Med. 1991 Feb; 90(2):223-8. PMID: 1996592.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    2342. Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, McCredie KB. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol. 1991 Jan; 9(1):44-9. PMID: 1702145.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    2343. Claxton D, Suh SP, Filaccio M, Ellerson D, Gaozza E, Andersson B, Brenner M, Reading C, Feinberg A, Moen R, et al. Molecular analysis of retroviral transduction in chronic myelogenous leukemia. Hum Gene Ther. 1991; 2(4):317-21. PMID: 1665348.
      Citations: 1     Fields:    Translation:HumansCells
    2344. Keating MJ, Kantarjian H, O'brien S, Robertson L, Huh Y. New Agents and Strategies in CLL Treatment. Leuk Lymphoma. 1991; 5 Suppl 1:139-42. PMID: 27463496.
      Citations:    Fields:    
    2345. Wedrychowski A, Seong D, Paslidis N, Johnson E, Howard OM, Sims S, Talpaz M, Kantarjian H, Hester J, Turpin J, et al. Characterization of nuclear proteins which bind to interferon-inducible transcriptional enhancers in hematopoietic cells. J Biol Chem. 1990 Dec 15; 265(35):21433-40. PMID: 2174873.
      Citations: 1     Fields:    Translation:HumansCells
    2346. Haber LM, Childs CC, Hirsch-Ginsberg C, Nellis K, Kantarjian HM, Cork A, Trujillo JM, Stass SA. Strategy for breakpoint cluster region analysis in chronic myelocytic leukemia in a routine clinical laboratory. Am J Clin Pathol. 1990 Dec; 94(6):762-7. PMID: 2244594.
      Citations:    Fields:    Translation:HumansCells
    2347. Seong DC, Sims S, Johnson E, Howard OM, Reiter B, Hester J, Talpaz M, Kantarjian H, Deisseroth A. A phosphatase activity present in peripheral blood myeloid cells of chronic myelogenous leukemia patients but not normal individuals alters nuclear protein binding to transcriptional enhancers of interferon-inducible genes. J Clin Invest. 1990 Nov; 86(5):1664-70. PMID: 2243138; PMCID: PMC296917.
      Citations: 1     Fields:    Translation:HumansCells
    2348. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W. Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res. 1990 Nov 01; 50(21):6823-6. PMID: 2208147.
      Citations: 48     Fields:    Translation:HumansCells
    2349. Walters R, Kantarjian HM, Keating MJ, Estey EH, Trujillo J, Cork A, McCredie KB, Freireich EJ. The importance of cytogenetic studies in adult acute lymphocytic leukemia. Am J Med. 1990 Nov; 89(5):579-87. PMID: 2239977.
      Citations: 5     Fields:    Translation:HumansCells
    2350. Kantarjian HM, Redman JR, Keating MJ. Fludarabine phosphate therapy in other lymphoid malignancies. Semin Oncol. 1990 Oct; 17(5 Suppl 8):66-70. PMID: 1699285.
      Citations: 5     Fields:    Translation:Humans
    2351. Wetzler M, Kurzrock R, Taylor K, Spitzer G, Kantarjian H, Baiocchi G, Ku S, Gutterman JU, Talpaz M. Constitutive and induced expression of growth factors in normal and chronic phase chronic myelogenous leukemia Ph1 bone marrow stroma. Cancer Res. 1990 Sep 15; 50(18):5801-5. PMID: 2203522.
      Citations: 1     Fields:    Translation:HumansCells
    2352. Howard OM, Talpaz M, Kantarjian H, Seong D, Wedrychowski A, Paslidis N, Hester J, Cork A, Turpin J, Lopez-Berestein G, et al. Interferon affects nuclear proteins in cells of clinically sensitive chronic myelogenous leukemia patients. Blood. 1990 Sep 15; 76(6):1117-30. PMID: 2400807.
      Citations: 1     Fields:    Translation:HumansCells
    2353. Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, Talpaz M, Cork A, Freireich EJ, Trujillo JM, Lee MS, Stass SA. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood. 1990 Sep 15; 76(6):1214-9. PMID: 2205309.
      Citations: 18     Fields:    Translation:Humans
    2354. Spinolo JA, Dicke KA, Horwitz LJ, Jagannath S, McCredie K, Estey E, Kantarjian H, Zander AR, Keating M, Spitzer G. High-dose chemotherapy and unpurged autologous bone marrow transplantation for acute leukemia in second or subsequent remission. Cancer. 1990 Aug 15; 66(4):619-26. PMID: 2386890.
      Citations:    Fields:    Translation:HumansCells
    2355. Kantarjian HM, Hirsch-Ginsberg C, Yee G, Huh Y, Freireich EJ, Stass S. Mixed-lineage leukemia revisited: acute lymphocytic leukemia with myeloperoxidase-positive blasts by electron microscopy. Blood. 1990 Aug 15; 76(4):808-13. PMID: 2166608.
      Citations: 10     Fields:    Translation:Humans
    2356. Dicke KA, Dicke-Evinger MJ, Spinolo JA, Estey EH, Kantarjian HM, Spitzer GS. Double intensification including autologous bone marrow transplantation (ABMT) in AML: long term follow-up and detection of residual disease. Bone Marrow Transplant. 1990 Jul; 6 Suppl 1:27-34. PMID: 2390639.
      Citations:    Fields:    Translation:Humans
    2357. Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Update on therapeutic options for chronic myelogenous leukemia. Semin Hematol. 1990 Jul; 27(3 Suppl 4):31-6. PMID: 2197731.
      Citations: 1     Fields:    Translation:Humans
    2358. Kantarjian HM, Walters RS, Keating MJ, Smith TL, O'Brien S, Estey EH, Huh YO, Spinolo J, Dicke K, Barlogie B, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol. 1990 Jun; 8(6):994-1004. PMID: 2189958.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    2359. Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ. Fludarabine therapy in macroglobulinemic lymphoma. Blood. 1990 May 15; 75(10):1928-31. PMID: 1692487.
      Citations: 6     Fields:    Translation:Humans
    2360. Estey EH, Dixon D, Kantarjian HM, Keating MJ, McCredie K, Bodey GP, Kurzrock R, Talpaz M, Freireich EJ, Deisseroth AB, et al. Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1990 May 01; 75(9):1766-9. PMID: 2184901.
      Citations: 11     Fields:    Translation:Humans
    2361. Kantarjian HM, Kurzrock R, Talpaz M. Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. Hematol Oncol Clin North Am. 1990 Apr; 4(2):389-404. PMID: 2182598.
      Citations: 6     Fields:    Translation:Humans
    2362. Kurzrock R, Kantarjian HM, Shtalrid M, Gutterman JU, Talpaz M. Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course. Blood. 1990 Jan 15; 75(2):445-52. PMID: 2403827.
      Citations: 12     Fields:    Translation:Humans
    2363. Kantarjian HM, Walters RL, Keating MJ, Estey EH, O'Brien S, Schachner J, McCredie KB, Freireich EJ. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer. 1990 Jan 01; 65(1):5-8. PMID: 2293869.
      Citations: 3     Fields:    Translation:Humans
    2364. Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med. 1990 Jan; 88(1):1-8. PMID: 2294759.
      Citations: 18     Fields:    Translation:HumansCells
    2365. Claxton D, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU, Talpaz M. Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia. Acta Haematol. 1990; 83(3):149-51. PMID: 2109455.
      Citations:    Fields:    Translation:HumansCells
    2366. Keating MJ, Kantarjian H, Estey E, Plunkett W, Trujillo J, McCredie KB. Karyotype of leukemia cells consistently predicts for response to therapy and survival following salvage therapy in acute myeloblastic leukemia. Haematol Blood Transfus. 1990; 33:593-603. PMID: 2182449.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    2367. Mashal R, Shtalrid M, Talpaz M, Kantarjian H, Smith L, Beran M, Cork A, Trujillo J, Gutterman J, Deisseroth A. Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood. 1990 Jan 01; 75(1):180-9. PMID: 1967214.
      Citations: 19     Fields:    Translation:HumansCells
    2368. Seong D, Sims SS, Johnson E, Swan F, Lyding J, Lopez A, Talpaz M, Kantarjian H, Emerson S, Lopez-Berestein G, et al. Regulation of gene expression by tumor necrosis factor-alpha and interferon-gamma in chronic myelogenous leukemia. Trans Assoc Am Physicians. 1990; 103:236-41. PMID: 2132534.
      Citations:    Fields:    Translation:HumansCells
    2369. Estey EH, Kantarjian HM, Beran M, McCredie KB, Keating MJ, Deisseroth A, Gutterman JU. Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF. Haematol Blood Transfus. 1990; 33:732-6. PMID: 2182463.
      Citations: 1     Fields:    Translation:Humans
    2370. Bodey GP, Fainstein V, Elting LS, Anaissie E, Rolston K, Khardori N, Kantarjian H, Plager C, Murphy WK, Holmes F, et al. Beta-lactam regimens for the febrile neutropenic patient. Cancer. 1990 Jan 01; 65(1):9-16. PMID: 2403484.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    2371. O'Brien S, Kantarjian HM, Keating M, Gagnon G, Cork A, Trujillo J, McCredie KB. Association of granulocytosis with poor prognosis in patients with acute myelogenous leukemia and translocation of chromosomes 8 and 21. J Clin Oncol. 1989 Aug; 7(8):1081-6. PMID: 2754449.
      Citations: 3     Fields:    Translation:HumansCells
    2372. Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol. 1989 Aug; 7(8):1071-80. PMID: 2666590.
      Citations: 19     Fields:    Translation:Humans
    2373. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989 Jul; 74(1):19-25. PMID: 2473795.
      Citations: 63     Fields:    Translation:Humans
    2374. Kantarjian HM, Walters RS, Keating MJ, Barlogie B, McCredie KB, Freireich EJ. Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia. Cancer. 1989 Jul 01; 64(1):16-22. PMID: 2659160.
      Citations: 4     Fields:    Translation:Humans
    2375. Lee MS, LeMaistre A, Kantarjian HM, Talpaz M, Freireich EJ, Trujillo JM, Stass SA. Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction. Blood. 1989 Jun; 73(8):2165-70. PMID: 2730954.
      Citations: 14     Fields:    Translation:HumansCells
    2376. Taylor KM, Shetta M, Talpaz M, Kantarjian HM, Hardikar S, Chinault AC, McCredie KB, Spitzer G. Myeloproliferative disorders: usefulness of X-linked probes in diagnosis. Leukemia. 1989 Jun; 3(6):419-22. PMID: 2566725.
      Citations: 3     Fields:    Translation:HumansCells
    2377. Anaissie E, Bodey GP, Kantarjian H, Ro J, Vartivarian SE, Hopfer R, Hoy J, Rolston K. New spectrum of fungal infections in patients with cancer. Rev Infect Dis. 1989 May-Jun; 11(3):369-78. PMID: 2749101.
      Citations: 47     Fields:    Translation:Humans
    2378. Talpaz M, Kurzrock R, Kantarjian H, O'Brien S, Gutterman JU. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. Am J Med. 1989 May; 86(5):554-8. PMID: 2712063.
      Citations: 1     Fields:    Translation:HumansCells
    2379. Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB, Freireich EJ. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer. 1989 Mar 01; 63(5):813-7. PMID: 2914287.
      Citations: 19     Fields:    Translation:Humans
    2380. LeMaistre A, Lee MS, Talpaz M, Kantarjian HM, Freireich EJ, Deisseroth AB, Trujillo JM, Stass SA. Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia. Blood. 1989 Mar; 73(4):889-91. PMID: 2645949.
      Citations: 4     Fields:    Translation:Humans
    2381. Horwitz LJ, Kantarjian HM, Jagannath S, Keating MJ, McCredie KB, Spitzer G, Vellekoop L, Zander AR, Dicke KA. Piperazinedione plus total body irradiation: an alternative preparative regimen for allogeneic bone marrow transplantation in advanced phases of chronic myelogenous leukemia. Bone Marrow Transplant. 1989 Jan; 4(1):101-5. PMID: 2647172.
      Citations:    Fields:    Translation:Humans
    2382. Kurzrock R, Gutterman JU, Kantarjian H, Talpaz M. Therapy of chronic myelogenous leukemia with interferon. Cancer Invest. 1989; 7(1):83-91. PMID: 2472193.
      Citations:    Fields:    Translation:Humans
    2383. Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Clinical studies with interferons in Philadelphia positive chronic myelogenous leukemia. Bone Marrow Transplant. 1989 Jan; 4 Suppl 1:63. PMID: 2496883.
      Citations:    Fields:    Translation:Humans
    2384. Talpaz M, Kurzrock R, Kantarjian H, Gutterman J. Therapy of chronic myelogenous leukaemia with interferons. Cancer Surv. 1989; 8(4):793-8. PMID: 2701727.
      Citations: 1     Fields:    Translation:Humans
    2385. Hittelman WN, Agbor P, Petkovic I, Andersson B, Kantarjian H, Walters R, Koller C, Beran M. Detection of leukemic clone maturation in vivo by premature chromosome condensation. Blood. 1988 Dec; 72(6):1950-60. PMID: 3196873.
      Citations: 1     Fields:    Translation:HumansCells
    2386. Kantarjian HM, Walters RS, Smith TL, Keating MJ, Barlogie B, McCredie KB, Freireich EJ. Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood. 1988 Nov; 72(5):1784-9. PMID: 3052630.
      Citations: 14     Fields:    Translation:Humans
    2387. Kantarjian HM, Shtalrid M, Kurzrock R, Blick M, Dalton WT, LeMaistre A, Stass SA, McCredie KB, Gutterman J, Freireich EJ, et al. Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. Am J Med. 1988 Nov; 85(5):639-44. PMID: 3189367.
      Citations: 2     Fields:    Translation:HumansCells
    2388. Schachner J, Kantarjian H, Dalton W, McCredie K, Keating M, Freireich EJ. Cytogenetic association and prognostic significance of bone marrow blast cell terminal transferase in patients with acute myeloblastic leukemia. Leukemia. 1988 Oct; 2(10):667-71. PMID: 3172842.
      Citations: 2     Fields:    Translation:Humans
    2389. Zander AR, Keating M, Dicke K, Dixon D, Pierce S, Jagannath S, Peters L, Horwitz L, Cockerill K, Spitzer G, et al. A comparison of marrow transplantation with chemotherapy for adults with acute leukemia of poor prognosis in first complete remission. J Clin Oncol. 1988 Oct; 6(10):1548-57. PMID: 3049949.
      Citations: 6     Fields:    Translation:Humans
    2390. Shtalrid M, Talpaz M, Blick M, Romero P, Kantarjian H, Taylor K, Trujillo J, Schachner J, Gutterman JU, Kurzrock R. Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy. J Clin Oncol. 1988 Oct; 6(10):1569-75. PMID: 3171624.
      Citations: 5     Fields:    Translation:HumansCells
    2391. Lee MS, Chang KS, Freireich EJ, Kantarjian HM, Talpaz M, Trujillo JM, Stass SA. Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction. Blood. 1988 Sep; 72(3):893-7. PMID: 2458151.
      Citations: 7     Fields:    Translation:HumansCells
    2392. Kantarjian HM, Walters RS, Keating MJ, Talpaz M, Andersson B, Beran M, McCredie KB, Freireich EJ. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer. 1988 Aug 15; 62(4):672-6. PMID: 3165046.
      Citations: 5     Fields:    Translation:Humans
    2393. Walters RS, Kantarjian HM, Keating MJ, Plunkett WK, Estey EH, Andersson B, Beran M, McCredie KB, Freireich EJ. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer. 1988 Aug 15; 62(4):677-82. PMID: 3165047.
      Citations: 9     Fields:    Translation:Humans
    2394. Shtalrid M, Talpaz M, Kurzrock R, Kantarjian H, Trujillo J, Gutterman J, Yoffe G, Blick M. Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia. Blood. 1988 Aug; 72(2):485-90. PMID: 3165294.
      Citations: 8     Fields:    Translation:HumansCells
    2395. Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trujillo JM, McCredie KB, Gehan EA, Freireich EJ. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia. 1988 Jul; 2(7):403-12. PMID: 3164797.
      Citations: 11     Fields:    Translation:Humans
    2396. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988 Apr 01; 61(7):1441-6. PMID: 3162181.
      Citations: 43     Fields:    Translation:Humans
    2397. Keating MJ, Scouros M, Murphy S, Kantarjian H, Hester J, McCredie KB, Hersh EM, Freireich EJ. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia. 1988 Mar; 2(3):157-64. PMID: 3347094.
      Citations: 3     Fields:    Translation:Humans
    2398. Anaissie EJ, Fainstein V, Bodey GP, Rolston K, Elting L, Kantarjian H, Cabanillas F, McCredie KB. Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients. Am J Med. 1988 Mar; 84(3 Pt 2):581-9. PMID: 3279774.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    2399. Anaissie E, Kantarjian H, Ro J, Hopfer R, Rolston K, Fainstein V, Bodey G. The emerging role of Fusarium infections in patients with cancer. Medicine (Baltimore). 1988 Mar; 67(2):77-83. PMID: 3352514.
      Citations: 35     Fields:    Translation:HumansAnimals
    2400. Amato R, Kantarjian H, Walters R, Keating M. Rebound peripheral blastosis with subsequent remission during remission induction in a patient with acute promyelocytic leukemia. Cancer. 1988 Feb 15; 61(4):650-3. PMID: 3422175.
      Citations:    Fields:    Translation:HumansCells
    2401. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Freireich EJ. The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol. 1988 Feb; 6(2):232-8. PMID: 3276823.
      Citations: 19     Fields:    Translation:Humans
    2402. O'Brien S, Kantarjian H, Shtalrid M, Blick M, Beran M, Talpaz M. Lack of breakpoint cluster region rearrangement in marrow fibroblasts of patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Hematol Pathol. 1988; 2(1):25-9. PMID: 3235381.
      Citations:    Fields:    Translation:HumansCells
    2403. Kantarjian HM, Talpaz M. Definition of the accelerated phase of chronic myelogenous leukemia. J Clin Oncol. 1988 Jan; 6(1):180-2. PMID: 3422090.
      Citations: 7     Fields:    Translation:Humans
    2404. Talpaz M, Kantarjian HM, Kurzrock R, Gutterman J. Therapy of chronic myelogenous leukemia: chemotherapy and interferons. Semin Hematol. 1988 Jan; 25(1):62-73. PMID: 2450402.
      Citations: 8     Fields:    Translation:Humans
    2405. Keating MJ, Kantarjian H, Talpaz M, Redman J, McCredie KB. Fludarabine therapy in chronic lymphocytic leukemia (CLL). Nouv Rev Fr Hematol (1978). 1988; 30(5-6):461-6. PMID: 2464794.
      Citations: 3     Fields:    Translation:Humans
    2406. Talpaz M, Kurzrock R, Kantarjian HM, Gutterman JU. Recent advances in the therapy of chronic myelogenous leukemia. Important Adv Oncol. 1988; 297-321. PMID: 3042607.
      Citations:    Fields:    Translation:Humans
    2407. Kantarjian HM, Talpaz M, Gutterman JU. Chronic myelogenous leukemia--past, present, and future. Hematol Pathol. 1988; 2(2):91-120. PMID: 3058675.
      Citations: 9     Fields:    Translation:Humans
    2408. Kantarjian HM, Keating MJ. Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol. 1987 Dec; 14(4):435-43. PMID: 3321448.
      Citations: 7     Fields:    
    2409. Walters RS, Kantarjian HM, Keating MJ, Talpaz M, Childs CC, McCredie KB, Freireich EJ. Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron. Cancer. 1987 Oct 15; 60(8):1708-12. PMID: 3477315.
      Citations: 3     Fields:    Translation:Humans
    2410. Kantarjian H, Walters R. Implications of cytogenetic findings in secondary leukemia. Am J Clin Oncol. 1987 Oct; 10(5):453-6. PMID: 3477944.
      Citations:    Fields:    Translation:HumansCells
    2411. O'Brien S, Kantarjian HM, Anaissie E, Dodd G, Bodey GP. Successful medical management of neutropenic enterocolitis in adults with acute leukemia. South Med J. 1987 Oct; 80(10):1233-5. PMID: 3477870.
      Citations: 5     Fields:    Translation:Humans
    2412. Kantarjian HM, Keating MJ, McCredie KB, Walters R, Talpaz M, Smith TL, Freireich EJ. Old age: a sign of poor prognosis in patients with chronic myelogenous leukemia. South Med J. 1987 Oct; 80(10):1228-32. PMID: 3477869.
      Citations: 5     Fields:    Translation:Humans
    2413. Kurzrock R, Talpaz M, Kantarjian H, Walters R, Saks S, Trujillo JM, Gutterman JU. Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. Blood. 1987 Oct; 70(4):943-7. PMID: 3115339.
      Citations: 14     Fields:    Translation:Humans
    2414. Kassamali H, Anaissie E, Ro J, Rolston K, Kantarjian H, Fainstein V, Bodey GP. Disseminated Geotrichum candidum infection. J Clin Microbiol. 1987 Sep; 25(9):1782-3. PMID: 3477570; PMCID: PMC269330.
      Citations: 10     Fields:    Translation:HumansAnimals
    2415. Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med. 1987 Sep; 83(3):445-54. PMID: 3477958.
      Citations: 43     Fields:    Translation:HumansCells
    2416. Kantarjian HM, Talpaz M, Gutterman J. Biologic therapy of chronic myelogenous leukemia. Oncology (Williston Park). 1987 Sep; 1(7):35-40, 48-9, 52. PMID: 3152810.
      Citations: 1     Fields:    Translation:Humans
    2417. Yoffe G, Chinault AC, Talpaz M, Blick MB, Kantarjian HM, Taylor K, Spitzer G. Clonal nature of Philadelphia chromosome-positive and -negative chronic myelogenous leukemia by DNA hybridization analyses. Exp Hematol. 1987 Aug; 15(7):725-8. PMID: 2440709.
      Citations:    Fields:    Translation:HumansCells
    2418. Walters RS, Kantarjian HM, Keating MJ, Estey EH, McCredie KB, Freireich EJ. Intensive treatment of acute leukemia in adults 70 years of age and older. Cancer. 1987 Jul 15; 60(2):149-55. PMID: 3474052.
      Citations: 6     Fields:    Translation:Humans
    2419. Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res. 1987 Jun 01; 47(11):3005-11. PMID: 3471322.
      Citations: 37     Fields:    Translation:Humans
    2420. Dekmezian R, Kantarjian HM, Keating MJ, Talpaz M, McCredie KB, Freireich EJ. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer. 1987 May 15; 59(10):1739-43. PMID: 2435399.
      Citations: 11     Fields:    Translation:Humans
    2421. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood. 1987 May; 69(5):1280-8. PMID: 3471281.
      Citations: 45     Fields:    Translation:HumansCells
    2422. Keating MJ, Gehan EA, Smith TL, Estey EH, Walters RS, Kantarjian HM, McCredie KB, Freireich EJ. A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. J Clin Oncol. 1987 May; 5(5):710-21. PMID: 3553435.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    2423. Kantarjian HM, Keating MJ, Walters RS, Smith TL, McCredie KB, Freireich EJ. Role of maintenance chemotherapy in acute promyelocytic leukemia. Cancer. 1987 Apr 01; 59(7):1258-63. PMID: 3469011.
      Citations: 4     Fields:    Translation:Humans
    2424. Talpaz M, Rosenblum M, Kurzrock R, Reuben J, Kantarjian H, Gutterman J. Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia--a pilot study. Am J Hematol. 1987 Apr; 24(4):341-50. PMID: 3494396.
      Citations: 4     Fields:    Translation:HumansCells
    2425. Lee JS, Dixon DO, Kantarjian HM, Keating MJ, Talpaz M. Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood. 1987 Mar; 69(3):929-36. PMID: 3814821.
      Citations: 17     Fields:    Translation:Humans
    2426. Yoffe G, Blick M, Kantarjian H, Spitzer G, Gutterman J, Talpaz M. Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia. Blood. 1987 Mar; 69(3):961-3. PMID: 2880616.
      Citations: 9     Fields:    Translation:HumansCells
    2427. Anaissie E, Kantarjian H, Jones P. Fungal infection caused by Fusarium in cancer patients. Am J Clin Oncol. 1987 Feb; 10(1):86-8. PMID: 3469902.
      Citations: 2     Fields:    Translation:HumansAnimals
    2428. Talpaz M, Kantarjian H, McCredie K, Trujillo J, Keating M, Gutterman JU. Therapy of chronic myelogenous leukemia. Cancer. 1987 Feb 01; 59(3 Suppl):664-7. PMID: 10822467.
      Citations: 5     Fields:    Translation:HumansCells
    2429. Terjanian T, Kantarjian H, Keating M, Talpaz M, McCredie K, Freireich EJ. Clinical and prognostic features of patients with Philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary disease. Cancer. 1987 Jan 15; 59(2):297-300. PMID: 3467820.
      Citations: 6     Fields:    Translation:HumansCells
    2430. Keating MJ, Estey E, Kantarjian HM, Walters R, Smith T, McCredie KB, Freireich EJ. Comparison of results of salvage therapy in adult acute myelogenous leukemia. Acta Haematol. 1987; 78 Suppl 1:120-6. PMID: 3124434.
      Citations: 2     Fields:    Translation:Humans
    2431. O'Brien S, Kantarjian HM, Talpaz M, Cork A, Trujillo J, Beran M. The effect of long-term marrow culture on the nonadherent Philadelphia chromosome-positive clone in chronic myelogenous leukemia: preliminary observations. Hematol Pathol. 1987; 1(3):167-72. PMID: 3509052.
      Citations:    Fields:    Translation:HumansCells
    2432. Kantarjian HM, Talpaz M, Kurzrock R, Keating MJ, McCredie KB, Gutterman J, Freireich EJ. Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia. Acta Haematol. 1987; 78 Suppl 1:70-4. PMID: 2449026.
      Citations: 1     Fields:    Translation:Humans
    2433. McCredie KB, Talpaz M, Kantarjian H, Rosenblum M, Keating M, Gutterman J. Biologic agents for the management of hematological disorders: chronic myeloid leukemia. Haematol Blood Transfus. 1987; 31:120-2. PMID: 2450815.
      Citations:    Fields:    Translation:Humans
    2434. Kantarjian HM, Keating MJ. The eosinophilic variant of acute myelomonocytic leukemia developing as a secondary leukemia in a patient with mycosis fungoides. Hematol Pathol. 1987; 1(3):191-2. PMID: 3509053.
      Citations:    Fields:    Translation:Humans
    2435. Beran M, Andersson B, Kantarjian H, Keating M, Rios A, McCredie KB, Freireich EJ, Gutterman J. Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure gamma interferon. Leukemia. 1987 Jan; 1(1):52-7. PMID: 2444829.
      Citations: 3     Fields:    Translation:HumansCells
    2436. Kantarjian HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol. 1986 Dec; 4(12):1748-57. PMID: 3783201.
      Citations: 44     Fields:    Translation:Humans
    2437. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Smith TL, Talpaz M, Beran M, Cork A, Trujillo JM, Freireich EJ. Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer. 1986 Nov 01; 58(9):2023-30. PMID: 3463397.
      Citations: 5     Fields:    Translation:HumansCells
    2438. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Bodey GP, Freireich EJ. Early intensification and short-term maintenance chemotherapy does not prolong survival in acute myelogenous leukemia. Cancer. 1986 Oct 15; 58(8):1603-8. PMID: 3463390.
      Citations:    Fields:    Translation:Humans
    2439. Ventura GJ, Kantarjian HM, Anaissie E, Hopfer RL, Fainstein V. Pneumonia with Cunninghamella species in patients with hematologic malignancies. A case report and review of the literature. Cancer. 1986 Oct 01; 58(7):1534-6. PMID: 3461876.
      Citations: 9     Fields:    Translation:Humans
    2440. Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med. 1986 Sep; 81(3):387-94. PMID: 3463209.
      Citations: 20     Fields:    Translation:Humans
    2441. Talpaz M, McCredie K, Kantarjian H, Trujillo J, Keating M, Gutterman J. Chronic myelogenous leukaemia: haematological remissions with alpha interferon. Br J Haematol. 1986 Sep; 64(1):87-95. PMID: 3463363.
      Citations: 10     Fields:    Translation:HumansCells
    2442. Kantarjian HM, Keating MJ, Walters RS, Beran M, McLaughlin P, McCredie KB, Freireich EJ. The association of specific "favorable" cytogenetic abnormalities with secondary leukemia. Cancer. 1986 Aug 15; 58(4):924-7. PMID: 3719557.
      Citations: 3     Fields:    Translation:Humans
    2443. Talpaz M, Spitzer G, Hittelman W, Kantarjian H, Gutterman J. Changes in granulocyte-monocyte colony-forming cells among leukocyte-interferon-treated chronic myelogenous leukemia patients. Exp Hematol. 1986 Aug; 14(7):668-71. PMID: 3460811.
      Citations: 4     Fields:    Translation:HumansCells
    2444. Iacoboni SJ, Plunkett W, Kantarjian HM, Estey E, Keating MJ, McCredie KB, Freireich EJ. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol. 1986 Jul; 4(7):1079-88. PMID: 3459811.
      Citations: 8     Fields:    Translation:Humans
    2445. Anaissie E, Kantarjian H, Jones P, Barlogie B, Luna M, Lopez-Berestein G, Bodey GP. Fusarium. A newly recognized fungal pathogen in immunosuppressed patients. Cancer. 1986 Jun 01; 57(11):2141-5. PMID: 3457624.
      Citations: 21     Fields:    Translation:HumansAnimals
    2446. Talpaz M, Plager C, Quesada J, Benjamin R, Kantarjian H, Gutterman J. Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients. Eur J Cancer Clin Oncol. 1986 Jun; 22(6):685-9. PMID: 3091371.
      Citations: 2     Fields:    Translation:Humans
    2447. Vellekoop L, Zander AR, Kantarjian HM, Jagannath S, Hester JP, Trujillo J, McCredie KB, Zagars G, Spitzer G, Dicke KA. Piperazinedione, total body irradiation, and autologous bone marrow transplantation in chronic myelogenous leukemia. J Clin Oncol. 1986 Jun; 4(6):906-11. PMID: 3519881.
      Citations:    Fields:    Translation:HumansCells
    2448. Kantarjian HM, Keating MJ, Walters RS, Estey EH, McCredie KB, Smith TL, Dalton WT, Cork A, Trujillo JM, Freireich EJ. Acute promyelocytic leukemia. M.D. Anderson Hospital experience. Am J Med. 1986 May; 80(5):789-97. PMID: 3458366.
      Citations: 24     Fields:    Translation:Humans
    2449. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med. 1986 Apr 24; 314(17):1065-9. PMID: 3457264.
      Citations: 82     Fields:    Translation:HumansCells
    2450. Nogueira-Costa R, Spitzer G, Khorana S, Pham Q, Kantarjian HM, Manning JT, Ordonez NG, Dicke KA. T-cell involvement in benign phase chronic myelogenous leukemia. Leuk Res. 1986; 10(12):1433-9. PMID: 3099099.
      Citations: 2     Fields:    Translation:HumansCells
    2451. Kantarjian HM, Smith TL, McCredie KB, Keating MJ, Walters RS, Talpaz M, Hester JP, Bligham G, Gehan E, Freireich EJ. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood. 1985 Dec; 66(6):1326-35. PMID: 3864497.
      Citations: 24     Fields:    Translation:HumansCells
    2452. Kantarjian HM, Barlogie B, Keating MJ, Hall RR, Smith TL, McCredie KB, Freireich EJ. Pretreatment of cytokinetics in acute myelogenous leukemia. Age-related prognostic implications. J Clin Invest. 1985 Jul; 76(1):319-24. PMID: 3860508; PMCID: PMC423776.
      Citations: 2     Fields:    Translation:Humans
    2453. Kantarjian HM, Barlogie B, Pershouse M, Swartzendruber D, Keating MJ, McCredie KB, Freireich EJ. Preferential expression of double-stranded ribonucleic acid in tumor versus normal cells: biological and clinical implications. Blood. 1985 Jul; 66(1):39-46. PMID: 4005432.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    2454. Kantarjian HM, Keating MJ, McCredie KB, Beran M, Walters R, Dalton WT, Hittleman W, Freireich EJ. A characteristic pattern of leukemic cell differentiation without cytoreduction during remission induction in acute promyelocytic leukemia. J Clin Oncol. 1985 Jun; 3(6):793-8. PMID: 3859586.
      Citations: 1     Fields:    Translation:Humans
    2455. Keating MJ, Estey E, Plunkett W, Iacoboni S, Walters R, Kantarjian H, Andersson B, Beran M, McCredie KB, Freireich EJ. Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. Semin Oncol. 1985 Jun; 12(2 Suppl 3):98-104. PMID: 3859935.
      Citations: 1     Fields:    Translation:Humans
    2456. Srigley J, Barlogie B, Butler JJ, Osborne B, Blick M, Johnston D, Kantarjian H, Reuben J, Batsakis J, Freireich EJ. Heterogeneity of non-Hodgkin's lymphoma probed by nucleic acid cytometry. Blood. 1985 May; 65(5):1090-6. PMID: 3995168.
      Citations: 12     Fields:    Translation:HumansCells
    2457. Kantarjian HM, Vellekoop L, McCredie KB, Keating MJ, Hester J, Smith T, Barlogie B, Trujillo J, Freireich EJ. Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. J Clin Oncol. 1985 Feb; 3(2):192-200. PMID: 3855444.
      Citations: 11     Fields:    Translation:HumansCells
    2458. Kantarjian H, Ajani JA, Karlin DA. Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract. Oncology. 1985; 42(2):69-71. PMID: 3921891.
      Citations: 2     Fields:    Translation:Humans
    2459. McCredie KB, Kantarjian H, Keating MJ, Hester JP, Freireich EJ. New approaches to the treatment of chronic myelogenous leukemia. Haematol Blood Transfus. 1985; 29:51-2. PMID: 3896975.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    2460. Kantarjian HM, Hortobagyi GN, Smith TL, Blumenschein GR, Montague E, Buzdar AU, Martin RG. The management of locally advanced breast cancer: a combined modality approach. Eur J Cancer Clin Oncol. 1984 Nov; 20(11):1353-61. PMID: 6548710.
      Citations: 3     Fields:    Translation:Humans
    2461. Uwaydah M, Nassar NT, Harakeh H, Vartivarian S, Talhouk A, Kantarjian H. Treatment of typhoid fever with cefamandole. Antimicrob Agents Chemother. 1984 Sep; 26(3):426-7. PMID: 6508273; PMCID: PMC176187.
      Citations: 6     Fields:    Translation:Humans
    2462. Kantarjian HM, McLaughlin P, Fuller LM, Dixon DO, Osborne BM, Cabanillas FF. Follicular large cell lymphoma: analysis and prognostic factors in 62 patients. J Clin Oncol. 1984 Jul; 2(7):811-9. PMID: 6376721.
      Citations: 4     Fields:    Translation:Humans
    2463. Kantarjian H, Farha PA, Spitzer G, Murphy WK, Valdivieso M. Systemic combination chemotherapy as primary treatment of brain metastasis from lung cancer. South Med J. 1984 Apr; 77(4):426-30. PMID: 6324383.
      Citations: 6     Fields:    Translation:Humans
    2464. Kantarjian H, Dreicer R, Barlogie B, Plunkett W, Alexanian R. High-dose cytosine arabinoside in multiple myeloma. Eur J Cancer Clin Oncol. 1984 Feb; 20(2):227-31. PMID: 6538488.
      Citations: 2     Fields:    Translation:Humans
    2465. Jadeja L, Kantarjian H, Bolivar R. Streptococcus bovis septicemia and meningitis associated with chronic radiation enterocolitis. South Med J. 1983 Dec; 76(12):1588-9. PMID: 6648628.
      Citations:    Fields:    Translation:HumansPHPublic Health
    2466. Kanojia M, Kantarjian H, Ajani J, Barlogie B. High-dose cytosine arabinoside (Ara-C) in colorectal cancer. Br J Cancer. 1983 Dec; 48(6):869-71. PMID: 6652028; PMCID: PMC2011573.
      Citations:    Fields:    Translation:Humans
    2467. Kantarjian H, Barlogie B, Plunkett W, Velasquez W, McLaughlin P, Riggs S, Cabanillas F. High-dose cytosine arabinoside in non-Hodgkin's lymphoma. J Clin Oncol. 1983 Nov; 1(11):689-94. PMID: 6366130.
      Citations: 11     Fields:    Translation:Humans
    2468. Kantarjian HM, Bledin AG, Kim EE, Cogan BM, Chuang VP, Wallace S, Haynie TP. Arterial perfusion with Tc-99m macroaggregated albumin (MAAAP) in monitoring intra-arterial chemotherapy of sarcomas. J Nucl Med. 1983 Apr; 24(4):297-301. PMID: 6220136.
      Citations:    Fields:    Translation:Humans
    2469. Kantarjian HM, Saad MF, Estey EH, Sellin RV, Samaan NA. Hypercalcemia in disseminated candidiasis. Am J Med. 1983 Apr; 74(4):721-4. PMID: 6837596.
      Citations: 16     Fields:    Translation:Humans
    2470. Kantarjian H, Yap HY, Hortobagyi G, Buzdar A, Blumenschein G. Hormonal therapy for metastatic male breast cancer. Arch Intern Med. 1983 Feb; 143(2):237-40. PMID: 6824391.
      Citations: 12     Fields:    Translation:Humans
    2471. Uwaydah M, Tannir N, Kantarjian H, Osseiran M, Bal'a F. Moxalactam therapy of bacterial meningitis in adults. Antimicrob Agents Chemother. 1983 Feb; 23(2):289-92. PMID: 6220673; PMCID: PMC186039.
      Citations: 6     Fields:    Translation:HumansCells
    2472. Kantarjian HM, Bledin AG, Kim EE, Gutierrez CR, Haynie TP. Uptake of 99mTc-methylene disphosphonate in calcinosis cutis. J Am Acad Dermatol. 1982 Dec; 7(6):804-6. PMID: 6217232.
      Citations: 1     Fields:    Translation:Humans
    2473. Uwaydah M, Kantarjian H, Osseiran M, Bal'a F. Cefamandole bile levels in patients with hepatobiliary disease. Antimicrob Agents Chemother. 1982 Dec; 22(6):1087-9. PMID: 7159070; PMCID: PMC185730.
      Citations: 3     Fields:    Translation:Humans
    2474. Bledin AG, Kantarjian HM, Kim EE, Wallace S, Chuang VP, Patt YZ, Haynie TP. 99mTc-labeled macroaggregated albumin in intrahepatic arterial chemotherapy. AJR Am J Roentgenol. 1982 Oct; 139(4):711-5. PMID: 6214932.
      Citations: 10     Fields:    Translation:Humans
    2475. Bedikian AY, Kantarjian H, Nelson RS, Stroehlein JR, Bodey GP. Colorectal cancer in young adults. South Med J. 1981 Aug; 74(8):920-4. PMID: 7268491.
      Citations: 10     Fields:    Translation:Humans
    2476. Bedikian AY, Kantarjian H, Young SE, Bodey GP. Prognosis in metastatic choroidal melanoma. South Med J. 1981 May; 74(5):574-7. PMID: 7244714.
      Citations: 16     Fields:    Translation:Humans
    2477. The clinical challenge of imatinib resistance in chronic myeloid leukemia. Targeted Oncology. 1:186-196.
    2478. Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome. Leukemia. 30:325-330.
    2479. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica. 100:898-904.
    2480. Streptococcus Bovis Septicemia and Meningitis Associated with Chronic Radiation Enterocolitis. Southern Medical Journal. 76:1-2.
    2481. Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate. Leukemia and Lymphoma.
    2482. Erratum. Cancer. 109:2625.
    2483. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatric Blood and Cancer. 61:369-372.
    2484. Proceedings of the Annual Meeting of the Society of Hematologic Oncology, 2014. Clinical Lymphoma, Myeloma and Leukemia. 15:S1.
    2485. Treatment of acute myelogenous leukemia with chemotherapy and hematopoietic growth factors. Cancer Bulletin. 42:156-161.
    2486. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Science Signaling. 9.
    2487. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. American Journal of Hematology.
    2488. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nature Communications. 7.
    2489. Development and targeted use of nilotinib in chronic myeloid leukemia. Drug Design, Development and Therapy. 233-243.
    2490. Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Modern Pathology.
    2491. Biliary concentrations of moxalactam. Infection. 12:104.
    2492. New agents and strategies in CLL treatment. Leukemia and Lymphoma. 5:139-142.
    2493. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients with Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clinical Lymphoma, Myeloma and Leukemia. 16:152-162.
    2494. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. American Journal of Hematology.
    2495. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractor y acute lymphoblastic leukemia. Haematologica. 101:1524-1533.
    2496. Adult acute lymphocytic leukaemia. Cancer Forum. 19:290.
    2497. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer.
    2498. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/progenitor cells. Oncotarget. 7:55083-55097.
    2499. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer.
    2500. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 122:238-248.
    2501. Erratum. Cancer Research. 64:2306.
    2502. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. Journal of Hematology and Oncology. 8.
    2503. Time-dependent changes in mortality and transformation risk in MDS. Blood. 128:902-910.
    2504. Utilization of Tc-99m macroaggregated albumin (MAA) perfusion studies in arterial infusion cancer chemotherapy. Journal of Nuclear Medicine. 23.
    2505. Decitabine in myelodysplastic syndromes. Therapy. 2:835-842.
    2506. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia.
    2507. Acute Lymphoblastic Leukemia. 228-243.
    2508. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. OncoTargets and Therapy. 7:13-21.
    2509. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Clinical Lymphoma, Myeloma and Leukemia. 15:323-334.
    2510. Acute lymphoblastic leukemia (all) in the elderly - the significance of the philadelphia chromosome. Blood. 96.
    2511. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology.
    2512. Hairy-cell leukemia. Cancer Bulletin. 37:88-90.
    2513. Erratum. Leukemia. 26:2302.
    2514. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase (Cancer (2009) 115 (551-160)). Cancer. 116:3750.
    2515. Introduction. Seminars in Hematology. 35:1-2.
    2516. The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica. 101:e224-e227.
    2517. Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood Cancer Journal. 6.
    2518. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA. The Lancet Oncology. 18:22-23.
    2519. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma. British Journal of Haematology.
    2520. Insurance denial of coverage for patients enrolled in cancer clinical trials is still a problem in the affordable care act era. Journal of Oncology Practice. 12:283-285.
    2521. A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). Leukemia Research. 48:92-100.
    2522. CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count. Leukemia and Lymphoma. 1-4.
    2523. Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment. Leukemia.
    2524. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis. Haematologica. 102:79-84.
    2525. Genetic therapy of human disease. Bone Marrow Transplantation. 15.
    2526. Proceedings of the Third Annual Meeting of the Society of Hematologic Oncology. Clinical Lymphoma, Myeloma and Leukemia. 16:S1.
    2527. New tyrosine kinase inhibitors for chronic myelogenous leukemia. P and T. 31:732.
    2528. Response. Blood. 114:224.
    2529. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. American Journal of Hematology.
    2530. Chemotherapy Foundation Symposium XXVI. P and T. 33:713.
    2531. Prediction of response and survival in patients with chronicphase chronic myeloid leukemia treated with omacetaxine mepesuccinate. Blood Cancer Journal. 5.
    2532. The Affordable Care Act, or Obamacare, 3 years later. Cancer. 123:25-28.
    2533. Chronic Myelogenous Leukemia. 76-88.
    2534. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia. 16:139-145.
    2535. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. British Journal of Haematology.
    2536. Chronic Myeloid Leukemia. 1944-1957.e2.
    2537. Biology of Adult Myelocytic Leukemia and Myelodysplasia. 421-432.
    2538. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Reports.
    2539. Erratum. Nature Reviews Drug Discovery. 10:318.
    2540. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes. Cancer.
    2541. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget. 6:30487-30499.
    2542. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 127:1269-1275.
    2543. Hormonal therapy in the male breast cancer advanced stages.
    2544. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia Research. 39:1367-1374.
    2545. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. American Journal of Hematology.
    2546. Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis. Blood. 128:877-880.
    2547. The Chronic Leukemias. 1209-1218.
    2548. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia.
    2549. Drs. Kantarjian and Shah reply. New England Journal of Medicine. 363:1674-1675.
    2550. Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia. Leukemia Research Reports. 3:17-20.
    2551. Introduction. Seminars in Hematology. 44:1-3.
    2552. Introduction. Seminars in Oncology. 34.
    2553. Reply to M. Keyhani and N. Mahmoudi. Journal of Clinical Oncology. 30:220-222.
    2554. Hematology/Oncology Clinics of North - America. Hematology/Oncology Clinics of North America. 15.
    2555. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 126:1699-1706.
    2556. Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leukemia and Lymphoma. 56:2092-2097.
    2557. The authors reply. New England Journal of Medicine. 375:2100-2101.
    2558. Management of imatinib-resistant patients with chronic myeloid leukemia. Therapeutic Advances in Hematology. 4:103-117.
    2559. NCCN guidelines® insights. JNCCN Journal of the National Comprehensive Cancer Network. 14:1505-1512.
    2560. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 100:927-934.
    2561. A phase I/II study of the mTOR inhibitor everolimus in combination with hyperCVAD chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia. Clinical Cancer Research. 21:2704-2714.
    2562. Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia. Journal of the National Cancer Institute. 108.
    2563. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. American Journal of Hematology. 91:E478-E479.
    2564. The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms. Cancer.
    2565. Introduction. Seminars in Hematology. 36:1-2.
    2566. Nilotinib appears beneficial in phase I study for patients with Gleevec-resistant CML. Cancer Biology and Therapy. 5:711.
    2567. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer Journal. 5.
    2568. Hypomethylating strategies in leukemia and myelodysplastic syndromes. P and T. 31:732-733.
    2569. Prognostic significance of serum beta-2 microglobulin in myelodisplastic syndromes. Blood. 96.
    2570. The role of local radiation in mediastinal T-cell lymphoblastic lymphoma. Blood. 96.
    2571. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer.
    2572. Correction regarding data on blinatumomab-associated seizures. Nature Reviews Clinical Oncology.
    2573. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica. 100:1058-1063.
    2574. Dr. Saglio and colleagues reply. New England Journal of Medicine. 363:1673-1674.
    2575. Characteristics of sweet syndrome in patients with acute myeloid leukemia. Clinical Lymphoma, Myeloma and Leukemia. 15:358-363.
    2576. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 121:3612-3621.
    2577. Chronic Myelogenous Leukemia. Hematology/Oncology Clinics of North America. 18.
    2578. Myelopathy following intrathecal chemotherapy in adults. Journal of Neuro-Oncology.
    2579. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nature Communications. 7.
    2580. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 127:2742-2750.
    2581. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer.
    2582. ASH 2009 meeting report - Top 10 clinically oriented abstracts in acute leukemia. American Journal of Hematology. 85:277-280.
    2583. Acute lymphoblastic leukemia, version 2.2015. JNCCN Journal of the National Comprehensive Cancer Network. 13:1240-1279.
    2584. Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers. Leukemia Research. 38:91-94.
    2585. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. British Journal of Haematology. 172:97-110.
    2586. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia.
    2587. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer.
    2588. Future directions in molecular and genetic therapy for Leukemias and solid tumors. Cancer Bulletin. 42:173-180.
    2589. Novel therapeutic approaches for chronic myelogenous leukemia. Cancer Bulletin. 42:149-155.
    2590. Role of the 340B drug discount program in recent cancer care trends. Journal of Oncology Practice. 11:303-307.
    2591. Influenza B in hospitalized immunocompromised adults. Clinical Infectious Diseases. 25:376.
    2592. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 100:1139-1145.
    2593. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Science Translational Medicine. 8.
    2594. Phase i study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clinical Cancer Research. 21:1267-1272.
    2595. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leukemia Research. 48:1-5.
    2596. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 128:504-507.
    2597. American Society of Clinical Oncology. P and T. 33:400.
    2598. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 30:649-657.
    2599. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clinical Lymphoma, Myeloma and Leukemia. 16:163-168.
    2600. Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies. ONCOLOGY (United States). 26.
    2601. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-Term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 127:303-309.
    2602. Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. Journal of Blood Medicine. 6:25-29.
    2603. Letter to the editor [2]. Leukemia and Lymphoma. 22:186.
    2604. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. British Journal of Haematology. 171:471-477.
    2605. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia. The Lancet Haematology. 2:e12-e20.
    2606. Reply to price and value in cancer care. Cancer.
    2607. Phase i study of S-trans, trans-farnesylthiosalicylic acid (Salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clinical Lymphoma, Myeloma and Leukemia. 15:433-438.
    2608. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies. The Lancet Haematology. 2:e339-e346.
    2609. New drugs in acute myeloid leukemia. Annals of Oncology. 27:770-778.
    2610. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia. The Lancet Haematology.
    2611. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. Chemtracts. 14:733-738.
    2612. Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized phase iii trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. Journal of Blood Medicine. 6:25-29.
    2613. Leukemias.
    2614. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). American Journal of Hematology. 91:227-232.
    2615. The Enright/McGlave Article Reviewed. Oncology. 11:1302-1306.
    2616. Biology of Chronic and Acute Myeloid Leukemia. 371-383.
    2617. Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Expert Opinion on Orphan Drugs. 1:607-623.
    2618. Adult Acute Lymphoblastic Leukemia. Mayo Clinic Proceedings. 91:1645-1666.
    2619. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. Journal of Experimental Medicine. 213:1723-1740.
    2620. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults. Blood. 127:1863-1869.
    2621. Contract research organizations in oncology clinical research. Cancer.
    2622. Acute Myeloid Leukemia With t(v;5q33) Is Associated With Poor Overall Survival and Often Lacks Myelodysplastic Features. Clinical Lymphoma, Myeloma and Leukemia. 15:S85-S90.
    2623. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. Alimentary Pharmacology and Therapeutics. 44:1235-1241.
    2624. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 30:268-273.
    2625. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer.
    2626. Are high drug prices for hematologic malignancies justified? A critical analysis. Cancer. 121:3372-3379.
    2627. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival forPatients with Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation.
    2628. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib (Blood (2011) 118, 17 (4567-4576)). Blood. 122:2524.
    2629. The role of decitabine in hematologic malignancies. Leukemia. 11.
    2630. Detection and quantitation of BCR-ABL transcripts using a comprehensive quantitative rtpcr analysis system for minimal residual disease in CML patients. Blood. 96.
    2631. Management of B-Cell Acute Lymphoblastic Leukemia. 22-28.
    2632. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. The Lancet Oncology. 16:1547-1555.
    2633. Final 5-year study results of DASISION. Journal of Clinical Oncology. 34:2333-2340.
    2634. In reply [6]. Journal of Clinical Oncology. 24:3813.
    2635. Phase i trials using sleeping beauty to generate CD19-specific CAR T cells. Journal of Clinical Investigation. 126:3363-3376.
    2636. 2-Chlorodeoxyadenosine. Cancer Bulletin. 43:253-258.
    2637. Value of interphase fluorescent in situ hybridization (iFISH) studies in monitoring response to STI571 therapy in patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). Blood. 96.
    2638. TP53 mutations in newly diagnosed acute myeloid leukemia. Cancer. 122:3484-3491.
    2639. New tyrosine kinase inhibitors in chronic myeloid leukemia (CML). Leukemia Research. 31.
    2640. Erratum. Seminars in Hematology. 42:274.
    2641. The Hippocratic Oath, the US Health Care System, and the Affordable Care Act in 2015. American Journal of Medicine. 128:1162-1164.
    2642. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. The American Journal of Medicine. 86:554-558.
    2643. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis. Haematologica. 101:e324-e327.
    2644. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clinical Lymphoma, Myeloma and Leukemia. 15:556-562.
    2645. Treatment of Newly-Diagnosed AML with Idarubicin + ARA-C. Leukemia and Lymphoma. 7:121.
    2646. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase. The Lancet Haematology.
    2647. Emerging role of epigenetic therapy. Seminars in Hematology. 42.
    2648. Hematology/Oncology Clinics of North America. Hematology/Oncology Clinics of North America. 14.
    2649. The authors reply. New England Journal of Medicine. 370:577.
    2650. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms. The Lancet Oncology. 18:100-111.
    2651. Treatment of adolescents and young adults with acute lymphoblastic leukemia in the modern era. 225-236.
    2652. Nilotinib in patients with systemic mastocytosis. Journal of Cancer Research and Clinical Oncology. 141:2047-2060.
    2653. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry Part A. 87:346-356.
    2654. Hormonal Therapy for Metastatic Male Breast Cancer. Archives of Internal Medicine. 143:237-240.
    2655. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 7:14172-14187.
    2656. Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Investigational New Drugs. 33:870-880.
    2657. In Reply - Lowering the High Cost of Cancer Drugs. Mayo Clinic Proceedings. 91:401-403.
    2658. Relapsed refractory BRAF-negative, IGHV4-34-positive variant of hairy cell leukemia. Journal of Clinical Oncology. 34:e57-e60.
    2659. Unraveling Myelodysplastic Syndromes. Current Oncology Reports. 18:1-11.
    2660. Decitabine for the treatment of acute myeloid leukemia. Expert Opinion on Orphan Drugs. 1:661-673.
    2661. Nilotinib for the treatment of chronic myeloid leukemia after imatinib failure. American Journal of Hematology/ Oncology. 7.
    2662. The incidence and impact of thrombocytopenia in myelodysplastic syndrome. Journal of Supportive Oncology. 5:74-75.
    2663. Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia. Journal of Infection and Chemotherapy. 21:663-667.
    2664. Decitabine response with chromosome 7 abnormality in MDS, and decitabine optimal schedule [10]. Blood. 110:1083.
    2665. From the guest editors. Cancer Journal. 13:355-356.
    2666. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leukemia Research. 41:43-47.
    2667. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clinical Cancer Research. 21:985-994.
    2668. DNA cross-linking and repair in cisplatin-resistant human tumor cells following exposure to a new cisplatin analogue, CI-973. International Journal of Oncology. 5:597-602.
    2669. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer.
    2670. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia [2]. Blood. 108:4291-4292.
    2671. Molecular biology and cytogenetics of chronic myeloid leukemia. 29-44.
    2672. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation. 22:1218-1226.
    2673. Neurologic toxicity of intrathecal liposomal cytarabine when used for CNS prophylaxis in conjunction with the hyper-CVAD regimen [2]. Blood. 110:1698-1699.
    2674. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia. The Lancet Oncology. 17:612-621.
    2675. The role of imatinib in the treatment of chronic myelogenous leukemia. American Journal of Cancer. 3:337-348.
    2676. BCR-ABL1INS35 is not uncommon in CML patients and is related to resistance and sensitivity to inhibitors in CML treatment - Response. Molecular Cancer Therapeutics. 9:772.
    2677. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leukemia and Lymphoma. 1-6.
    2678. Standard Management of Patients with Chronic Myeloid Leukemia. 71-85.
    2679. Erratum. British Journal of Haematology. 108:461.
    2680. High dose (hd) chemotherapy in high risk (hr) myelodisplastic syndrome (mds). Blood. 96.
    2681. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer.
    2682. Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression. Molecular Cytogenetics. 8.
    2683. Erratum. Blood. 124:981.
    2684. ASH 2009 meeting report - Top 10 clinically oriented abstracts in chronic myeloid leukemia. American Journal of Hematology. 85:283-286.
    2685. Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future Oncology. 12:293-302.
    2686. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leukemia and Lymphoma. 56:390-394.
    2687. Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. Therapeutic Advances in Hematology. 5:29-34.
    2688. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia.
    2689. Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphoma. The Lancet.
    2690. Vosaroxin. Expert Opinion on Orphan Drugs. 1-8.
    2691. New directions in the biology and therapy of chronic myeloid leukemia. Leukemia and Lymphoma. 6:89-95.
    2692. Health care in the United States-basic human right or entitlement?. Annals of Oncology. 26:2193-2195.
    2693. The addition of all-trans retinoic acid to chemotherapy may not improve the outcome of patient with NPM1 mutated acute myeloid leukemia. Frontiers in Oncology. 3 SEP.
    2694. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia. The Lancet Haematology. 2:e118-e128.
    2695. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Cancer genetics.
    2696. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer. 120:3494-3501.
    2697. Oncogenic Signals as Treatment Targets in Classic Myeloproliferative Neoplasms. Biology of Blood and Marrow Transplantation. 15:114-119.
    2698. Erratum. Expert Opinion on Biological Therapy. 15:915.
    2699. Erratum. Clinical Cancer Research. 10:7787.
    2700. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. Leukemia and Lymphoma. 56:1342-1345.
    2701. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clinical Lymphoma, Myeloma and Leukemia. 16:616-624.
    2702. Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors. Leukemia and Lymphoma. 1-4.
    2703. Blood. 96.
    2704. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia.
    2705. Prognostic determinants in patients (PTS) with Philadelphia chromosome-negative (Ph-Ve) benign phase chronic myelogenous leukemia (CML).
    2706. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. 127:703-712.
    2707. Dr. Verstovsek and Colleagues reply. New England Journal of Medicine. 366:2034.
    2708. Targeting IL11 receptor in leukemia and lymphoma. Clinical Cancer Research. 21:3041-3051.
    2709. The urgent need for clinical research reform to permit faster, less expensive access to new therapies for lethal diseases. Clinical Cancer Research. 21:4561-4568.
    2710. Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. Blood. 127:1398-1402.
    2711. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis. Haematologica. 100:479-488.
    2712. In vitro effects of STI571-containing drug combinations on growth of Ph-posittve myelogenous leukemia-derived cells. Blood. 96.
    2713. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - Single center experience. Leukemia and Lymphoma. 57:237-239.
    2714. Meir Wetzler, MD. Cancer.
    2715. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica. 101:e482-e484.
    2716. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase. Leukemia.
    2717. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood. 128:2096-2097.
    2718. Acute myeloid leukemia. Expert Review of Hematology. 1-13.
    2719. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. American Journal of Hematology. 91:606-616.
    2720. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME). The Lancet Oncology.
    2721. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. American Journal of Hematology. 92:7-11.
    2722. Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD). Leukemia.
    2723. Leukemia in the elderly. Cancer Bulletin. 47:203-211.
    2724. Cancer Genomics in Clinical Context. Trends in Cancer. 1:36-43.
    2725. Chronic myeloid leukemia. Hematology. 3:263-276.
    2726. Dorsal column myelopathy after intrathecal chemotherapy for leukemia. American Journal of Hematology. 92:155-160.
    2727. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy. Leukemia and Lymphoma. 56:1643-1650.
    2728. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood. 126:2491-2501.
    2729. Fludarabine treatment of chronic lymphocytic leukemia and indolent lymphomas. Cancer Bulletin. 42:136-144.
    2730. Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. British Journal of Haematology.
    2731. Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies. Blood Cancer Journal. 5.
    2732. Targeted therapy. Nature Reviews Clinical Oncology. 13:270-272.
    2733. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 122:3336-3343.
    2734. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leukemia and Lymphoma. 55:1451-1462.
    2735. Hemophagocytic lymphohistiocytosis in adults. BBA Clinical. 7:36-40.
    2736. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute Myelogenous Leukemia. Cancer Discovery. 6:1106-1117.
    2737. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British Journal of Haematology. 171:726-735.
    2738. Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML. American Journal of Hematology. 92:E14-E15.
    2739. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia.
    2740. American Journal of Hematology. 92:E3-E4.
    2741. Gene therapy. Cancer Bulletin. 45:139-145.
    2742. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. Immunotherapy. 8:135-143.
    KANTARJIAN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (2110)
    Explore
    _
    Co-Authors (323)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _